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Abstract 
 
Desmosomes are macromolecular, dynamic and adaptable complexes that connect 
intermediate filaments of neighboring cells in a variety of tissues, generating a large 
mechanically resilient structure. The importance of maintaining desmosome 
homeostasis for tissue integrity and optimal organ function has been revealed 
through the identification of desmosome-associated disorders and mechanistic 
studies into desmosome regulation. This thesis focuses on inherited skin and heart 
conditions linked to mutations in desmosomal genes or in genes believed to be 
implicated in desmosome regulation. 
Part of this thesis is focused on the molecular analysis and identification of novel 
desmosomal mutations in patients clinically diagnosed with Arrhythmogenic Right 
Ventricular Cardiomyopathy, and the genetic diagnosis of patients with 
hypotrichosis, hypotrichosis and PPK or acral peeling skin syndrome. Patients were 
analysed using a number of different genetic techniques including custom capture 
array, HaloPlex targeted resequencing, exome capture and Sanger sequencing. Both 
novel and previously reported mutations were identified in DSP, DSC2, DSG2, PKP2, 
DSG4 or CSTA in patients diagnosed with these disorders. 
The molecular mechanisms behind mutations in the protease inhibitors cystatin A 
and calpastatin, leading to the skin disorders exfoliative ichthyosis and PLACK 
syndrome, were also investigated. In vitro analysis, using siRNA-mediated 
knockdown in the immortalised keratinocyte cell line HaCaT, demonstrated that 
these mutations, affecting the structure and function of the protease inhibitors, lead 
to deficient intercellular adhesion, possibly through the indirect regulation of 
desmosomal complexes through their target proteases. 
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1.1. The Skin 
The skin is key in maintaining the integrity and healthy functioning of the human 
organism. The skin’s most critical function is to form a barrier between the “outer” 
and “inner” environments, and by this regulating processes such as water loss, thus 
preventing desiccation, and protecting against chemical (irritants, allergens), 
mechanical (UV light, temperature variations, mechanical stress) and microbial 
assaults (fungus, bacteria, viruses) through a permanent rearrangement and 
regulation of its structural and molecular components (Egberts et al., 2004). 
The three consisting layers of the skin are the epidermis, the dermis and the 
hypodermis. The hypodermis is the deepest skin layer, with roles such as body 
insulation, energy resource and skin protection, and cushion against mechanical 
stress while serving as a shelter for nerve fibres, blood and lymph vessels. The 
dermis is the intermediate layer and also the thickest layer of the skin, formed of 
fibrous, filamentous, diffuse and connective tissue elements which accommodate 
nerves, glands and vascular components. It serves as a thermal regulator, binds 
water, protects against mechanical injury and is the main sensorial receptor. The 
epidermis is the outer layer of the skin and the first barrier against external assaults. 
Some of the key roles of this layer are UV protection, immune defence and adhesion 
(Wolff et al., 2007).   
1.1.1. The epidermis 
The epidermis is structured on four layers named after their position or a specific 
characteristic. These layers stratify from the basal layer, the spinous layer, the 
granular layer to the stratum corneum which is shed during desquamation (Figure 
1.1.). Keratinocytes represent 80% of the cells forming the epidermal layers and 
intercalate with various other cells such as melanocytes, Langerhans cells, Merkel 
cells and lymphocytes (Houben et al., 2008).  
The structure of all keratinocytes is directed by a family of intermediate filaments, 
named keratins, through a cell-type and tissue-type differentiation stage, 
developmental stage and disease-dependent co-expression of fifty-four keratins.  
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The basal layer is where keratinocyte differentiation, a genetically-programmed, 
carefully regulated and complex morphologic and metabolic process, begins only to 
end with a terminally differentiated dead keratinocyte which contains keratin and 
matrix proteins with surface-associated lipids. This layer contains mitotically active 
keratinocytes which get their columnar shape and attachment to the basement 
membrane function from keratins 5 (KRT5) and 14 (KRT14). Melanocytes, another 
epidermal cell type, produce melanin, which is the pigment in these cells, giving the 
overall skin pigmentation perceived macroscopically. Various studies suggest that 
the basal layer can exhibit three proliferative potentials, as stem cells, transit 
amplifying cells and post mitotic cells. It is believed that stem cells are located within 
the follicular bulge region and that these cells are not only capable of forming the 
entire pilo-sebaceous unit but also the interfollicular epidermis. The transit 
amplifying cells arise from stem cells as a consequence of their infrequent division. 
These daughter cells are the most common cells in the basal layer and represent the 
stable self-renewed cells which reach their end terminal point in the stratum 
corneum after a succession of divisions (Wolff et al., 2007). 
The spinous layer takes its name from the special shape the composing 
keratinocytes have, which changes as the cells differentiate into the granular layer. 
These cells retain the stable KRT5 and KRT14 filaments produced in the basal layer, 
localised around the nucleus and tethered to desmosomes, but do not synthesize 
any new mRNA, instead they produce KRT1 and KRT10 specific to this epidermal 
layer. These keratins are specific to differentiated/keratinised cells and their down-
regulation together with the up-regulation of KRT6 and KRT16 are a hallmark of 
hyperproliferative disorders (Wolff et al., 2007). 
The basophilic keratohyalin granule-containing cells make up the granular layer, 
which takes its name from this attribute. These granules are composed primarily of 
profilaggrin, keratin filaments and loricrin. This layer is where many of the 
characteristics of the epidermal barrier are formed. Release of profilaggrin from the 
granules results in its calcium-dependent cleavage into filaggrin monomers which 
aggregate with keratin to form macrofilaments, eventually filaggrin being degraded 
into UV protective molecules (Wolff et al., 2007). 
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The final stage of keratinocyte differentiation ends with flattened cornified cells that 
form the stratum corneum. During this differentiation process an apoptotic 
mechanism results in the destruction of the nucleus together with all intracellular 
components excepting the keratin filaments and filaggrin matrix. Regulation of 
permeability, desquamation, antimicrobial peptide activity, toxin exclusion and 
selective chemical absorption, some of the most important functions of the 
extracellular lipid matrix, together with mechanical reinforcement, hydration, 
cytokine-mediated inflammation and protection from UV damage provided by the 
corneocytes represent the first defence barriers of the human organism against 
external factors (Egberts et al., 2004, Houben et al., 2007, Fuchs, 1990, Fuchs, 2007). 
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Figure 1.1. Schematic structure of the human epidermis. The different epidermal layers 
indicative of layer-specific cellular differentiation are shown including the basal, spinous, 
granular and cornified layers. 
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1.1.2. The dermal-epidermal junction 
The dermal-epidermal junction (DEJ) is a complex form of the basement membrane 
and it underlies the basal layer of the epidermis, extending into the upper layers of 
the dermis, and covering the entire length of the epidermis and epidermal 
appendages such as sweat glands, sebaceous glands and hair follicles. The DEJ 
consists of three zones which through complex protein-protein interactions provide 
a strong mechanical stability between the epidermal and dermal structures. The 
first zone is formed of keratin filaments spanning from the nuclear area of the basal 
cells of the epidermis into the plasma membrane and associate to hemidesmosomal 
plaques. External to the plasma membrane of the basal cells, anchoring filaments, 
seen throughout the lamina lucida, connect to the lamina densa. The second zone, 
called lamina densa, has been described under higher magnification with a granular-
fibrous appearance, mainly formed of collagen IV, nidogen-entactin, perlecan, and 
laminins, which can polymerize to form networks of variable thickness. The third 
zone is the subbasal lamina formed of microfibrilar structures such as the anchoring 
fibrils, mainly collagen VII aggregates, and the elastic fibers. The majority of 
anchoring fibrils bind to the basal lamina with one end and the fibrous structures of 
the dermis with the other end. Other fibrils originating from the lamina densa curve 
in a horse shoe manner and reinsert themselves into the lamina densa or insert into 
amorphous structures named anchoring plaques. These microfibrils insert into the 
basal lamina perpendicularly to the basement membrane, and extend into the 
dermis merging with the elastic fibers to form a plexus parallel to the DEJ (Burgeson 
and Nimni, 1992, Christiano and Uitto, 1994, Kielty and Shuttleworth, 1997, Tamai 
et al., 2009, Ko and Marinkovich, 2010). The DEJ therefore provides a variety of 
complex attachments between the reticular dermis and the intermediate filament 
cytoskeleton of the basal cells of the epidermis. 
1.1.3. The dermis 
The dermis is the skin layer below the epidermis, usually much thicker than the 
layer above, it serves as physical support and a source of nutrients for the avascular 
epidermis, but also as a thermal regulator and a sensorial receptor due to the 
numerous nervous endings. It is largely composed of a network of collagen and 
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elastin fibres embedded in the extra-cellular matrix (ECM), a heterogeneous 
network of complex molecules including proteins and polysaccharides, such as 
fibronectin, laminins, hyaluronic acid and proteoglycans. Scattered throughout the 
dermis are cells called fibroblasts which regulate the organisation of the fibrillar 
dermal matrix and responsible with the synthesis and maintenance of the 
precursors of the ECM. This complex macromolecular network provides a scaffold 
through which cells can move, influencing cell behaviour through the constant 
turnover and remodelling of its components (Halper and Kjaer, 2014).  
Structurally, the dermis is divided into the superficial papillary dermis and the 
deeper reticular dermis. The papillary dermis, presents a looser fibrous texture in 
comparison to the reticular layer, and is formed of vascular networks, parallel to the 
skin surface, that communicate between themselves through vertical vessels, 
together forming the superficial plexus serving different dermal papillae. Similarly 
to the superficial blood vessels, the collagen bundles follow the structures they 
surround. The reticular dermis is the thicker layer of the dermis and is formed of 
larger blood and lymph vessels, thicker collagen and elastic fibres and nerve endings 
(Halper and Kjaer, 2014). 
1.1.4. Keratinocyte adhesion and communication in the epidermis 
The skin, as the first defence organ, can successfully accomplish its basic functions 
with the essential assistance of intercellular junctions which serve to create a tight 
barrier between keratinocytes. The barrier, formed by adherens junctions, tight 
junctions and desmosomes together with gap junctions, facilitates both the 
structural integrity and cell-cell communication homeostasis (Figure 1.2.).  
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Figure 1.2.  Diagram of epidermal intercellular junctions. Intercellular junctions 
include gap junctions (orange), adherens junctions (purple), desmosomes (red, Sobolik-
Delmaire et al., 2010) and tight junctions (blue), connecting keratinocytes. Adherens and 
tight junctions are shown to be connected to actin microfilaments (dark red). Desmosomes 
are connected to keratin intermediate filaments (green). Adhesion between adherens 
junctions and desmosomes is mediated by cadherin proteins, which form links between 
neighbouring keratinocytes. 
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1.1.4.1. Adherens junctions 
The adherens junctions are major cell-cell links that mediate cell recognition, 
adhesion, morphogenesis and tissue integrity, their importance being highlighted 
by the maintenance of their structural similarities during evolution (Yonemura, 
2011, Oda and Takeichi, 2011). This type of junction is not only found in epithelial 
tissues but also in non-epithelial cells such as fibroblasts, cardiac muscles and 
neurons. They are characterised as regions at the interface of two neighbouring cells 
and enclose a dense undercoat associated with actin filaments at the cytoplasmic 
surface. 
Cadherins, the major components of these junctions, are structurally formed of 
repeating extracellular cadherin domains and a cytoplasmic region that binds p120-
catenin and β-catenin at opposing ends (Oda and Takeichi, 2011). A variety of 
cadherins are known, with different names depending on their localisation, such as 
E-cadherin in the epithelium, N-cadherin in the neuronal tissue (Meng and Takeichi, 
2009). P120-catenin is known to stabilise cadherins at the intercellular surface, 
while β-catenin is thought to mediate the interactions of cadherins with the actin 
filaments through α-catenin, until recently when this theory was dismissed 
(Yamada et al., 2005). Alongside its function in adherens junctions, β-catenin is also 
a crucial component of the Wnt signalling pathway, which regulates development 
and homeostasis via gene expression, cell growth, survival and polarity (Moon et al., 
2002). Under normal conditions Wnt pathway signalling is regulated by 
phosphorylation and subsequent degradation of β-catenin, meaning that somatic 
mutations in β-catenin itself, or in those proteins involved in its phosphorylation or 
degradation (including Dishevelled, Axin, Adenomatous Polyposis Coli [APC], and 
glycogen synthase kinase-3β) can lead to constitutive β-catenin activation and lead 
to cancer development (Moon et al., 2002). 
1.1.4.2. Tight junctions 
Tight junctions form the boundary between the apical and basolateral domains of 
epithelia and serve in preventing the paracellular passage of fluids, electrolytes and 
macromolecules (Bonazzi and Cossart, 2011). The four main protein groups which 
constitute the junction are the occludins, the claudins, the junction adhesion 
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molecules (JAM) and the coxsackievirus and adenovirus receptor proteins (CAR) 
(Citi and Cordenonsi, 1998). The first two types of proteins, occludins and claudins, 
have four transmembrane domains and form homodimers via their extracellular 
loops, while JAMs and CARs have only one transmembrane domain and extracellular 
IgG-like domain that mediate adhesion. These transmembrane components bind to 
intracellular components which link them to the actin cytoskeleton. Due to their 
apical location, tight junctions are easily disrupted by pathogens during host 
infection and virus spread (Bonazzi and Cossart, 2011). 
1.1.4.3. Gap junctions 
The main role of gap junctions is to permit intercellular communication, a function 
vital for controlling homeostasis, and responding to external stimuli, which they 
accomplish by allowing the transfer of ions (including Ca2+ and Mg2+) and small 
molecules of less than 1 kDa (such as cAMP, cGMP and ATP) between cells (Scott 
and Kelsell, 2011). Gap junctions consist of plaques of many small channels, each 
the product of two hexameric hemi-channels on closely apposed cell membranes. 
Each hemi-channel is a homo- or heteromeric hexamer made up of connexins (Cx) 
(Storme et al.), a protein family of 21 members in humans, named according to their 
molecular mass (Wei et al., 2004). Cx are differentially expressed in the human body, 
with multiple types expressed in any single tissue type. Microtubules are believed 
to facilitate the trafficking of hemi-channels to the cell surface where they can be 
found unopposed to another channel or docked with a hemi-channel on an adjacent 
cell to form a gap junction connecting the cytoplasms of these two neighbouring 
cells. Hemi-channels can be either homo- or heterotypic which means that they are 
composed of identical or different hemi-channels respectively (Caspar et al., 1977). 
Gap junctions composed of different connexins have different properties due to a 
varied permeability to molecules and ions (Goldberg et al., 2004). 
1.1.5. The desmosome – a complex intercellular junction 
Desmosomes are complex macromolecular structures with a key role in the 
maintenance of collateral epidermal integrity. These structures were discovered by 
Italian pathologist Giulio Bizzozero (1846-1901), in a variety of tissue types exposed 
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to mechanical stress, such as the intestinal mucosa, gallbladder, uterus and oviduct, 
liver, pancreas, stomach, salivary and thyroid glands, and the epithelial cells of the 
nephron, but are most abundant in the skin and myocardium  (Farquhar and Palade, 
1963, Kelly, 1966, Staehelin, 1974, Holthofer et al., 2007). A primary function of 
desmosomes is the anchoring of cytoskeletal keratin intermediate filaments in the 
epidermis, desmin intermediate filaments in the heart, vimentin intermediate 
filaments in meningeal cells and the follicular dendritic cells of lymph nodes to the 
cell membrane (Green and Gaudry, 2000). 
1.1.5.1. Ultrastructural organisation of the desmosomal complex 
All desmosomes, independent of their localisation, are formed of three main classes 
of proteins divided into three parallel individual zones, arranged symmetrically on 
the cytoplasmic faces of the plasma membranes of bordering cells and separated by 
the extracellular domain. The five known desmosomal components are: the 
desmosomal cadherins, represented by four desmogleins (DSG1-4) and three 
desmocollins (DSC1-3), the armadillo family members, plakoglobin (PG)/γ-catenin 
and the three plakophilins (PKP1-3), and the plakin linker protein desmoplakin 
(DSP) which anchors the intermediate keratin filaments (Figure 1.3.).  
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Figure 1.3. Structural organisation of the desmosomal complex. Schematic diagram of 
the desmosome with the relative localisation of desmosome-associated proteins, the 
cadherin family (desmogleins, in pink and desmocollins, in orange), the armadillo family 
(plakoglobin, in purple and plakophillins, in green), the plakin linker (desmoplakin, in dark 
red) and the intermediate filaments (in light purple) bound to desmoplakin. PM – plasma 
membrane; ECD – extracellular core domain; ODSP – outer dense plaque; IDSP – inner dense 
plaque. 
 
 
 
 
 
 
43 
 
1.1.5.2. Molecular composition of desmosome-associated proteins 
1.1.5.2.1. The cadherin superfamily of intercellular linkers 
The desmosomal cadherins belong to the larger cadherin superfamily which also 
includes T-cadherin, FAT family cadherins (Angst et al., 2001), seven pass 
transmembrane cadherins, proto-cadherins and classic cadherins, all sharing an 
approximately 110 amino acid motif involved in adhesion and calcium binding 
(Takeichi, 1977, Takeichi, 1990). 
Desmogleins (DSGs) and desmocollins (DSCs) are the transmembrane components 
that bridge adjacent cells and are embedded in the cytoplasmic plaques, forming the 
dense extracellular midline seen in mature desmosomes. They share 30% amino 
acid identity between each other and with classical cadherins (Garrod et al., 2002), 
with DSC genes being more closely related to the classical cadherins than they are 
to DSGs (Kljuic et al., 2004). 
Structurally, the desmosomal cadherins are formed of five extracellular cadherin 
repeats (EC1-5) containing Ca2+-binding sites and a cell-adhesion recognition (CAR) 
site (Tselepis et al., 1998, Runswick et al., 2001). A unique characteristic of all DSC 
genes is the alternative splicing which generates a complete DSCa form and a 
shorter DSCb form of the protein by the insertion of a mini-exon containing a stop 
codon, the shorter C-terminal domain being the only difference between the two 
isoforms (Collins et al., 1991). Desmogleins contain an extended 500 amino acid tail 
with not yet fully understood functions (Figure 1.4.). 
Desmosomal cadherins show complex developmental and differentiation-specific 
patterns of expression (Holthofer et al., 2007), which suggests that desmosomes 
within different tissues are biochemically and functionally distinct. The precise role 
for the tissue-specific expression pattern of desmosomal cadherins is not fully 
understood, however manipulation of desmosomal cadherins expression suggests 
that tight regulation of their expression pattern is critical to tissue homeostasis 
(Bannon et al., 2001). Within the epidermis these genes are differentially expressed 
as keratinocytes undergo terminal differentiation (Kottke et al., 2006, Holthofer et 
al., 2007) as follows: DSG1 and DSC1 are strongly expressed in the granular and 
44 
 
spinous layers, their levels decreasing in the lower layers of the epidermis (King et 
al., 1995, Shimizu et al., 1995, North et al., 1996); DSG2 and DSC2 are expressed in 
all desmosome-bearing tissues, represent the predominant isoforms in simple 
epithelia (Legan et al., 1994, Schafer et al., 1996), and are mainly expressed in the 
basal layers of stratified epidermis (Garrod et al., 2002, North et al., 1996). DSG4 is 
primarily expressed in the hair follicle and is restricted to the more differentiated 
layers in stratified epithelia (Delva et al., 2009). DSGs 1, 3, and 4, and DSCs 1 and 3 
are predominantly expressed in the epidermis, while DSG2 and DSC2 are highly 
expressed in the myocardium (Li and Radice, 2010) (Figure 1.5.).  
Within the cornified layer of the epidermis (stratum corneum), desmosomes are 
modified into corneodesmosomes, structures which contain DSG1, DSC1 and 
corneodesmosin as their major extracellular constituents. The relative thickness of 
the stratum corneum is achieved by the controlled degradation of 
corneodesmosomes, any modifications at this level leading to severe barrier defects 
(Ishida-Yamamoto et al., 2011).  
1.1.5.2.2. The armadillo family of proteins with multiple complex functions 
PG together with the three known plakophilins PKP1-3 (Hatzfeld, 2007, Hatzfeld, 
2005), all members of the armadillo family, are adaptor proteins with roles in 
facilitating the adhesion of DSP to keratin intermediate filaments, in regulating 
clustering of the desmosomal components, and in mediating important signal 
transduction pathways. PG is formed of 12 arm repeats that share 65% amino acid 
identity with β-catenin, the equivalent protein associated with adherens junctions. 
The central armadillo domain of PG interacts with DSP, which in turn tethers 
intermediate filaments to the desmosomal plaque (Figure 1.4.). PG can also 
translocate to adherens junctions and bind E-cadherin in the same manner as β-
catenin, but its higher affinity for DSP may explain why PG and not β-catenin locates 
to desmosomes (Choi et al., 2009).  
Both PKP1 and 2 exist in two isoforms, a shorter “a” form and a longer “b” form 
(Mertens et al., 1996, Schmidt et al., 1997), with the short “a” form more 
predominant and PKP1b form exclusive to the nucleus. The presence of PKP2 in the 
nucleus is regulated by the 14-3-3 protein and contributes to the RNA polymerase 
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III holoenzyme complex (Desai et al., 2009). The presence of a previously reported 
fourth PKP protein, in the desmosome and the adherens junctions, has since been 
questioned (Hofmann et al., 2009).  
PKPs 1-3 share 50-55% sequence similarity with the arm domain of p120-catenin 
(Hatzfeld, 2007), another armadillo family protein. Based on structural analysis 
studies, PKPs contain 9 arm repeat domains (Choi and Weis, 2005), with 21 
additional amino acids added to PKP1 and 44 amino acids added to PKP2. PKPs 
show tissue and differentiation specific patterns of expression similar to the 
desmosomal cadherins. It has been observed that while PKP3 shows expression 
throughout simple epithelia and all layers of stratified epithelia, apart from 
hepatocytes, PKP1 is mostly expressed in the suprabasal layers of stratified 
epithelia, and PKP2 expression extends to simple epithelia, lower layers of stratified 
epithelia and non-epithelial tissues such as lymph nodes and the cardiac muscle, 
where it is the only isoform (Heid et al., 1994, Mertens et al., 1996, Schmidt et al., 
1997, Mertens et al., 1999, Bonne et al., 1999, Franke et al., 2007) (Figure 1.5.). 
PKPs appear to play a role in the clustering of desmosomal proteins during the 
formation of desmosomes. The N-terminal head domain of PKP1 can associate with 
DSG1, PG, keratin and actin filaments, and ultimately with DSP through what 
appears to be a robust association which drives DSP recruitment to cell-cell 
junctions (Kowalczyk et al., 1999, Hatzfeld et al., 2000, Wahl, 2005, Hofmann et al., 
2000). PKP3 interacts with the largest number of desmosomal proteins, including 
DSP, PG, DSG1-3, DSC3a and DSC3b, and DSC1a and DSC2a (Hatzfeld, 2007). PKP2 
plays an important role in transport of DSP to the plasma membrane during 
desmosome assembly, but does so less efficiently than PKP1 (Green et al., 2010, 
Chen et al., 2002). The mechanism behind PKP1 and PKP3 mediated-desmosomal 
assembly is not yet fully determined, although it appears that PKP2 functions as a 
scaffold for PKC-α and regulates DSP association to the intermediate filaments 
(Godsel et al., 2010, Godsel et al., 2005, Bass-Zubek et al., 2008).  
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Figure 1.4. Structure of desmosome-associated proteins. (a) Similar to the classic 
cadherins, desmosomal cadherins are type I membrane molecules with extracellular 
calcium binding sites. The four members of the desmoglein subfamily (~160 kDa) are 
unique in having extended tails beyond the intracellular catenin-binding site (Coonrod et 
al., 2014). The three members of the desmocollin subfamilly (110–115 kDa) each have two 
splicing isoforms. The ‘b’ isoform lacks the ICS making it unable to bind plakoglobin. (b) The 
desmosomal armadillo family includes plakoglobin, and the plakophilins. Plakoglobin, 
functionally related to β-catenin, links the desmosomal cadherin tails to desmoplakin 
through binding sites, but is believed to engage in lateral interactions as well. Plakophilins, 
more related to p120, appear to have more restrictive binding sites than plakoglobin. (c) 
Desmoplakin is formed of three domains, a central α-helical coiled-coil ROD, flanked by 
globular C- and N-terminal domains, which interact with intermediate filaments and 
armadillo/cadherin family members. The N-terminus contains a series of predicted α-
helical bundles designated NN, Z, Y, X, W and V, whereas the C-terminus contains the 
intermediate-filament-binding domain formed of homology units A, B and C (Adapted from 
Green and Gaudry, 2000). 
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1.1.5.2.3. The plakin linkers – tethers of intermediate filaments 
DSP, the most abundant desmosomal protein, plays a key role as the linker between 
the plasma membrane and the intermediate filament complex (Delva et al., 2009). 
The protein is predicted to form homodimers through an α-helical coiled-coil rod 
domain which also interconnects a globular N-terminus domain, responsible for 
binding the arm proteins PG and PKPs, and a C-terminus domain, responsible for 
the attachment of intermediate filaments (Holthofer et al., 2007, Kowalczyk et al., 
1994, Bornslaeger et al., 2001, Choi et al., 2002, Yin and Green, 2004) (Figure 1.4.). 
Until recently only two isoforms of DSP (DSP I and DSP II) have been known. As with 
the “a” and “b” forms of desmocollins, DSP I and II isoforms are produced as a result 
of alternative mRNA splicing, with DSP II the shorter isoform of the two. Both are 
widely expressed in numerous tissues, although DSP II is absent from the heart and 
from simple epithelia (Angst et al., 1990). A minor DSP isoform derived from DSP I, 
named DSP Iα, produced by the alternative splicing of DSP I mRNA has also been 
described, detectable in lower levels than the dominant isoforms, and presenting a 
similar tissue distribution (Cabral et al., 2010b). 
By immunogold labelling of DSP, Franke et al. have observed that in normal heart 
muscle DSP is located in all plaques of the desmosome-like and fascia adherens-type 
junctions, with a very intense signal within the desmosome-like junctions (Franke 
et al., 2006). Several in vivo and in vitro studies support the importance of DSP in 
desmosome assembly and function, and show its pivotal role in the development of 
epidermis, neuro-epithelium, heart and blood vessels (Gallicano et al., 2001, 
Vasioukhin et al., 2001). In keratinocytes, DSP II appears to play a more significant 
role than DSP I, in maintaining robust adhesion, suggesting cell-type specific 
functions for the DSP isoforms (Cabral et al., 2012b) (Figure 1.5.).   
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Figure 1.5. Desmosome-associated proteins in the epidermis. The figure illustrates the 
differential distribution and approximate expression levels of the desmosome-associated 
proteins in the human epidermis.   
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1.2. Modulation of desmosomal adhesion 
Desmosomes are not just static structures that glue cells together; instead, they are 
very dynamic and adaptable complexes as shown by their ability to adopt different 
conformations with different adhesive affinities, suppressing pathways important 
for establishing cell polarity and determining the balance between proliferation and 
differentiation, all done through interactions with signalling cascades. Modulation 
of these structures is highlighted in pre-programmed processes such as apoptosis 
but also in malignant processes such as tumour invasion and metastasis. 
Desmosome regulation is ultimately the indirect regulator of downstream nuclear 
and signalling processes through regulation of subcellular distribution of 
desmosomal components. 
The hyper-adhesiveness of desmosomes is regulated by the presence or absence of 
Ca2+, PKC, proteolytic processing through ADAM proteins, EGFR expression levels, 
raft regulation and the yet unclear mechanism of the ubiquitin-proteasome system 
(UPS), all with a role in mediating desmosome assembly and function (Nekrasova 
and Green, 2013, Yin and Green, 2004, Stahley et al., 2014, Loffek et al., 2012, 
Blaydon et al., 2011a, Blaydon et al., 2011b).  
1.2.1. Calcium-dependent modulation 
During Ca2+ regulation the key players are DSGs and DSCs, required for strong cell-
cell adhesion (Getsios et al., 2004), via their interaction with each other, across the 
intercellular space, in a homophilic and/or heterophilic manner. Via several binding 
motifs within their structure, DSGs and DSCs bind Ca2+ and assume a rigidified 
functional conformation (Pokutta and Weis, 2007), thereby increasing the level of 
adhesion between neighbouring cells and creating what has been described as the 
dense midline of desmosomes. In low-Ca2+ conditions (less than 0.5 mM) the 
desmosomal plaque components and membrane proteins are transported to the 
plasma membrane, together or in separate compartments, but when desmosomal 
assembly is triggered, cadherins and DSP complexes do not associate as in normal 
Ca2+ conditions and remain separated (Cirillo et al., 2010). It has been observed that 
during the early stages of desmosome formation the assembly can reverse between 
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the mature and young phases but ultimately desmosomes mature and can no longer 
be dissociated by calcium depletion (Watt et al., 1984), especially in stratified 
epithelia. Adhesion strength in cultured keratinocytes increases after 6 days in 
culture due to this phenomenon (Cirillo et al., 2010), in a similar way to intact 
epithelia in vivo (Garrod et al., 2005, Wallis et al., 2000). This is referred to as hyper-
adhesion, and represents the result of high-affinity and stable adhesive binding of 
desmosomal components into mature structures. It has not been observed in 
adherens or tight junctions, making it specific to desmosomes and explaining the 
hyper-adhesive state of keratinocytes (Kimura et al., 2007).  
There are various situations in which desmosomes switch from a Ca2+-independent 
to a Ca2+-dependent state. It has been observed that upon “wounding” of 
keratinocyte cell monolayers the desmosomes of cells situated at the edge of the 
“wound” lose their hyper-adhesiveness and become Ca2+-dependent, permitting the 
cell motility required for wound re-epithelialisation (Wallis et al., 2000). In this case, 
protein kinase C-alpha (PKCα), a conventional PKC isoenzyme and serine-threonine 
kinase, localises to the dense plaque of wound-edge epidermal desmosomes, 
normally absent from hyperadhesive desmosomes. 
Desmosomal proteins undergo both serine-threonine and tyrosine phosphorylation 
that regulate their fate and interactions with other proteins, and this is where PKC 
can play both positive and negative roles in desmosome assembly with protein 
phosphatase activity being a requirement for the final stages of desmosomal plaque 
formation (Yin and Green, 2004). The main focus of these studies has been PG as 
this desmosomal protein is regulated by all of the above processes. It appears that 
PG is more highly phosphorylated in the soluble non-junction pool therefore it is 
believed that phosphorylation regulates its fate during desmosome assembly 
(Pasdar et al., 1995). 
While the passage of desmosomes from a less adhesive to a hyper-adhesive state is 
Ca2+-dependent, O-glycosylation of the desmosomal plaque component PG has also 
been shown to augment desmosomal adhesion in keratinocytes (Hu et al., 2006). 
Activation of PKCα has been reported to stimulate desmosome formation under 
low-Ca2+ conditions and in the absence of adherens junctions (Green et al., 2010), 
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by regulating the availability of DSP for desmosome assembly (Bass-Zubek et al., 
2008). A recent report by Kroger et al., showed that cells lacking all keratin 
intermediate filaments exhibited higher PKC-dependent DSP phosphorylation 
levels, resulting in an increase in desmosome dynamics and internalisation (Kroger 
et al., 2013). 
With regards to desmosomal cadherins, the levels of DSG1 were found to be 
regulated by two Ca2+-independent ‘novel’ PKC isoforms, increased by the 
differentiation-promoting PKCδ and decreased by the growth-promoting PKCε. The 
expression of DSG3 is also regulated by these isoenzymes, but also inhibited by 
PKCα (Szegedi et al., 2009). Kimura et al. have shown that there are other situations, 
such as mitotically active basal cells and during tumour invasion, when the 
transition from a Ca2+-dependent to a Ca2+-independent state happens with the 
induction of hyper-adhesion via modulation of PKCα signalling (Kimura et al., 2007).  
More recent research studies indicate that intact membrane rafts and therefore 
cholesterol could be another mechanism of desmosome regulation. Membrane rafts 
are cholesterol-enriched membrane domains which have been shown to associate 
desmosomal proteins and release them during desmosomal assembly. Resnik et al. 
have shown that a reduction in cholesterol is equivalent to DSC2 release from the 
rafts and decrease in cell-cell adhesion (Resnik et al., 2011). These findings are 
supported by a more recent study by Stahley et al., which has added DSG3 to the 
other desmosomal proteins, DSC2, DSG2, PG and DSP, previously observed to be raft 
associated, and therefore suggest that their integration and assembly into 
desmosomes is cholesterol regulated (Stahley et al., 2014, Resnik et al., 2011, Nava 
et al., 2007, Brennan et al., 2012). 
1.2.2. Apoptotic modulation  
During apoptosis, between the substrates targeted by effector caspases, a number 
of proteins involved in the regulation of cell contacts and of the cytoskeleton such 
as focal adhesion kinase (Crouch et al., 1996), E-cadherin (Schmeiser and Grand, 
1999), PG (Brancolini et al., 1998), fodrin (Janicke et al., 1998), Gas2 (Brancolini et 
al., 1995) and β-catenin (Brancolini et al., 1998) were identified. In addition to 
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previously published research showing that PG is cleaved by caspase3 during 
apoptosis, recent biochemical and cell biological studies have shown that DSGs and 
DSCs are also specifically cleaved. These studies suggest that the cytoplasmic tail of 
human DSG3 is cleaved by caspases at two distinct sites and that the extracellular 
domain is released from the cell surface by metalloproteinases. Inhibition studies 
have shown that the DSG3 release during apoptosis is different to the release of the 
extracellular domain of E-cadherin. Weiske et al., have also shown that PKP1 and 
both isoforms of DSP are being cleaved by caspases during apoptosis, this process 
leading to the disruption of the desmosomal structure and thus facilitating apoptotic 
cell-specific changes (Weiske et al., 2001). 
1.2.3. Desmosomal dysregulation promotes cancer 
Desmosome regulation was observed to play a role in cancer progression, with 
various desmosome-associated proteins dysregulated in a variety of tumours. 
Numerous models have been used to provide a clarification for how desmosome 
regulation promotes tumour metastasis and invasion, with little success as these 
studies produced contradictory and confusing results. Some cancers, such as head 
and neck, prostate, lung and some skin cancers present with an overexpression of 
desmosomal proteins DSG2, DSG3 and PKP3, in comparison to normal tissue 
(Brennan and Mahoney, 2009, Chen et al., 2007, Furukawa et al., 2005, Kurzen et al., 
2003, Breuninger et al., 2010). In contrast, the down-regulation of other 
desmosomal components, DSG1-3, DSC2, DSC3, PG, PKP1-3 and DSP was observed 
in the metastatic progression and development of other human cancers such as 
breast, bladder, prostate, cervical and endometrial, head and neck, gastric, 
colorectal and some skin cancers (Dusek and Attardi, 2011), and in some instances 
no changes in expression of desmosome-associated proteins was noted (Kurzen et 
al., 2003). 
The most studied model is based on the release of specific desmosomal components, 
such as PG which can display oncogenic activity through its β-catenin-like signalling 
activity. It is believed that PG replaces β-catenin in adherens junctions thus freeing 
β-catenin which can stimulate the transcription of Wnt target genes, including 
oncogenic targets such as CCDN1 (cyclin D1) (Conacci-Sorrell et al., 2002). In 
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addition to this, PG can transit to the nucleus and directly activate the oncogenic β-
catenin-LEF/TCF target genes or potentially stimulating the expression of 
uncharacterised targets which promote proliferation or transformation (Zhurinsky 
et al., 2000), while concomitantly inhibiting apoptosis by induction of Bcl-2, an anti-
apoptotic protein (Hakimelahi et al., 2000). Recently, Chen et al. have shown in their 
in vitro studies that a PG-dependent mechanism can be activated by knockdown of 
DSG3, which led to translocation of PG to the nucleus and suppression of TCF/LEF 
transcriptional activity, thus leading to the inhibition of expression of c-myc, CCDN1 
and MMP-7 target genes (Chen et al., 2013). 
The nuclear localisation of PKPs in specific conditions suggests that these proteins 
could modulate gene expression and it has been shown that PKP2 can interact with 
β-catenin leading to increased β-catenin-TCF transcriptional activity; whether this 
process is direct or takes place through mediators it remains unknown (Sobolik-
Delmaire et al., 2010). In addition PKP1 and PKP3 localise to certain cytoplasmic 
compartments where they can interact with translation-initiation factors and 
stimulate translation, the implication of PKPs in tumourigenesis being supported by 
the observed redistribution of these proteins from the plasma membrane to the 
cytoplasm (Wolf and Hatzfeld, 2010). It is believed that the simple loss of the hyper-
adhesive strength that is unique to desmosomes may contribute to cancer 
progression by releasing a barrier to invasion and metastasis (Dusek and Attardi, 
2011). Similarly to in vivo observations, several in vitro studies have reported 
conflicting results with regards to a clear mechanism behind metastatic 
proliferation, apoptosis and invasion, and whether this mechanism is dependent on 
the up-regulation or down-regulation of desmosomal proteins (Dusek and Attardi, 
2011). 
Another desmosome-related protein associated with cancer is PERP (p53 apoptosis 
effector related to PMP-22), a p53/p63 regulated membrane protein, required for 
desmosome assembly. Initially identified as a transcriptional target of the p53 
tumour suppressor, upregulated during apoptosis, and subsequently seen as a 
target of p63, promoting intercellular adhesion and preserving epithelial integrity 
(Attardi et al., 2000, Ihrie et al., 2005). Mouse studies have shown that mice with 
Perp knockout or LOF mutations, exposed to UVB light have an increased tendency 
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to develop squamous cell carcinomas (SCCs), Perp-ablation leading to both tumour 
initiation and progression in various types of tumours (Beaudry et al., 2010b, 
Beaudry et al., 2010a). Moreover, Perp-deficient tumours show a significant down-
regulation of desmosomal components, while adherens junctions remain intact, 
suggesting a specific role for desmosomes in tumourigenesis. These observations 
were confirmed in human SCCs, and suggest a clear implication of Perp, as a critical 
mediator of p53 tumour suppressor, in SCC development (Beaudry et al., 2010b).  
1.2.4. Regulation of desmosomal adhesion through proteases and their 
inhibitors 
Proteases are key factors in orderly processes such as desquamation and regulation 
of the skin's barrier function. On the basis of their catalytic domain, proteases were 
classified into aspartate-, cysteine-, glutamate-, metallo-, serine-, and threonine 
proteases. Particularly, serine proteases (SPs) contribute to epidermal permeability 
barrier homeostasis, as acute barrier disruption increases SP activity in skin and 
inhibition by topical SP inhibitors accelerated recovery of barrier function (Meyer-
Hoffert and Schroder, 2011). 
Endogenous and exogenous proteases such as kallikreins, matriptase, caspases, 
cathepsins, and proteases derived from microorganisms are important in the 
desquamation of the stratum corneum and are able to regulate the activity of 
defence molecules in the human epidermis. Protease inhibitors such as LEKTI, 
elafin, SLPI, SERPINs and cystatins regulate their proteolytic activity and contribute 
to the integrity and protective barrier function of the skin. Changes in the proteolytic 
balance of the skin can result in inflammation, which leads to the typical clinical 
signs of redness, scaling, and itching (Meyer-Hoffert, 2009). 
As two of the results chapters of this thesis are focused on exfoliative ichthyosis, an 
inherited skin disorder linked to mutations in CSTA encoding for cystatin A (Blaydon 
et al., 2011b), and on a novel clinical entity which we have named PLACK syndrome, 
linked to mutations in CAST, the gene encoding for calpastatin (Lin et al., 2015), the 
following introductory subsections will expand on these specific protease inhibitors 
and their target proteases.  
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1.2.4.1. Cysteine protease inhibitors of papain-like proteases 
Cystatins are part of a large superfamily of cysteine protease inhibitors, also named 
class I cystatins, initially described as inhibitors of lysosomal cysteine proteases, 
and in recent years also reported to have a variety of other roles. Cystatins have 
been divided into four protein families, three families of inhibitory proteases and 
one family of enzymes with non-inhibitory function (Rawlings and Barrett, 1990). 
The three families with inhibitory functions are: family I, comprised of the mainly 
endogenous stefins A and B with one inhibitory domain, expressed in a variety of 
organisms and tissue types, stefin C discovered in bovine thymus (Turk et al., 1993) 
and stefin D identified in pigs (Lenarcic et al., 1996); family II, comprised of 
exogenous cystatins C, D, E/M, F, G, S, SN and SA (Abrahamson et al., 2003), the male 
reproductive tract cystatins 8 (CRES, cystatin-related epididymal spermatogenic 
protein), 9 (testatin), 11 and 12 (cystatin T), the bone marrow-derived cystatin-like 
molecule CLM (cystatin 13) and the secreted phosphoprotein ssp24 (cystatin 14) 
with one inhibitory domain (Keppler and Sierra, 2005), where cystatin C is 
expressed in a variety of tissues while the other cystatins are more tissue-specific 
(Magister and Kos, 2013), and family III, comprised of the so called L- and H-
kininogens in a variety of species and T-kininogen only in rats (DeLa Cadena and 
Colman, 1991), intravascular inhibitors, with three inhibitory domains. The fourth 
non-inhibitory family consists of homologues of two cystatin-like domains, the 
human α-2SH-glycoprotein (fetuin) and histidine-rich glycoprotein (Brown and 
Dziegielewska, 1997).  
1.2.4.1.1. Cystatin A protease inhibitor – structure and function 
Cystatin A (also known as stefin A, acid cysteine protease inhibitor, epidermal SH-
protease inhibitor), a member of family I of cysteine protease inhibitors, isolated 
initially from rat skin, is the first cysteine inhibitor described in mammals (Jarvinen 
and Hopsu-Havu, 1975). With a selective expression pattern, CSTA is abundantly 
expressed in the cytoplasm of epithelial cells (Rinne et al., 1978, Rasanen et al., 1978, 
Rinne et al., 1980), dendritic reticulum cells of lymphoid tissue (Soderstrom et al., 
1995), Hassall’s corpuscles (Soderstrom et al., 1994), liver neutrophils (Davies and 
Barrett, 1984) and in thymic medullary cells (Soderstrom et al., 1994), suggesting a 
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key role in the first line defence mechanism against pathogens in various organs. 
CSTA is thought to play an important role in a variety of mechanisms, from skin 
protection against allergens such as dust mites (Kato et al., 2005) and cellular 
proliferation to regulating the activity of several target proteases in different types 
of cancers, including tumours of the breast (Kuopio et al., 1998), lung (Butler et al., 
2011), prostate (Sinha et al., 1999), and SCCs of the head and neck (Strojan et al., 
2000). 
Structurally, CSTA is a 98-amino acid protein, with a molecular mass of 
approximately 11 kDa, sharing 58% identity with stefin B. The 3D structure of CSTA 
was studied for the first time in solution and through its interaction with cathepsin 
H, one of the target proteases of CSTA (Machleidt et al., 1983). Although it is believed 
that CSTA is less selective in its inhibitory function than the exogenous cystatins, 
some of the more studied target proteases of CSTA are cathepsins B, H, L, V and S, 
with the first three frequently dysregulated in a variety of cancers, appearing to 
facilitate tumour invasion and metastasis through cleavage of cell-to-cell junctions 
(Strojan et al., 2000). 
The conformation of this inhibitor, initially suggested following a study on chicken 
CSTA, is formed of five stranded antiparallel β-sheets wrapped around a five turn α-
helix with an additional C-terminal strand running along the convex side of the sheet 
(Bode et al., 1988). The N-terminal end and two β-hairpins form the edge of a wedge-
shaped surface which binds into the active site cleft of the target proteases in what 
was called the “elephant trunk” model. Jenko et al. have looked at the crystal 
structure of CSTA in relation to cathepsin H and have confirmed the mode of 
interaction previously described. It appears that on binding, the N-terminal end of 
CSTA becomes like a hook which pushes away the mini-chain residues of cathepsin 
H, leading to structural changes on the surface of both proteins involved in the 
complex (Jenko et al., 2003), a mechanism confirmed for the interaction between 
CSTA with cathepsin B (Renko et al., 2010).  
Some of the pathologic processes that CSTA has been linked with cover both 
disorders arisen due to a defective inhibitory function, the inhibition of the major 
dust mite allergens Der f 1 and Der p 1 (Kato et al., 2005), and its dysregulation in a 
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variety of cancers (Rivenbark and Coleman, 2009, Rinne, 2010), and also disorders 
arisen due to sequence variations in the CSTA gene, such as a polymorphism leading 
to the inflammatory condition atopic dermatitis (Vasilopoulos et al., 2007), the 
association with  psoriasis (Vasilopoulos et al., 2008), loss-of-function mutations 
linked to exfoliative ichthyosis (Blaydon et al., 2011b, Moosbrugger-Martinz et al., 
2014) and acral peeling skin syndrome (APSS) (Krunic et al., 2013).  
Up to date the target proteases inhibited by CSTA, cathepsins B, H and L have only 
been described in relation to a variety of cancers through their role in the 
degradation of the ECM, facilitating the growth, invasion and metastasis of tumour 
cells, and also in tumour angiogenesis (Rivenbark and Coleman, 2009). Increased 
activity of cathepsins B, L and H is associated with a lower CSTA inhibitory activity 
in the majority of examined patients with breast neoplasms (Lah et al., 1992, 
Gabrijelcic et al., 1992) and in non-small-cell lung cancer patients (Leinonen et al., 
2007). In contrast, Kuopio et al. have demonstrated that positive expression of CSTA 
in breast tumours is associated with a poor outcome, and that co-expression of CSTA 
with p53 in this type of cancers is associated with a high risk of death (Kuopio et al., 
1998). An independent study has revealed that inhibition of cathepsin B in vitro 
reduced bone metastasis in breast cancer patients (Withana et al., 2012). Similarly, 
in the cytosol of patients suffering from head and neck carcinoma, the activities of 
cathepsins B and L correlated significantly with those of CSTA (Kos et al., 1995). 
Strojan et al. have observed that, in patients with SCC of the head and neck, the CSTA 
activity could predict both the tumour aggressiveness as well as the likelihood of 
disease recurrence (Strojan et al., 2011), with patients that present with low CSTA 
expression having a significantly higher recurrence rate than patients with high 
CSTA expression (Strojan et al., 2000). Two other studies looking at patients with 
SCCs have revealed that the immunohistochemical analysis of cathepsin L and CSTA 
is a very good indicator for an aspect of malignancy in human epidermal 
keratinocytes (Palungwachira et al., 2002) and overexpression of CSTA delayed the 
in vivo and in vitro cell growth and metastasis of oesophageal SCC (Li et al., 2005). 
The direct role of CSTA in various human neoplasms requires further study, as up 
to date studies have shown its implication in cell mobility, invasion and tumorigenic 
potential. 
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1.2.4.2. Calpastatin protease inhibitor and the target proteases  
Calpastatin (CAST) is a ubiquitously expressed, specific endogenous protease 
inhibitor of the cysteine proteases calpains 1 and 2, existing in two types: tissue type 
and erythrocyte type, resulted from alternative splicing and proteolytic processing 
(Takano et al., 1991, Takano et al., 1993). Biochemical analysis of CAST has revealed 
that the 126 kDa structure is formed of a unique leader domain (L-domain) in the 
N-terminal end, with no inhibitory properties, and four homologous repetitive 
domains (domains 1-4) with the capacity to bind and inhibit several calpain 
molecules (Minobe et al., 2011). Each of the four inhibitory domains of CAST are 
structured into three subdomains A, B and C, with A and C responsible for binding 
to different domains of calpain and having inhibitory function only due to the 
presence of subdomain B, however increasing the inhibitory capacity of this 
subdomain. It has also been observed that the peptides of subdomain B have no 
inhibitory activity unless they are 13 amino acids or over, the increase in the 
number of amino acids of this subdomain being directly proportional with the 
inhibitory strength, suggesting the need of a large calpain interaction area. Also, as 
this subdomain has not been seen to interact with the active site of calpains, it is 
believed that it may bind to a domain of calpain only after calpain activation by Ca2+ 
(Wendt et al., 2004, Hanna et al., 2008, Moldoveanu et al., 2008).  
A study by Kawasaki et al. has revealed two roles for CAST: a role in inhibiting the 
proteolytic activity of calpains through the interaction between the catalytic site of 
calpain and the inhibitory sequence of CAST, and a role in inhibiting the binding of 
calpains to the cell membrane through the interaction between the regulatory site 
of calpain and the regulatory inhibition site of CAST. Moreover, it appears that the 
modes of action of the two CAST sites do not overlap. Kawasaki et al. concluded that 
the regulation of calpain binding to the cell membrane is essential for the regulation 
of calpain activity (Kawasaki et al., 1993). 
The target cysteine proteases of CAST, “conventional” calpains 1 and 2, initially 
named µ-calpain and m-calpain, based on the concentration of calcium required for 
their activation (Ando et al., 1988, Goll et al., 2003), are non-lysosomal, Ca2+-
activated neutral cysteine proteases with an intracellular localisation, expressed 
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ubiquitously. Crystal analysis of the calpain structure showed that both enzymes are 
heterodimers, sharing one 29 kDa light subunit to which another 83 kDa or 80 kDa 
heavy subunit is added for calpain 1 and 2 respectively, both proteases initially seen 
to cleave keratin filaments into small fragments (Ando et al., 1988).  
CAST together with its target proteases have been named the calpain system, which 
controls a variety of cellular functions such as cytoskeletal remodelling, cell cycle 
progression, gene expression, apoptotic and necrotic cell death, ischemia formation 
and exocytosis (Hanna et al., 2008, Salehin et al., 2011).   
Up to date the calpain system has been linked to numerous disorders, from its 
influence in the tumour formation and progression of various cancers such as skin, 
breast, renal cell, ovarian and prostate (Moretti et al., 2014), to CAST depletion and 
calpain 2 activation in Alzheimer’s Disease (Rao et al., 2008), calpains 1 and 2 
overexpression in Duchenne muscular dystrophy (Ueyama et al., 1998), 
autoantibodies targeting CAST in rheumatoid arthritis (Goldbach-Mansky et al., 
2000), calpain regulation in Huntington’s disease (Menzies et al., 2014) and a 
requirement for a balanced expression of calpain 1 and CAST in acute renal allograft 
rejection (Letavernier et al., 2011), to name a few. Also, calpains play a key role in 
myogenesis, especially in the early stages of this process, myoblast migration and 
fusion. It was observed that calpain activity increases significantly during fusion and 
that CAST inhibits myoblast migration and fusion (Barnoy et al., 1996, Barnoy et al., 
2005, Cottin et al., 1994, Dedieu et al., 2004, Temm-Grove et al., 1999, Leloup et al., 
2006). With regards to the skin, the calpain system has previously been linked with 
psoriasis due to autoantibodies targeted against CAST but also other autoimmune 
skin disorders, suggesting that CAST may play a role in the inflammation process 
associated with these disorders (Matsushita et al., 2005).  
1.3. Acquired desmosome-linked disorders 
The crucial role played by accurate desmosomal assembly and function in skin 
homeostasis, is also highlighted by autoimmune and infectious disorders and also 
through desmosome-linked cancers. 
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1.3.1. Autoimmune disorders 
Pemphigus foliaceus (PF) and Pemphigus vulgaris (PV), a pair of potentially fatal 
autoimmune disorders, characterised by the loss of intercellular adhesion in 
keratinocytes (a process named acantholysis) together with blister formation, 
appear as a consequence of autoantibodies targeting a pair of desmosomal 
cadherins, DSG1 (in PF; (Ishii et al., 1997)) and DSG3 with or without DSG1 (in PV; 
(Amagai et al., 1991)). Independent studies have reported that in early-PV patients, 
presenting with mucosal lesions only, the autoantibodies are targeted only against 
DSG3, and that patients in the later disease stages, presenting with both skin and 
mucosal lesions, autoantibodies target both DSG1 and DSG3 (Ding et al., 1997), 
giving a more severe phenotype, reflective of the desmosomal cadherin expression 
patterns between skin and mucosal tissues (Shirakata et al., 1998).  
These clinical differences between PF and PV patients were explained by the 
compensatory theory, which takes into consideration the difference in expression 
of DSG1 and DSG3 in the epidermis and mucosal tissues. While DSG1 is expressed in 
the upper layers of the epidermis with very low, if any, expression in mucosal 
tissues, DSG3 is expressed in the basal layers of the epidermis and is the main 
cadherin expressed in mucosal tissues. It has been suggested that in PF patients, 
autoantibodies targeting DSG1 disturb the cell-cell adhesion in the more superficial 
layers of the epidermis, generating the PF-characteristic superficial acantholysis 
and blistering, the more subtle phenotype being a result of DSG3 compensation for 
DSG1 in the basal layers of the skin and in mucosal tissues. On the contrary, in PV 
patients (mucous type), whose sera contains DSG3 autoantibodies, the blistering 
occurs mainly in the mucosal tissues, where DSG1 is expressed in very low levels 
and therefore cannot compensate for the lack of DSG3, and rarely causing blisters in 
the skin where DSG1 is expressed and can therefore compensate. This theory 
becomes evident in PV patients (muco-cutaneous type) whose sera contains 
autoantibodies for both DSG1 and DSG3, leading to severe epidermal and mucosal 
blistering due to severe dysregulation of intercellular adhesion in all layers of the 
epidermis, linked to loss of DSG1 and DSG3 (Mahoney et al., 1999, Amagai et al., 
2006). Two independent theories were suggested in an attempt to explain the 
mechanism of autoimmune DSG3 antibodies in PV.  
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Initial studies have shown half-formed desmosomes covered with IgG-labelled 
particles (Iwatsuki et al., 1989, Shimizu et al., 2004), suggesting that PV 
autoantibodies targeting the N-terminal domain of DSG3 could interfere with the 
adhesive function of DSG3, directly leading to breakage of desmosomal connections 
(Mahoney et al., 1999, Sekiguchi et al., 2001, Futei et al., 2003, Stanley and Amagai, 
2006). An in vitro study by Aoyama et al. has revealed that the use of IgG-labelled 
particles, in low calcium conditions, leads to attachment of these particles to half-
desmosomes, and that upon switching to high-Ca2+ these desmosomes couple to 
form complete-desmosomes (Aoyama et al., 2010). These results suggest that 
binding of the PV-specific anti-DSG3 autoantibodies could not split the desmosome 
as the forces are not strong enough to cause the splitting, also supported by a Dsg3-
deficient knockout mouse that formed nearly structurally-intact desmosomes, as 
observed in independent studies (Koch et al., 1997, Chernyavsky et al., 2007). 
The second theory suggests that anti-DSG3 autoantibodies bind to DSG3 prior to the 
assembly of DSG3 into desmosomes, and thus triggering a mechanism of 
endocytosis of the autoimmune complexes (Calkins et al., 2006, Delva et al., 2008, 
Sato et al., 2000, Mao et al., 2009). Oktarina et al. have used double staining to show 
that in skin biopsies from PV patients only DSG3 co-localised with IgG antibodies 
and not DSG1, suggesting that DSG3 becomes sequestered from desmosomes 
leaving only DSG1, thus leading to disturbed desmosome assembly and DSG3-
depleted desmosomes (Oktarina et al., 2011). All these observations support the 
non-assembly and depletion hypothesis, by which the compromised function of PV-
affected desmosomes, with an insufficient amount of DSG3, are being split by 
external factors, such as mechanical stress (Aoyama et al., 2010, Amagai, 2010, 
Kitajima, 2013). 
1.3.2. Infectious diseases  
Bullous impetigo, and its generalised form Staphylococcal Scalded Skin Syndrome 
(SSSS), are two infectious disorders mostly affecting children under the age of 6 and 
immuno-compromised adults (Amagai, 2010), characterized by severe blistering as 
a result of keratinocyte acantholysis. This condition is a result of exfoliative toxins 
(ETs), unique serine proteases that show lock and key specificity to the desmosomal 
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cadherin DSG1, and not the closely related DSG3. These peptide toxins are produced 
by some strains of pathogenic Staphylococcus aureus bacteria (Amagai et al., 2000, 
Amagai et al., 2002). The three known ETs affecting humans, ETA, ETB and ETD, use 
Ca2+ to cleave a single peptide bond at a Ca2+-binding site within the extracellular 
domain of DSG1, thus removing residues 1-381 of the DSG1 ectodomain, producing 
a truncated protein which in turn disrupts keratinocyte adhesion leading to 
formation of blisters (Hanakawa et al., 2003). The severity of the phenotype is 
reflected by the location and depth of the blisters, and resembles characteristics 
seen in PF (see section 1.3.1.), most likely as a result of the same compensatory 
theory, by which DSG3 can only compensate if expressed in the areas where DSG1 
is affected. Amagai et al. have shown that by injecting neonatal mice with PF IgGs or 
ET, the mice developed blisters with essentially the same histology, suggesting that 
the two disorders may share a similar mechanism of action targeting DSG1, thus 
supporting the compensatory theory. In the same study Amagai et al. have 
demonstrated that DSG1 expression was significantly affected in the suprabasal 
layers of neonatal mice after incubation with ETA toxin for an hour. Furthermore, 
the direct proteolysis of DSG1 by ETA toxin was demonstrated by incubating mouse 
and human soluble recombinant forms of the extracellular domains of DSG1 and 
DSG3 with ETA toxin, which cleaved both the human and mouse recombinant forms 
of DSG1 in a dose-dependent manner (Amagai, 2010). These studies taken together 
suggest that cleavage of the N-terminal domain of DSG1 is enough to induce 
epidermal blister formation (Nishifuji et al., 2010).  
1.4. Inherited cardio-cutaneous disorders in humans and 
mouse models 
The complexity and incomplete understanding of how desmosomal components 
interact with each other and with other compartments in a cell-type and 
differentiation-dependent manner is reflected by the wide range of genetic 
disorders arising from mutations in desmosomal genes (Table 1.1.). The large 
number of publications reporting various mutations affecting all desmosomal genes 
highlight the phenotypic heterogeneity behind these conditions, different mutations 
resulting in similar cutaneous disorders with or without cardiac and hair 
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implications, named generically cardio-cutaneous disorders (Bolling and Jonkman, 
2009). In vivo mouse models are also being used to decipher the disease 
mechanisms behind these inherited disorders. 
A large number of mutations in genes encoding for desmosome-associated proteins 
and interacting partners were reported to date (Al-Jassar et al., 2013), leading to 
disorders such as woolly hair with/without cardiac implications (Norgett et al., 
2000, Simpson et al., 2009b), striate palmoplantar keratoderma (SPPK) (Simpson et 
al., 2009b) and hypotrichosis (Kljuic et al., 2003a).   
1.4.1. Human disorders associated to mutations in Armadillo proteins 
Twelve mutations in PKP1 reported to date, arising from missense and nonsense 
mutations to splice-site and compound heterozygous changes, appear to result in 
phenotypes ranging from skin fragility to severe autosomal recessive ectodermal 
dysplasia, including peri-oral cracking and inflammation, scant hair, reduced 
sweating and astigmatism (McGrath et al., 1997, Boyce et al., 2012, Hernandez-
Martin et al., 2013, Pieperhoff et al., 2010, Tanaka et al., 2009, Zheng et al., 2005, 
Ersoy-Evans et al., 2006). PKP2 mutations are a major genetic cause of non-
syndromic autosomal dominant ARVC (Gerull et al., 2004). 
With regards to the armadillo family member PG, the first human genetic studies in 
individuals from the Greek Island of Naxos, affected with an autosomal recessive 
condition known today as “Naxos Disease”, clinically characterised by ARVC, woolly 
hair and mild epidermolytic PPK, have revealed homozygous truncating mutations 
in JUP, the gene encoding for PG, as responsible for this disorder (McKoy et al., 2000, 
Protonotarios and Tsatsopoulou, 2004, Delmar and McKenna, 2010). In two other 
independent studies, Erken et al. have described a recessive missense mutation in 
JUP in a patient presenting with PPK and total alopecia with a cardiac phenotype 
(Erken et al., 2011), while Pigors et al. reported a lethal phenotype caused by a 
homozygous nonsense mutation in JUP leading to severe congenital skin fragility, 
generalized epidermolysis, massive transcutaneous fluid loss and no apparent 
cardiac dysfunction, due to a complete loss of PG in patient skin, leading to fewer 
desmosomes and no adhesion structures between keratinocytes (Pigors et al., 
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2011). The complexity of the disease mechanisms behind these disorders is 
highlighted by yet another report of loss-of-function JUP mutations linked to a 
recessive syndrome of skin fragility, diffuse PPK and woolly hair with no signs of 
ARVC (Cabral et al., 2010a), leading to little or no expression of PG. 
1.4.1.1. Armadillo mouse models 
Pkp2-null mice studies have shown mid-gestational embryonic lethality caused by 
cardiac patterning defects and fragility of the myocardium (Grossmann et al., 2004), 
alongside retraction of intermediate filaments from the plasma membrane, thus 
demonstrating the importance of PKPs in DSP recruitment and intermediate 
filament tethering to desmosomes (Delva et al., 2009). Despite no disease-causing 
mutations reported, to our knowledge, in humans for PKP3, ablation of this isoform 
in mice results in defective hair follicle morphogenesis, increased keratinocyte 
proliferation and DSP mislocalisation, leading to susceptibility to dermatitis and 
secondary alopecia (Sklyarova et al., 2008).  
The key role for PG in desmosome assembly has been demonstrated by knockout 
studies in mice, which show acantholysis, indicative of compromised desmosome 
function, and are lethal due to fragility of myocardium (Bierkamp et al., 1996, 
Acehan et al., 2008). In some cases mouse pups were born but presented epidermal 
fragility, heart defects and died shortly after birth (Bierkamp et al., 1996, Ruiz et al., 
1996). Recently, Li et al. created an epidermal conditional Jup-knockout mouse with 
a skin phenotype characterised by perturbed cell proliferation, apoptosis, 
differentiation and compromised immune defence (Li et al., 2012). 
1.4.2. Desmoplakin mutations in cardio-cutaneous disorders  
DSP is the most abundant component of the desmosomal complex and a variety of 
genetic disorders are associated with mutations in this gene, resulting in conditions 
with varying degrees of severity (Lai Cheong et al., 2005). The first reported link 
between DSP mutations and human skin disease was in association with autosomal 
dominant SPPK, characterised by a longitudinal pattern of hyperkeratosis, the loss-
of-function mutations suggesting that the disease mechanism was 
haploinsufficiency and that dosage of DSP was critical in the stressed areas of the 
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skin such as the palm and sole (Armstrong et al., 1999). In addition, the first 
recessive DSP mutation was identified in Ecuadorian families with Carvajal 
syndrome, an ARVC variant which presents with dilated cardiomyopathy, 
accompanied by woolly hair and SPPK, but also with hyperkeratosis at other stress 
sites in the skin including the flexure. The homozygous mutation truncates the DSP 
protein leading to the loss of a portion of the IF-binding site, again leading to loss of 
cell adhesion and a collapsed IF network (Norgett et al., 2000, Huen et al., 2002).  
Moreover, a significant number of genetic DSP-associated conditions known as 
cardio-cutaneous disorders have been reported, presenting with varied degrees of 
severity.  A homozygous mutation, identified by Uzumcu et al., leads to complete 
absence of DSP I, but normal levels of DSP II, the loss of DSP I being associated with 
autosomal recessive mild epidermolytic PPK, woolly hair and aggressive ARVC, 
leading to severe ventricular dysfunction and associated arrhythmia (Uzumcu et al., 
2006). An example of DSP-compound heterozygosity is the identification of an N-
terminal missense mutation and a C-terminal nonsense mutation leading to severe 
keratoderma, skin fragility and woolly hair, or alopecia with or without cardiac 
involvement (Asimaki et al., 2007, Whittock et al., 2002). Another variation of the 
cardio-cutaneous disorders in association with woolly hair and tooth agenesis, was 
reported by Norgett et al. in a patient with a 30 bp insertion in the DSP gene (Norgett 
et al., 2006, Chalabreysse et al., 2011, Boule et al., 2012). 
Alongside DSP mutations linked to cardio-cutaneous disorders, a number of 
cutaneous conditions with and without hair implications have also been reported. A 
heterozygous mutation which truncated the C-terminus of DSP leads to severe 
acantholytic epidermolysis bullosa, a lethal disorder characterised by complete 
alopecia, neonatal teeth, nail loss and death due to transcutaneous fluid loss as a 
result of extensive skin erosion (Jonkman et al., 2005). Furthermore, dominant DSP 
mutations have also been reported linked to non-syndromic ARVC but no obvious 
cutaneous phenotype (Rampazzo et al., 2002, Norman et al., 2005).  
1.4.2.1. Desmoplakin mouse models  
All previous studies on Dsp knockout mice confirm the lethality of this model in early 
embryonic stages, presumably due to loss of integrity of the embryonic ectoderm, 
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as a result of a significant reduction in the number of desmosomes coupled with a 
disrupted IF network and lack of keratin IF attachment in the remaining 
desmosomes (Gallicano et al., 1998, Vasioukhin et al., 2001).  
1.4.3. Inherited cadherin-linked disorders 
The first linkage of human disease to mutations in desmosomal cadherins came 
from the autosomal dominant skin disorder SPPK, linked to DSG1 haploinsufficiency 
mutations (Rickman et al., 1999, Kljuic et al., 2003b, Amagai and Stanley, 2012). 
Recently, two homozygous variations for these loss-of-function DSG1 mutations 
underlie a syndrome characterised by severe dermatitis, allergies and metabolic 
wasting (SAM) (Samuelov et al., 2013). A number of monogenic human disorders 
have also been linked to mutations in desmosomal cadherins (Brooke et al., 2012), 
such as dominant DSC2 and DSG2 associated with non-syndromic ARVC (Syrris et 
al., 2006, Pilichou et al., 2006). Moreover, a variety of DSG4 mutations ranging from 
frameshift, splice-site, missense and nonsense are responsible for the autosomal 
recessive condition Monilethrix and for the hair-follicle differentiation-deficient 
phenotype known as hypotrichosis (Zlotogorski et al., 2006, Schaffer et al., 2006, 
Shimomura et al., 2006). DSC3 is another desmosomal gene associated with 
hypotrichosis, where homozygous nonsense mutations resulted in large skin 
vesicles filled with watery fluid with sparse and fragile hair on the scalp and absent 
eyebrows and eyelashes (Ayub et al., 2009). It has been observed that the impact 
level of DSG1 and DSG4 mutations in the skin is proportional to their expression 
profiles.  
1.4.3.1. Cadherin mouse models 
Knockout mouse models have shown that the lack of Dsg2 and Dsc3 result in early 
embryonic lethality, while Dsg2 deficiency leads to defects in embryonic stem-cell 
viability and proliferation (Desai et al., 2009) Dsc3-deficient mice are lethal in the 
very early embryonic stage, highlighting its importance in desmosomal assembly.  
Despite of the lack of disease-causing mutations being identified in DSG3 and DSC1 
in humans, a Dsg3-knockout mouse presented with hair loss and loss of epithelial 
integrity (Koch et al., 1997), while the Dsc1 deficient mice causes defects of the skin 
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which become more apparent 2 days after birth, and later on develop into localised 
lesions and epidermal fragility with localised hair loss (Chidgey et al., 2001). 
Mutations leading to Dsg4 deficiency present with a lanceolate hair phenotype, 
characterised by sparse, fragile, broken hair shafts, follicular dystrophy and 
ichthyosiform dermatitis (Jahoda et al., 2004, Bazzi et al., 2005).   
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Gene Inheritance Disorder 
DSP 
Dominant 
ARVC alone (Rampazzo et al., 2002, 
Norman et al., 2005) 
SPPK (Armstrong et al., 1999) 
PPK, woolly hair & ARVC (Norgett et 
al., 2006) 
Recessive 
SPPK, woolly hair & ARVC (Carvajal 
syndrome) (Norgett et al., 2000, Alcalai 
et al., 2003) 
Skin fragility & woolly hair (SFWHS) 
(Whittock et al., 2002) 
Lethal acantholytic epidermolysis 
bullosa (Jonkman et al., 2005) 
Naxos-like disease affecting DSP I only 
(Uzumcu et al., 2006) 
JUP 
Dominant ARVC alone (Asimaki et al., 2007) 
Recessive 
Focal and diffuse PPK & woolly hair 
(Cabral et al., 2010a) 
ARVC, PPK & total alopecia (Erken et 
al., 2011) 
Lethal acantholytic epidermolysis 
bullosa (Pigors et al., 2011) 
PPK, woolly hair & ARVC (Naxos 
disease) (McKoy et al., 2000) 
PKP1 Recessive 
Ectodermal dysplasia/Skin fragility 
syndrome & ARVC (McGrath et al., 
1997) 
PKP2 
Dominant ARVC alone (Gerull et al., 2004) 
Recessive ARVC alone (Awad et al., 2006) 
PKP3 No mutations in humans to date 
DSG1 Recessive SPPK (Rickman et al., 1999) 
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Gene Inheritance Disorder 
PPK, Hypotrychosis & hyper-IgE 
(EPKHE) (Samuelov et al., 2013) 
DSG2 
Dominant ARVC alone (Pilichou et al., 2006) 
Recessive ARVC alone (Syrris et al., 2007) 
DSG3 No mutations in humans to date 
DSG4 Recessive 
Hypotrichosis (Kljuic et al., 2003a)  
Monilethrix-like Hypotrichosis 
(Shimomura et al., 2006) 
DSC1 No mutations in humans to date 
DSC2 Recessive 
ARVC alone (Syrris et al., 2006, Heuser 
et al., 2006)  
ARVC, PPK  & woolly hair (Simpson et 
al., 2009b) 
DSC3 Recessive 
Hypotrichosis with skin vesicles (Ayub 
et al., 2009) 
Table 1.1. Inherited cardio-cutaneous disorders with/without hair association, 
linked to mutations in genes encoding for desmosome-associated proteins (adapted 
from Nitoiu et al., 2014).  
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1.5. Hypotheses of this study 
Two major hypotheses constitute the basis of this project and together they look at 
the role desmosome homeostasis plays in epidermal integrity, directly though 
mutations in desmosome-associated proteins and indirectly through mutations in 
protease inhibitors, ultimately targeting desmosome regulation.  
The first investigations were based on a cohort of patients with non-syndromic 
ARVC, seen both in the UK and New Zealand. Based on the large number of 
publications reporting mutations in genes encoding for proteins specific to the 
cardiac desmosome linked to heart disorders, we suspected that our patients would 
also present mutations in genes encoding for the desmosome-associated proteins, 
DSP, PG, PKP2, DSC2 and DSG2 (Brooke et al., 2012, Nitoiu et al., 2014). Additionally, 
patients with acral peeling skin syndrome, hypotrichosis and hypotrichosis with 
PPK were also studied. As it has previously been shown that different desmosome-
associated protein isoforms may have different functions within the desmosome, it 
is expected that the identified mutations will affect different aspects of keratinocyte 
and cardiomyocyte adhesion, differentiation and/or signalling (Cabral et al., 2012b). 
A number of molecular techniques were used in the identification of mutations 
including the application of two high throughput sequencing platforms. 
The second hypothesis is based on the identification of loss-of-function mutations 
in CSTA (Blaydon et al., 2011b) and CAST (Lin et al., 2015) genes encoding for the 
protease inhibitors cystatin A and calpastatin. CSTA LOF mutations are linked to 
exfoliative ichthyosis, a skin disorder characterised by dry, scaly skin over most of 
their body with nonerythematous peeling of skin on their palms and feet, 
exacerbated by moisture and minor trauma (Hatsell et al., 2003). Cystatin A is a 
cysteine protease inhibitor of cathepsins B, H and L, frequently dysregulated in a 
variety of cancers, facilitating tumour invasion and metastasis through cleavage of 
cell-to-cell junctions (Strojan et al., 2000). CAST LOF mutations lead to a new clinical 
entity, named PLACK syndrome characterised by peeling skin, leukonychia, acral 
punctate keratoses, cheilitis and knuckle pads with milia. Calpastatin is a specific 
protease inhibitor of calpains, intracellular cysteine proteases that require calcium 
or epidermal growth factor for their catalytic activity, and have been related to a 
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variety of processes such as the growth, migration and death of keratinocytes 
(Carragher and Frame, 2004).  
Based on previous observations on the mechanisms of action of these protease 
inhibitors and their target proteases in other disorders, it is expected that the 
disease phenotypes observed are the result of the indirect regulation of epidermal 
homeostasis through the target proteases and perhaps through desmosome 
assembly and function.  
The four sub-hypotheses addressed in this thesis are: (1) unrelated non-syndromic 
ARVC patients harbour disease-associated mutations in genes encoding for 
desmosome-associated proteins essential for cardiomyocyte adhesion and function; 
(2) independent patients with hypotrichosis and hypotrichosis with PPK, 
presenting with a similar clinical phenotype, harbour mutations in genes encoding 
for desmosome-associated proteins important in keratinocyte intercellular 
adhesion; (3) and (4) LOF mutations in CSTA and CAST  lead to dysregulation of 
activity of their target proteases leading to disruption of epidermal homeostasis 
through dysregulation of desmosome assembly and/or activity. 
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1.6. Aims of this study 
In order to test the first hypothesis, genetic analyses were undertaken: 
1. Identification of desmosomal gene variants by custom capture array and  
HaloPlex targeted resequencing in patients with non-syndromic ARVC; 
2. SNP array and exome capture analysis in patients with hypotrichosis and 
PPK; 
3. Validation of variants and assignment to corresponding patients by PCR and 
conventional sequencing techniques; 
4. Sanger sequencing analysis of DSG4 and CSTA genes in patients with 
hypotrichosis and acral peeling skin syndrome. 
 
In order to test the second hypothesis the following approaches were carried out: 
1. Analysis of expression of CSTA, CSTA target proteases and CAST in skin 
(control and/or patient) and immortalised keratinocytes by immuno-microscopy 
and western blotting; 
2. siRNA technology was used to mimic the LOF mutations in CSTA  and CAST; 
3. Observations on the effects of CSTA and CAST knockdown on intercellular 
adhesion and migration in keratinocyte monolayers by mechanical stretch, dispase-
based dissociation assay and scratch assay; 
4. Examination of cell death in CAST knockdown monolayers; 
5. Analysis of desmosomal proteins following CSTA and CAST knockdown by 
immunocytochemistry and/or western blotting; 
6. Examination of cathepsin expression in CSTA knockdown cell monolayers 
following mechanical stretch. 
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Materials and Methods 
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2.1. Chemicals and tissue culture consumables 
All chemicals were purchased form Sigma-Aldrich (St. Louis, MO) and all laboratory 
consumables were purchased from Fisher (Leicestershire, UK), unless otherwise 
stated. 
2.2. Molecular Biology I – DNA and RNA methods 
2.2.1. Patient samples  
All patient samples, processed as described in the following chapters were received 
as blood or genomic DNA, are enumerated in Appendix Table A1., together with the 
country of origin and screening method. The projects presented in this thesis were 
approved by the Clinical Research Ethics Committee of the Peking University First 
Hospital, East London and City Health Authority Research Ethics Committee, 
Western Institutional Review Board, Health Research Council of New Zealand and 
the Institutional Review Board of the University Hospital of Munster, which all 
comply with all principles of the Helsinki Accord, and all patients enrolled gave their 
informed consent. 
2.2.2. Extraction of DNA from blood 
DNA was extracted from whole blood samples using the QIAamp DNA blood 
midi/maxi kit (QIAGEN) following the manufacturer’s specifications. Briefly, 200 µl 
proteinase K was mixed with 1-2 ml blood. 2.4 ml buffer AL were added and mixed 
by inversion of the tube, followed by incubation for 2 min. The tubes were incubated 
at 700C for 10 min, and mixed by inversion 10 times with 2 ml 96-100% ethanol. 
The above mixture was added onto the QIAamp Midi column placed in a 15 ml 
centrifuge tube and spun at 3000 rpm for 3 min. The column was firstly washed with 
2 ml of buffer AW1 followed by 2 ml buffer AW2 and spun between washes at 5000 
rpm for 1 min after the AW1 buffer and 15 min after the AW2 buffer. 300 µl buffer 
AE were added onto the membrane of the Midi column and incubated at room 
temperature for 5 min followed by centrifugation at 5000 rpm for 2 min.  DNA was 
resuspended in 200-300 µl distilled water by centrifugation at 5000 rpm for 3 min. 
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2.2.3.  RNA isolation from cells 
Total RNA was isolated from cultured cells at 80-90% confluency, using the RNeasy 
mini kit (Qiagen) according to the manufacturer’s specifications. Briefly, cells were 
washed in phosphate buffered saline (PBS), and subsequently pelleted and lysed 
directly by the addition of disruption buffer. The lysates were transferred to mini 
columns and washed several times with several ethanol supplemented buffers in 
order to remove any residues. RNA was resuspended in 30 µl RNase-free water. 
2.2.4. Nucleic acid quantification 
Nucleic acid concentration was measured by NanoDrop ND-1000 
Spectrophotometer (Thermo Fisher Scientific, Waltham, MA), according to the 
manufacturer’s specifications. An assessment of nucleic acid purity was achieved by 
determining the ratios of spectrophotometric absorbance of the sample at 
260/230nm and 260/280nm. Pure preparations of DNA and RNA have an 
A260/A280 ratio of approximately 1.8 and 2.0, respectively, and an A260/A230 
ratio of approximately 2.2. 
2.2.5. Polymerase Chain Reaction (PCR) 
2.2.5.1. Primer design 
All primers were purchased from Sigma-Aldrich (Appendix B). Specific primer pairs 
were designed either to PCR amplify or sequence the regions of interest, using 
Primer3 software (v.0.4.0). The oligonucleotide length varied from 18 to 24 bp 
depending on the GC content, which ranged from 45-65%. The annealing 
temperature (AT) for each primer pair was initially optimised using a gradient PCR 
with temperatures varying between 550-650C and the optimum AT was then used 
for further screening. 
2.2.5.2. Genomic PCR for mutation screening 
PCRs for the screening of all mutations described in this report were performed 
using either the GoTaq DNA Polimerase (Promega, UK) or the BioTaq PCR Kit 
(Bioline, UK). Briefly 25 µl PCR reaction comprised: 5 µl of 5x (2.5 µl of 10x) reaction 
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buffer, 1.5 µl of 25 mM (0.75 µl of 50 mM) MgCl2, 0.25 µl of 5 U/µl of Taq enzyme; 
200 µM of each nucleotide (Bioline, UK); 1 µM of each primer and 20-30 ng of 
template DNA. Reactions were incubated on a DNA engine Tetrad 2 Peltier 
Thermocycler (MJ Research) and the cycling conditions consisted of 950C for 5 min, 
followed by 35 cycles of 950C for 30 s, optimised primer annealing temperature for 
30 s and 720C for 30 s, with a final extension step at 720C for 10 min and incubation 
at 40C for 10 min. In addition to patient DNA, control DNA was used to amplify 
desired sequences. Resulting PCR products were resolved on DNA agarose gel 
electrophoresis (as described in section 2.2.6.) or digested using restriction digest 
enzymes (as described in section 2.2.12.). 
2.2.5.3. Reverse Transcription-PCR (RT-PCR) 
RNA extracted as previously described in section 2.2.3. was used to make cDNA by 
RT-PCR. Briefly, 50 ng of RNA were added to 0.64 µl random hexamers (200 µM), 1 
µl dNTPs (10 mM) made up to 12 µl final volume with dH2O. The reactions were 
incubated at 650C for 5 min, chilled on ice and 4 µl of 5x first strand buffer, 2 µl of 
0.1 M DTT and 1 µl RNase OUT (all Invitrogen, California, USA) were added to the 
reaction. The mixtures were then incubated at 250C for 2 min before 1 µl (200 units) 
of superscript II reverse transcriptase (RT) (Invitrogen) was added. A negative 
control was simultaneously prepared using RNase free water instead of the enzyme. 
Samples were incubated at 420C for 50 min, followed by heat inactivation at 700C 
for 15 min. One µl of cDNA was added to a standard PCR. The primer binding sites 
for RT-PCR primers are located in the exons and apart from cDNA amplification they 
would also amplify genomic DNA with short intronic sequences.  
2.2.6. Agarose Gel Electrophoresis 
Agarose gels were used to identify and separate PCR products and restriction digest 
fragments. For separation of fragments shorter than 800 bp, 1.5% (w/v) agarose 
(Bioline, London, UK) gels were prepared. Briefly, the agarose was melted in the 
appropriate volume of Tris-Borate-EDTA buffer and 0.5 µg/ml of ethidium bromide 
or 10 µl of 10,000x PAGE GelGreen (Biotium) were added to the solution. The clear 
mixture was poured into a gel tray with a suitable comb to form the sample wells, 
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and left to solidify. The gel was flooded with TBE in an electrophoresis tank. For 
detection of fragments longer than 800 bp, 1% (w/v) agarose gels were prepared in 
a similar way. DNA samples were mixed with 6 x Orange G DNA loading buffer and 
loaded on the gel alongside a 1 Kb Plus DNA ladder (10% (v/v) (Invitrogen), 16% 
(v/v) loading buffer). Samples were electrophoresed at a constant voltage of 80-120 
V. DNA was visualised and photographed under UV transillumination (MultiImage 
Light Cabinet, Alpha Innotech Corporation; pictures printed on Sony P-D890).  
2.2.7. Sanger Sequencing 
Sequencing was performed using the BigDye Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems, Foster City, CA). The optimal amount of PCR product (0.5-3 µl) 
was incubated with 6 µl ExoSAP-IT (Affymetrix) at 370C for 45 min followed by 800C 
for 15 min and 40C for 5 min; this enzymatic reaction eliminated any unincorporated 
primers and dNTPs. Clean sequences were then added to a reaction containing 1 µl 
of BigDye® Terminator Master mix v3.1, 3 µl of better buffer (Microzone, Ottawa, 
Canada), 1 µl of 10 µM specific forward or reverse primer and ddH2O up to a final 
volume of 11.5 µl. Cycling conditions consisted of 25 cycles at 960C for 30 s, 580C for 
15 s, 600C for 1 min, followed by a final incubation at 40C for 10 min. 
The reaction products were precipitated with ethanol and EDTA. Briefly, 2.5 µl of 
125 mM EDTA and 30 µl of ice cold absolute ethanol were added to the sequencing 
reaction and incubated on ice for 10 min. The mixture was centrifuged at 4000 rpm 
at 40C for 20 min; the pellet was washed with 125 µl 70% ethanol and incubated on 
ice for another 2 min, then centrifuged for 5 min at 4000 rpm. Precipitated DNA was 
air dried at room temperature (RT) or on the hot block at 620C for 10 s. Precipitated 
products were resuspended in 10 µl HiDi formamide (Sigma-Aldrich, UK), incubated 
at 950C for 3 min and on ice for 3 min, centrifuged for 2 min to remove any air 
bubbles and loaded on the ABI Prism 3130xl Genetic Analyser (Applied Biosystems, 
Life Technologies, USA). Traces were visualised using the Chromas LITE v 2.01 
software (Free software from Technelysium Pty Ltd). The DSP plasmids obtained 
following site-directed mutagenesis were sequenced using the Sanger sequencing 
service offered by Source BioScience (Source BioScience LifeSciences, UK). 
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2.2.8. Capture array 
For this experiment a customised 385K Sequence Capture Array (NimbleGen, 
Roche) was designed. All enzymes and reagents used for this procedure were 
purchased from New England Biolabs (NEB, UK) unless otherwise stated. Adapters 
and Primers used in the final reaction were custom made by Sigma-Aldrich. The 
manufacturer’s protocol was used with a few modifications described below. 
2.2.8.1. Quant-iT PicoGreen DNA quantification 
DNA was quantified using the Quant-iT PicoGreen dsDNA kit (Invitrogen) following 
the manufacturer’s instructions, and was run on the FLUOstar OPTIMA fluorescence 
plate reader (BMG Labtech). 
2.2.8.2. Preparing the DNA pool 
Equal amounts of genomic DNA from all patients were pooled to a final DNA 
concentration of 20 µg which was split into 4 lo-bind tubes. ddH2O was added up to 
a final volume of 100 µl. DNA was fragmented using the Bioruptor UCD-200 (Life 
Technologies) at 40C for 10 min on high, this step was repeated 3 times, replacing 
the ice and spinning tubes after each 10 min burst. Size was confirmed by running 1 
µl of each DNA pool on a Bioanalyzer 7500 chip (Agilent Technologies), using the 
Agilent 2100 Bioanalyzer (Agilent Technologies), following the manufacturer’s 
specifications. The 4 samples were then cleaned using the QIAquick PCR purification 
kit (Qiagen, UK), and each sample was eluted in 30 µl of buffer EB into new lo-bind 
tubes.  
The end repair, adenylation of 3’ ends, ligation of adapters and SPRI bead 
(Invitrogen) purification were performed as per manufacturer’s specifications. 
After the end repair and adenylation of 3’ ends reactions the samples were purified 
using the QIAquick PCR purification kit; 1.2 µl of each sample were kept before each 
purification and run on the Bioanalyzer 7500 chip. After the final purification using 
AMPure XP beads (Beckman Coulter), sample concentration was read on the 
NanoDrop. Only 5 µg of DNA pool were needed to hybridise to the capture array. At 
this point DNA samples were stored at -200C.  
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2.2.8.3. Hybridisation to array 
All volumes prepared in this step are given for the 385K array. 100 µl of 1 mg/ml 
Cot-1 DNA (Invitrogen) were added to the sample to be hybridised, then the mixture 
was fully dried in a DNA concentrator (Divac 2.4 l DNA Concentrator) at 600C. DNA 
was rehydrated with 4.8 µl of ddH2O. Samples were then incubated on the heat block 
at 700C for 10 min to fully solubilise the DNA. 8 µl of 2x SC Hybridisation buffer and 
3.2 µl of SC Hybridisation Component A were added to the mixture and incubated 
on the hot block at 950C for 10 min to denature the DNA. The sample was centrifuged 
at maximum speed for 30 s and hybridised to array within 15 min of denaturation. 
The capture array slide was prepared and loaded as per manufacturer’s 
specifications. The reaction was incubated at 420C for 64-72 h. 
2.2.8.4. Washing and eluting hybridised DNA 
Wash and elution buffers were prepared 2 days in advance as per manufacturer’s 
specifications and the buffers which needed a specific temperature were incubated 
at 47.50C until temperature was equilibrated. DNA was eluted at RT immediately 
after the washing steps, by pipetting 425 µl of 125 mM fresh NaOH through the top 
of the elution chamber. Eluted DNA was collected into a new lo-bind 1.5 ml tube and 
any remaining 125 mM NaOH which did not fit into the elution chamber was added 
to the eluted DNA. 16 µl of 20% acetic acid was mixed with 500 µl Qiagen buffer PBI 
and the mixture was added to the eluted DNA. The solution was pipetted to a single 
QIAquick column and centrifuged for 1 min at 13000 rpm. 750 µl of buffer PE was 
used to wash the column before replacing the collection tube with a fresh 1.5 ml 
tube and resuspending the DNA in 50 µl of buffer EB. 
2.2.8.5. Post capture LM-PCR 
The LM-PCR reaction mix was prepared for 13 reactions, 2 reactions with DNA and 
SYBR green I dye (Invitrogen) at 1x concentration, 2 reactions with SYBR green I 
dye at 1x concentration and no DNA and 10 reactions with DNA and no SYBR green. 
A 1x reaction contained 10 µl of 5x Phusion Buffer, 1 µl of 10 mM dNTPs, 1 µl of each 
homemade Primer PE 1.0 and 2.0 (25 µM) (Sigma-Aldrich), 1 µl of 1x SYBR green, 
0.5 µl Phusion polymerase, 4 µl eluted DNA and ddH2O up to 50 µl reaction. 
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Reactions were run on the Rotor Gene-3000 (Corbett Research, Australia) using the 
following cycling programme: 980C for 30 s, 980C for 10 s, 650C for 30 s and 720C for 
30 s (results were collected at this step). The reactions were terminated before 
amplification reached plateau curve. 
Two pools were made from the 10 reactions without SYBR green and diluted with 
1250 µl Qiagen PBI buffer. The mixtures were then purified using the QIAquick PCR 
purification kit (Qiagen, UK) and eluted with 50 µl buffer EB. The two resulting pools 
were mixed together and DNA concentration was quantified on the NanoDrop 
before being sent for Next Generation Sequencing performed by the Genome Centre 
on the Illumina Genome Analyser IIx (Illumina, San Diego, USA). 
2.2.9. Exome capture 
Paired end PCR primers and adapters were purchased from Sigma, library 
preparation kit components for exome sequence capture and subsequent Illumina 
GAllx paired end sequencing were purchased from NEB.  
2.2.9.1.  Preparing the DNA pool 
DNA was quantified and fragmented as described above (2.1.8.1. and 2.1.8.2.) with 
some changes. The samples were pooled to a final concentration of 5 µg and ddH2O 
was added up to 80 µl. End repair, adenylation to the 3’ end and ligation of adaptors 
reactions were performed as previously described, and reactions were cleaned 
using a QIAquick PCR purification kit (Qiagen). Final purification, before 
hybridisation, was performed using AMPure XP beads (Beckman Coulter). DNA was 
resuspended in 100 µl molecular biology water.  1.2 µl of each reaction before 
purification steps was run on the Agilent Bioanalyzer 7500 chip (Agilent) as per 
manufacturer’s specifications. Samples were quantified on the NanoDrop 
(NanoDrop Spectrophotometer ND-1000, Software NanoDrop 1000 version 3.7.1.) 
and stored at -200C until hybridisation. 
2.2.9.2. Hybridisation to beads 
1 µg pooled DNA was mixed with 100 µl of 1 mg/ml Cot-1 DNA and 1 µl of each 1000 
µM PE-HE1 and PE-HE2 oligos. The mixture was dried in a SpeedVac DNA 
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concentrator at 600C. To each dried library, 7.5 µl of 2x SC Hybridisation buffer and 
3 µl of SC Hybridisation component A were added. Samples were vortexed and 
centrifuged at maximum speed for 10 s then incubated in a 950C hot block for 10 
min to denature DNA. The sample was then centrifuged and transferred to a 0.2 ml 
PCR tube and incubated on a thermal cycler at 470C for 64-72 h. 
2.2.9.3. Washing and eluting hybridised DNA 
Wash buffers and Streptavidin Dynabead elution buffer were prepared in advance 
and equilibrated at the required temperature. Streptavidin Dynabeads M-270 
(Invitrogen) were prepared as per manufacturer’s indications and used 
immediately. DNA was washed and eluted onto the Streptavidin Dynabeads 
following the manufacturer’s instructions and resuspended in 50 µl PCR-grade 
water (Sigma). Hybridised DNA was stored at -200C post-bead clean-up. 
2.2.9.4. Amplification of hybridised DNA sequences 
Amplification protocol, cycling conditions and post LM-PCR clean-up steps were 
identical to the ones described in section 2.1.8.5. Next Generation Sequencing was 
performed by the Genome Centre on the Illumina Genome Analyser IIx (Illumina, 
San Diego, USA). 
2.2.10. HaloPlex Target Enrichment System 
For this experiment all target sequences were specifically prepared to cover 
required regions of interest (Table 2.1.). All restriction enzymes and reagents used 
for this procedure were purchased from Agilent Technologies unless otherwise 
stated. The manufacturer’s protocol was used with a few modifications described 
below. 
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Gene Coverage Source 
ADAM17 99.7 % CCDS1665.1, User modified 
DES 93.5 % CCDS33383.1, User modified 
DSC2 98.7 % NM_024422, NM_004949, User modified 
DSG2 97.7 % CCDS42423.1, User modified 
DSP 99.1 % CCDS47368.1, CCDS4501.1, User modified 
JUP 99.8 % NM_002230, NM_021991, User modified 
PKP2 97.5 % CCDS31771.1, CCDS8731.1, User modified 
TMEM43 99.4 % CCDS2618.1,User modified 
Table 2.1. Sequence coverage of selected genes and source information. 
2.2.10.1. Restriction enzyme digestion 
Initially all DNA samples were diluted to 20 ng/µl in a final volume of 45 µl (900 ng). 
Enrichment Control DNA (ECD) was also included in this step. A restriction enzyme 
mix was prepared by mixing 8 different sets of restriction enzymes. 5 µl of DNA from 
each patient were mixed with 5 µl from each of the 8 restriction enzyme mixtures, 
mixed gently and incubated at 370C for 4 h followed by an inactivation incubation at 
800C for 20 min. Each restriction digest reaction was verified on a 2% agarose gel 
prepared as previously described. The 8 restriction digests from the same sample 
were pooled together.  
2.2.10.2. Hybridisation to HaloPlex probes 
Each digested sample pool was mixed with 65 µl hybridisation buffer, 14 µl HaloPlex 
Probes and 1 µl primer cassette, then incubated overnight on a thermal cycler on 
the following program: 950C for 10 min, 750C for 30 min, 680C for 30 min, 620C for 
30 min, 550C for 30 min, 460C for 10 min and 80C forever. 
2.2.10.3. Solid phase capture and DNA ligation 
Using a magnetic plate (Life Technologies), the storage buffer of 20 µl of magnetic 
beads was removed and 40 µl of capture solution was added over the remaining 
beads and incubated at RT for 15 min. The supernatant was removed and 100 µl 
wash solution was added to each reaction and incubated in a thermal cycler at 460C 
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for 10 min. The supernatant was removed and the beads were resuspended in 47.5 
µl ligation solution and 2.5 µl DNA ligase and incubated at 550C for 10 min. Finally 
the supernatant was removed. 
2.2.10.4. Enrichment by PCR 
To each sample 22.5 µl Haloase A Buffer, 0.5 µl Haloase A1 and 2 µl Haloase A2 were 
added and the mix was incubated in a thermal cycler at 370C for 30 min. The 
supernatant was then removed and 21.5 µl Haloase B Buffer were added and the 
mix was incubated in a thermal cycler at 800C for 20 min. The reactions were then 
cooled down to RT and 3.5 µl Haloase B enzyme were added; the mix was incubated 
in a thermal cycler at 370C for 30 min. The PCR mix was prepared as detailed in 
Table 2.2. 20 µl of PCR master mix were distributed to 0.2 µl tubes and 10 µl of the 
appropriate barcode primer from the 96-barcode plate were added. Using the 
magnetic plate 20 µl of the supernatant from the Haloase B reaction were added to 
the corresponding PCR reaction and incubated on a thermal cycler as follows:  980C 
for 30 s, 17 cycles at 980C for 10 s, 650C for 30 s, 720C for 30 s, followed by 720C for 
5 min and 80C forever.  
 
Reagent Concentration 1x 
Phusion HF Buffer 
(Thermo Scientific) 
5x 6 µl 
dNTP 25 mM 0.4 µl 
PCR Primer 1.0 25 µM 1 µl 
Phusion HotStart II 
(Thermo Scientific) 
2 U/µl 0.5 µl 
ddH2O --------- 12.1 µl 
Total volume: 20 µl 
Table 2.2. HaloPlex Enrichment PCR Mix. 
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2.2.10.5. HaloPlex Cleanup 
Following the PCR reaction, 40 µl of each reaction were mixed with 60 µl of 1.5x 
(v/v) Agencourt Ampure XP beads (Beckman Coulter) and incubated at RT for 10 
min. The supernatant was removed after separation on a 96-well magnetic plate and 
200 µl freshly prepared ethanol were added to each reaction without removing the 
reactions from the magnetic plate. The mix was incubated at RT for 1 min and the 
step was repeated one more time. Following the ethanol wash the samples were air 
dried and 40 µl Tris-HCl buffer (10mM pH 8.0) were added to each reaction and 
incubated at RT for 10 min to elute DNA. Reactions were placed on the magnetic 
plate and when the liquid was clear the supernatants were transferred to new tubes. 
Quality was assessed using a High Sensitivity DNA Bioanalyzer chip (Agilent 
Technologies), as per the manufacturer’s specifications. Following quality control 
peak analysis was performed by the Genome Centre prior to Next Generation 
Sequencing of samples, also by the Genome Centre on the Illumina Genome Analyser 
IIx (Illumina, San Diego, USA). 
2.2.11. Analysis of next generation sequencing data 
Raw paired end FASTQ reads were aligned against the reference genome sequence 
(Hg19). Unique homozygous changes were identified by filtering the resultant data 
set against variations reported on dbSNP (www.ncbi.nlm.nih.gov/snp/) and the 1000 
genome project (www.1000genomes.org/). Initial sequence analysis, including soft 
clipping, adapter trimming, and quality calibration options were performed by Dr 
Vincent Plagnol (University College London, UK) or Dr Michael Barnes (William 
Harvey Research Institute) and subsequently examined using the Integrative 
Genomics Viewer (IGV, Broad Institute). 
2.2.12. Restriction enzyme digest 
Restriction enzyme digests were used to confirm the presence of mutations in 
patient against control genomic DNA samples and to specifically linearise plasmid 
vectors to confirm the presence of the required DNA constructs in the desired 
orientation prior to site-directed mutagenesis experiments. Digests were 
performed according to the manufacturer’s specifications. Generally, the required 
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quantity of DNA (between 1-2 µg of plasmid DNA or 5 µl of PCR amplified DNA) was 
incubated with 1 µl of the suitable restriction endonuclease (New England Biolabs, 
Ipswich, MA) and 1 µl of the appropriate 10x reaction buffer in a final volume of 10 
µl. Where necessary, the reaction was scaled up to a larger final volume and when 
more than one enzyme was used in the same reaction the total volume of enzyme 
did not exceed 1/10 of the final reaction volume. The reactions were incubated on 
the DNA engine Tetrad 2 Peltier Thermocycler (MJ Research) on the following 
program: 4 h at 370C, 20 min at 650C and a final incubation at 40C. The restrictions 
digests were verified on a 1% agarose gel as previously described in section 2.2.6. 
2.3. Molecular Biology II – DSP cloning strategies 
 
2.3.1. DSP clone amplification on agar plates 
 
DSP I Piece number Clone number 
1 + 2 + 3a C2 
1 + 2 C5 
1 + 2 + 3a + 3 (complete seq) C2 
1 C7 
2 C8 
1 + 2 + 3a + 3 (complete seq) C1 
1 + 2 + 3a + 3 (complete seq) C8 
2 + 3a C12 
3 C8 
1 C8 
1 + 2 + 3a + 3 (complete seq) C3 
2 + 3a C5 
2 C5 
Table 2.3. Summary of the DSP I clones used for site-directed mutagenesis and have 
been cloned by Dr Rita Cabral. 
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2.3.2. Small scale plasmid preparation 
Small scale plasmid DNA preparations were obtained using the QIAprep Miniprep 
kit (Qiagen) according to the manufacturer’s specifications, with some 
modifications. Briefly, a single colony was picked from a freshly streaked selective 
plate and grown in 5 ml LB broth (Invitrogen) containing 50 µg/ml of ampicillin for 
16-18 h at 370C. Cell cultures were transferred to 1.5 ml tubes and pelleted by 
centrifugation for 5 min at 13,000 rpm and the pellet was re-suspended in cell re-
suspension solution. Cells were lysed and then the lysis buffer was neutralised. The 
lysate was centrifuged at 13,000 rpm for 10 min and the supernatant was applied 
to a mini column. The column was firstly centrifuged at 13,000 rpm for 1 min, then 
washed twice with column wash solution and centrifuged for 1 min at 13,000 rpm 
after each wash. The plasmid DNA was eluted from the column with 50 µl of 
nuclease-free ddH2O by centrifugation at 13,000 rpm and stored at -200C. 
2.3.3. Site-directed mutagenesis 
Site-directed mutagenesis (SDM) was performed using the QuikChange II XL site-
directed mutagenesis kit (Agilent Technologies), as per the manufacturer’s 
specifications. Briefly for the control reaction, 10 ng of pWhitescript 4.5 kb control 
plasmid were incubated with 5 µl of 10x reaction buffer, 125 ng of each control 
primers, 1 µl of dNTP mix, 3 µl of QuikSolution reagent and 1 µl of PfuUltra HF DNA 
polymerase (2.5 U/µl) and ddH2O water up to 50 µl final volume. For the test 
reactions, 10 ng of plasmid DNA were used for each reaction together with specific 
primers (Table 2.4.). The reactions were incubated for 1 cycle at 950C for 1 min, for 
18 cycles at 950C for 50 s, 600C for 50 s, 680C for 14 min (varies according to plasmid 
size, 1 min per kb of plasmid), for 1 cycle at 680C for 7 min and for 1 cycle at 370C 
for 2 min. SDM products were incubated with 1 µl DpnI (10 U/µl) restriction digest 
enzyme for 1 h at 370C in order to linearise plasmid and verify, by Sanger 
sequencing, whether SDM was successful. 
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Genetic 
variation 
Primer 
name 
Primer sequence 
DSP 11G>C 
(ARVC) 
G63C AGGTGCAGAACTTGGTAAACAACTCTAAGAAGA
TTGTACAG 
DSP 11G>C 
(ARVC) 
G63C -
antisense 
CTGTACAATCTTCTTAGAGTTGTTTACCAAGTT
CTGCACCT 
DSP 12C>T 
(hypotrichosis 
and PPK) 
 
C113T 
 
CGTGACGGGCCTGGGAGGCGTTG 
DSP 12C>T 
(hypotrichosis 
and PPK) 
C113T - 
antisense 
 
CAACGCCTCCCAGGCCCGTCACG 
Table 2.4. Primers used for site-directed mutagenesis of novel gene variations in DSP 
identified in patients with ARVC and hypotrichosis and PPK. 
2.3.4. Transformation of chemically competent bacterial cells 
Following restriction digest with DpnI, as described in section 2.3.3., the confirmed 
required constructs were used to transform chemically competent E. coli cells. The 
chemical transformation protocol was performed using XL10-Gold ultracompetent 
E. coli cells (Agilent Technologies), according to the manufacturer’s instructions. 
Briefly, 2 µl of each construct generated by SDM were mixed with XL10-Gold 
ultracompetent E. coli cells and β-mercaptoethanol. Following an incubation of 30 
min on ice, cells were heat-shocked for 30 s at 420C and then immediately 
transferred to ice for another 2 min. After addition of 1 ml of RT LB-broth, cells were 
incubated with shaking at 225-250 rpm at 370C for 1 h to allow expression of the 
antibiotic resistance genes. After the 1 h incubation cells were centrifuged for 5 min 
at 13,000 rpm and resuspended in 100 µl LB-broth. Cells were then plated on a pre-
warmed LB agar plate containing 50 µg/ml ampicillin. Inoculated agar plates were 
incubated at 370C overnight (minimum 16 h). 
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2.4. Molecular Biology III – Protein Methods 
2.4.1. Antibodies 
Primary antibodies used for western blotting and microscopy and associated 
information and working dilutions are listed in Appendix C, Table C1. 
2.4.2.  Immunocytochemistry 
Immunocytochemistry was performed both on cells plated on coverslips as well as 
on cells plated on Flexcell membranes following mechanical stretch. Cells were 
plated on coverslips at approximately 80% confluency in 12-well plates and grown 
overnight at 37°C. Cells were washed twice in PBS and fixed either in ice-cold 
methanol : acetone (1:1) or in 4% paraformaldehyde (PFA). Following fixation, cells 
were washed three times in PBS, then permeabilised in 0.1% Triton X-100 in PBS 
(PBST) for 5 min at RT (PFA fixed cells only), and finally blocked with 3% BSA in 
PBS (blocking buffer) for 30 min at RT. The cell-containing coverslips/membranes 
were then inverted onto a 50 µl drop of primary antibody-containing blocking buffer 
at the appropriate dilution and incubated for 2 h at RT or 40C overnight. Cells were 
washed three times in PBS and then incubated with the appropriate Alexa Fluor 
488- (green) conjugated goat anti-rabbit, mouse or guinea pig IgG secondary 
antibody (Invitrogen), at a 1:800 dilution in PBS, for 1 h at RT. Cells were washed 
twice in PBS, incubated in DAPI (nuclear stain at 100 ng/ml) for 2 min at RT and 
washed three times in PBS. Cells were mounted with Immu-mount (Thermo Fisher 
Scientific). 
Immunofluorescence images were acquired with a Zeiss LSM 510 and Zeiss LSM 710 
laser scanning confocal microscopes (Carl Zeiss Ltd, Hertfordshire, UK) and 
processed using the LSM image browser (Zeiss). 
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2.4.2.1. Methanol-Acetone fixation 
Cells were washed twice with PBS and fixed in ice cold methanol:acetone (50:50) 
for 5 min at -20°C. This fixation method was used for staining with all primary 
antibodies targeting membranous proteins. If cells were not used immediately they 
were left to air dry following fixation and stored at -200C until use. 
2.4.2.2. Paraformaldehyde fixation  
A fresh solution of 4% PFA in PBS was prepared (described below), aliquoted and 
stored at -200C and defrosted prior to each use. To this end, 2 g of PFA were 
dissolved in approximately 40 ml of boiling ddH2O containing 20 µl of 2 M NaOH. 
The solution was cooled to RT and 5 ml of 10 x PBS were added. Water was added 
to a final volume of 50 ml. Cells were washed twice with PBS and fixed in 4% PFA 
for 20 min. This fixation method was used for staining with the primary antibodies 
targeting non-membranous proteins. 
2.4.3. Immunohistochemistry 
Immunohistochemistry was performed on frozen sections of normal and palm skin. 
Briefly, frozen skin sections were air-dried at RT for 1 h, then fixed with 4% PFA in 
PBS for 20 min or briefly in methanol:acetone (50:50) at RT and permeabilised in 
0.1% Triton X-100 in PBS (PBST) for 5 min at RT, and finally blocked with 3% BSA 
in PBS (blocking buffer) for 30 min at RT. Sections were then incubated with 100-
150 µl of primary antibody for 2 h at RT or at 40C overnight. Sections were then 
washed three times in PBS and then incubated with the appropriate Alexa Fluor 
488- (green) conjugated goat anti-rabbit, mouse or guinea pig IgG secondary 
antibody (Invitrogen), at a 1:800 dilution in PBS, for 1 h at RT. Cells were washed 
twice in PBS and incubated with DAPI (nuclear stain at 100 ng/ml) for 2 min at RT 
prior to washing three times in PBS. Stained skin sections were mounted with 
Immu-mount (Thermo Fisher Scientific). Immunofluorescence images were 
acquired with the same apparatus as described for immunocytochemistry 
visualization. 
 
 
90 
 
2.4.4. Western Blotting 
2.4.4.1. Protein preparation from cell extracts 
Whole-cell protein extracts were prepared from HaCaT keratinocytes when 
approximately 90% confluent. The cells were washed in ice-cold PBS before lysis 
and then detached with boiling SDS sample buffer. Cells were scraped and the cell 
lysates were transferred to microcentrifuge tubes and heated to 95°C for 5 min 
before being spun briefly and stored at -200C.   
2.4.4.2. SDS-polyacrylamide gel electrophoresis (PAGE) and transfer 
Briefly, a separating polyacrylamide gel mixture (10-12% depending on protein 
size) was prepared and poured between two glass plates and 0.75 mm spacers in a 
gel electrophoresis apparatus (BioRad, Hemel Hempsted, UK). The gel mixture was 
overlaid with 1 ml of isopropanol, and left to polymerise at RT for approximately 20 
min. When the gel was polymerised, the isopropanol was removed. A 5% stacking 
gel mixture was prepared and cast with sample combs over the resolving gel, and 
left to polymerise at RT for approximately 30 min. Between 10-20 µl of protein 
sample as well as 6-10 µl of full-range Rainbow molecular weight marker (GE 
Healthcare) were loaded on the SDS-polyacrylamide gel. The gel was run at 12 
mA/gel in running buffer until the desired separation was obtained. 
Proteins were transferred onto a Hybond–C Extra nitrocellulose membrane (GE 
Healthcare) in a wet transfer electrophoretic cell (BioRad) with transfer buffer, 
usually at 300 mA/tank for 1.5 h (or 100 mA/tank overnight). Quality of loading for 
each transfer was assessed by staining of the membrane with Ponceau Red stain 
solution for 5 min, followed by de-stain in ddH2O and a final wash in Tris-Buffered 
Saline–Tween 20 (TBS-T). 
2.4.4.3. Pre-cast gradient SDS-polyacrylamide gels and transfer 
Whole cell lysates were resolved on NuPAGE Novex 4-12% Bis-Tris Mini Gels for 
NuPAGE Novex 3-8% Tris-acetate Mini Gels (Invitrogen), when western blotting for 
DSP according to the manufacturer’s specifications. Approximately 10-20 μl of 
protein sample and 10-12 μl of High Mark Pre-stained Molecular Weight Marker 
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(Invitrogen) were loaded on the pre-cast SDS-polyacrylamide gels. The gel was run 
at 24 mA/gel until the desired separation was obtained. Proteins were subsequently 
transferred onto a Hybond – C Extra nitrocellulose membrane (GE Healthcare, 
Buckinghamshire, UK) in a wet transfer electrophoretic cell (Invitrogen) with 
transfer buffer, usually at 300 mA/tank for 1.5 h (or 100 mA/tank overnight). 
Quality of loading/transfer was assessed by staining of the membrane with Ponceau 
Red stain solution for 5 min, followed by de-stain in ddH2O and a final wash in TBS-
T. 
2.4.4.4. Immunoblotting and visualisation 
Non-specific antibody binding to the membrane was prevented by incubating the 
membrane in 10% (w/v) non-fat milk diluted in TBS-T or 5% (w/v) BSA diluted in 
TBS-T for 30 min at RT. Blocked membranes were incubated at RT for 2 h or at 40C 
overnight in 5% (w/v) non-fat milk TBS-T or 5% (w/v) BSA TBS-T containing the 
appropriate primary antibody at the suitable dilution. Following three 5 min washes 
in TBS-T, membranes were incubated in TBS-T containing the appropriate 
peroxidase-conjugated anti-mouse or anti-rabbit immunoglobulins (Dako, Ely, 
Cambridgeshire, UK), for 1 h at RT. Membranes were subsequently washed again as 
described above, incubated in ECL, ECL Plus solution (Amersham, GE Healthcare, 
Buckinghamshire, UK) or ECL Immobilon (Merck Millipore, UK) for 3 min, sealed in 
a plastic sheet, and exposed to chemiluminescence sensitive film (GE Healthcare).  
2.4.4.5. Stripping membranes for antibody re-probing 
Western blotting membranes were incubated in stripping buffer, prepared in house, 
at 500C-550C for 30 min. Membranes were then washed 3 times in TBS-T and 
developed as described above to check efficiency of stripping. For use the 
membrane was firstly blocked in the appropriate blocking buffer, 10% milk in TBS-
T or 5% BSA in TBS-T, before proceeding with incubation with primary antibody 
and the steps described above.  
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2.5. Cell Methods 
2.5.1. Cell culture conditions 
The HaCaT spontaneously immortalised human keratinocyte cell line was cultured 
in DMEM : Ham’s F12 or DMEM (Sigma-Aldrich, UK) supplemented with 10% (v/v) 
FBS (Biosera), 2 mM L-glutamine (Biosera), 100 U/ml penicillin, 100 µg/ml 
streptomycin and 1% RM+ or no RM+ when DMEM was used. Cells were maintained 
at 370C in a 5% CO2 humidified incubator. When 80-90% confluent cells were 
washed in PBS and incubated in a mixture of one part 10% trypsin-EDTA and two 
parts PBS at 370C until detached. The reaction was stopped using complete medium, 
cells were pelleted by centrifugation at 1200 rpm for 5 min and re-suspended in 
complete medium. Approximately 2 million cells were then transferred to a new 
flask. Growth medium was changed every 3 days.  All in vitro studies presented in 
this thesis used cells passaged for no more than 30 passages. 
2.5.2. Cryopreservation of cells 
For cryopreservation, 80-90% confluent cells were detached from the culture dish 
with trypsin-EDTA as described (section 2.3.1), pelleted by centrifugation and 
resuspended in 90% FBS:10% DMSO. Vials were frozen slowly at -80°C for at least 
24 h and then transferred into vapour-phase nitrogen for long term storage. When 
a new cell culture was started, vials were defrosted quickly, in order to minimise 
cell death, and mixed with complete medium. The resuspended cells were pelleted 
at 1200 rpm for 5 min and reseeded into a flask with complete medium.  
2.5.3. Mycoplasma testing 
All cell cultures were tested using the MycoAlert™ Mycoplasma Detection Kits LT07-
418 and MycoAlert Assay Control Set LT07-518 (Cambrex) as per manufacturer’s 
specifications. Briefly, the reagent and substrate buffers and the positive and 
negative controls were thawed to RT.  1.5 ml of cell culture medium, kept on cells 
for 72 h,  was cleared by centrifuging at 1500 rpm for 5 min. 100 µl of cleared 
supernatant from each sample was transferred to a well of a 96-well plate and 
incubated for 5 min with 100 µl of MycoAlert reagent. The plate was read in the plate 
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reader on the luminescence program (Bio-Tek Synergy HT Multi-Detection 
Microplate Reader, KC4 version 3.4 REV. 18). 100 µl of MycoAlert substrate was 
added to each sample and incubated for 10 min. After the 10 min incubation the 
plate was read on the luminescence program and the ratio between the second 
reading and the first reading was calculated. A ratio less than 1 was indicative of 
uninfected cells. 
2.5.4. Transient siRNA mediated knockdown 
Transfection conditions were optimised using siGLO Cyclophilin B Control siRNA 
(Thermo Fisher Scientific). For transient down-regulation siRNA OnTarget plus 
SmartPool (Dharmacon) was used to target all possible splice variants. Table 2.5. 
summarises the characteristics of these siRNAs. 
Transfections were performed in RNase-free conditions according to the 
DharmaFECT general transfection protocol (Dharmacon) and optimised for a 6-well 
plate format. HaCaT cells were plated at a density of 2x105 cells per well of a 6-well 
plate and incubated in complete medium at 37°C, 24 h prior to siRNA transfection. 
In separate polystyrene tubes, 10 µl of CSTA siRNA (200 nM final 
concentration)/10-20 µl of CAST siRNA (200-400 nM final concentration)/10 µl of 
DSP I/II (200 nM final concentration) and 6 µl of DharmaFECT were mixed in serum- 
and antibiotic-free media, up to 200 µl per reaction and incubated at RT for 5 min. 
The siRNA-containing medium was added to the tube containing the DharmaFECT, 
mixed and incubated for 20 min at RT. Complete antibiotic-free media was added to 
the mix (transfection media). The culture media was then removed from the cells in 
the 6-well plate and 2 ml of transfection media were added to each well. Cells were 
incubated in transfection media for approximately 24 h at 37°C and then this media 
was replaced by complete medium. Cells were maintained in this media for 2-10 
days and subsequently harvested for experiments. Cells transfected with a pool of 
non-targeting (NT) siRNAs (OnTarget plus siControl non-targeting pool; Thermo 
Fisher Scientific) were used as a negative control.  
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 siRNA siRNA sequence Target 
mRNA 
Position in 
target 
mRNA# 
 
CSTA 
siRNA 
pool 
si1 GGAGAUUGUUGAUAAGGUU  
 
 
CSTA 
180 - 198 
si2 ACAAAUGAGACUUACGGAA 220 - 238 
si3 GUACGAGCAGGUGAUAAUA 298 - 316 
si4 AAUGAGGACUUGGUACUUA 358 - 376 
 
CAST 
siRNA 
pool 
si1 UGACAAAGACCUCGAUGAU  
 
 
CAST 
1623 - 
1641 
si2 UAAACUCUCUGACAGUCUA 1650 - 
1668 
si3 GACACUAUCCCACCUGAAU 1768 - 
1786 
si4 GCGAAGGAUUCAGCAAAGA 2008 - 
2026 
DSP I/II 
siRNA 
 
siI/ II 
 
AACCCAGACTACAGAAGCAAT 
 
DSPI/II 
 
1633-1653 
Table 2.5. Characteristics of the siRNAs used. #Position of siRNAs according to NCBI 
reference sequences NM_005213.3 for CSTA, NM_173060 for CAST and NM_004415.2 
for DSPI.  
2.6. Adhesion assays 
2.6.1. Dispase-based assay 
Cells were grown to a high density and treated in cell culture flasks, then detached 
using 10% trypsin-EDTA (diluted 1:3 with PBS) and reseeded at a density of 3 x 106 
cells/ml in 60 mm dishes. After 24 h cells were washed once in Ca2+ and Mg2+ 
enriched PBS before being incubated with 5 mg/ml dispase. Ca2+ and Mg2+ enriched 
PBS was used in order to preserve intercellular connections intact upon exposure 
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to dispase. After 20 min incubation, pellets were gently transferred to 15 ml tubes 
containing 5 ml PBS with Ca2+ and Mg2+. Tubes were inverted rapidly 10-20 times 
(until breakage was observed) then the fragments were transferred back into the 
corresponding dishes and counted under a dissecting microscope. 
2.6.2. Flexcell adhesion assay 
The Flexcell FX-4000 Tension System (Flexcell, Hillsborough, NC) is a computer-
regulated bioreactor that uses vacuum pressure to apply cyclic or static strain to 
cells cultured on flexible-bottomed culture plates. This system was used to subject 
cell monolayers to mechanical stress. HaCaT cells were grown to approximately 
90% confluency on BioFlex 6-well plates (Flexcell) which contain a rubber 
membrane coated with pronectin in each 35 mm well. Each plate was placed over 
the loading station containing 6 planar faced cylinders or posts. Each post (25 mm) 
is centred beneath the rubber membrane of each 35 mm well. Cells were subjected 
to cyclic mechanical stretch with a frequency of 5 Hz (i.e. five cycles of stretch and 
relaxation per second) and an elongation of amplitude ranging from 11 to 14% (i.e. 
increase in diameter across the silicone membrane from 11 to 14%). Cells were 
stretched for different periods of time, between 0 h (non-stretched) and 4 h, and 
then prepared for immunocytochemistry as described. In order to stain the cells 
contained in each well of the 6-well dish with more than one antibody, the flexible 
rubber membrane was cut into 8 triangular segments with a scalpel. Each of these 
cell-containing segments was stained with a different antibody. 
2.7. Wound-healing assay 
Cells were plated and treated in 6-well plates and left to reach confluency (time-
course permitting). The medium was removed and cells were incubated at 370C, 5% 
CO2 for 2 h in Mitomycin C (10 µg/ml) diluted in complete medium to inhibit cellular 
proliferation. After 2 h the medium with Mitomycin C was removed and cells were 
washed 3 times in PBS. Using the top of the plate as a ruler and a P1000 tip the cell 
monolayers were scratched in the shape of a cross connecting the well edges. The 
cells were washed 3 times in PBS to remove any debris and complete medium was 
added. Pictures were taken at various time points using either a simple microscope 
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(Nikon Eclipse TE 2000-S and Nikon Digital Sight) or by Timelapse (Timelapse Epi 
inverted – TES, Zeiss), as per manufacturer’s specifications. 
2.8. Enzyme-Linked Immunosorbent Assay (ELISA) 
All reagents were purchased from R&D Systems except for PBS, wash buffer, reagent 
diluent and stop solution which were made in house. The assay was performed as 
per manufacturer’s instructions. Briefly, complete medium was removed from cells 
after 72-96 h and spun at 1200 rpm for 5 min. The supernatant was moved to fresh 
tubes and kept at -800C until use. Capture antibody was diluted to a suggested 
concentration (as per manufacturer’s specifications) in PBS and each well of a 96-
well plate was coated with 100 µl and incubated overnight. The next day the capture 
antibody was removed and the plate was washed 3 times in wash buffer and blotted 
against clean paper towels to remove all liquid. 300 µl of reagent diluent were added 
to each well and the plate was incubated at RT for 1 h. The wash step described 
above was repeated 3 times. 100 µl of sample or standard diluted in reagent diluent 
were added to the corresponding well and the plate was incubated at RT for 2 h. 
This step was repeated 3 times. 100 µl detection antibody, diluted in reagent diluent 
were added to each well and the plate was incubated at RT for 2 h. The wash step 
was repeated 3 times. 100 µl of the working dilution (suggested by the 
manufacturer) of streptavidin-HRP were added to each well and the plate was 
incubated in the dark at RT for 20 min. Wash step was repeated 3 times. 100 µl of 
substrate solution were added to each well and the plate was incubated in the dark 
at RT for 20 min. 50 µl stop solution were added to each well and mixed by gentle 
tapping. The optical density of the reactions was read using a plate reader (Bio-Tek 
Synergy HT Multi-Detection Microplate Reader, KC4 version 3.4 Rev. 18) set to 450 
nm with a wavelength correction set to 540 nm. 
2.9. Fluorescence-Activated Cell Sorting (FACS) 
All media, wash buffers and cells have been kept for apoptosis analysis by FACS. 
Cells plated in 6-well plates were detached using trypsin-EDTA as previously 
described and all buffers used for each well were mixed in separate tubes. Tubes 
were pelleted by centrifugation at 1500 rpm for 5 min and the supernatants were 
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discarded. The pellet was resuspended in 400 µl Annexin V binding buffer and 
moved into FACS tubes. 1.7 µl Annexin V–FITC were added to the cell – buffer mix 
and incubated at RT for 15 min. 16 µl DAPI (200 ng/ml) were added to each tube. 
30,000 events were analysed for each tube. Cells were counted and the percentage 
of early and late apoptotic death in each cell group was analysed using (BD 
FACSCanto II Flow Cytometer, BD Biosciences and FlowJo software, Tree Star Inc.).  
2.10. Statistical analysis 
The tools used were the two-tailed, paired t-test on Microsoft Excel. p<0.05 was 
significant (*); p<0.01 was highly significant (**); p<0.001 was very highly 
significant (***). 
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3.1. Introduction 
A variety of mutations have been identified in genes encoding desmosomal proteins 
as the underlying cause of an array of cardio-cutaneous syndromes (Brooke et al., 
2012). Studies have been performed to try and elucidate the disease mechanisms 
behind these mutations using both in vivo and in vitro methods. However, it is still 
unclear why distinct mutations in the same desmosomal gene lead to different 
phenotypes and how mutations in different genes lead to similar phenotypes.  
The focus of this chapter is the molecular analysis and identification of novel 
desmosomal mutations in patients clinically diagnosed with Arrhythmogenic Right 
Ventricular Cardiomyopathy/Dysplasia (ARVC/D), and secondly the genetic 
diagnosis of patients with hypotrichosis, hypotrichosis and PPK or acral peeling skin 
syndrome (APSS). In the latter patient cohort, mutations in protease-inhibitors were 
identified and shown to regulate aspects of desmosomal cell adhesion. Patient DNA 
was analysed using a number of different genetic techniques including custom 
capture array, HaloPlex targeted resequencing, exome capture and conventional 
Sanger sequencing. The following sections describe these different sequencing 
approaches and the novel mutations identified.  
3.2. Results 
3.2.1. Capture array and HaloPlex targeted resequencing in patients 
with ARVC 
Forty-nine patients were recruited from Barts and The London NHS Trust and from 
two collaborating centres, Bristol Heart Institute and the Cardiac Inherited Disease 
Group based in Auckland, New Zealand (Dr Dominic Abrams). Specific information 
on patient demographics is presented in Appendix A. Clinicopathological data was 
not available for patients seen in New Zealand.  The vast majority of patients 
recruited fulfilled diagnostic criteria for the condition, either using standard or 
modified ARVC criteria, or presented with an increasingly recognised variant of 
ARVC, namely predominant left ventricular involvement. The family pedigree below 
is representative for patient ARVC 2010 0009 (Figure 3.1.). 
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Figure 3.1. Pedigree structure of a family investigated in the ARVC study, where other 
family members have been diagnosed with ARVC. Filled symbols represent affected 
family members (diagnosed in this study ARVC 2010 0009). Squares represent male and 
circles represent female individuals. (*) represent patients treated at another hospital and 
(#) represent patients screened with nothing abnormal detected (NAD). No other members 
from this family have been screened in this study. 
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3.2.1.1. Illumina custom capture array  
Twelve patient DNA samples were analysed on the 385K sequence capture array 
containing genomic DNA sequences from five different desmosomal genes that are 
known to be involved in ARVC namely: DSP, PKP2, JUP, DSC2 and DSG2. Following 
PCR enrichment, samples were run on the Illumina Genome Analyser IIx (GAIIx) at 
the QMUL Genome Centre, London.  Raw 76 bp paired-end FASTQ reads were 
aligned against the reference genome sequence (Hg19). Unique sequence variants 
were identified by filtering the resultant data set against variations reported on 
dbSNP (www.ncbi.nlm.nih.gov/snp/) and the 1000 genome project database 
(www.1000genomes.org/). Initial sequence analysis, including soft clipping, adapter 
trimming, and quality calibration options were performed by Dr Vincent Plagnol at 
University College London.  
Following initial analysis, the BAM files corresponding to the unique homozygous 
changes were aligned in the Integrative Genomics Viewer (IGV) against the genomic 
reference sequence (bottom of each IGV window); the IGV layout for six of the 
confirmed likely ARVC-associated DNA variants are shown in Figure 3.2. A-F. The 
centre of each alignment shows a variant present in the heterozygous state. Due to 
the DNA pooling strategy, it was unknown at this stage which patients harboured 
these specific sequence variants. The percentage of reads for each variation was 
analysed. A percentage of variation reads of approximately 4% was representative 
for a heterozygous variation and a multiple of 4%, such as 8%, 16%, was 
representative for a homozygous variation or a heterozygous variation present in 
more than one patient. This was indicative of a real or false call prior to Sanger 
sequencing analysis. 
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Figure 3.2.  IGV layout of NGS results following a targeted-capture array of ARVC 
patients. Data was analysed for a high number of variation reads and aligned against the 
Human Reference Genome version 19 (GRCh37/Hg19). A percentage of reads of 
approximately 4% was indicative of a variation affecting one allele only whilst a multiple of 
4% (such as 8%, 16%) was indicative of a number of alleles being affected. (A) to (F) are 
the representations (as seen in IGV) of NGS data corresponding to affected ARVC patients: 
(A) NM_001008844:c.G1323C:p.K441N in DSP, (B) IVS11-1G>C in PKP2 and (C) 
IVS12+1G>A in PKP2. 
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Figure 3.2.  IGV layout of NGS results following a targeted-capture array of ARVC 
patients (continued). Data was analysed for a high number of variation reads and aligned 
against the Human Reference Genome version 19 (GRCh37/Hg19). A percentage of reads of 
approximately 4% was indicative of a variation affecting one allele only whilst a multiple of 
4% (such as 8%, 16%) was indicative of a number of alleles being affected. (A) to (F) are 
the representations (as seen in IGV) of NGS data corresponding to affected ARVC patients: 
(D) NM_001005242:c.G870A:p.W290X in PKP2, (E) NM_024422:c.T2194G:p.L732V in 
DSC2, (F) NM_001943:c.C874T:p.R292C in DSG2. 
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3.2.1.2.  Genetic screening of DSP, PKP2, JUP, DSC2 and DSG2 genes in patients 
clinically diagnosed with ARVC following custom capture array 
Preliminary data analysis, selecting against read depth, gene of interest and 
percentage of reads, revealed nine likely disease-causing mutations in the twelve 
sequenced patients (Table 3.1.).  
Sanger sequencing was performed to confirm each of the sequence variants and to 
identify the specific patients harbouring these variants. Three were identified as 
false positive variants and six were confirmed in five patients as follows (Figure 
3.3.):   
i) a heterozygous transversion from guanine to cytosine at coding position 
1323 of DSP, which changes a lysine amino acid codon to an asparagine 
amino acid (c.G1323C:p.K441N) in patient ARVC 2010 0006; 
ii) two heterozygous transversions from a guanine to cytosine and guanine 
to adenine, respectively, predicted to affect the splice sites of exons 11 
(IVS11-1G>C) and 12 (IVS12+1G>A, rs111517471 – Minor Allele 
Frequency (MAF): < 0.01) of PKP2 in patients ARVC 2010 0006 and ARVC 
2010 0009; 
iii) a heterozygous transversion from guanine to adenine at coding position 
870 of PKP2, which changes a tryptophan amino acid codon to a STOP 
codon (c.G870A:p.W290X) in patient ARVC 2010 0004; 
iv) a homozygous transversion from thiamine to guanine at coding position 
2194 of DSC2, which changes a leucine amino acid codon to a valine 
amino acid (c.T2194G:p.L732V; Mutation L732V) in patient ARVC 2010 
0010; 
v) a heterozygous transversion from cytosine to thiamine at coding position 
874 of DSG2, which changes an arginine amino acid codon to a cysteine 
amino acid (c.C874T:p.R292C; Mutation R292C) in patient ARVC 2010 
0005;  
vi) No variations were found in these five genes in the other seven patients, 
by capture array.  
 
105 
 
Patient Gene Chr. Exon Variation 
Reads 
(%) 
Novel (Y/N) 
ARVC 
2010 
0006 
DSP 6 11 
NM_001008844: 
c.G1323C:p.K441N 
4.17 N 
ARVC 
2010 
0006 
PKP2 12 N/A IVS11-1G>C 3.11 N 
ARVC 
2010 
0009 
PKP2 12 N/A IVS12+1G>A 5.19 rs111517471 
False 
positive 
PKP2 12 10 
NM_001005242: 
c.T1900G:p.W634G 
17.88 N/A 
ARVC 
2010 
0004 
PKP2 12 3 
NM_001005242: 
c.G870A:p.W290X 
4.11 N 
False 
positive 
PKP2 12 3 
NM_001005242: 
c.A742C:p.T248P 
7.36 N/A 
ARVC 
2010 
0010 
DSC2 18 14 
NM_024422: 
c.T2194G:p.L732V 
3.69 
Mutation 
L732V 
ARVC 
2010 
0005 
DSG2 18 8 
NM_001943: 
c.C874T:p.R292C 
3.29 
Mutation 
R292C 
False 
positive 
DSG2 18 15 
NM_001943: 
c.A2568C:p.K856N 
23.87 N/A 
Table 3.1. NGS results following a targeted-capture array on ARVC patients. Data 
analysis has revealed 9 likely disease causing mutations in 12 patients, out of which 3 were 
false positive calls. Table 3.1 above contains details of the possible affected genes and 
variations as well as details of patients affected and confirmed by Sanger sequencing. 
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Figure 3.3.  Confirmation of mutations in the DSP, PKP2, DSG2 and DSC2 genes of five 
affected individuals. Electropherograms of control and patient genomic DNA sequences. 
(A) Sequencing of patient DNA revealed a heterozygous transversion from guanine to 
cytosine at coding position 1323 of DSP, which changes a lysine amino acid codon to an 
asparagine amino acid (c.G1323C:p.K441N). (B) and (C)  Sequencing of patient DNA 
revealed two heterozygous transversions, from a guanine to cytosine and guanine to 
adenine, respectively, believed to affect the splice sites of exons 11 (IVS11-1G>C) and 12 
(IVS12+1G>A) of PKP2. (D) Sequencing of patient DNA revealed a heterozygous 
transversion from guanine to adenine at coding position 870 of PKP2, which changes a 
tryptophan amino acid codon to a STOP codon (c.G870A:p.W290X). 
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Figure 3.3. Confirmation of mutations in the DSP, PKP2, DSG2 and DSC2 genes of five 
affected individuals (continued). Electropherograms of control and patient genomic DNA 
sequences. (E) Sequencing of patient DNA revealed a homozygous transversion from 
thiamine to guanine at coding position 2194 of DSC2, which changes a leucine amino acid 
codon to a valine amino acid (c.T2194G:p.L732V). (F) Sequencing of patient DNA revealed 
a heterozygous transversion from cytosine to thiamine at coding position 874 of DSG2, 
which changes an arginine amino acid codon to a cysteine amino acid (c.C874T:p.R292C). 
Genomic DNA from an unaffected individual was used as control. 
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3.2.1.3. HaloPlex targeted enrichment system 
Given that the molecular analysis of a higher number of ARVC diagnosed patients 
had to be performed and due to the large volume of Sanger sequencing required for 
variant confirmation with the previous targeted capture method, a HaloPlex 
targeted enrichment system was used for targeted NGS. This technique offered the 
possibility to screen up to 96 patients using unique barcodes which would speed up 
the confirmation process. 
Forty eight genomic DNA samples were analysed on the HaloPlex target enrichment 
system. This system was specifically designed to cover 120 target regions, where 
each region was separated by another region by at least one base, with a total target 
region size of 36978 bp, covered by an average 98.5%. Custom designed probes 
covered eight genes associated with ARVC: DSP, JUP, PKP2, DSG2, DSC2, DES, 
ADAM17 and TMEM43. The patient samples screened using this system were as 
follows: thirty-seven new patients from the UK and NZ, seven patients screened on 
the capture array and in which no mutations were found, two patients with an 
unknown, possibly desmosome-related disorder and two control patients screened 
on the capture array and in which novel mutations were identified by custom 
capture array (ARVC 2010 0006 and ARVC 2010 0010).  
Following enrichment PCR, samples were run on the Illumina Genome Analyser IIx 
(GAIIx) at the QMUL Genome Centre.  Raw 100 bp paired-end FASTQ reads were 
aligned against the reference genome sequence (Hg19). Unique homozygous 
changes were identified by filtering the resultant data set against variations 
reported on dbSNP (www.ncbi.nlm.nih.gov/snp/) and the 1000 genome project 
database (www.1000genomes.org/). Initial sequence analysis, including the soft 
clipping, adapter trimming, and quality calibration options was performed by Dr 
Michael Barnes at the William Harvey Research Institute.  Following initial analysis 
the remaining calls were filtered by read depth, gene specificity and coverage as 
described above (Figure 3.4.). Seventeen possible disease-associated variations 
were identified with the majority in the PKP2 gene, with one call in ADAM17 and two 
in DSP. All these variations appeared to be novel (Table 3.2.). The two variations in 
patients ARVC 2010 0006 and ARVC 2010 0010 were also confirmed.  
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Figure 3.4. Diagram of percentage variation reads for ARVC patients analysed on the 
HaloPlex targeted resequencing system. NGS data was aligned and analysed against the 
Human Reference Genome version 19 (Hg19). Index numbers 1 to 48 represent the number 
for each patient analysed. The four real sequence variants confirmed by Sanger sequencing 
correspond to index numbers 5 (c.T1926A:p.Y642X), 17 (c.C5299T:p.R1767C), 42 
(c.G1939A:p.A647T) and 48 (c.A148C:p.T50A). 
 
 
 
 
 
 
 
 
110 
 
Patient Gene Exon Variation 
Reads 
(<2% poor, 
>2% good) 
Real 
(Y/N) 
 
9305427 
 
DSP 24 
NM_001008844:c.C5299T: 
p.R1767C 
Good Y 
RY8012 PKP2 4 
NM_001005242:c.C1162T: 
p.R388W 
Good N 
OG0660 PKP2 11 
NM_001005242:c.T2193C: 
p.V731V 
Poor N 
FP9310 PKP2 2 
NM_004572:c.413delC: 
p.G99Q 
Good N 
ARVC 
2011 
0020A 
PKP2 2 
NM_001005242:c.T332C: 
p.L111P 
Poor N 
LW9068 PKP2 9 
NM_001005242:c.T1926A: 
p.Y642X 
Good Y 
CM4130 PKP2 9 
NM_001005242:c.G1939A: 
p.A647T 
Poor Y 
LU4246 PKP2 12 
NM_004572:c.2469delT: 
p.Y786L 
Poor N 
ARVC 
2011 
0022 
PKP2 14 
NM_001005242:c.C2479A: 
p.R827R 
Poor N 
LV7711 PKP2 5 
NM_001005242:exon5:c.1170
+1G>A 
Poor N 
OG0660 PKP2 10 
NM_001005242:c.C2120A: 
p.S707X 
Poor N 
WN2786 PKP2 6 
NM_001005242:c.C1539T: 
p.N513N 
Good N 
LI8308 ADAM17 8 
NM_003183:c.1139delA: 
p.E319G 
Poor N 
LH5926 PKP2 1 
NM_001005242:c.A148C: 
p.T50A 
Poor Y 
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LH5926 PKP2 12 
NM_001005242:c.C2407G: 
p.L803V 
Poor N 
LH5930 DSP 23 
NM_004415:c.G5078T: 
p.S1693I 
Poor N 
WN2786 PKP2 12 
NM_001005242:c.A2176G: 
p.T726A 
Good N 
Table 3.2. NGS results following a HaloPlex targeted resequencing system on ARVC 
patients. Data analysis has revealed 17 likely ARVC-causing mutations in 44 ARVC patients, 
out of which 4 were real calls. Table above contains details of the possible affected genes 
and variations as well as details of patients affected and confirmed by Sanger sequencing. 
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3.2.1.4. Genetic screening of DSP, PKP2, JUP, DSC2, DSG2, DES, TMEM43 and ADAM17 
genes in patients clinically diagnosed with ARVC following HaloPlex targeted 
resequencing 
Confirmation analysis by PCR and Sanger sequencing of the variations described in 
Table 3.2. dismissed thirteen calls as false positive and confirmed four novel 
variants in four unrelated patients (Figure 3.5.). Sequencing of patient DNA revealed 
a heterozygous transversion from guanine to adenine at coding position 1939 of 
PKP2, which changes an alanine amino acid codon to a threonine amino acid 
(c.G1939A:p.A647T) in patient CM4130 (Figure 3.5.); a homozygous transversion 
from adenine to cytosine at coding position 148 of PKP2, which changes a threonine 
amino acid codon to an alanine amino acid (c.A148C:p.T50A) in patient LH5926 
(Figure 3.5.); a heterozygous transversion from a thymine to adenine at coding 
position 1926 of PKP2, which changes a tyrosine amino acid codon to a STOP codon 
(c.T1926A:p.Y642X) in patient LW9068 (Figure 3.5.) and a heterozygous 
transversion from cytosine to thymine at coding position 5299 of DSP, which 
changes an arginine amino acid to a cysteine amino acid (c.C5299T:p.R1767C; 
rs28931610) in patient 9305427. Patient 9305427 has a cutaneous syndrome - and 
this heterozygous variant has previously been associated with a Skin Fragility – 
Woolly Hair Syndrome (Dimas et al., 2008). 
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Figure 3.5. Confirmation of mutations in the PKP2 gene in three affected individuals. 
Electropherograms of patient genomic DNA sequences. Sequencing of patient DNA reveals 
a heterozygous transversion from guanine to adenine at coding position 1939 of PKP2, 
which changes an alanine amino acid codon to a threonine amino acid (c.G1939A:p.A647T) 
in patient CM4130; a homozygous transversion from adenine to cytosine at coding position 
148 of PKP2, which changes a threonine amino acid codon to an alanine amino acid 
(c.A148C:p.T50A) in patient LH5926 and a heterozygous transversion from thymine to 
adenine at coding position 1926 of PKP2, which changes a tyrosine amino acid codon to a 
STOP codon (c.T1926A:p.Y642X) in patient LW9068. 
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3.2.2. SNP array and exome analysis reveal DSP mutation in patients 
with hypotrichosis and PPK 
Three siblings from a consanguineous Pakistani family (Figure 3.6. A) were clinically 
examined at Birmingham Children’s Hospital. The patients, aged between seven 
months and ten years at the time of examination, had comparable hair and skin 
phenotypes, which consisted of hypotrichosis of the head, eyebrows and eyelashes, 
and diffuse, erythematous non-transgradiens palmoplantar keratoderma, (Figure 
3.6. B). After ritual shaving, their hair regrew sparse, short and woolly with 
perifollicular erythema. The middle boy was also atopic and had more marked PPK 
and hypotrichosis. No other observations were noted and otherwise they appeared 
healthy. Cardiac assessment, echocardiograph and electrocardiography were 
performed and did not reveal any cardiac abnormalities. The parents and older 
sister were unaffected. 
Due to the similarity of this phenotype to the cutaneous observations made in 
patients with desmosomal mutations, a mutation affecting a desmosome-associated 
protein was expected. The genetic analysis of patients 656 and 657, together with 
their unaffected parents is described in this subchapter. 
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Figure 3.6. Pedigree structure of Pakistani family investigated in this study and 
clinical phenotype of affected patients showing the hypotrichosis and PPK. (A) Filled 
symbols represent affected family members (656, 657 and a younger clinically examined 
sibling) and unaffected family members tested as controls (parents 658 and 655 and an 
older clinically examined sibling). Squares represent male and circles represent female 
individuals. (B) Clinical phenotype of two older affected siblings. Hypotrichosis of the scalp 
(656A and 657A), eyebrows and eyelashes (656B and 657B) in older and middle siblings 
and diffuse, non-transgrediens plantar keratoderma with fissuring in middle aged patient 
(657 C1 and C2). 
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3.2.2.1. SNP genomic mapping 
Given the apparent recessive mode of inheritance and consanguinity, a genome 
wide search for regions of common ancestry (homozygosity) was carried out 
previously by our group in collaboration with Dr Charles Mein from the QMUL 
Genome Centre. Common regions of genomic homozygosity were identified using 
the Illumina HumanHap550v3_A Genotyping BeadChip SNP mapping array and size 
range of clocks of homozygosity common to both patients were identified on 
chromosomes 1, 4, 5, 6, 11 and 14 (Table 3.3.). Because these regions of 
homozygosity were too large to explore, exome sequencing was performed on 
genomic DNA from one of the affected siblings. 
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Chromosom
e 
Start End 
Size 
CSID Position CSID Position 
1 10801043 
18967299
0 
1049472
3 
19347250
4 
3,691,286 
4 
cnvi001205
2 
45038666 2680758 56992092 
11,953,42
6 
5 12521501 31966942 37353 58647773 
26,680,83
1 
6 887509 6827116 669036 10620308 3,793,192 
11 1852755 13953262 2702703 19357949 5,404,687 
14 11543947 22573861 
1049831
3 
29468627 6,894,766 
Table 3.3. SNP Genomic Mapping analysis on siblings with hypotrichosis and PPK. 
Data analysis has revealed large homozygous SNP regions on chromosomes 1, 4, 5, 6, 11 
and 14. Table 3.3 shows the start and end positions and Chromosomal-SNP ID (CSID) 
together with the size of the homozygous SNP regions. 
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3.2.2.2. Exome capture 
Genomic DNA from one of the siblings clinically diagnosed with hypotrichosis and 
PPK was analysed on the SeqCap EZ Human Exome Library v2.0. This assay covered 
approximately 20,000 genes in the human genome, with gene information taken 
from the following sources: NCBI Reference Sequence RefGene from UCSC - January 
2010, CCDS from NCBI - September 2009, miRNAs from miRBase - version 14, 
September 2009 and customer inputs. A total of 44.1 Mb regions were covered in 
this assay (www.nimblegen.com).  
Following enrichment PCR, samples were run on the Illumina Genome Analyser IIx 
at the QMUL Genome Centre.  Raw 72 bp paired-end FASTQ reads were aligned 
against the reference genome sequence (Hg19). Unique homozygous changes were 
identified by filtering the resultant data set against variations reported on dbSNP 
(www.ncbi.nlm.nih.gov/snp/) and the 1000 genomes project 
(www.1000genomes.org/). Sequence analysis, including the soft clipping, adapter 
trimming, and quality calibration options was performed by Dr Vincent Plagnol at 
University College London.  
Table 3.4. presents details of the possible disease-associated genes together with 
the associated homozygous variation call and percentage depth for each variation.  
The novel identified DSP variant, c.C1493T:p.P498L, presented the highest 
percentage read depth (also covered in one of the regions of homozygosity 
identified in the SNP array data) and appeared to be the most likely disease-
associated mutation. Confirmation Sanger sequencing was performed on patient 
and control genomic DNA. 
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Gene Chromosome Variation Depth (%) 
MAP3K11 11 NM_002419:c.C1876A:p.P626T 7 
RAD9A 11 NM_004584:c.A1028T:p.E343V 33 
C14orf21 14 NM_174913:c.A1417G:p.M473V 17 
DCAF16 4 NM_017741:c.A124G:p.M42V 66 
ACSL6 5 NM_015256:c.A1913G:p.Q638R 130 
DSP 6 NM_001008844:c.C1493T:p.P498L 214 
Table 3.4. NGS results following a genome wide exome analysis on one patient with 
hypotrichosis and PPK. Taken together, the SNP array and exome data analyses have 
revealed six likely homozygous disease-causing mutations. Table 3.4 above contains details 
of the possible affected genes and variations as well as details of variation read depth. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
120 
 
Further analysis by PCR (Figure 3.7. A) followed by Sanger sequencing confirmed 
this autosomal recessive mutation from a cytosine to a thymine at coding position 
1493 of DSP, which changes a proline amino acid codon to a leucine amino acid 
(c.C1493T:p.P498L) in both affected siblings (Figure 3.7. B). Parents were 
heterozygous carriers for this mutation and genomic DNA from an unrelated 
individual, used as control, was wild type for this change (Figure 3.7. C). The 
remaining affected and unaffected siblings have not been screened.  
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Figure 3.7. Confirmation of mutations in the DSP gene of two affected siblings. 
Electropherograms of control, unaffected parents and patients genomic DNA sequences. (A) 
PCR of control, unaffected parents and patients genomic DNA covering the DSP variation as 
seen on agarose DNA gel electrophoresis.  (B) Sequencing of patient DNA reveals 
homozygous transversion from cytosine to thymine at coding position 1493 of DSP, which 
changes a proline amino acid codon to a leucine amino acid (c.C1493T:p.P498L) in both 
siblings (657 and 656). (C) Parents (655 and 658) of affected individuals are heterozygous 
for this variation. Genomic DNA from an unaffected individual was used as control. 
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3.2.3. Candidate gene analysis in patients with Acral Peeling Skin 
Syndrome 
Two sisters aged 4 and 6 years, born from non-consanguineous parents, presented 
with a history of skin peeling on the hands and feet since 6 months of age (Figure 
3.8. A). The peeling was notably worse following sweating, friction and immersion 
in water with development of maceration. Clinical examination revealed superficial 
peeling on the palms and soles, which extended onto the dorsal surfaces (Figure 3.8. 
B). Wrinkling and maceration of the palmoplantar skin after contact with water was 
noted. One sister also had atopic eczema and sinusitis due to confirmed house dust 
mite allergy. The other sister had ichthyosis vulgaris. Both had asthma and high 
hypermetropia.  
The observed cutaneous phenotype resembles acral peeling skin syndrome (APSS), 
which is a rare autosomal recessive condition characterised by asymptomatic 
peeling of the skin of the hands and feet. APSS has been described in association 
with mutations in TGM5 gene, which encodes for Transglutaminase 5. Initial 
screening for mutations in Keratin 5 (KRT5) and 14 (KRT14), underlying 
Epidermolysis Bullosa Simplex (EBS), and in TGM5, underlying APSS, was negative.  
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Figure 3.8. Pedigree structure of the family investigated in this study and clinical 
features showing distinct phenotype of skin fragility and exfoliation. (A) Filled 
symbols represent affected family members (KL and SL). Squares represent male and 
circles represent female individuals. (B) Clinical phenotype of the two affected patients. 
Peeling skin on hands and feet.   
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3.2.3.1. Screening of CSTA by Sanger sequencing  
As no mutations were identified in these patients following genetic testing of the 
KRT5, KRT14 and TGM5 genes, it was decided that the CSTA gene encoding cystatin 
A should be screened, as CSTA mutations had recently been identified with APSS 
(Krunic et al., 2013). PCR analysis of genomic DNA from these patients, followed by 
DNA electrophoresis for visualisation under UV light (Figure 3.9 A) were performed. 
Due to repeated absence of DNA amplification across exon 1 of CSTA in the two 
tested patients, two new primer pairs flanking this exon were designed in order to 
avoid any polymorphisms that would interfere with the annealing process. DNA 
electrophoresis with the new primer pairs, designed to amplify exon 1 in two 
sequences, showed the absence of amplicons in both patients (Figure 3.9 B) which 
suggested the existence of a large deletion covering all 66 bp of exon 1 and possibly 
fragments of the flanking introns. This large deletion of 66 bp at the cDNA level, 
which includes the START codon, leads to a deletion of 22 amino acids at the protein 
level, this most likely resulting in loss of CSTA expression.  
DNA amplification of exon 2 of CSTA, followed by Sanger sequencing revealed the 
existence of a polymorphism, a heterozygous transversion from cytosine to thymine 
at coding position 154 of CSTA, which does not alter the tyrosine amino acid 
(c.C154T:p.Y34Y; rs17589). This polymorphism was also detected in the control 
genomic DNA (Figure 3.9. C). Exon 3 of CSTA was wild type in both affected siblings 
(Table 3.5.). 
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Figure 3.9. Confirmation of mutations in the CSTA gene of two affected individuals. (A) PCR with control and patients genomic DNA targeting all exons 
of the CSTA gene as seen on agarose DNA gel electrophoresis. (B) PCR on control and patients genomic DNA with two primer sets covering exon 1 in two 
halves as seen on agarose DNA gel electrophoresis. (C) Sequencing of exon 2 of patient genomic DNA reveals a heterozygous transversion from cytosine to 
thymine at coding position 154 of CSTA, which does not alter the tyrosine amino acid (c.C154T:p.Y34Y). This variation is a polymorphism previously 
identified in the healthy control population (rs17589 – MAF: 0.3928). Genomic DNA from an unaffected individual was used as control and presents the same 
variation in exon 2 as patient genomic DNA.  
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Exon Variation SNP reference 
number 
Genotype 
1 c.1_66del:p.1_22del  Novel Homozygous 
2 c.C154T:p.Y34Y rs17589 Homozygous 
3 Wild type N/A Wild Type 
Table 3.5. Sanger sequencing analysis on two patients with Acral Peeling Syndrome 
due to CSTA mutation. Table above contains details of the affected exons of the CSTA gene 
with variation description.  
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3.2.4. Candidate gene analysis in a patient with hypotrichosis 
3.2.4.1. Screening of DSG4 by Sanger sequencing 
Initial screening of this patient, which included PCR amplification of several exons 
of DSG4 previously deleted in patients with hypotrichosis (Kljuic et al., 2003a), 
revealed no homozygous deletions in these exons.  
Analysis of all fifteen exons of DSG4 subsequently revealed 3 homozygous changes 
in exons 4, 5 and 12 as follows: a homozygous transversion from guanine to adenine 
at coding position 258 in exon 4, which does not alter the arginine amino acid 
(c.G258A:p.R86R; rs16959856), a homozygous transversion from cytosine to 
thymine at coding position 495 in exon 5, which does not alter the serine amino acid 
(c.C495T:p.S165S; rs9956865) and a homozygous transversion from adenine to 
cytosine at coding position 1930 in exon 12, which changes an isoleucine amino acid 
into a leucine amino acid (c.A1930C:p.I644L; rs4799570) (Figure 3.10.). 
It is believed that these homozygous variations are non-disease causing 
polymorphisms, as they have also been observed in control genomic DNA from an 
unaffected individual and were found in the genome database (Table 3.6.). 
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Exon 
 
Variation 
SNP 
reference 
number 
 
MAF 
 
Genotype 
4 c.G258A:p.R86R rs16959856 0.2794 Homozygous 
5 c.C495T:p.S165S rs9956865 0.1951 Homozygous 
12 c.A1930C:p.I644L rs4799570 0.0341 Homozygous 
Table 3.6. Sanger sequencing analysis of a patient with hypotrichosis. Table above 
contains details of the affected exons of the DSG4 gene with variation description. Variation 
details were extracted using the NCBI reference genome NM_001134453. 
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Figure 3.10. DSG4 mutation analysis by Sanger sequencing of affected individual. 
Sequencing of DSG4 in patient genomic DNA revealed (A) a homozygous transversion from 
guanine to adenine at coding position 258 in exon 4, which does not alter the arginine amino 
acid (c.G258A:p.R86R; rs16959856), (B) a homozygous transversion from cytosine to 
thymine at coding position 495 in exon 5, which does not alter the serine amino acid 
(c.C495T:p.S165S; rs9956865) and (C) a homozygous transversion from adenine to 
cytosine at coding position 1930 in exon 12, which changes an isoleucine amino acid into a 
leucine amino acid (c.A1930C:p.I644L; rs4799570). 
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3.3. Discussion 
The principal goal of the work described in this chapter was the identification of 
novel and previously disease-associated genetic mutations in patients clinically 
diagnosed with ARVC from the UK and New Zealand.  
During the course of this study, three additional families with members diagnosed 
with hypotrichosis, hypotrichosis and PPK or APSS, all characterised by hair and/or 
cutaneous abnormalities, were screened for mutations in the disease associated 
genes DSG4 and CSTA for hypotrichosis and APSS patients, respectively, with a novel 
disease causing mutation in DSP identified in patients with hypotrichosis and PPK. 
3.3.1. Candidate gene approach in patients with ARVC reveals novel and 
known disease-associated mutations 
A total of forty-nine patients clinically diagnosed with ARVC were screened for 
mutations in the known and possibly disease associated genes DSP, DSC2, DSG2, 
PKP2, JUP, DES, TMEM43 and ADAM17. Following Sanger sequencing, nine variations 
in eight patients have been confirmed as real calls, in the DSP, PKP2, DSC2 and DSG2 
genes.  
As disease-causing mutations were identified in only 16% of the patients screened, 
we suggest that the lack of candidate identification in the remaining 84% may be 
related to phenotypic errors, incomplete sensitivity of the mutation screening 
techniques, presence of mutations in non-analysed sequences in some cases due to 
poor gene coverage and very likely the yet undefined genes. Distribution of the full 
disease associated genes out of the 49 patients was as follows: DSP, 11%; DSC2, 
11%; DSG2, 11% and PKP2, 67%.  
These results differ from previous reports in which 50-70% of ARVC-related 
mutations identified were in genes encoding for desmosomal components (Brooke 
et al., 2012), compared to only 16% in our reports. Regardless of the low percentage 
diagnosis rate, our results support previous statistic data revealing mutations in 
PKP2 as responsible for approximately 70% of desmosome related ARVC cases. This 
difference could be attributed to slightly different methods of patient recruitment 
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with 66% of mutations identified in twenty-four UK patients and only 33% 
identified in twenty-five New Zealand patients.  
Out of six variations identified in PKP2, five mutations were heterozygous and one 
was homozygous as follows: two heterozygous transversions believed to affect the 
splice sites of exons 11 (IVS11-1G>C) and 12 (IVS12+1G>A; rs111517471), a 
heterozygous transversion which changes a tryptophan amino acid codon to a STOP 
codon (c.G870A:p.W290X), a heterozygous transversion which changes an alanine 
amino acid codon to a threonine amino acid (c.G1939A:p.A647T), a heterozygous 
transversion which changes a tyrosine amino acid codon to a STOP codon 
(c.T1926A:p.Y642X) and a homozygous transversion which changes a threonine 
amino acid codon to an alanine amino acid (c.A148C:p.T50A). 
The IVS11-1G>C mutation at the splice site of exon 11 of PKP2 was identified 
together with a heterozygous transversion in DSP, which changes a lysine amino 
acid codon to an asparagine amino acid (c.G1323C:p.K441N) leading to what is 
called a double heterozygote. Based on a study by Bauce et al., exon 11 skipping in 
RNA transcripts and the possible generation of a premature STOP codon following 
the PKP2 mutation could prove highly pathogenic (Bauce et al., 2010). With regards 
to the DSP variant, whether this has any subsequent effect on protein structure 
and/or its function is unknown. 
Two additional variations, previously reported, were identified as follows: a 
homozygous transversion in DSC2, which changes a leucine amino acid codon to a 
valine amino acid (c.T2194G:p.L732V), and a heterozygous transversion in DSG2, 
which changes an arginine amino acid codon to a cysteine amino acid 
(c.C874T:p.R292C). Mutation L732V identified in DSC2, reported in the Exome 
Sequencing Project (ESP) database and predicted by PolyPhen as benign, was 
previously described by Bhuiyan et al. in conjunction with a DSG2 mutation V392I, 
which suggested that perhaps a single mutation is less likely to cause a full-blown 
ARVC phenotype (Bhuiyan et al., 2009). Variant R292C in DSG2 confirmed as 
heterozygous within this chapter has previously only been described in the 
homozygous state (Sato et al., 2012), or in association with a synonymous mutation 
in DSP, D782D, dismissed by Cox et al. as silent after initially being listed as likely 
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pathogenic based on Sorting Intolerant From Tolerant (SIFT) and PolyPhen and its 
absence in the control population (Cox et al., 2011). Variant R292C has also 
previously been described as a double heterozygote associated with variation S194L 
in DSG2 and R577DfsX5 in PKP2 (Nakajima et al., 2012). Despite confirmation of 
these two variations in DSC2 and DSG2 by Sanger sequencing, a causatory effect 
between these mutations and ARVC requires segregation studies and perhaps 
analysis of these affected patients by exome sequencing which may reveal 
alternative causative gene variants.  
3.3.2. Candidate gene analysis in patients with hypotrichosis with and 
without PPK 
3.3.2.1. Novel DSP variant identified in siblings with hypotrichosis and PPK 
The three affected siblings of Pakistani origin, diagnosed with hypotrichosis and 
PPK, presented with comparable hair and skin phenotypes consisting of 
hypotrichosis of the head, eyebrows and eyelashes, together with diffuse, 
erythematous non-transgradiens PPK. Cardiac assessment, echocardiograph and 
electrocardiography were performed and did not reveal any cardiac abnormalities 
in our patients.  
SNP array homozygoisty mapping of two of the affected siblings followed by exome 
sequencing  of one of the affected patients revealed a homozygous variant in exon 
12 of DSP, c.C1493T:p.P498L mapping within a large region of homozygosity on 
chromsome 6. This call was also confirmed in a second affected sibling and in 
parents who were heterozygous carriers. Due to the age of the third affected sibling, 
and no DNA sample having been collected from the unaffected sibling, these 
individuals have not been tested. 
Two significant studies linking mutations in DSP to skin disorders reported an 
autosomal dominant nonsense (p.Q331X) and splice site (939+1G>A) mutations 
leading to haploinsufficiency (Armstrong et al., 1999, Whittock et al., 1999). These 
genetic variations suggest that protein dosage could perhaps be critical for skin 
integrity. Also, the first recessive DSP mutation, identified by Norgett et al., 
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associated with the Carvajal syndrome leads to truncation of the protein and loss of 
cell adhesion and collapsed IF network (Norgett et al., 2000).  
We suggest that due to its position in the protein sequence, the recessive DSP 
variation described in this chapter could possibly affect the normal structure and 
conformation of the amino-terminus of the protein, involved in binding PG and PKPs 
and, therefore, destabilise the formation of the desmosomal complex and, indirectly, 
the tethering of IF network to the plasma membrane. 
3.3.2.2. Whole gene analysis reveals DSG4 mutation in patient with hypotrichosis 
One other genetic diagnosis described in this chapter was performed in a patient 
clinically diagnosed with hypotrichosis, presenting with typical clinical disease 
characteristics as described above, but without any cardio-cutaneous implication.  
Initial analysis of this patient, which included PCR amplification of several exons of 
DSG4 previously found to be deleted in patients with hypotrichosis, leading to loss-
of-function of DSG4 (Kljuic et al., 2003a), revealed no obvious changes in these 
exons. Exon sequencing revealed three known variations in exons 4, 5 and 12 as 
follows: a homozygous transversion which does not alter the arginine amino acid 
(c.G258A:p.R86R; rs16959856), a homozygous transversion which does not alter the 
serine amino acid (c.C495T:p.S165S; rs9956865) and a homozygous transversion 
which changes an isoleucine amino acid into a leucine amino acid 
(c.A1930C:p.I644L; rs4799570). 
The first two variations identified in exons 4 and 5, rs16959856 and rs9956865 
respectively, with a MAF of 0.28 and 0.19 would not alter the protein conformation 
due to these variations being synonymous, and are unlikely to be disease-causing 
based on the high (> 1%) MAF. The last variation present in exon 12, rs4799570, 
with a MAF of 0.03 appears as tolerated in SIFT and as benign in PolyPhen despite 
the amino acid change and a MAF < 1%. 
Based on these findings we believe that further genetic analysis would be required 
to accurately diagnose this patient. One possible technique would be exome 
sequencing which would reveal multiple genetic candidates, including any 
alternative variants in DSG4 missed in the initial screening analysis, followed by 
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conventional Sanger sequencing for mutation confirmation and ideally recruitment 
of family members for segregation study. 
3.3.3. APS syndrome due to novel deleterious CSTA mutation 
We describe here two siblings, from a non-consanguineous family, which present 
phenotypical characteristics resembling those of APSS and EBS patients. APSS, as 
previously described by Cassidy et al. is characterised by noninflammatory acral 
peeling skin with peeling accompanied by erythema (Cassidy et al., 2005, Shwayder 
et al., 1997, Hashimoto et al., 2000). The abnormality is exacerbated by elevated 
ambient temperature and humidity. Histological observations, showing that the 
breakage takes place in the superficial layers of the epidermis, make it 
distinguishable from EBS where peeling begins in the basal layer.  
Cassidy et al. are also the first to link APSS to a homozygous missense mutation is 
TGM5 (Cassidy et al., 2005), the gene encoding transglutaminase 5, whereas EBS has 
been linked to mutations in the KRT5 and KRT14 genes encoding for keratin proteins  
(Chan et al., 1993, Chen et al., 1993). Initial genetic testing of the affected siblings 
for mutations in these three candidate genes, revealed wild type TGM5, KRT5 and 
KRT14 genes. 
Blaydon et al. reported two independent families diagnosed with exfoliative 
ichthyosis linked to loss-of-function mutations in the gene CSTA encoding the 
protease inhibitor cystatin A (Blaydon et al., 2011b). The clinical phenotype of these 
patients, characterised by peeling of skin on palms and soles worsened upon 
mechanical stress and humidity (Hatsell et al., 2003), and resembled that of the 
patients described in this chapter which led us to consider CSTA as a possible 
candidate for APSS in these patients.  
Genetic analysis of CSTA in the two affected siblings revealed two variants in exons 
1 and 2. One of these variants was a previously reported polymorphism in exon 2, 
c.C154T:p.Y34Y described under rs17589 – MAF of 0.40, and a deletion covering 
exon 1 c.1_66del:p.1_22del and possibly part of the intronic flanking regions. This 
deletion covers the START codon and affects both splice variants of CSTA, most 
likely leading to almost complete loss of expression, and any expressed protein 
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would lack the N-terminal domain required for the specific inhibition of the target 
cathepsins. These findings could be addressed further by analysis of patient skin 
biopsies and in vitro analysis using siRNA mediated-knockdown of CSTA. 
3.4. Summary 
In this chapter we describe a number of molecular techniques used to identify 
possible disease-associated mutations in genes encoding desmosome-associated 
proteins and in CSTA, the gene encoding the protease inhibitor cystatin A, thought 
to be involved in desmosomal regulation (discussed in Chapter 4). The majority of 
screened patients were clinically diagnosed with ARVC without cutaneous or hair 
abnormalities.  
In parallel, in two independent studies, siblings diagnosed with hypotrichosis and 
PPK presented with a novel homozygous mutation in DSP, the gene encoding the 
desmosomal protein desmoplakin, and a patient diagnosed with hypotrichosis 
without cutaneous abnormalities was found to present three polymorphisms in 
DSG4, the gene previously linked to this disorder. We discuss here the importance 
of segregation studies for an accurate genetic diagnosis and also consider other 
broader genome analysis for novel disease-causing mutations in unidentified 
disease-associated genes. 
The possible reasons behind the variety of mutations affecting different genes 
leading to the same disorder and mutations affecting the same gene leading to 
different disorders, together with limitations of genetic testing techniques will be 
addressed in more detail in Chapter 6. 
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-Chapter 4- 
 
Functional analysis of loss-of-function 
mutations in the protease inhibitor 
Cystatin A 
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4.1. Introduction 
The focus of this chapter was to investigate the functional aspects of recessive loss-
of-function (LOF) mutations in the gene encoding the protease inhibitor cystatin A 
(CSTA). Homozygous LOF mutations in CSTA are associated with the skin disorder 
exfoliative ichthyosis. The following introductory section describes the clinical and 
genetic aspects of this disorder. Part of the findings presented in this chapter have 
been published by our group (Blaydon et al., 2011b). 
4.1.1. Loss-of-function mutations in CSTA result in exfoliative ichthyosis 
Hatsell et al. previously described a large, consanguineous Bedouin family with five 
members presenting with exfoliative ichthyosis characterised by dry, scaly skin 
over most of their body with nonerythematous peeling of skin on their palms and 
feet, exacerbated by moisture and minor trauma (Hatsell et al., 2003). Recently, our 
group identified a homozygous LOF mutation in CSTA underlying this disorder in 
the previously described Bedouin family. In addition, we reported another 
homozygous CSTA mutation in a consanguineous Turkish family (Blaydon et al., 
2011b). The affected family members from this Turkish family presented a similar 
clinical phenotype as the initially described Bedouin family.  
Genetic screening of the CSTA gene in affected individuals from the two families 
revealed a homozygous 3’ splice-site variant (c.67-2A>T) in the Bedouin family and 
a homozygous nonsense mutation (c.256C>T) in the Turkish family (Blaydon et al., 
2011b). Electron microscopy of patient skin biopsies showed widening of 
intercellular spaces in the basal/suprabasal layers of the epidermis together with 
thickening of the keratin intermediate filaments. Analysis of splicing using a CSTA 
minigene construct revealed that the splice-site mutation, segregating with the skin 
disorder in  the Bedouin patient, leads to skipping of the first 12 base pairs of exon 
2 in CSTA, resulting in an in-frame deletion of four amino acids in the protein 
sequence of CSTA. In silico modelling supports these observations, revealing that the 
CSTA splice-site mutation would bring conformational changes which would affect 
the protease-binding and inhibitory role of CSTA. Furthermore, in vitro analysis 
revealed very low level expression of the variant protein, possibly due to low 
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efficiency of the mutant splice site or instability of the variant protein (Blaydon et 
al., 2011b, Gupta et al., 2015). 
4.1.2. Summary 
This chapter is based on the association of LOF mutations in CSTA with exfoliative 
ichthyosis and focuses on the effect of CSTA depletion on keratinocyte cell-cell 
adhesion and migration to investigate a possible mechanism of action through 
desmosome-associated proteins. The importance of protease inhibitors and the 
target proteases in tissue integrity is once more highlighted through this work. 
4.2. Results 
4.2.1. Functional analysis of loss-of-function mutations in CSTA 
Throughout this chapter the influence of CSTA LOF mutations on the expression and 
activity of the inhibited proteases and their subsequent targets was investigated. 
The patient phenotype was modelled in HaCaT cells, a spontaneously immortalised 
keratinocyte cell line, using the ON-TARGETplus SMART Pool siRNA targeting all 
isoforms of CSTA. 
4.2.1.1. Immunofluorescence of CSTA and the target proteases in the skin and 
immortalised HaCaT keratinocytes 
Immunostaining of CSTA in normal interfollicular (Figure 4.1. Ai) and palm skin 
(Figure 4.1. Bi) showed that CSTA is expressed throughout all layers of the 
epidermis with a cytoplasmic diffuse localisation and higher expression levels in the 
granular layer. In palm skin, CSTA appeared as bright granulations throughout the 
thick stratum corneum (Figure 4.1. Bi). Immunostaining of the target proteases of 
CSTA, cathepsins B, H and L in normal skin showed expression throughout all layers 
of the epidermis (Figure 4.2. Ai-Ci). Due to the lack of patient material for an in depth 
study of this condition, the HaCaT cell line was used to mimic the CSTA LOF 
phenotype. CSTA (Figure 4.1. Ci) and the three target cathepsins (Figure 4.2. Aiii-
Ciii) were also investigated in the immortalised HaCaT cell line. 
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Figure 4.1. Immunofluorescence of CSTA. Immunohistochemistry (IHC) with an anti-
CSTA antibody on frozen facelift skin sections (A) and frozen palm skin (B) from control 
individuals in the absence (Ai and Bi) and presence (Aii and Bii) of DAPI nuclear stain, 
showed protein expression throughout all layers in both facelift and palm skin with a 
granular aspect in palm skin. ICC with the same anti-CSTA antibody in HaCaT cells, in the 
absence (Ci) and presence (Cii) of DAPI nuclear stain, showed a diffuse cytoplasmic pattern 
of expression. Negative controls are shown in (Aiii) for IHC and (Ciii) for ICC. All IHC images 
were taken at 20 X magnification and Immunocytochemistry (ICC) images at 40 X 
magnification. IHC imaging was carried out on the Zeiss Meta 710 confocal microscope and 
ICC imaging was carried out on the LSM 510 confocal microscope. NS – Normal Skin; PS – 
Palm Skin. CSTA staining is shown in green and DAPI in blue (Scale bar – 50 µm for A-B and 
20 µm for C). 
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Figure 4.2. Immunofluorescence of the target proteases of CSTA. IHC with anti-
cathepsins B (A), H (B) and L (C) antibodies on frozen facelift skin sections from control 
individuals in the absence (Ai, Bi and Ci) and presence (Aii, Bii and Cii) of DAPI nuclear 
stain, showed protein expression throughout all layers of the epidermis. ICC with the same 
antibodies in immortalised HaCaT cells, in the presence (Aiii, Biii and Ciii) of DAPI nuclear 
stain, showed good levels of expression with a diffuse localisation pattern similar to 
observations made in skin sections. Negative controls are shown in (D and E) for IHC and 
(F) for ICC. All IHC and ICC images were taken at 40 X magnification. Imaging was carried 
out on the LSM 510 confocal microscope. NS – Normal Skin. Cathepsins B, H and L staining 
is shown in green and DAPI in blue (Scale bar – 20 µm). 
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4.2.1.2. Transient siRNA knockdown of CSTA isoforms in HaCaT keratinocytes mimics 
CSTA LOF mutation  
The two identified CSTA LOF mutations target both isoforms of CSTA. To mimic 
homozygosity for these LOF mutations, a pool of four siRNAs targeting all mRNAs 
was purchased from Dharmacon (GE Healthcare). The sequences and targeting sites 
of this functional siRNA pool are found in Table 2.5. A number of optimisations were 
performed prior to the siRNA experiments described in this chapter, including 
optimisation of transfection conditions and time course analysis of CSTA 
knockdown in HaCaT cells. Optimisation of transfection conditions was carried out 
to find the highest transfection efficiency with reduced cell death. The concentration 
of the siRNA pool was varied to determine the lowest concentration resulting in 
significant down-regulation of CSTA, in order to reduce off-target effects. A time 
course analysis was performed to determine the duration of CSTA down-regulation. 
These optimisations are described in Appendix F.1. 
The CSTA siRNA pool (Figure 4.3. E) reduced CSTA expression by 85% in HaCaT 
cells. Cells transfected with the CSTA siRNA pool were designated as CSTA siRNA 
HaCaT cells (Figure 4.3. B). A pool of four non-targeting (NTP) siRNAs was used as 
a negative control (NTP siRNA cells; Figure 4.3. A).  
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Figure 4.3. Immunocytochemistry and western blot of CSTA in HaCaT cells following 
siRNA transfection to mimic CSTA LOF mutations. ICC with an anti-CSTA antibody in 
HaCaT cells transfected with a pool of NTP siRNA (A) or CSTA siRNA (B) for 72 h in the 
absence (Ai and Bi) and presence (Aii and Bii) of DAPI as nuclear marker (in blue). A 
reduction in the CSTA (in green) protein levels can be seen in the CSTA siRNA treated cells 
compared to control cells. siRNA targeting cyclophilin B (C; in red) was used as control of 
transfection. Negative control for ICC is depicted in (D). (E) Total protein from HaCaT cell 
lysates 72 h after transfection with CSTA siRNA (lane 1) and NTP siRNA (lane 2) was 
incubated with an anti-CSTA antibody. Tubulin was used as a loading control. Knockdown 
of CSTA mimics the LOF mutations observed in patients. Imaging was performed with an 
LSM 510 confocal microscope and images were taken at 63 X magnification (Scale bar – 20 
µm). 
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4.2.1.3. Influence of CSTA LOF mutations on HaCaT intercellular adhesion 
To investigate the effects of mechanical stress in CSTA siRNA transfected HaCaT 
cells, the FX-4000TM Cell Stretcher was used. This assay was performed using 
conditions previously optimised within the group for the same cell line, in order to 
assess intercellular adhesion (Cabral et al., 2012b). Experimental conditions where 
NTP control cells showed some degree of mechanical stress but remained attached 
to the culture dish were used for the assays described in this chapter. Under these 
conditions and following the electron microscopy observations in patient skin, it 
was predicted that CSTA knockdown cells will have altered cell-cell adhesion 
properties compared with NTP cells.  
CSTA siRNA transfected cells together with NTP siRNA transfected cells as control, 
were subjected to mechanical stretch at a frequency of 5 Hz (five cycles of stretch 
and relaxation per second) and an elongation of amplitude ranging from 10% to 
14% (increase in diameter across the silicone deformable membrane from 10% to 
14%). Cells were stretched for 0 h (non-stretched) and 4 h. Western blots of CSTA 
siRNA HaCaT cell lysates were performed, as previously described, to confirm that 
CSTA knockdown was achieved prior to the stretch assay.  
Immunocytochemistry of CSTA siRNA-treated cells was performed using an 
antibody raised against keratin 14 (in green) (Figure 4.4.). After 4 h stretch, under 
lower magnification, the NTP cell sheet (Figure 4.4. Ai) appeared intact in 
comparison to the CSTA siRNA-transfected cells where the cell monolayer was 
significantly disrupted (Figure 4.4. Bi). Under higher magnification, in NTP cells, the 
keratin intermediate filaments appeared normal, however, despite minor 
intercellular widening of intercellular spaces these cells still appeared connected to 
each other through intercellular junctions (Figure 4.4. Aii). By comparison, in the 
CSTA siRNA cells, widening of intercellular spaces (arrows) was observed together 
with thickening of the keratin filaments and in some cases these filaments were 
retracted towards the nucleus (stars) (Figure 4.4. Bii). 
These results suggest that in contrast to NTP cells, which showed a minor increase 
in intercellular spaces proportional to the exposure to mechanical stretch and no 
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obvious changes to the keratin filaments, CSTA siRNA cells exhibited thicker and 
retracted filaments and wider intercellular spaces. 
To independently assess and quantify the effects of the CSTA LOF mutation on cell 
adhesion, a dispase-based adhesion assay was performed (three independent siRNA 
experiments with each tested condition in triplicate) (Figure 4.4. C). The cells 
simulating the CSTA LOF mutation showed a much larger, statistically significant, 
decrease in cell-cell adhesion (indicated by a large number of monolayer fragments 
produced upon agitation). Additionally, weakened intercellular adhesion could be 
visualised upon detachment of the cell monolayer from the tissue culture dish by 
the degree of elastic condensation of the cell sheet. The CSTA siRNA monolayer acted 
identically to the DSP I/II siRNA treated cells, used as control for impaired cell-cell 
adhesion, as previously described by Cabral et al., 2012. In contrast, the NTP cell 
sheet broke into only a small number of fragments. These results are consistent with 
observations made in the stretch-immunofluorescence assay (Figure 4.4. A), 
suggesting a role for CSTA in regulation of intercellular adhesion.  
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Figure 4.4. Mechanical stress causes reduced cell-cell adhesion and increased IF 
instability in CSTA siRNA treated HaCaT cells. NTP control HaCaT cells (Ai and Aii) and 
CSTA siRNA cells (Bi and Bii) mimicking the LOF mutation were subjected to cyclic 
mechanical stress at a frequency of 5 Hz and amplitude of 10-14% using the Flexcell FX-
4000 Tension System for 0 h (non-stretched; Appendix F.2.) and 4 h. ICC with an anti-
Keratin 14 antibody revealed that after 4 h stretch, the CSTA siRNA cells display thicker and 
more compact keratin IFs (Bii; stars) retracted towards the nuclei. Large intercellular gaps 
(Bii; arrows) were observed predominantly in CSTA siRNA, particularly after 4 h stretch, 
suggesting an adhesion defect. Keratin 14 – in green; DAPI – in blue. Imaging was performed 
on the LSM 510 confocal microscope and images taken at 10 X (Ai and Bi) and 63 X 
magnification (Aii and Bii) (Scale bar – 100 µm for Ai and Bi; 20 µm for Aii and Bii).  
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Figure 4.4. Mechanical stress causes reduced cell-cell adhesion and increased IF 
instability in CSTA siRNA treated HaCaT cells (continued). (C) A dispase-based 
dissociation assay was performed to assess intercellular adhesion by the degree of cell 
monolayer integrity upon mechanical stress. CSTA siRNA cells showed a significant increase 
in the number of monolayer fragments produced upon agitation, suggesting a statistically 
significant decrease in cell-cell adhesion, similar to the one observed for DSPI/II siRNA 
treated cells (*** - p≤0.05) (n=9).  
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4.2.1.4. Migration is not impaired in CSTA knockdown keratinocytes 
A scratch assay was performed to investigate the effects of CSTA LOF mutations on 
cell migration. Three independent knockdown experiments were performed with 
three repeats per experiment for each siRNA condition. After applying a scratch 
throughout the CSTA siRNA and NTP siRNA cell monolayers, both vertically and 
horizontally in a cross shape, pictures were taken at set time intervals, 0 h, 24 h and 
48 h (Figure 4.5. A), in order to assess and compare the time and speed of scratch 
closure in CSTA siRNA cells compared to control cells. Light microscopy showed 
normal cell migration in CSTA siRNA cells after 48 h comparable to control, and in 
order to quantify this, the size of the scratch wound was measured for all time 
intervals. No statistically significant difference was observed, indicative of a normal 
scratch closure pattern and normal migration process (Figure 4.5. B). Scratch 
measurements were made using Image J software and resulting scratch 
measurements are given as arbitrary numbers from a maximum set number.  
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Figure 4.5. “Wound-healing” assay shows normal wound closure after 48 h. (A) 
Scratch assay to assess migration by the degree of scratch closure after 24 h and 48 h. (B) 
No significant difference was observed between NTP siRNA and CSTA siRNA treated cells 
suggesting that there is no significant reduction in cell migration and scratch closure (n=9). 
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4.2.1.5. Observations on the expression of CSTA target proteases 
Following observations on the intercellular adhesion levels in cells mimicking the 
CSTA LOF phenotype, we decided to assess the expression of the CSTA regulated 
proteases, cathepsins B and L, in CSTA siRNA-treated cells. Cathepsin H was not 
analysed further due to the low expression observed in the immortalised HaCaT cell 
line. The levels of secreted and intracellular protein were analysed in cell culture 
supernatants by ELISA and total protein lysates by western blotting. A number of 
optimisations for the analysis of cell culture supernatants were performed in order 
to identify the optimal sample dilutions that would give a clear reading on the 
luminescence plate reader. Due to the difference in observations following the 
mechanical stretch and wound-healing assays it was decided that expression of the 
target cathepsins should be analysed in CSTA siRNA-treated cells following both of 
these assays.  
The expression levels of both cathepsins increased upon scratch-wound in both 
control and CSTA siRNA-treated cells with no significant difference between the two 
conditions. In mechanically stretched cell monolayers the expression of cathepsins 
B and L presented a slight decrease after 1 h stretch but did not alter significantly 
after 4 h stretch in comparison to non-stretched cells (Figure 4.6. A). A significant 
difference was observed between the two proteases in their secreted levels with 
cathepsin B being secreted at significantly higher levels compared to cathepsin L, 
following both wound-healing and mechanically-induced stress. This observation 
was confirmed by western blotting of total protein lysates of CSTA siRNA and NTP 
siRNA cells. Cathepsin B appeared to be expressed in higher levels in comparison to 
cathepsin L, the observed difference in secretion levels could be interpreted as being 
due to a difference in baseline expression levels in HaCaT cells (Figure 4.6. B). 
Cathepsin expression in stretched cells was assessed in triplicate and in scratched 
cells in duplicate; optical density analysis for the remaining two and respectively 
one repeat(s) is included in Appendix F.3.  
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Figure 4.6. ELISA and total protein analysis show unchanged cathepsin B and L levels in culture supernatants and total protein cell lysates. (A) 
ELISA assay to assess the levels of secreted cathepsins B and L in culture supernatants post scratch-wound (0 h, 6 h, 16 h and 20 h post wound) or mechanical 
stretch (for 0 h, 1 h and 4 h) in CSTA siRNA compared to NTP siRNA. No significant difference was observed between CSTA siRNA and control cells (n = 1). 
(B) Total protein cell lysates from HaCaT cells incubated for 72 h with CSTA siRNA and NTP siRNA were blotted and incubated with anti-cathepsin L, 
cathepsin B and CSTA antibodies to check the levels of expression of these proteins. No difference in expression between the two cathepsins was seen 
between control and CSTA siRNA cells.
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4.2.1.6. Influence of CSTA LOF mutations on the expression levels of desmosome-
associated proteins  
The aim of this section was to analyse the expression and localisation of 
desmosome-associated proteins before and after mechanical stretch in CSTA siRNA 
cells compared to NTP control. This analysis was performed in order to get details 
about a possible mechanism of action of the target proteases inhibited by CSTA, 
cathepsins B and L, which possibly could impact on desmosome function.  
Total protein cell lysates from HaCaT cells mimicking the LOF CSTA mutations and 
from control cells were obtained and analysed by western blotting. Antibodies 
targeting DSP, DSC2, DSC3, DSG2, DSG3, PG and PKP2 were used together with anti-
vinculin and anti-GAPDH antibodies as loading controls. Three independent siRNA 
knockdown experiments were conducted and replicate western blots were carried 
out for each protein in each experiment. Densitometry measurements of western 
blots were calculated using an image analysis program (Image J, v1.47v) and are 
graphically depicted in Figure 4.7. B for DSG3, which was consistent between 
repeats, and Appendix F.4. for all of the other proteins analysed. 
A key observation was that DSG3 protein levels showed an increase in expression 
levels following CSTA siRNA knockdown (Figure 4.7. B). Protein levels were 
normalised against the loading control band, GAPDH, and are presented as a fold 
change from NTP control for the western blot for DSG3 in Figure 4.6. A. Variable 
results were observed for DSG2 and DSP expression levels between the three 
independent experiments, and further repeats would be necessary to draw a 
conclusion. No detectable differences were observed in the expression levels of the 
other desmosome-associated proteins, DSC2, DSC3, PG and PKP2, between CSTA 
siRNA cells and NTP control cells, in any of the independent knockdown 
experiments. All three independent knockdown experiments showed consistent 
results for the expression level of DSG3, which was increased in CSTA siRNA cells 
compared to NTP cells. Figure 4.7. B shows densitometry analysis results of protein 
levels of DSG3 calculated from the western blot shown in Figure 4.7. A. The 
remaining two independent knockdown experiments have been included in 
Appendix F.4. together with their densitometric analysis.  
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Figure 4.7. Protein levels of desmosomal proteins following CSTA knockdown show 
that DSG3 expression levels are increased in CSTA siRNA treated cells. (A) Total 
protein cell lysates from CSTA siRNA and NTP HaCaT cells, non-stretched and stretched for 
4 h, were blotted and incubated with anti-DSP, DSC2, DSC3, DSG2, DSG3, PG or PKP2 to 
check the levels of expression of these proteins. (B) Protein levels of DSG3 calculated from 
densitometry measurements of the western blot image and normalised to loading control 
(GAPDH). Total DSG3 expression levels are presented as a fraction of the total DSG3 levels 
of NTP cells; standard error bars are shown on the protein analysis graph included in 
Appendix F.4. No change was observed for DSC2, DSC3, DSG2, PKP2 and PG. DSP gave 
variable results and will need to be analysed further (n = 3 blots; densitometry analysis in 
Appendix F.4.). 
153 
 
Following these observations on western blotting, immunocytochemistry of CSTA 
siRNA-treated cells in comparison to NTP control was performed for DSG3, DSP and 
DSG1/2. Unfortunately, the anti-DSG3 antibody did not work well by this method 
(data not shown). 
Immunocytochemistry using an anti-DSP antibody on NTP siRNA (Figure 4.8. A and 
C) and CSTA siRNA (Figure 4.8. B and D) treated cells, both in non-stretched and 
after 4 h stretch conditions, showed similar expression levels in non-stretched CSTA 
siRNA and in NTP control cells. However, following 4 h stretch there appears to be 
an up-regulation of DSP expression together with an evident increase in DSP levels 
in the cytoplasmic compartment of cells treated with CSTA siRNA (Figure 4.8. D). 
Staining using an antibody targeting both DSG1 and 2 on siRNA-treated cells showed 
up-regulation in protein expression together with an aberrant expression of these 
cadherins in the cytoplasmic compartment of CSTA siRNA-treated cells (Figure 4.9. 
A), following 4 h mechanical stretch, compared to NTP control treated under the 
same conditions (Figure 4.9. B).  
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Figure 4.8. Immunocytochemistry of DSP in HaCaT cells following siRNA transfection and mechanical stretch. ICC with an anti-DSP (in green) 
antibody in HaCaT cells transfected with a pool of NTP siRNA (A and C) or CSTA siRNA (B and D) both in non-stretched (A and B) and post 4 h stretch (C and 
D) in the absence (Ai-Di) and presence (Aii-Dii) of DAPI as nuclear marker (in blue). Similar protein levels can be observed for non-stretched NTP and CSTA 
siRNA treated cells (A and B). CSTA siRNA treated cells post 4 h stretch present with an increased DSP expression and a more significant cytoplasmic 
appearance (D) than NTP control (C). Imaging was performed with the Zeiss Meta 710 confocal microscope and images were taken at 100 X magnification 
(Scale bar – 20 µm).
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Figure 4.9. Immunocytochemistry of DSG1/2 in HaCaT cells following siRNA 
transfection and mechanical stretch. ICC with an anti-DSG1/2 (in green) antibody in 
HaCaT cells transfected with a pool of NTP siRNA (A) or CSTA siRNA (B) post 4 h stretch in 
the absence (Ai and Bi) and presence (Aii and Bii) of DAPI as nuclear marker (in blue). 
CSTA siRNA treated cells post 4 h stretch present with an increased DSG1/2 expression and 
a slightly increased cytoplasmic appearance (B) than NTP control (A). Imaging was 
performed with the LSM 510 confocal microscope and images were taken at 100 X 
magnification (Scale bar – 20 µm). 
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4.3. Discussion 
The main focus of the work described in this chapter was the in vitro analysis of the 
mechanism of action by which CSTA LOF mutations lead to exfoliative ichthyosis, 
possibly via regulation of desmosome assembly and migration towards the upper 
layers of the epidermis. We describe for the first time the importance of CSTA in the 
basal-suprabasal layers of the epidermis, with a previously unknown role and 
possibly a novel mechanism of action. Part of the results presented here have been 
published by Blaydon et al. (Blaydon et al., 2011b). 
4.3.1. Expression of cystatin A in normal skin and in vitro cell model 
CSTA was previously described as an intracellular protease inhibitor, despite being 
identified in sweat and in medium from cultured keratinocytes, with functions 
limited to its involvement in the upper layers of the epidermis, including its role in 
protection against dust mite allergens Der p 1 and Der f 1 and also associated with 
psoriasis and atopic dermatitis linked to a defective skin barrier (Kato et al., 2005, 
Vasilopoulos et al., 2007, Vasilopoulos et al., 2008). No studies have looked at the 
role played by CSTA in the lower layers of the epidermis, prior to our research 
findings linking CSTA LOF mutations to the skin disorder exfoliative ichthyosis 
(Blaydon et al., 2011b). 
Staining of CSTA in normal facelift and palm skin revealed a diffuse cytoplasmic 
localisation and expression throughout all layers of the epidermis, with increased 
expression in the granular layer and distinct granulation-like formations mostly in 
the stratum corneum of palm skin which could perhaps be explained as CSTA-
transporting vesicles, possibly due to its function in anti-allergenic protection. 
To study further the effect of CSTA LOF mutations and due to the lack of patient skin 
biopsy material, we have manipulated CSTA expression in HaCaT keratinocytes. ICC 
confirmed observations made on staining of normal epidermis, showing a diffuse 
cytoplasmic expression of CSTA in the above mentioned cell line. 
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4.3.2. CSTA transient down-regulation leads to impaired intercellular 
adhesion but normal cell migration 
To model the phenotype observed in patients with exfoliative ichthyosis in vitro, we 
used the HaCaT cell line coupled with siRNA mediated knockdown of CSTA. This 
experiment was performed together with the use of an NTP knockdown control and 
siRNA targeting the cyclophilin B gene (siGlo) as transfection control. A robust CSTA 
knockdown with a significant protein reduction was obtained which remained low 
between 48 h and 136 h, which was as long as we needed for any of the analyses 
executed. No obvious effect on cell viability was observed. 
One specific phenotypical characteristic of exfoliative ichthyosis is epidermal 
peeling on areas exposed to mechanical stress and increased humidity such as the 
palmoplantar regions and the neck area. By electron microscopy, as reported by 
Blaydon et al., widening of the intercellular spaces and thickening of the keratin 
filaments in the lower layers of the epidermis in patient skin was observed (Blaydon 
et al., 2011b). These observations were replicated in vitro in CSTA knockdown 
monolayers by subjecting them to cycling mechanical stretch. Similarly to EM 
observations, clear widening of the intercellular spaces was noted in CSTA 
knockdown cells post-stretching together with breakage of the cell sheet into a 
larger number of fragments compared to NTP control and thickening of the keratin 
intermediate filaments together with retraction from the plasma membrane 
towards the nucleus. A dispase-based dissociation assay performed on CSTA 
knockdown monolayers versus NTP control strenghtened the observations made by 
mechanical stretch assay highlighting yet again a significant dysregulation in 
intercellular adhesion.  
Our hypothesis is that this dysregulation of intercellular adhesion, mostly as its seen 
together with thickening of keratin filaments and their retraction towards the 
nucleus, could possibly be due to an indirect mechanism targeting some of the 
adhesive intercellular structures, most likely the desmosomes responsible for 
binding keratin filaments to the plasma membrane. This mechanism will be 
discussed further. 
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The target proteases of CSTA, cathepsins B, H and L, are observed to be frequently 
upregulated in cancer, and appear to facilitate tumour invasion and metastasis 
through cleavage of cell-cell adhesion junctions (Strojan et al., 2000). This 
observation, in conjunction with the observations of the dysregulated intercellular 
connections in stretched CSTA knockdown monolayers, cell migration in CSTA 
siRNA treated cell monolayers by the scratch assay was assessed. However, no 
change in the rate of cell migration was noted following CSTA knockdown in 
comparison to NTP control. 
4.3.3. Cathepsin B expression appears significantly upregulated 
following scratch assay, compared to cathepsin L expression 
A study by Strojan et al., looking at patients with squamous cell carcinoma (SCC) of 
the head and neck has observed that decreased expression of CSTA correlates with 
increased activity of the target proteases, cathepsins B, H and L (Strojan et al., 2000). 
In addition, reduced expression of CSTA was observed in SCC of the head and neck 
(Anicin et al., 2013). Another analysis by Li et al., looking at laryngeal cancer patients 
has reported that in in vitro conditions down-regulation of cathepsin B together 
with up-regulation of CSTA expression significantly inhibited the migration, 
invasion and proliferation of laryngeal cancer cells (Li et al., 2011). 
Two in vitro studies looking at cathepsin B secretion following scratch assays in 
HaCaT monolayers have revealed that following wounding these cells secreted 
increased levels of cysteine protease cathepsin B, which was present in vesicles 
within cellular protrusions forming cell-cell contact sites (Buth et al., 2004, Buth et 
al., 2007). It is, therefore, believed that cysteine proteases contribute to the 
remodeling of the extracellular matrix and thus the loss or decreased expression of 
cysteine protease inhibitors could lead to uncontrolled breakage of intercellular 
connections, as observed in the stretch and dispase-based analyses performed in 
this thesis. 
The expression of cathepsins B and L in CSTA siRNA treated cell monolayers in 
comparison to NTP control cells revealed overall higher endogenous levels of 
cathepsin B expression compared to cathepsin L, independent of treatment 
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conditions, with a significant increase in expression of both cathepsins following the 
application of a scratch wound. No significant change was observed for 
mechanically stretched monolayers for either of the cathepsins.  
These findings confirm the studies reported by Buth et al., which have also used 
HaCaT cells in their experiments. This analysis could be replicated in other 
keratinocyte cell lines which may present with different baseline cathepsin 
expression levels.  
4.3.4. Dysregulation of desmosome-associated proteins in CSTA 
knockdown cells following mechanical induced stress 
A number of studies have reported an overexpression of cathepsin B mRNA, 
increased cathepsin B staining and elevated cathepsin B activity in different human 
cancers; these leading to degradation of components of the basement membrane 
and extracellular matrix, both intracellularly and extracellularly in a cell type-
dependent manner (Yan et al., 1998, Kos et al., 2014). However, there are no reports 
associating directly cathepsin activity to desmosome regulation.  
However, insights into protease regulation are emerging from the studies of genetic 
skin diseases. For example, Netherton syndrome is associated with mutations in 
SPINK5 encoding LEKTI-1 which targets the proteases KLK5, KLK7 and KLK14 
(Deraison et al., 2007) ultimately leading to DSG1 degradation and desmosome 
cleavage with detachment of the stratum corneum (D'Alessio et al., 2013, 
Hovnanian, 2013). Inhibition of these proteases by SPINK6 and SPINK9, is 
reportedly leading to desquamation through their action on DSG1, DSC1 and 
corneodesmosin (Meyer-Hoffert et al., 2009, Meyer-Hoffert et al., 2010, Brattsand et 
al., 2009).   
Another study reporting a syndrome of severe skin and bowel inflammation, 
increased susceptibility to infection and cardiomyopathy, associated with ADAM17 
LOF mutations, revealed an increase in DSG2 protein expression, implying a 
reduction in DSG2 shedding by ADAM17 (Blaydon et al., 2011a). By contrast, 
patients with tylosis with oesophageal cancer (TOC), characterized by PPK, 
follicular papules and oral keratosis (Ellis et al., 1994, Hennies et al., 1995, Stevens 
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et al., 1996), linked to mutations in the RHBDF2 gene, encoding for iRHOM2 
(Blaydon et al., 2012, Saarinen et al., 2012), present with immature desmosomes 
lacking the electron dense midlines (Brooke et al., 2014). Furthermore, in vitro 
studies in TOC patient derived keratinocyte cell lines revealed a dramatic increase 
in the iRHOM2-mediated processing and activity of ADAM17, together with an 
increase in processing of DSG2 (Brooke et al., 2014). 
In Pemphigus vulgaris (PV), an acquired skin disorder affecting the basal layers of 
the epidermis, DSG3 autoantibodies lead to internalization of this protein, 
impairment of correct desmosome assembly, with deficient Ca2+-independent 
desmosome formation ultimately leading to severe blistering (Cirillo and Al-Jandan, 
2013). A more recent study has revealed that enhanced expression of PKP1 protects 
keratinocytes from PV IgG-induced intercellular loss of adhesion, by clustering 
DSG3 to DSP through the PG binding tail of DSP and enabling the formation of Ca2+-
independent desmosomes in a hyperadhesive state (Tucker et al., 2014). The 
significant difference between PV and Pemphigus foliaceus (PF), characterized by 
superficial blisters due to autoantibodies targeted against DSG1 (Ishii et al., 1997), 
highlights the important role played by DSG3 in the more basal layers of the 
epidermis, where DSG1 is not present and cannot therefore compensate for the anti-
DSG3 autoantibodies in PV, through the so-called DSG compensation theory 
(Shirakata et al., 1998). 
The complex interaction between DSG3 and PG has also been studied in SCC of the 
head and neck (HNC) by Chen et al., showing that DSG3 is overexpressed in HNC and 
the degree of overexpression is associated with clinico-pathologic features. 
Silencing of DSG3 significantly suppressed carcinogenic potential in cellular and in 
vivo animal studies by reducing cell growth, cell migration and invasion abilities 
through PG translocation to the nucleus and reduction in tumoral target gene 
expression (Chen et al., 2007, Chen et al., 2013). 
Following the observations of dysregulation of adhesion in CSTA LOF cells following 
mechanical stretch, the expression and localisation of most of the desmosomal 
proteins expressed in the basal/suprabasal layers of the epidermis, where widening 
of the intercellular spaces was noted in patient skin, was investigated. 
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Total protein analysis from stretched CSTA siRNA treated cells revealed an up-
regulation in DSG3 expression in siRNA treated cells independent of mechanical 
stress. DSP and DSG1/2 expression appeared increased in siRNA treated cells but as 
the expression levels varied between experiments we believe that these results 
should be replicated further. No changes in expression levels were noted for the 
other desmosomal proteins analysed.  
However, immunocytochemical staining of DSP and DSG1/2 in cell monolayers, 
under the above mentioned conditions, revealed an apparent up-regulation of 
expression with a clear change in localisation to the cytoplasmic compartment 
compared to a membranous localisation in NTP cells. This suggests that CSTA could 
possibly regulate cell-cell adhesion via desmosomes through its target proteases. 
Staining of the other desmosomal components could also be investigated. 
4.4. Summary 
This chapter investigated a role for the protease inhibitor CSTA in the 
basal/suprabasal layers of the epidermis. CSTA and its target cathepsins, B, H and L 
appear to be expressed throughout all layers of the epidermis and in a keratinocyte 
cell line. A robust CSTA knockdown mimicking the LOF mutations, coupled with 
mechanical stretch and a dispase-based dissociation assay has revealed a significant 
reduction in intercellular adhesion levels, but no change in cell migration by scratch 
assay. We believe that a possible mechanism of action of this protease inhibitor 
could indirectly target desmosome assembly and remodelling through the target 
proteases of CSTA. This hypothesis is supported by observations showing that DSG3 
appears overexpressed in CSTA siRNA treated monolayers independent of 
mechanical stress, and that DSG1/2 and DSP appear to re-localise to the cytoplasm 
following mechanical stretch suggesting that breakage of the keratin filaments could 
also result from dysregulation of the desmosomal complex. 
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PLACK syndrome due to loss-of-function 
mutations in the protease inhibitor 
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5.1. Introduction 
In this chapter, the functional aspects of loss-of-function mutations in the CAST gene, 
encoding the protease inhibitor calpastatin, are explored.  Our group identified LOF 
CAST mutations associated with a novel clinical entity which we have named PLACK 
(PSS with Leukonychia, Acral punctate keratoses, Cheilitis and Knuckle pads) 
syndrome. The following introductory section describes the clinical and genetic 
aspects of this condition.  
5.1.1. CAST LOF mutations linked to PLACK syndrome 
We identified LOF mutations in CAST, the gene encoding for the protease inhibitor 
calpastatin, as the genetic cause of the autosomal recessive skin disease PLACK 
syndrome. Three unrelated families were included in this study. One affected 
individual (PK1) from a Chinese consanguineous family presented as an adult with 
generalised skin peeling and a history of superficial acral blistering in childhood, as 
well as the features above. A second affected individual (PK2) from a Nepalese 
family developed acral punctate keratoses and cheilitis at the age of 1, acral and limb 
superficial peeling at the age of 3, as well as leukonychia (Figure 5.1. B). Punctate 
lesions on the dorsum of the hands coalesced into knuckle callosities with milia. Two 
affected siblings (PK3 and PK4) were previously described as having a recessive 
form of pachyonychia congenital. Further clinical investigation revealed a history of 
blistering and peeling of skin from the age of about 3 months on the hands, feet, 
knuckles, elbows and knees, leukonychia, leukokeratosis, angular cheilitis, papules 
on the extensor surface of the fingers and toes, and punctate palmar keratosis and a 
plantar keratoderma (Haber and Rose, 1986). Exome sequencing of the four affected 
individuals revealed homozygous LOF mutations in CAST, which segregated with 
the disorder in all families: 
PK1: frameshift mutation (c.607_608insAfs, p.I203Nfs*8), 
PK2: nonsense mutation (c.A232T, p.K78X),  
PK3 and PK4: frameshift mutation (c.1750delG, p.Val584Trpfs*37).  
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All three mutations were predicted to lead to complete loss of expression of CAST. 
Calpastatin is a specific protease inhibitor of calpains, intracellular cysteine 
proteases that require calcium or epidermal growth factor for their catalytic 
activity. The calpains have been related to a variety of processes such as the growth, 
migration and death of keratinocytes (Carragher and Frame, 2004).  
In this chapter we focus on the genetic and functional analysis of the LOF mutations 
by using siRNA to knockdown CAST expression in the immortalised keratinocyte cell 
line HaCaT. Some of the results presented in this chapter are included in Lin et al. 
(Lin et al., 2015). 
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Figure 5.1. PLACK syndrome in PK2 homozygous for p.K78X. (A) Clinical features of 
PK2 are shown, including skin peeling (iii), cheilitis (iv), punctate keratosis of the soles (i), 
blistering (ii), leukonychia (v), and knuckle pads with hyperkeratotic micropapules (v). (B) 
Family pedigree of PK2 (Square – Male; Circle – Female; Filled symbol – PK2 homozygous 
for p.K78X in CAST). 
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5.1.1. Summary 
Briefly, the identification of three CAST LOF mutations leading to a new clinical 
entity, which we suggest to be named PLACK syndrome, is described in this thesis. 
The histological and ultrastructural characteristics of affected skin biopsies are 
presented together with the in vitro analyses of adhesion, cell viability and 
migration, and desmosome regulation following siRNA-mediated knockdown of 
CAST in HaCaT cells. 
5.2. Results 
5.2.1. Functional analysis of LOF mutations in CAST 
This chapter describes the genetic analysis of patient PK2 who harbours the 
homozygous p.K78X CAST mutation, and investigates the effects of the CAST LOF 
mutation on epithelial integrity. The affected phenotypical characteristics were 
mimicked in an immortalised keratinocyte cell line using the ON-TARGETplus 
SMART Pool siRNA targeting all isoforms of CAST. 
5.2.1.1. CAST LOF mutation identified in PK2  
Given that the clinical phenotype was complex and no disease-associated genes 
were known for this condition, an exome capture was performed on affected 
genomic DNA. Exome sequencing revealed a homozygous nonsense mutation 
(c.A232T, p.K78X) in CAST as the likely underlying genetic cause of the syndrome. 
Sanger sequencing of affected DNA, performed by Dr Claire Scott, confirmed the 
existence of a change from adenine to thymine at the genomic DNA level, which 
changes a lysine amino acid into a STOP codon at the protein level. Control genomic 
DNA was wild type and parent DNA was heterozygous for this mutation (Figure 
5.2.).  
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Figure 5.2. Confirmation of p.K78X mutation in the CAST gene of PK2. 
Electropherograms of wild type control, heterozygous parent of PK2, and PK2 genomic DNA 
sequences. Sanger sequencing revealed a homozygous transversion from adenine to 
thymine at coding position 232 of CAST, which changes a lysine amino acid to a STOP codon 
at the protein level (c.A232T:p.K78X). Genomic DNA from a non-affected individual was 
used as wild type control. Sanger sequencing was performed by Dr Claire Scott.  
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5.2.1.2. Histological and immunohistochemical observations of PK2 skin 
Histological examination of a non-lesional skin biopsy from PK2, homozygous for 
p.K78X in CAST, showed minor thickening of the basal layer and widening of 
intercellular spaces in the basal and suprabasal layers of the epidermis (Figure 5.3. 
B), in comparison to control skin (NS) (Figure 5.3. A).  
Immunohistochemistry of paraffin embedded skin from PK2 with an antibody 
raised against calpastatin showed a significant reduction in protein expression in 
skin from PK2 (Figure 5.3. D), compared to bright cytoplasmic staining throughout 
all layers of the epidermis in normal control skin (Figure 5.3. C). 
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Figure 5.3. Haematoxilin and Eosin (H&E) and immunohistochemistry staining of 
PK2 skin biopsy. H&E stain of normal skin (NS; A) and skin from PK2 (B) revealed widened 
intercellular spaces in the basal - suprabasal layers in affected skin in contrast to NS. H&E 
was performed by Mr Benjamin Fell. IHC with an anti-calpastatin antibody (in green) 
showed normal expression of calpastatin throughout all layers of normal skin (NS, C) and 
protein absent from all layers in affected skin (p.K78X; D), in the presence of DAPI as 
nuclear marker (in blue). IHC was performed by Dr Claire Scott. Imaging of H&E staining 
was carried out on the Nikon Eclipse TE 2000-S and Nikon Digital Sight at 10 X 
magnification. IHC imaging was carried out on the Zeiss Meta 710 confocal microscope and 
images were taken at 40 X magnification. NS – Normal skin; PK2 – Affected skin (Scale bar 
–20 µm for C and D). 
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5.2.1.3. Transient siRNA down-regulation of CAST isoforms in HaCaT keratinocytes  
To determine the functional consequences of CAST LOF mutations in vitro, siRNA-
mediated knockdown of CAST was performed in HaCaT cells, using a specific pool of 
four siRNAs (ON-TARGETplus Human CAST siRNA SMARTpool, GE Healthcare 
Dharmacon). The sequences and targeting sites of this functional siRNA pool are 
found in Table 2.5. NTP siRNA (ON-TARGETplus Non-Targeting Pool, GE Healthcare 
Dharmacon) was used as a control.  
A number of optimisations were performed prior to the siRNA-based experiments 
described in this chapter, including optimisation of transfection conditions and time 
course analysis of CAST down-regulation. Optimisation of transfection conditions 
was carried out to find the highest transfection efficiency while maintaining cell 
viability (as described in section 5.2.1.5.). The concentration of the siRNA pool was 
varied to determine the lowest concentration resulting in down-regulation of CAST 
with minimised risk of off-target effects. The time course analysis was performed to 
determine the duration of the CAST down-regulation. These optimisations are 
described in Appendix G.1. 
Immunocytochemistry performed with an anti-calpastatin antibody on CAST siRNA-
treated cells and NTP control cells (Figure 5.3.), revealed down-regulation of 
calpastatin in CAST siRNA monolayers compared to a cytoplasmic expression in NTP 
cells (Figure 5.3. B). Western blots of CAST siRNA-treated HaCaT cell lysates were 
performed, as previously described, to confirm that CAST knockdown was achieved 
prior to any other analysis (Figure 5.4. C). A CAST knockdown was obtained which 
down-regulated all CAST isoforms by 50-65% in HaCaT cells. 
To investigate in vitro the effects of mechanical stress in CAST siRNA transfected 
HaCaT cells, the FX-4000TM cell stretcher was used as previously described for the 
CSTA siRNA studies in HaCaT cells (Chapter 5.2.1.3.). CAST siRNA transfected cells  
together with NTP siRNA transfected cells as control, were subjected to mechanical 
stretch at a frequency of 5 Hz (five cycles of stretch and relaxation per second) and 
an elongation of amplitude ranging from 10% to 14% (increase in diameter across 
the silicone deformable membrane from 10% to 14%). Cells were stretched for 4 h.  
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Staining of non-stretched and 4 h-stretched CAST siRNA-treated cell monolayers 
and control cells, using an anti-keratin 14 antibody, revealed widening of the 
intercellular spaces in CAST siRNA cells independent of mechanical stress, together 
with breakage of intercellular junctions (Figure 5.4. Ei and Eii) compared to NTP 
treated cells where after 4 h stretch these connections appeared disrupted but not 
broken (Figure 5.4. Dii). 
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Figure 5.4. CAST siRNA transfection and mechanically induced stress on knockdown 
cell monolayers. HaCaT cells transfected with a pool of CAST siRNA (B) and NTP siRNA (A) 
for 72 h were stained with an anti-calpastatin antibody (in green) in the absence (Ai and 
Bi) and presence (Aii and Bii) of DAPI (in blue) as nuclear marker. A reduction in the 
calpastatin protein levels can be seen in CAST siRNA treated cells compared to NTP siRNA 
cells; this was confirmed by western blotting of total cell lysates (C). A reduction in CAST 
levels can be observed for the CAST siRNA treated cells (lane 2). GAPDH was used as a 
loading control. Imaging was performed on the Zeiss Meta 710 confocal microscope and 
images taken at 40 X magnification (A and B) (Scale bar – 20 µm).  
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Figure 5.4. CAST LOF by siRNA transfection and mechanically induced stress on 
knockdown cell monolayers (continued). NTP control HaCaT cells (Di and Dii) and CAST 
siRNA cells (Ei and Eii) mimicking the LOF mutation were subjected to cyclic mechanical 
stress at a frequency of 5 Hz and amplitude of 10-14% using the Flexcell FX-4000 Tension 
System for 0 h (non-stretched, Di and Ei) and 4 h stretch (Dii and Eii). ICC with an anti-
keratin 14 antibody revealed that CAST siRNA cells display large intercellular gaps (*) both 
before and after 4 h stretch, suggesting an adhesion defect independent of mechanical stress 
(Ei and Eii). Keratin 14 filaments appeared stretched, but not broken, in NTP treated cells 
following 4 h stretch (arrows). Keratin 14 – in green; DAPI – in blue. Imaging was performed 
on the Zeiss Meta 710 confocal microscope and images taken at 63 X magnification (D and 
E) (Scale bar – 20 µm).  
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5.2.1.4. Cell migration appears normal in CAST knockdown keratinocytes 
To investigate the effects of the CAST LOF mutations on cell migration and “wound-
healing”, a scratch assay was performed as previously described for the CSTA siRNA 
treated cells. After applying a scratch throughout the CAST siRNA and NTP cell 
monolayers pictures were taken at set time intervals, up to 24 h post-scratch in 
order to assess and compare the time and speed of scratch-wound closure in CAST 
siRNA cells compared to control cells. Pictures taken at the 0 h, 12 h and 24 h time 
points showed no significant differences in cell migration in CAST siRNA cells after 
24 h compared to control (Figure 5.5. A). In order to quantify this, the size of the 
scratch was measured for these three time intervals. Analysis of measurements of 
areas migrated between the 0 h, 12 h and 24 h time points showed no significant 
difference, indicative of a normal cell migration pattern and normal scratch-wound 
healing process (Figure 5.5. B). The graphical representation below illustrates the 
analysis of three independent siRNA knockdown experiments (n = 8). Scratch 
measurements were made with Image J software and resulting scratch 
measurements are given as arbitrary numbers from a maximum set number. 
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Figure 5.5. “Wound-healing” assay showed normal cell migration after 24 h. (A) 
Scratch-wound assay to assess migration by the degree of scratch closure after 24 h. (B) No 
significant difference was observed between NTP siRNA and CAST siRNA treated cells 
suggesting that there is no obvious difference in cell migration and scratch closure (n = 8). 
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5.2.1.5. Analysis of cell viability in CAST siRNA treated cells  
Previous studies have reported calpastatin and the target proteases as being 
implicated in growth, migration and apoptotic cell death (Carragher and Frame, 
2004). We have analysed the percentage of early and late apoptosis in CAST siRNA 
cells in comparison to NTP control. CAST LOF cells were stained with annexin V – 
FITC. One siRNA knockdown assay was performed, with three samples for each 
condition analysed by FACS. Two representative images for the NTP and CAST siRNA 
samples are shown in Figure 5.6. A, together with the graphical representation of 
the statistical analysis of the three samples from the one siRNA knockdown (Figure 
5.6. B). No statistically significant difference was observed between CAST siRNA and 
the control cells. This is indicative of normal apoptotic cell death in CAST knockdown 
cells.  
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Figure 5.6. Apoptosis analysis by FACS in CAST siRNA treated cells. (A) Dot plot of 
readings for NTP and CAST siRNA treated cells. A number of 30,000 events were allowed 
for each repeat. Gates were used initially to exclude debris and then to separate between 
living, apoptotic and dead cells. (B) Representation of cell death analysis in NTP and CAST 
siRNA treated cells. The columns represent the percentage of live, apoptotic and dead cells. 
A normal level of apoptotic cell death was observed for CAST siRNA treated cells, similar to 
control. 
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5.2.1.6. Expression of desmosome-associated proteins in skin from PK2 homozygous for 
a CAST LOF mutation 
Due to the cell adhesion defect in CAST LOF skin, the expression and localisation of 
some of the desmosome-associated proteins was analysed. Immunofluorescence 
was performed with anti-DSG2 (Figure 5.7.), DSG3 (Figure 5.8.) and DSP I/II (Figure 
5.9.) specific antibodies in non-lesional skin sections from PK2 and control skin.  In 
normal epidermis DSG2 appeared with a diffuse cytoplasmic and membranous 
localisation (Figure 5.7. A), while DSG3 and DSP presented with a membranous 
localisation (Figure 5.8. A and 5.9. A). In affected skin, DSG2 appeared to present 
with an expression profile similar to control skin, with areas of increased expression 
in the basal layer (Figure 5.7. B). Staining of DSG3 and DSP showed a significant 
increase in protein expression, with both a plasma membrane and cytoplasmic 
localisation pattern (Figure 5.8. B and 5.9. B), in comparison to the specific 
membranous pattern in control skin. Staining of DSP in affected skin also 
highlighted intercellular gaps in the basal/suprabasal layers as seen by histological 
analysis (Figure 5.9. Bi). 
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Figure 5.7. Immunofluorescence of DSG2 in skin sections from PK2. IHC with an anti-
DSG2 antibody (in green) in control skin (A) and skin sections from PK2 (B) in the absence 
(Ai and Bi) and presence (Aii and Bii) of DAPI as a nuclear marker (in blue), revealed areas 
of increased protein expression (arrows) in the basal layer of affected skin compared to 
control skin. Imaging was performed with the Zeiss Meta 710 confocal microscope and 
images were taken at 20 X magnification (A and B) and 10 X magnification for negative 
control (C) (Scale bar – 20 µm for A and B and 50 µm for C). 
 
 
 
 
 
 
 
180 
 
 
Figure 5.8. Immunofluorescence of DSG3 in skin sections from PK2, homozygous for 
p.K78X, and control skin. IHC with an anti-DSG3 antibody (in green) in control skin (A) 
and skin sections from PK2 (B) in the absence (Ai and Bi) and presence (Aii and Bii) of 
DAPI as a nuclear marker (in blue), revealed a significant increase in protein expression in 
the basal/suprabasal layers of the epidermis in affected skin compared to control skin. A 
change from a typical membranous localisation to a both membranous and cytoplasmic 
localisation of this protein was also noted (lower exposure of DSG3 in Appendix G.2.). 
Imaging was performed with the Zeiss Meta 710 confocal microscope and images were 
taken at 20 X magnification (A and B) and 10 X magnification for negative control (C) (Scale 
bar – 20 µm for A and B and 50 µm for C). 
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Figure 5.9. Immunofluorescence of DSP in skin sections from PK2, homozygous for 
p.K78X and control skin. IHC with an anti-DSP antibody (in green) in control skin (A) and 
skin sections from PK2 (B) in the absence (Ai and Bi) and presence (Aii and Bii) of DAPI as 
nuclear marker (in blue), revealed a significant increase in protein expression in all layers 
of the epidermis in affected skin compared to control skin. A change from a typical 
membranous localisation to a both membranous and cytoplasmic localisation of this protein 
was also noted, together with more apparent intercellular spaces in the basal/suprabasal 
layers. Imaging was performed with the Zeiss Meta 710 confocal microscope and images 
were taken at 20 X magnification (A and B) and 10 X magnification for negative control (C) 
(Scale bar – 20 µm for A and B and 50 µm for C). 
 
 
 
 
 
 
182 
 
5.2.1.7. Desmosome-associated proteins appear affected by CAST LOF mutations 
Following observations on the altered expression and localisation of the 
desmosome-associated proteins DSG2, DSG3, and DSP I/II in affected skin, these 
proteins were investigated in CAST siRNA-treated cells before and after 4 h 
mechanically-induced stress.  
Total protein cell lysates from NTP and CAST siRNA-treated HaCaT cells were 
obtained and analysed by western blotting. Antibodies targeting DSG2, DSG3, PG 
and DSP I/II were used together with anti-vinculin and anti-GAPDH antibodies as 
loading controls (Figure 5.10. A). Independent siRNA knockdown experiments were 
conducted and replicate western blots were carried out for each protein. 
Densitometry measurements of western blots were calculated using an image 
analysis program (Image J, v1.47v) and are graphically depicted in Figure 5.10. B 
and C for DSG2 and DSG3, which were consistent between repeats, and in Figure 
5.10. D for DSP II and Appendix G.3. for PG which appeared with more variability 
between repeats but with similar expression levels between CAST siRNA and NTP 
treated cells.  
DSG2, DSG3 and DSP II protein expression levels appeared increased following CAST 
siRNA knockdown, while PG expression appeared consistent and similar to 
expression in NTP control cells independent of mechanical stress.  Protein levels 
were normalised against the loading control band, GAPDH for DSG2 and DSG3 and 
vinculin for DSP I/II, and are presented as a fold change from NTP control for the 
western blots for DSG2, DSG3 and DSP II in Figure 5.10. A. No change in expression 
levels was observed for DSP I and PG (Appendix G.3.). Due to the variability in 
expression levels, despite an overall trend towards up-regulation, further repeats 
would be necessary together with protein quantification prior to western blotting, 
in order to draw a conclusion.  
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Figure 5.10. Up-regulation of DSG2, DSG3 and possibly DSP II in CAST siRNA treated 
cells. (A) Total protein cell lysates from CAST siRNA and NTP siRNA HaCaT cells, non-
stretched and stretched for 4 h, were blotted and incubated with anti-DSG2, DSG3, PG or 
DSP I/II to check the levels of expression of these proteins. (B-D) Protein levels of DSG2, 
DSG3 and DSP II calculated from densitometric measurements of the western blot images 
and normalised to loading controls (GAPDH for DSG2 and DSG3; Vinculin for DSP II). Total 
DSG2, DSG3 and DSP II expression levels are presented as a fraction of the total protein level 
in NTP siRNA cells; more repeats would be necessary for DSP II in order to include standard 
error bars. Densitometric analysis for PG and DSP I can be found in Appendix G.3. and are 
showing similar expression levels between CAST siRNA and NTP siRNA.  
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5.3. Discussion 
In this chapter, a new clinical entity named PLACK syndrome, and the research on 
three independent families presenting with mutations in the CAST gene, which 
encodes for the protease inhibitor calpastatin, are described as being linked to this 
disorder. The main focus of the work described was the characterisation of a skin 
biopsy from PK2, homozygous for CAST p.K78X and in vitro studies on desmosomal 
cell adhesion. Calpastatin and the target calpains appear to regulate cell adhesion in 
the basal/suprabasal layers of the epidermis.  
5.3.1. CAST LOF mutations linked to PLACK syndrome, a new clinical 
entity 
We identified three families with a complex type of peeling skin syndrome (PSS), 
which we have named PLACK syndrome due to the observed clinical phenotype 
characterised by PSS with leukonychia, acral punctate keratoses, cheilitis and 
knuckle pads (Lin et al., 2015).  
Two types of PSS have previously been described, acral PSS (APSS), involving the 
palmar, plantar and dorsal surfaces of the hands and feet (Shwayder et al., 1997, 
Hashimoto et al., 2000), associated with mutations in the TGM5 gene (Cassidy et al., 
2005), and generalized PSS (GPSS), which together with the characteristics 
described for APSS also presents with severe pruritus, food allergies and repeated 
episodes of angioedema, urticaria, and asthma (Oji et al., 2010, Mallet et al., 2013), 
and was associated with mutations in the CDSN gene (Oji et al., 2010). Recently 
Blaydon et al. (Blaydon et al., 2011b) and Krunic et al. (Krunic et al., 2013) described 
homozygous nonsense mutations in the CSTA gene associated with exfoliative 
ichthyosis and APSS respectively, while Cabral et al. (Cabral et al., 2012a) identified 
CHST8 as a novel gene linked to PSS. 
Through independent exome capture analyses, three distinct homozygous LOF 
mutations were identified in affected individuals from three PLACK families. All 
these mutations, c.607dup:p.Ile203Asnfs*8 in PK1, c.A424T:p.Lys142* in PK2 
(analysed in this chapter) and c.1750delG:p.Val584Trpfs*37 in PK3 and PK4, were 
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identified in the CAST gene and are predicted to encode for a truncated non-
functional protein.  
Calpastatin is a specific endogenous inhibitor of the classical calpains 1 and 2, also 
known as calpains µ (micro) and m (mili) (Corrado et al., 2006), on the basis of the 
calcium concentration required for their activation: a low concentration is needed 
for µ-calpain and a higher concentration needed for m-calpain (Ono and Sorimachi, 
2012).  
To investigate the consequences of the CAST LOF mutation p.K78X, immunostaining 
was performed with an anti-calpastatin antibody on non-lesional skin sections from 
PK2. This has revealed an almost complete absence of protein expression in all 
layers of the epidermis, in comparison to normal control skin where calpastatin was 
expressed throughout all layers of the epidermis and had a cytoplasmic appearance. 
Histologically, intercellular gaps in the basal/suprabasal layers of the epidermis 
were observed, together with what appears to be a thicker basal layer with specific 
apical oriented cells.  
5.3.2. Transient CAST down-regulation leads to disrupted intercellular 
adhesion in vitro 
To analyse further the consequences of the CAST LOF mutations in vitro, siRNA-
mediated knockdown of CAST using a specific siRNA pool was performed in the 
immortalised keratinocyte cell line HaCaT, with NTP siRNA used as control. 
Knockdown of CAST was obtained, which reduced calpastatin expression by 
approximately 50-65%. The level of knockdown was assessed by 
immunocytochemistry and/or total protein lysates by western blotting prior to any 
other analysis.  
Due to the observed cell adhesion defect in the basal/suprabasal layers in the 
epidermis from the affected individual, an in vitro mechanically-induced stress 
assay was used to investigate the role of calpastatin in keratinocyte adhesion in 
CAST siRNA and NTP siRNA-treated cells as control. Immunocytochemistry with a 
specific anti-keratin 14 antibody in non-stretched and 4 h-stretched cell monolayers 
revealed widened intercellular spaces both in the non-stretched and stretched CAST 
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knockdown cells, which suggests that this disruption happens independently of 
mechanical stress. In contrast, NTP cells presented with extended keratin 14 
filaments post-stretching but no disruption in intercellular adhesion prior to 
mechanical stress. The direct implication of calpastatin in intercellular adhesion has 
not, to our knowledge, been reported previously and a possible mechanism of action 
is discussed below. 
Independent studies looking at a variety of cancers have associated calpains, the 
specific targets of calpastatin, with adhesion, motility, invasion, cell-cycle 
regulation, cell spreading, apoptosis and myogenesis (Leloup et al., 2006). A recent 
study by Nassar et al., using a calpastatin overexpression mouse model observed 
changes in the wound-healing process in comparison to wild type mice. A significant 
delay in wound-healing was noted, associated with reduced proliferation and re-
epithelialisation, most prominently in the early stages of the wound-healing process 
(Nassar et al., 2012). 
To address the possible effects of the CAST LOF mutations on keratinocyte migration 
in vitro, a scratch assay was performed in CAST knockdown keratinocyte 
monolayers following inhibition of proliferation. NTP cells were used as a control 
and were treated in the same manner. Results showed a normal scratch-wound 
closure pattern, similar to the one observed for NTP control cells, which signifies a 
normal cell migration process. A CAST LOF 3D organotypic cell model or analysis of 
Cast KO mouse may give a more accurate view of any wound-healing and cell 
migration processes regulated by calpastatin. 
Tan et al. observed that in embryonic fibroblasts derived from Capn4 genetically 
disrupted mice, the calpain deficiency correlated with resistance to ER stress-
induced apoptosis, directly related to calpain requirement for activation of both 
caspase-12 and the ASK1-JNK cascade (Tan et al., 2006). Another in vitro study 
demonstrated that increased activity of m-calpain results in apoptosis of HaCaT 
cells, and that the activation of m-calpain is directly proportional to EGF 
concentration (Inoue et al., 2004). 
Analysis of lesional patient skin sections by TUNEL assay and TEM (performed by 
Dr Zhimiao Lin, Peking University First Hospital, Beijing, China) revealed a 
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significant increase in the number of apoptotic cells and apoptotic bodies formed, 
compared to normal control skin. To look at the consequences of CAST knockdown 
in vitro, FACS analysis of the cell cycle was performed in CAST siRNA treated cells 
against control NTP cells. The results from one knockdown experiment with each 
condition in triplicate were analysed and revealed similar percentages of cells in all 
stages of the cell cycle between CAST siRNA and NTP siRNA treated cells. 
TUNEL and TEM results suggest that analysis of apoptosis in skin sections from 
other PLACK patients and the use of a CAST LOF 3D cell model may reveal different 
results to the ones seen in cell monolayers, as the increase in apoptotic cell number 
in PK1 was in the suprabasal layers of the epidermis.  
5.3.3. Dysregulation in expression and appearance of desmosome-
associated proteins  
Observations in CAST LOF affected skin and in vitro studies, coupling CAST siRNA-
mediated knockdown with mechanically-induced stress, indicate a key role for 
calpastatin in intercellular adhesion. 
In order to address the possibility of a direct correlation between CAST LOF 
mutations and an increased calpain activity leading to excessive proteolysis of 
epidermal desmosomal components, the expression and localisation of some of 
these proteins in affected skin sections and in CAST siRNA keratinocytes was 
analysed.  
Staining of skin sections from PK2, homozygous for p.K78X, with anti-DSG2, DSG3 
and DSP I/II specific antibodies, revealed an apparent up-regulation of DSG2 
expression in areas of the basal layer of the epidermis and a significant up-
regulation of DSG3 and DSP I/II in all layers of the epidermis. Aberrant localisation 
of these proteins to the cytoplasmic compartment was observed, when compared to 
normal control skin where DSG3 and DSP I/II appeared mainly expressed at the 
plasma membrane. Furthermore, western blotting of total protein lysates from CAST 
knockdown cells revealed a general trend towards up-regulation of DSG2, DSG3 and 
DSP II independent of mechanical stress when compared to NTP cells. Any variation 
in the levels of up-regulation of DSG2, DSG3 and DSP II between CAST knockdown 
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repeat experiments, may be due to variations in CAST knockdown levels and could 
be addressed by quantification of total protein levels prior to western blotting. 
These observations could suggest that the reduction in expression of calpastatin due 
to CAST LOF mutations directly correlates with an increase in the concentration of 
active calpains. This in turn could lead to proteolysis of DSG2, DSG3 and DSP II in 
the affected individuals, resulting in acantholysis and impaired resistance of the 
epidermis to mechanical stretch, seen in affected individuals as blistering and skin 
peeling.  
As calpain-mediated proteolysis of talin and focal adhesion kinase (FAK) reportedly 
leads to regulation of adhesion dynamics (Franco et al., 2004, Chan et al., 2010), 
these proteins could be analysed in PK patient skin and CAST siRNA transfected 
keratinocytes. 
5.4. Summary 
To summarise, this chapter described the features of a new clinical entity named 
PLACK syndrome, characterised by PSS, leukonychia, acral punctate keratosis, 
cheilitis and knuckle pads. Through three independent exome capture analyses of 
the three families, our group identified autosomal recessive mutations in CAST, 
leading to LOF of calpastatin, the only known inhibitor of calpains. 
CAST knockdown mimicking the LOF mutations, coupled with mechanical stretching 
revealed reduction in intercellular adhesion levels independent of mechanical 
stress. No change in cell migration or cell cycle was seen by scratch assay or FACS 
analysis. A possible mechanism of action following CAST LOF mutations could be 
through increased calpain activity leading to the proteolysis of desmosome-
associated proteins, as indicated by the in vivo and in vitro observations showing up-
regulation and aberrant localisation of DSG2, DSG3 and DSP II.  
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6.1. Background 
Desmosomes are complex macromolecular structures, playing both structural and 
signalling roles in bordering cells. Although the precise role of desmosomes as 
adhesion structures and signalling centres is not yet fully understood, it is widely 
accepted that their correct assembly and function is crucial in desmosome-
presenting tissues such as the skin and myocardium. It has been well acknowledged 
in a number of studies that dysregulation of desmosome assembly and function, due 
to genetic variations in desmosomal genes, leads to an array of conditions featuring 
cardio-cutaneous phenotypes including some with hair abnormalities including 
woolly hair or alopecia. 
The two main focuses of this thesis were, firstly, the genetic analysis of patients 
clinically diagnosed with ARVC or genodermatoses, resulting in the discovery of 
novel and previously disease-linked mutations in genes encoding for desmosome-
associated proteins, and secondly, the in vitro analysis of loss-of-function (Loffek et 
al.) mutations in two genes encoding for the protease inhibitors, cystatin A and 
calpastatin, leading to the skin disorders exfoliative ichthyosis and PLACK 
syndrome respectively. The molecular mechanisms behind mutations affecting the 
desmosomal complex, either directly through changes in desmosomal proteins or 
indirectly affecting proteins involved in desmosome regulation, are continuously 
being uncovered and highlight the importance of these structures in desmosome-
bearing organs. 
6.2. Genetic heterogeneity in ARVC and genodermatoses 
6.2.1.  PKP2 is the major affected desmosome-associated protein in 
ARVC 
A number of dominant and recessive mutations identified to date in genes encoding 
for the desmosome-associated proteins DSP, DSC2, DSG2, PKP2 and PG lead to non-
syndromic ARVC.  
PKP2 mutations account for a significant number of ARVC cases (Sen-Chowdhry et 
al., 2010), and were initially identified following a large study by Gerull et al. who 
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uncovered 25 different novel PKP2 mutations in 32 probands out of a total of 120 
patients, ranging from missense and nonsense to insertion, deletion and splice-site 
mutations, most of which affected the C-terminus end of the protein, while the 
others were scattered throughout the gene (Gerull et al., 2004). Both founder and 
recurrent mutations were identified up to date (van der Zwaag et al., 2010). The 
recurrent mutations suggest the presence of “hot spot” mutagenic regions in PKP2 
(Gerull et al., 2004, Dalal et al., 2006), the frequency in C>T mutations pointing at 
the CpG hot spots as targets of spontaneous mutations (Awad et al., 2008a). 
Here, six dominant and recessive variations in PKP2, ranging from splice-site of 
exons 11 (IVS11-1G>C) and 12 (IVS12+1G>A; rs111517471) to nonsense 
(c.G870A:p.W290X and c.T1926A:p.Y642X) and missense (c.G1939A:p.A647T and 
c.A148C:p.T50A) mutations were identified. Bauce et al. have shown that skipping 
of exon 11 in RNA transcripts and the possible generation of a premature STOP 
codon following the PKP2 mutation could prove highly pathogenic (Bauce et al., 
2010). The rs111517471 variation, with a minor allele frequency of less than 0.01, 
has also previously been associated with ARVC and is believed to be highly 
pathogenic (Scherer et al., 2006). We suggest that the two missense mutations 
identified by our studies would lead to conformational changes through single 
amino acid modifications while the two nonsense mutations would lead to more 
severe truncations of the PKP2 protein structure, which in turn would most likely 
affect desmosome assembly and function. Truncating mutations are thought to lead 
to haploinsuficiency because of their instability (Joshi-Mukherjee et al., 2008).  
Co-immunoprecipitation and yeast two hybrid system studies have reported direct 
interactions between PKP2 and other desmosome-associated proteins such as DSP, 
PG, DSC1a and 2a, DSG1 and 2, some of which are of high importance in cardiac 
desmosomes (Bonne et al., 1999, Chen et al., 2002). Additional interactions have 
been reported with the intermediate filaments (Hofmann et al., 2000) and β-catenin 
regulating its signalling activity (Chen et al., 2002). Thus mutant or reduced (due to 
haploinsufficiency mutation) PKP2 is likely to impair its association with other 
desmosomal proteins and their assembly in the heart, thus leading to cardiomyocyte 
adhesion problems. PKP2 is the only isoform in the heart, while in the epidermis is 
found to be expressed together with PKP1 and 3, which could perhaps compensate 
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for the PKP2-deficiency; this could possibly explain the non-syndromic phenotype 
in ARVC patients. This hypothesis is also supported by a Pkp2 knockout mouse 
model which resulted in lethal cardiac damage at mid-gestation, characterised by 
defective intercellular adhesion at the intercalated disks and blood loss into the 
pericardial cavity, associated with a reduction in expression of DSP and PG 
(Grossmann et al., 2004).  
Another hypothesis, supported by a number of in vitro siRNA studies on rat and 
human cardiomyocytes, associates ARVC-linked PKP2 mutations with a 
redistribution of connexins (Oxford et al., 2007, Pieperhoff et al., 2008), in particular 
with abnormalities in total connexin 43 (Cx43) expression which appears to be a 
consistent feature in patients with advanced ARVC (Antoniades et al., 2006, Fidler 
et al., 2009, Kannankeril et al., 2006, Lahtinen et al., 2008, Asimaki et al., 2009). In 
an independent study using neonatal rat ventricular myocytes, Joshi-Mukherjee et 
al. have shown that the p.Arg79X nonsense mutation in Pkp2 led to a reduction in 
Cx43 expression and the failure of the two proteins to interact (Joshi-Mukherjee et 
al., 2008).  
In desmosome-containing epithelial cells, PKP2 appears to be associated with DSP 
and together migrate from the cytoplasmic compartment to the plasma membrane 
during desmosome assembly (Godsel et al., 2005). These observations together with 
an in vitro study on PKP2-deficient cells, showing that DSP-PKCα complexes 
dissociate while DSP remains anchored to the intermediate filaments failing to reach 
the plasma membrane (Bass-Zubek et al., 2008). 
6.2.2. Disease heterogeneity associated with DSP mutations 
The most frequent genes mutated in ARVC except for PKP2 are DSP (10-15% of 
diagnosed cases) and DSG2 (10-15% of diagnosed cases) (Pilichou et al., 2006) and 
represent the “big 3” target genes (Sen-Chowdhry et al., 2010), with compound and 
double heterozygotes having been reported in up to 33% of genetically diagnosed 
cases.  
Here, a double heterozygote presenting one of the PKP2 mutations (IVS11-1G>C) 
presented above, together with a heterozygous transversion in exon 11 of DSP, 
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c.G1323C:p.K441N, is presented. Also, during the course of the ARVC study, genetic 
screening of two siblings with hypotrichosis and PPK revealed a homozygous 
mutation in exon 12 of DSP, c.C1493T:p.P498L. This phenotypical exclusivity 
resulting from mutations in the same gene is a matter of intense controversy and 
high interest, mostly as ARVC diagnosis is proving to be extremely difficult and 
variable despite the existing guidelines. 
A number of cardio-cutaneous syndromes with varying degrees of severity have 
been reported since the first linkage of DSP mutations with an exclusively cutaneous 
disorder, autosomal dominant SPPK (Armstrong et al., 1999, Whittock et al., 2002), 
and with the autosomal recessive Carvajal syndrome, a cardio-cutaneous phenotype 
coupled with hair abnormalities (Norgett et al., 2000). In SPPK, the dominantly 
inherited mutations were LOF suggesting that the mechanism of action was 
haploinsufficiency and that protein dosage was key in the stressed areas of the skin 
such as the palm and sole, a hypothesis confirmed by histology findings (Armstrong 
et al., 1999). In comparison, the homozygous DSP mutation linked to the Carvajal 
syndrome would lead to the loss of the IF-binding site and impaired cell adhesion 
with the collapse of the IF network (Huen et al., 2002, Getsios et al., 2004). The first 
case of non-syndromic ARVC linked to mutations in DSP was reported by Rampazzo 
et al. who noted that the missense DSP mutation was affecting the PG-binding 
domain of DSP (Rampazzo et al., 2002). It is well accepted now that the DSP isoforms 
have different functions and are differentially expressed in desmosome-presenting 
tissues, with DSP II expressed at very low levels in the heart (Uzumcu et al., 2006), 
while having a more significant role than DSP I in maintaining keratinocyte adhesion 
in the epidermis (Cabral et al., 2012b). 
Similarly to the mutation identified by Rampazzo et al., it is believed that the ARVC-
linked DSP mutation identified in this study (p.K441N) would affect the N-terminal 
end of all DSP isoforms and thus destabilise the binding of DSP to PG and PKPs, and 
at the same time the tethering of the intermediate filaments to the plasma 
membrane. It is yet unclear why no cutaneous phenotype was described in this 
patient, unless any existing skin modifications are very subtle compared to the 
cardiac manifestations aggravated by the PKP2 mutation. Skipping of PKP2 exon 11 
in mRNA transcripts and the possible generation of a STOP codon could prove highly 
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pathogenic (Bauce et al., 2010), but at the same time Xu et al. have shown that in 
42% of their affected individuals a second mutation in another desmosomal gene 
was needed to cause overt clinical disease (Xu et al., 2010), therefore the question 
of whether the DSP missense mutation contributes to the severity of the phenotype 
can only be clarified by in vitro studies. As mentioned before, a compensatory 
mechanism would be possible in the epidermis where PKP2 is expressed together 
with PKP1 which can promote desmosome formation by recruiting desmosomal 
proteins at the plasma membrane and within desmosomes (Wahl, 2005, 
Bornslaeger et al., 2001), and is able to bind to DSP, DSG1, DSC1, actin and keratin 
intermediate filaments (Hatzfeld et al., 2000, Hofmann et al., 2000, Kapprell et al., 
1988, Smith and Fuchs, 1998), thus explaining why no cutaneous phenotype is seen 
in this patient.  
In comparison, the second recessive missense DSP mutation (p.P498L) identified in 
siblings with hypotrichosis and PPK appears exclusive to the hair and palmoplantar 
areas exposed to mechanical stress. Due to the oldest sibling being only 11 years old 
at the time they were seen in clinic, we cannot completely exclude the possibility of 
any cardiac abnormalities appearing in the future. Clinically, it is important to 
regard PPK in combination with woolly hair or alopecia as a “warning signal” for the 
development of cardiomyopathy, as suggested by Norgett et al. (Norgett et al., 
2006). Whittock et al. have described a similar but more severe form of 
palmoplantar keratoderma and woolly hair associated with skin fragility due to 
compound heterozygous mutations in DSP. Each of the two patients described in 
their study was heterozygous for nonsense and missense mutations, transcript 
analysis demonstrating that the nonsense allele was probably degraded via the 
nonsense-mediated mRNA decay, and that each affected individual was in essence 
homozygous for the missense mutation in the N- or C-terminal domains (Whittock 
et al., 2002). It is possible that homozygosity for p.P498L could affect the formation 
of the protein secondary structure in the absence of wild-type DSP. These changes 
may affect binding of DSP to the intermediate filaments and/or other desmosomal 
proteins, such as PG and PKP1 (Kurzen et al., 1998), which represent the main 
armadillo members present in the hair follicle, explaining why in most recessive 
desmosomal diseases hair is absent or woolly. Mice expressing a truncated PG, 
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lacking its armadillo repeats, showed stunted hair growth indicating that PG 
supresses epithelial proliferation and hair growth in vivo (Charpentier et al., 2000). 
It is therefore likely that the functionally impaired DSP may lead to a reduction in 
PG and/or PKP1 levels, leading to the woolly hair phenotype seen in our patients. 
6.2.3. The importance of segregation studies is highlighted through 
mutations in cadherin genes linked to non-syndromic ARVC and 
hypotrichosis 
Dominant (Pilichou et al., 2006) and recessive (Syrris et al., 2007) DSG2 mutations 
are described in up to 15% of non-syndromic ARVC genetically diagnosed cases. The 
role of DSC2 is unclear, although a recessive 1-base pair deletion mutation in DSC2 
has been linked to ARVC with mild PPK and woolly hair (Simpson et al., 2009b). 
Mutation L732V identified in DSC2, and predicted by PolyPhen as benign, was 
previously described by Bhuiyan et al. in conjunction with a DSG2 mutation V392I 
(Bhuiyan et al., 2009).  
Following the genetic analysis on patients with ARVC, two previously reported 
variations, a heterozygous mutation in DSG2, c.C874T:p.R292C (R292C), and a 
homozygous mutation in DSC2, c.T2194G:p.L732V (L732V) were identified. Variant 
R292C in DSG2, heterozygous in our ARVC case has previously been described as 
homozygous (Sato et al., 2012), or in association with a synonymous probably non-
pathogenic mutation in DSP, D782D, (Cox et al., 2011). R292C has also been 
described in heterozygosity with S194L in DSG2 and R577DfsX5 in PKP2 (Nakajima 
et al., 2012).  
In a parallel study the genetic anaysis of a patient clinically diagnosed with 
hypotrichosis with no cardio-cutaneous phenotype was performed. A variety of 
mutations in DSG4, including frameshift, splice-site, missense and nonsense have 
been linked to the autosomal recessive hair conditions Monilethrix and 
hypotrichosis (Schaffer et al., 2006, Zlotogorski et al., 2006, Shimomura et al., 2006). 
In our patient, three known substitutions were identified in exons 4 
(c.G258A:p.R86R; rs16959856), 5 (c.C495T:p.S165S; rs9956865) and 12 
(c.A1930C:p.I644L; rs4799570) of DSG4. It is believed that the first two synonymous 
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changes in exons 4 and 5 would not alter the secondary protein conformation of 
DSG4 and therefore they are unlikely to be disease-associated. With regards to the 
third mutation in exon 12, despite the amino acid change, this change appears as 
tolerated in SIFT. Thus, the genetic basis of hypotrichosis in this patient is still to be 
identified. 
Even though previous studies have linked mutations in the desmosomal cadherin 
genes DSC2, DSG2 and DSG4 with the above mentioned disorders, the importance of 
segregation studies, particularly for DSC2 proposed mutations, and screening for 
mutations in yet unknown disease-associated genes is highlighted again as a basic 
requirement before establishing a causatory effect.    
6.2.4. Genetic testing limitations in ARVC diagnosis 
ARVC is a particularly heterogeneous disorder characterised by myocardial 
degeneration and fibrofatty replacement, mostly affecting the right ventricle, but in 
some cases extending to the left ventricle and the interventricular septum, 
culminating in ventricle failure, frequent arrhythmias and sudden cardiac death. 
The original International Task Force Criteria (TFC) for ARVC diagnosis was 
established in 1994 (McKenna et al., 1994) in the absence of a gold standard criteria, 
and was updated in 2010 to include quantitative parameters for improving 
diagnostic sensitivity while maintaining specificity (Marcus et al., 2010). 
The estimated prevalence of ARVC in the general population is 1:2000 to 1:5000 
(Corrado et al., 2006a), with men more frequently affected than women, at a ratio of 
up to 1:3 (Azaouagh et al., 2011), and most likely to manifest in the young, 
competing athletes and individuals previously resuscitated from sudden cardiac 
death. These numbers appear to be study- and population-specific, with 
Mediterranean countries, such as Spain and France reaching 1:1000 disease 
prevalence (Sen-Chowdhry et al., 2010), while in Italy ARVC is responsible of up to 
26% of sudden cardiac deaths (Corrado et al., 1990). These statistics support one of 
our hypotheses by which the low percentage of disease-causing mutations, 
identified in only 16% of the total number of screened patients, with 66% identified 
in patients seen in the UK and 33% in patients seen in New Zealand, could be 
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attributed to slightly different methods of patient recruitment and perhaps stricter 
phenotypic parameters applied in differentiating between ARVC and other heart 
disorders in the UK. 
Another variable in disease diagnosis is age of onset, as shown by independent 
studies looking at patients with PKP2 mutations which have presented conflicting 
data. A Japanese study reported a significantly earlier age of onset in their patients 
(Andreasen et al., 2013), compared to a later age of onset reported by Alcalde et al. 
in their Spanish patient cohort (Alcalde et al., 2014). Alcalde et al. have also shown 
that in their patient cohort with familial ARVC, patients presenting missense 
mutations in PKP2 had an earlier age of disease onset (Alcalde et al., 2014).  
Genetic variability and the yet incomplete genotype-phenotype associations, with 
only up to 50% of ARVC cases linked to mutations in the cardiac desmosomal genes 
DSP (10-15%), JUP, PKP2 (40% and up to 70% in familial ARVC), DSG2 (10-15%) 
and DSC2 (approximately 1%), add to the variability resulted from the clinical 
diagnosis of ARVC in the general population. Following our genetic analyses, the 
percentages of possibly disease-associated desmosomal genes were DSP, 11%; 
DSC2, 11%; DSG2, 11% and PKP2, 67%, support previous statistics regardless of the 
low percentage diagnosis rate.  
Other non-desmosomal genes where mutations have been linked to ARVC are the 
transforming growth factor (TGF-β3), which encodes for a cytokine-stimulating 
fibrosis and is believed to modulate cell adhesion (Beffagna et al., 2005), and the 
transmembrane protein TMEM43, which functions as a response element for the 
adipogenic transcription factor PPAR gamma, which may explain the fibrofatty 
replacement of the myocardium (Merner et al., 2008). Another gene initially 
associated with ARVC was the human ryanodine receptor 2 (RYR2), which induces 
the release of calcium from the myocardial sarcoplasmic reticulum (Bauce et al., 
2000), but since publication it is more likely to be a phenocopy rather than true 
ARVC (Basso et al., 2012). We have included TMEM43 in one of our genetic analyses 
on 39 of our patients, but no mutations were found in this gene.  
A number of gene candidates with increasing interest are several desmosomal 
components and related proteins, such as plectin (PLEC) and pinin (PNN) (Sen-
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Chowdhry et al., 2010), which have already been under investigation for their link 
to human dermatoses, desmin (DES), striatin (STRN), titin (TTN), lamins A (LMNA) 
and C (LMNC), more commonly associated with DCM (Taylor et al., 2011, van 
Tintelen et al., 2009, Merner et al., 2008, Klauke et al., 2010, Meurs et al., 2010, 
Quarta et al., 2011), and NFκB interacting protein 1 (PPP1R13L or iASPP) which has 
been identified in cattle/mice with ARVC and woolly haircoat syndrome (Simpson 
et al., 2009a, Herron et al., 2005). Nevertheless, the multitude of genetic studies have 
shown that from individuals with a desmosomal mutation, only 30-50% fulfil 
clinical diagnostic criteria (Towbin, 2008), and that modifier genes could play a 
great role in the variation between individuals, even within the same family.  
Another complexity of genetic testing in families is the presence of compound or 
digenic mutations, a characteristic of diseases with low penetrance (Xu et al., 2010). 
We have identified in our genetic studies one such case of a digenic ARVC patient, 
presenting a mutation in PKP2 and a second mutation in DSP, making it difficult to 
decide whether a “second” variant is sufficient to cause disease and making 
genotype-phenotype correlation difficult if only one allele is analysed.  
In addition to the likelihood of, as yet, unidentified genes for ARVC, the incomplete 
sensitivity of the mutation screening techniques used such as the presence of 
mutations in non-analysed sequences in some cases may contribute to the absence 
of unidentified mutations.  
With regard to highly heterogeneous disorders, like ARVC, mutation screening has 
improved considerably from the laborious, time consuming and ultimately 
expensive conventional PCR and Sanger sequencing techniques, while whole 
genome analysis is becoming an option when faced with the possibility of zooming 
on a region of interest as a more attractive and cost saving technique, mostly as a 
greater number of samples can be screened together. Array-based sequence capture 
using a 385K Roche NimbleGen and the HaloPlex target enrichment system were 
performed on 49 ARVC diagnosed patients to screen for mutations in eight disease-
associated genes, DSP, JUP, PKP2, DSC2, DSG2, DES, TMEM43, and the possibly 
disease-associated gene ADAM17.  
199 
 
While array-based sequence capture systems have been used successfully in the 
discovery of novel variants linked to a number of disorders, ultimately Sanger 
sequencing was required for the confirmation and allocation of mutations to specific 
samples thus making the process time consuming and laborious when the genetic 
diagnosis of a larger set of samples is needed. Less than a dozen studies have been 
published in the last two years, using the HaloPlex target enrichment system, on 
disorders such as cystic fibrosis (Nakano and Tluczek, 2014), chronic lymphocytic, 
acute lymphoblastic and acute myeloid leukaemias (Sutton et al., 2014, Berglund et 
al., 2013, Bolli et al., 2014), primary immunodeficiencies (PIDs) (Stoddard et al., 
2014), the Usher syndrome (Aparisi et al., 2014), neurodegenerative disorders 
(Pihlstrom et al., 2014, Liu et al., 2014), breast, ovarian and colon cancers (Arvai et 
al., 2014, Mathot et al., 2013) and ARVC (Green et al., 2014). This system allowed 
the use of smaller DNA samples, while sample indexing facilitated posterior 
identification of the sample where a variant occurred, resulting in a more accurate 
estimation of allele frequencies. However some studies have reported that the 
presence of an index tag complicated experimental procedures and decreased 
capture specificity in inappropriately indexed samples (Nijman et al., 2010, Ramos 
et al., 2012). Bolli et al. have used HaloPlex to screen a set of AML patients, and 
showed that the two most important parameters affecting coverage of target 
regions are amplicon tiling and read length relative to amplicon length, which could 
give variable coverage to adjacent genomic regions (Bolli et al., 2014). These taken 
into consideration in ARVC genetic diagnosis, the mutational hotspots, such as the 
CpG regions in PKP2 and the N-terminus of DSP, should be checked by Sanger 
sequencing to ensure adequate coverage.  
In this study, all but two samples had a higher than 70% base coverage above a read 
depth of 15 X, a cut off which would reduce the probability of missing variants 
caused by sampling error. As two previously confirmed mutations were also found 
by HaloPlex, we speculate that the difference between the expected average 
percentage coverage of 98.5% and achieved percentage coverage could be due to a 
number of reasons such as:  
(i) variations in sample concentrations which would give a lower sample 
coverage, 
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(ii) the enzymatic fragmentation step which creates blocks of reads with the 
same start and end positions, thus if the distance between two restriction sites is 
longer than the read length, then coverage gaps will occur (Coonrod et al., 2014), 
(iii) a poorly performed adapter trimming step, 
(iv) the lowest anticipated and observed coverage was for PKP2 and despite the 
high number of mutations expected only three mutations were real calls in 37 ARVC 
samples, which could possibly be due to low coverage of mutational “hot spots” in 
this gene. 
Although no INDELS were identified in our study, it has previously been shown that 
this system is proving efficient at detecting this particularly difficult to distinguish 
variation (Aparisi et al., 2014, Bolli et al., 2014). 
In our case the identification of disease-causing mutations in genes already known 
to be implicated in ARVC has proven challenging, with a high potential for false 
negatives due to variable coverage, perhaps associated to high GC-content, highly 
homologous sequences or repeat regions. Moreover these techniques would only 
cover exonic regions included in the sequencing panel, while any intronic, promoter 
and regulatory regions would not be detected (Stoddard et al., 2014). Any novel 
variants should be considered in the context of a region-by-region coverage report 
and would still require validation by Sanger sequencing and functional assays to 
prove genotype-phenotype correlations, mostly as ARVC presents such a high 
genetic and phenotypical variability.  
If to these observations we add some important environmental factors, including 
sex, exercise, hormones, emotional stress, inflammation and the use of medicines, 
all of which play a role in disease expression (Sen-Chowdhry et al., 2010), it is 
understandable why genetic, epigenetic and environmental factors should be 
considered a package in ARVC diagnosis. 
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6.3. In vitro studies reveal a new role for cystatin A in basal 
epidermal adhesion 
The in vitro analyses presented in Chapter 4 are based on the first reported LOF 
CSTA mutations linked to autosomal-recessive exfoliative ichthyosis (Blaydon et al., 
2011b), and they reveal a previously unknown role for the protease inhibitor 
cystatin A in keratinocyte adhesion in the basal layers of the skin epidermis. 
Initially described as an intracellular cysteine protease inhibitor of several 
cathepsins, and later on reported in sweat and secreted in medium from cultured 
keratinocytes, CSTA was functionally limited to the upper layers of the epidermis, 
mostly associated with atopic dermatitis and psoriasis (Kato et al., 2005, 
Vasilopoulos et al., 2007, Vasilopoulos et al., 2008). Furthermore, 
immunohistochemistry on facelift and palm skin samples confirmed that CSTA was 
expressed throughout the epidermis (Blaydon et al., 2011b), supporting previous 
studies (Basel-Vanagaite et al., 2007). 
Using in silico splice-site predictor programs Blaydon et al. have described that the 
splice-site CSTA mutation identified in homozygosity in one of the exfoliative 
ichthyosis families, would lead to the loss of the 3’ splice-acceptor site and a much 
lower maximum entropy score for the mutant splice-site when compared to wild 
type. This would lead to a substantial reduction in protein expression and due to 
changes in protein conformation any expressed protein would most likely be 
dysfunctional (Blaydon et al., 2011b). Due to the lack of patient material for the 
study of these mutations, the immortalised keratinocyte cell line HaCaT together 
with siRNA based knockdown of CSTA, were used for all in vitro analyses described. 
Electron microscopy of the basal and suprabasal layers of patient epidermis and in 
vitro CSTA LOF 3D models have revealed widening of intercellular spaces and 
thickening of keratin filaments in these layers of patient skin, believed to be due to 
impaired intercellular adhesion and increased mechanical stress in the 
palmoplantar regions (Blaydon et al., 2011b). The CSTA knockdown 3D skin model 
described by Blaydon et al., demonstrated hyperkeratosis, parakeratosis and 
moderate epidermal hyperplasia together with a disturbance of the basal epidermal 
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architecture and without changes in epidermal barrier (Blaydon et al., 2011b). 
Further analyses described in Chapter 4, performed using the in vitro cell model 
HaCaT, as also revealed breakage of intercellular connections upon stretching of 
CSTA knockdown monolayers together with thickening and retraction of the keratin 
14 filaments toward the nucleus. Also, a significant reduction in keratinocyte 
adhesion was observed following treatment with either dispase, or in mechanically 
stressed CSTA knockdown monolayers, in contrast to control keratinocytes.  The 
histological and cell biology studies indicate that CSTA plays an important role in 
adhesion in the basal layers of the epidermis. If the change in keratin 14 filaments, 
observed in stretched CSTA knockdown monolayers, is considered together with the 
information that these intermediate filaments connect to the plasma membrane 
through desmosomes then it can be speculated that indirectly the CSTA LOF 
mutations contribute to the dysregulation of desmosome assembly or function, 
most probably through some of the target proteases, cathepsins B, H, L, S or V. 
A number of desmosome-associated proteins have been reported as targets of 
proteases, for example, in Netherton syndrome associated with mutations in SPINK5 
encoding LEKTI-1 which targets the proteases KLK5, KLK7 and KLK14 (Deraison et 
al., 2007), ultimately leading to DSG1 degradation and desmosome cleavage with 
detachment of the stratum corneum (D'Alessio et al., 2013, Hovnanian, 2013). 
Inhibition of these proteases by SPINK6 and SPINK9, is reportedly leading to 
desquamation through their action on DSG1, DSC1 and corneodesmosin (Meyer-
Hoffert, 2009, Meyer-Hoffert et al., 2010, Brattsand et al., 2009).   
In a syndrome of severe skin and bowel inflammation, associated with ADAM17 LOF 
mutations, Blaydon et al. revealed an increase in DSG2 protein expression, implying 
a reduction in DSG2 shedding by ADAM17 (Blaydon et al., 2011a). In contrast, 
patients with TOC (Ellis et al., 1994, Hennies et al., 1995, Stevens et al., 1996), linked 
to mutations affecting iRHOM2 (Blaydon et al., 2012, Saarinen et al., 2012), present 
with immature desmosomes lacking the electron dense midlines (Brooke et al., 
2014). Furthermore, in vitro studies in TOC patient derived keratinocyte cell lines 
revealed a dramatic increase in the iRHOM2-mediated processing and activity of 
ADAM17, together with an increase in processing of DSG2 (Brooke et al., 2014). 
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One possible mechanism of action, explaining the phenotypical limitation to the 
basal layers of the epidermis, would be that the cathepsins target specific 
desmosomal components which are differentially expressed throughout the skin. A 
particular difference between desmosomes of the basal layers and 
corneodesmosomes of the stratum corneum is the expression of DSG1 and DSC1 in 
the stratum corneum compared to the expression of DSG2 and 3 and DSC2 and 3 
decreasing towards the upper layers. This hypothesis can be discussed through 
differences between the autoimmune disorders PV and PF, where DSG3 and/or 1 
are differentially targeted by autoantibodies leading to severe blistering in PV 
(Cirillo and Al-Jandan, 2013) and superficial blisters in PF (Ishii et al., 1997). The 
important role played by DSG3 in the more basal layers of the epidermis, where 
DSG1 is not present and cannot therefore compensate for the anti-DSG3 
autoantibodies in PV, through the so called DSG compensation theory, is very well 
highlighted in these disorders (Shirakata et al., 1998). This hypothesis was partially 
tested by analysis of DSP and DSG1/2 in CSTA knockdown monolayers which have 
shown an up-regulation and aberrant localisation of these components in the 
cytoplasmic compartment of CSTA knockdown stretched cells, while an up-
regulation in DSG3 expression in siRNA treated cells was seen independent of 
mechanical stretch.  
Another difference between the various layers of the epidermis is the 
differentiation-specific expression of diverse keratins as keratinocytes migrate 
towards the upper layers, with keratins 5 and 14 expressed exclusively in the basal 
layers. Additional immunomicroscopy analysis of keratin 5 and keratins 1 and 10 
expressed in the upper layers of the epidermis, on CSTA LOF 3D models could 
perhaps clarify the extent of breakage of these filaments and possibly give an 
indication on whether breakage is taking place on the cytoplasmic side of the plasma 
membrane or intercellularly. 
The expression and activity of the target proteases inhibited by CSTA, cathepsins B, 
H and L, have mainly been analysed in the context of tumour progression, invasion 
and metastasis, where dysregulation of their expression and activity was reported 
to play a role (Strojan et al., 2000, Leinonen et al., 2007, Li et al., 2011, Anicin et al., 
2013). The analysis of cathepsin expression, before and after mechanical stretch or 
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“scratch-wound” of CSTA KD monolayers, has revealed normal expression levels for 
both cathepsins B and L in all conditions. The analysis of the activity of these 
proteases under the conditions described above should be performed to decipher 
the role played by these proteins in the mechanism of epidermal disruption.  
A study looking at neonatal and adult murine skin has shown exceptionally strong 
expression of Csta in neonatal skin during periods of keratinocyte proliferation and 
differentiation suggesting a critical role for this protein either in the promotion or 
regulation of these processes (Scott et al., 2007). Interestingly, in double Csta and 
Stfa2l1 knockout mice, no obvious phenotype such as epidermal peeling was 
observed, including no spontaneous tumours being formed in mice observed for up 
to 12 months (Bilodeau et al., 2009). These observations probably reflect 
differences in human and mouse skin.  
6.4. New clinical entity linked to LOF mutations in CAST 
In Chapter 5 of this thesis we described the clinical aspects and genetic analysis of 
three unrelated families, presenting loss-of-function mutations in CAST, the gene 
encoding for the protease inhibitor calpastatin, linked to a novel clinical entity 
which we have assigned the acronym PLACK (Lin et al., 2015). This syndrome is a 
complex form of generalised PSS, previously linked to mutations in the CDSN gene 
(Oji et al., 2010), and in our patients is accompanied by leukonychia, acral punctate 
keratoses, cheilitis and knuckle pads. The genetic and in vitro analyses, presented in 
the above mentioned chapter of this thesis are included in a study published by Lin 
et al., expanding the spectrum of cutaneous disorders linked to mutations in 
protease inhibitors (Lin et al., 2015).  
As demonstrated by previous studies, mutations in genes encoding for protease 
inhibitors can cause a number of genetic cutaneous disorders, such as SPINK5 in 
Netherton syndrome (Chavanas et al., 2000), SERPINB7 in Nagashima-type 
palmoplantar keratosis (Kubo et al., 2013), CSTA in exfoliative ichthyosis (Blaydon 
et al., 2011b), by mechanisms involving disruption of the skin barrier, impairment 
of keratinocyte adhesion and/or dysregulation of cell signalling. 
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It is predicted that the identified CAST mutations lead to changes in the 
conformational structure of CAST and as confirmed by immunomicroscopy and 
hematological analysis, on non-lesional patient skin, they also lead to a significant 
down-regulation in protein expression. In comparison, normal control skin showed 
expression of CAST throughout all layers of the epidermis. 
One additional aspect observed in CAST LOF skin was abnormally thicker 
basal/suprabasal layers with typically apical-oriented cells, indicative of a possible 
dysregulation in keratinocyte differentiation, perhaps explaining the 
hyperkeratosis seen in patient skin. A number of in vitro and in vivo mouse model 
studies have looked at the role of CAST and the target proteases, calpains 1 and 2, in 
skin disorders and the mechanisms associated. These studies have shown that: 
calpain 1 and CAST are involved in the processing of profilaggrin to filaggrin 
monomers and the processing of keratin filaments in cell differentiation (Yamazaki 
et al., 1997), calpain 2 is involved in the catabolism of filaggrin and filaggrin 2 during 
terminal differentiation (Hsu et al., 2011, Kamata et al., 2009), and an increase in 
calpain 2 activity leads to apoptosis (Inoue et al., 2004), in turn this leading to skin 
hyperkeratosis (Lin et al., 2012, Wang et al., 2015). Lin et al. have observed a 
significant increase in apoptotic cells in lesional skin from another CAST LOF patient 
included in the study (Lin et al., 2015). We suggest that an increase in the activity of 
calpains 1 and 2 in CAST LOF patients may trigger apoptosis by cleavage of pro- or 
anti-apoptotic proteins, as previously shown (Tan et al., 2006). This process has also 
been demonstrated in HaCaT cells where an increase in activity of calpain 2 resulted 
in increased programmed cell death (Inoue et al., 2004). However, the analysis of 
apoptotic cell death, in an in vitro model using HaCaT cells and siRNA mediated 
knockdown of CAST, has revealed a normal cell cycle when compared to control NTP 
cells. 
In the same CAST siRNA cell model, the analysis of the strength of keratinocyte 
adhesion was addressed, as some intercellular gaps were observed in non-lesional 
patient skin. This analysis has confirmed that, in vitro, breakage of intercellular 
connections happens independently of mechanical stress in CAST siRNA 
monolayers. This could perhaps explain why the PLACK phenotype seen in affected 
individuals is not limited to the palmoplantar regions. As the CSTA knockdown 
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model presented breakage of intercellular connections, the analysis of desmosomal 
proteins was performed. Staining of non-lesional skin revealed an apparent up-
regulation of DSG2 expression in areas of the basal layers of the epidermis and a 
significant up-regulation in the expression of DSG3 and DSP I/II in all layers of the 
epidermis, together with an aberrant localisation to the cytoplasmic compartment. 
In vitro analysis of CAST knockdown monolayers presented variable results and 
more repeat experiments would be required to draw a clear conclusion. The 
variability of the in vitro observations could be due to a relatively low level of 
knockdown, of 50-65%, in comparison to the expected level of 85%, which can be 
attributed to a high protein stability or extended half-life of calpastatin. An 
increased level of CAST knockdown could be achieved by double siRNA-mediated 
CAST knockdown or alternatively by permanent knockout using shRNA or the 
CRISPR-Cas9 system. Based on the observations gathered, it is suggested that the 
reduction in expression of calpastatin due to CAST LOF mutations directly correlates 
with an increase in the concentration of calpains, which in turn could lead to 
proteolysis of DSG2, DSG3 and DSP II in the affected individuals, resulting in 
acantholysis and impaired resistance of the epidermis to mechanical stretch, seen 
as blistering and skin peeling. As calpain-mediated proteolysis of talin and focal 
adhesion kinase (FAK) is reportedly leading to regulation of adhesion dynamics 
(Franco et al., 2004, Chan et al., 2010), these proteins could be analysed in patient 
skin and CAST siRNA keratinocytes. In order to better address these probabilities, 
activation of calpains by Ca2+ mobilisation, with ionomycin, or GF stimulation, with 
EGF, should be performed following siRNA mediated CAST knockdown and prior to 
analysis of expression and localisation of any possible target proteins of calpains. 
Calpain activity could be monitored by zymography following Ca2+ activation. 
Independent studies looking at a variety of cancers have associated calpains with 
adhesion, motility, invasion, cell-cycle regulation, cell spreading, apoptosis and 
myogenesis (Leloup et al., 2006). Interestingly,  in in vivo mouse models, the up-
regulation in expression of both calpains 1 and 2 in skin wound healing was 
reported (Zhao et al., 2009), while more recently, Nassar et al. using Cast 
overexpression mice have shown a delay in wound healing, re-epithelialisation and 
angiogenesis (Nassar et al., 2012). In contrast, a Cast knockout mouse model, which 
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showed increased activity of the target calpains 1 and 2, revealed no defect under 
normal conditions (Takano et al., 2005), although only slight behavioural changes 
have been seen in a stressful environment (Nakajima et al., 2008). The in vitro 
analysis described here showed a normal scratch-wound closure pattern, 
suggesting a normal cell migration process. An analysis on Cast knockout mouse 
epidermis or CRISPR-Cas9 CAST knockout 3D models may give a more accurate view 
of any wound-healing and cell migration processes regulated by CAST. These 
phenotypical differences seen between humans and mice indicate once again the 
difference in physiological functions, and that observations made on mouse models 
should be considered carefully. 
6.5. Conclusion 
Although it is possible that common pathways lead to a variety of desmosome-
associated genetic disorders, the understanding of the consequences of those initial 
mutations or different molecular mechanisms leading to a common phenotype are 
crucial in unveiling the array of functions each desmosome-associated protein is 
playing and how these functions are altered in disease. The importance of the 
differential expression of desmosomal proteins in different tissues, such as the skin 
and heart, is becoming another factor of great importance in understanding 
different molecular mechanisms, mostly as some desmosomal proteins appear to be 
part of more complex signaling cascades. Therefore, the same protein might be 
subject to different regulation, perform different functions and genetic variations 
might lead to different outcomes, despite possibly overlapping mechanisms of 
disease. Moreover, regulation of desmosome assembly and/or function appears to 
be an indirect target of mutations in protease inhibitors, linked to a number of 
cutaneous disorders characterized by impaired intercellular adhesion. 
In summary, this thesis explored the increasing significance of genetic analyses in 
disease diagnosis using high-throughput sequencing platforms, coupled with the 
importance of the careful consideration of any novel variants in the disease context.  
Well-designed functional assays are essential to confirm disease causality and to 
investigate genotype-phenotype correlations.  
208 
 
Bibliography 
 
ABRAHAMSON, M., ALVAREZ-FERNANDEZ, M. & NATHANSON, C. M. 2003. 
Cystatins. Biochem Soc Symp, 179-99. 
ACEHAN, D., PETZOLD, C., GUMPER, I., SABATINI, D. D., MULLER, E. J., COWIN, P. & 
STOKES, D. L. 2008. Plakoglobin is required for effective intermediate 
filament anchorage to desmosomes. J Invest Dermatol, 128, 2665-75. 
AL-JASSAR, C., BIKKER, H., OVERDUIN, M. & CHIDGEY, M. 2013. Mechanistic basis of 
desmosome-targeted diseases. J Mol Biol, 425, 4006-22. 
ALCALAI, R., METZGER, S., ROSENHECK, S., MEINER, V. & CHAJEK-SHAUL, T. 2003. 
A recessive mutation in desmoplakin causes arrhythmogenic right 
ventricular dysplasia, skin disorder, and woolly hair. Journal of the American 
College of Cardiology, 42, 319-327. 
ALCALDE, M., CAMPUZANO, O., BERNE, P., GARCIA-PAVIA, P., DOLTRA, A., ARBELO, 
E., SARQUELLA-BRUGADA, G., IGLESIAS, A., ALONSO-PULPON, L., BRUGADA, 
J. & BRUGADA, R. 2014. Stop-gain mutations in PKP2 are associated with a 
later age of onset of arrhythmogenic right ventricular cardiomyopathy. PLoS 
One, 9, e100560. 
AMAGAI, M. 2010. Autoimmune and infectious skin diseases that target 
desmogleins. Proceedings of the Japan Academy, Series B, 86, 524-537. 
AMAGAI, M., AHMED, A. R., KITAJIMA, Y., BYSTRYN, J. C., MILNER, Y., GNIADECKI, R., 
HERTL, M., PINCELLI, C., KURZEN, H., FRIDKIS-HARELI, M., AOYAMA, Y., 
FRUSIC-ZLOTKIN, M., MULLER, E., DAVID, M., MIMOUNI, D., VIND-
KEZUNOVIC, D., MICHEL, B., MAHONEY, M. & GRANDO, S. 2006. Are 
desmoglein autoantibodies essential for the immunopathogenesis of 
pemphigus vulgaris, or just "witnesses of disease"? Exp Dermatol, 15, 815-
31. 
209 
 
AMAGAI, M., KLAUS-KOVTUN, V. & STANLEY, J. R. 1991. Autoantibodies against a 
novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. 
Cell, 67, 869-77. 
AMAGAI, M., MATSUYOSHI, N., WANG, Z. H., ANDL, C. & STANLEY, J. R. 2000. Toxin 
in bullous impetigo and staphylococcal scalded-skin syndrome targets 
desmoglein 1. Nat Med, 6, 1275-7. 
AMAGAI, M. & STANLEY, J. R. 2012. Desmoglein as a target in skin disease and 
beyond. J Invest Dermatol, 132, 776-84. 
AMAGAI, M., YAMAGUCHI, T., HANAKAWA, Y., NISHIFUJI, K., SUGAI, M. & STANLEY, 
J. R. 2002. Staphylococcal exfoliative toxin B specifically cleaves desmoglein 
1. J Invest Dermatol, 118, 845-50. 
ANDO, Y., IMAMURA, S., MURACHI, T. & KANNAGI, R. 1988. Calpain activates two 
transglutaminases from porcine skin. Arch Dermatol Res, 280, 380-4. 
ANDREASEN, C., NIELSEN, J. B., REFSGAARD, L., HOLST, A. G., CHRISTENSEN, A. H., 
ANDREASEN, L., SAJADIEH, A., HAUNSO, S., SVENDSEN, J. H. & OLESEN, M. S. 
2013. New population-based exome data are questioning the pathogenicity 
of previously cardiomyopathy-associated genetic variants. Eur J Hum Genet, 
21, 918-28. 
ANGST, B. D., MARCOZZI, C. & MAGEE, A. I. 2001. The cadherin superfamily. J Cell Sci, 
114, 625-6. 
ANGST, B. D., NILLES, L. A. & GREEN, K. J. 1990. Desmoplakin II expression is not 
restricted to stratified epithelia. J Cell Sci, 97 ( Pt 2), 247-57. 
ANICIN, A., GALE, N., SMID, L., KOS, J. & STROJAN, P. 2013. Expression of stefin A is 
of prognostic significance in squamous cell carcinoma of the head and neck. 
Eur Arch Otorhinolaryngol, 270, 3143-51. 
 
210 
 
ANTONIADES, L., TSATSOPOULOU, A., ANASTASAKIS, A., SYRRIS, P., ASIMAKI, A., 
PANAGIOTAKOS, D., ZAMBARTAS, C., STEFANADIS, C., MCKENNA, W. J. & 
PROTONOTARIOS, N. 2006. Arrhythmogenic right ventricular 
cardiomyopathy caused by deletions in plakophilin-2 and plakoglobin 
(Naxos disease) in families from Greece and Cyprus: genotype-phenotype 
relations, diagnostic features and prognosis. Eur Heart J, 27, 2208-16. 
AOYAMA, Y., NAGAI, M. & KITAJIMA, Y. 2010. Binding of pemphigus vulgaris IgG to 
antigens in desmosome core domains excludes immune complexes rather 
than directly splitting desmosomes. Br J Dermatol, 162, 1049-55. 
APARISI, M. J., ALLER, E., FUSTER-GARCIA, C., GARCIA-GARCIA, G., RODRIGO, R., 
VAZQUEZ-MANRIQUE, R. P., BLANCO-KELLY, F., AYUSO, C., ROUX, A. F., JAIJO, 
T. & MILLAN, J. M. 2014. Targeted next generation sequencing for molecular 
diagnosis of Usher syndrome. Orphanet J Rare Dis, 9, 168. 
ARMSTRONG, D. K., MCKENNA, K. E., PURKIS, P. E., GREEN, K. J., EADY, R. A., LEIGH, 
I. M. & HUGHES, A. E. 1999. Haploinsufficiency of desmoplakin causes a 
striate subtype of palmoplantar keratoderma. Hum Mol Genet, 8, 143-8. 
ARVAI, K., HORVATH, P., BALLA, B., TOKES, A. M., TOBIAS, B., TAKACS, I., NAGY, Z., 
LAKATOS, P. & KOSA, J. P. 2014. Rapid and cost effective screening of breast 
and ovarian cancer genes using novel sequence capture method in clinical 
samples. Fam Cancer, 13, 583-9. 
ASIMAKI, A., SYRRIS, P., WICHTER, T., MATTHIAS, P., SAFFITZ, J. E. & MCKENNA, W. 
J. 2007. A novel dominant mutation in plakoglobin causes arrhythmogenic 
right ventricular cardiomyopathy. Am J Hum Genet, 81, 964-73. 
ASIMAKI, A., TANDRI, H., HUANG, H., HALUSHKA, M. K., GAUTAM, S., BASSO, C., 
THIENE, G., TSATSOPOULOU, A., PROTONOTARIOS, N., MCKENNA, W. J., 
CALKINS, H. & SAFFITZ, J. E. 2009. A new diagnostic test for arrhythmogenic 
right ventricular cardiomyopathy. N Engl J Med, 360, 1075-84. 
211 
 
ATTARDI, L. D., RECZEK, E. E., COSMAS, C., DEMICCO, E. G., MCCURRACH, M. E., 
LOWE, S. W. & JACKS, T. 2000. PERP, an apoptosis-associated target of p53, 
is a novel member of the PMP-22/gas3 family. Genes Dev, 14, 704-18. 
AWAD, M. M., CALKINS, H. & JUDGE, D. P. 2008a. Mechanisms of disease: molecular 
genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nat 
Clin Pract Cardiovasc Med, 5, 258-67. 
AWAD, M. M., DALAL, D., TICHNELL, C., JAMES, C., TUCKER, A., ABRAHAM, T., 
SPEVAK, P. J., CALKINS, H. & JUDGE, D. P. 2006. Recessive arrhythmogenic 
right ventricular dysplasia due to novel cryptic splice mutation in PKP2. Hum 
Mutat, 27, 1157. 
AWAD, T. S., HELGASON, T., KRISTBERGSSON, K., WEISS, J., DECKER, E. A. & 
MCCLEMENTS, D. J. 2008b. Temperature scanning ultrasonic velocity study 
of complex thermal transformations in solid lipid nanoparticles. Langmuir, 
24, 12779-84. 
AYUB, M., BASIT, S., JELANI, M., UR REHMAN, F., IQBAL, M., YASINZAI, M. & AHMAD, 
W. 2009. A homozygous nonsense mutation in the human desmocollin-3 
(DSC3) gene underlies hereditary hypotrichosis and recurrent skin vesicles. 
Am J Hum Genet, 85, 515-20. 
AZAOUAGH, A., CHURZIDSE, S., KONORZA, T. & ERBEL, R. 2011. Arrhythmogenic 
right ventricular cardiomyopathy/dysplasia: a review and update. Clin Res 
Cardiol, 100, 383-94. 
BANNON, L. J., CABRERA, B. L., STACK, M. S. & GREEN, K. J. 2001. Isoform-specific 
differences in the size of desmosomal cadherin/catenin complexes. J Invest 
Dermatol, 117, 1302-6. 
BARNOY, S., GLASNER, T. & KOSOWER, N. S. 1996. The role of calpastatin (the 
specific calpain inhibitor) in myoblast differentiation and fusion. Biochem 
Biophys Res Commun, 220, 933-8. 
212 
 
BARNOY, S., MAKI, M. & KOSOWER, N. S. 2005. Overexpression of calpastatin 
inhibits L8 myoblast fusion. Biochem Biophys Res Commun, 332, 697-701. 
BASEL-VANAGAITE, L., ATTIA, R., ISHIDA-YAMAMOTO, A., RAINSHTEIN, L., BEN 
AMITAI, D., LURIE, R., PASMANIK-CHOR, M., INDELMAN, M., ZVULUNOV, A., 
SABAN, S., MAGAL, N., SPRECHER, E. & SHOHAT, M. 2007. Autosomal 
recessive ichthyosis with hypotrichosis caused by a mutation in ST14, 
encoding type II transmembrane serine protease matriptase. Am J Hum 
Genet, 80, 467-77. 
BASS-ZUBEK, A. E., HOBBS, R. P., AMARGO, E. V., GARCIA, N. J., HSIEH, S. N., CHEN, X., 
WAHL, J. K., 3RD, DENNING, M. F. & GREEN, K. J. 2008. Plakophilin 2: a critical 
scaffold for PKC alpha that regulates intercellular junction assembly. J Cell 
Biol, 181, 605-13. 
BASSO, C., BAUCE, B., CORRADO, D. & THIENE, G. 2012. Pathophysiology of 
arrhythmogenic cardiomyopathy. Nat Rev Cardiol, 9, 223-33. 
BAUCE, B., NAVA, A., BEFFAGNA, G., BASSO, C., LORENZON, A., SMANIOTTO, G., DE 
BORTOLI, M., RIGATO, I., MAZZOTTI, E., STERIOTIS, A., MARRA, M. P., 
TOWBIN, J. A., THIENE, G., DANIELI, G. A. & RAMPAZZO, A. 2010. Multiple 
mutations in desmosomal proteins encoding genes in arrhythmogenic right 
ventricular cardiomyopathy/dysplasia. Heart Rhythm, 7, 22-9. 
BAUCE, B., NAVA, A., RAMPAZZO, A., DALIENTO, L., MURIAGO, M., BASSO, C., 
THIENE, G. & DANIELI, G. A. 2000. Familial effort polymorphic ventricular 
arrhythmias in arrhythmogenic right ventricular cardiomyopathy map to 
chromosome 1q42-43. Am J Cardiol, 85, 573-9. 
BAZZI, H., MARTINEZ-MIR, A., KLJUIC, A. & CHRISTIANO, A. M. 2005. Desmoglein 4 
mutations underlie localized autosomal recessive hypotrichosis in humans, 
mice, and rats. J Investig Dermatol Symp Proc, 10, 222-4. 
BEAUDRY, V. G., IHRIE, R. A., JACOBS, S. B., NGUYEN, B., PATHAK, N., PARK, E. & 
ATTARDI, L. D. 2010a. Loss of the desmosomal component perp impairs 
wound healing in vivo. Dermatol Res Pract, 2010, 759731. 
213 
 
BEAUDRY, V. G., JIANG, D., DUSEK, R. L., PARK, E. J., KNEZEVICH, S., RIDD, K., VOGEL, 
H., BASTIAN, B. C. & ATTARDI, L. D. 2010b. Loss of the p53/p63 regulated 
desmosomal protein Perp promotes tumorigenesis. PLoS Genet, 6, e1001168. 
BEFFAGNA, G., OCCHI, G., NAVA, A., VITIELLO, L., DITADI, A., BASSO, C., BAUCE, B., 
CARRARO, G., THIENE, G., TOWBIN, J. A., DANIELI, G. A. & RAMPAZZO, A. 
2005. Regulatory mutations in transforming growth factor-beta3 gene cause 
arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovasc Res, 65, 
366-73. 
BERGLUND, E. C., LINDQVIST, C. M., HAYAT, S., OVERNAS, E., HENRIKSSON, N., 
NORDLUND, J., WAHLBERG, P., FORESTIER, E., LONNERHOLM, G. & 
SYVANEN, A. C. 2013. Accurate detection of subclonal single nucleotide 
variants in whole genome amplified and pooled cancer samples using 
HaloPlex target enrichment. BMC Genomics, 14, 856. 
BHUIYAN, Z. A., JONGBLOED, J. D., VAN DER SMAGT, J., LOMBARDI, P. M., WIESFELD, 
A. C., NELEN, M., SCHOUTEN, M., JONGBLOED, R., COX, M. G., VAN WOLFEREN, 
M., RODRIGUEZ, L. M., VAN GELDER, I. C., BIKKER, H., SUURMEIJER, A. J., VAN 
DEN BERG, M. P., MANNENS, M. M., HAUER, R. N., WILDE, A. A. & VAN 
TINTELEN, J. P. 2009. Desmoglein-2 and desmocollin-2 mutations in dutch 
arrhythmogenic right ventricular dysplasia/cardiomypathy patients: results 
from a multicenter study. Circ Cardiovasc Genet, 2, 418-27. 
BIERKAMP, C., MCLAUGHLIN, K. J., SCHWARZ, H., HUBER, O. & KEMLER, R. 1996. 
Embryonic heart and skin defects in mice lacking plakoglobin. Dev Biol, 180, 
780-5. 
BILODEAU, M., MACRAE, T., GABOURY, L., LAVERDURE, J. P., HARDY, M. P., 
MAYOTTE, N., PARADIS, V., HARTON, S., PERREAULT, C. & SAUVAGEAU, G. 
2009. Analysis of blood stem cell activity and cystatin gene expression in a 
mouse model presenting a chromosomal deletion encompassing Csta and 
Stfa2l1. PLoS One, 4, e7500. 
 
214 
 
BLAYDON, D. C., BIANCHERI, P., DI, W. L., PLAGNOL, V., CABRAL, R. M., BROOKE, M. 
A., VAN HEEL, D. A., RUSCHENDORF, F., TOYNBEE, M., WALNE, A., O'TOOLE, 
E. A., MARTIN, J. E., LINDLEY, K., VULLIAMY, T., ABRAMS, D. J., MACDONALD, 
T. T., HARPER, J. I. & KELSELL, D. P. 2011a. Inflammatory skin and bowel 
disease linked to ADAM17 deletion. N Engl J Med, 365, 1502-8. 
BLAYDON, D. C., ETHERIDGE, S. L., RISK, J. M., HENNIES, H. C., GAY, L. J., CARROLL, 
R., PLAGNOL, V., MCRONALD, F. E., STEVENS, H. P., SPURR, N. K., BISHOP, D. 
T., ELLIS, A., JANKOWSKI, J., FIELD, J. K., LEIGH, I. M., SOUTH, A. P. & KELSELL, 
D. P. 2012. RHBDF2 mutations are associated with tylosis, a familial 
esophageal cancer syndrome. Am J Hum Genet, 90, 340-6. 
BLAYDON, D. C., NITOIU, D., ECKL, K. M., CABRAL, R. M., BLAND, P., HAUSSER, I., VAN 
HEEL, D. A., RAJPOPAT, S., FISCHER, J., OJI, V., ZVULUNOV, A., TRAUPE, H., 
HENNIES, H. C. & KELSELL, D. P. 2011b. Mutations in CSTA, encoding Cystatin 
A, underlie exfoliative ichthyosis and reveal a role for this protease inhibitor 
in cell-cell adhesion. Am J Hum Genet, 89, 564-71. 
BODE, W., ENGH, R., MUSIL, D., THIELE, U., HUBER, R., KARSHIKOV, A., BRZIN, J., KOS, 
J. & TURK, V. 1988. The 2.0 A X-ray crystal structure of chicken egg white 
cystatin and its possible mode of interaction with cysteine proteinases. 
EMBO J, 7, 2593-9. 
BOLLI, N., MANES, N., MCKERREL, T., CHI, J., PARK, N., GUNDEM, G., QUAIL, M. A., 
SATHIASEELAN, V., HERMAN, B., CRAWLEY, C., CRAIG, J. I., CONTE, N., 
GROVE, C., PAPAEMMANUIL, E., CAMPBELL, P. J., VARELA, I., COSTEAS, P. & 
VASSILIOU, G. S. 2014. Characterization of gene mutations and copy number 
changes in acute myeloid leukemia using a rapid target enrichment protocol. 
Haematologica. 
BOLLING, M. C. & JONKMAN, M. F. 2009. Skin and heart: une liaison dangereuse. Exp 
Dermatol, 18, 658-68. 
BONAZZI, M. & COSSART, P. 2011. Impenetrable barriers or entry portals? The role 
of cell-cell adhesion during infection. J Cell Biol, 195, 349-58. 
215 
 
BONNE, S., VAN HENGEL, J., NOLLET, F., KOOLS, P. & VAN ROY, F. 1999. Plakophilin-
3, a novel armadillo-like protein present in nuclei and desmosomes of 
epithelial cells. J Cell Sci, 112 ( Pt 14), 2265-76. 
BORNSLAEGER, E. A., GODSEL, L. M., CORCORAN, C. M., PARK, J. K., HATZFELD, M., 
KOWALCZYK, A. P. & GREEN, K. J. 2001. Plakophilin 1 interferes with 
plakoglobin binding to desmoplakin, yet together with plakoglobin promotes 
clustering of desmosomal plaque complexes at cell-cell borders. J Cell Sci, 
114, 727-38. 
BOULE, S., FRESSART, V., LAUX, D., MALLET, A., SIMON, F., DE GROOTE, P., BONNET, 
D., KLUG, D. & CHARRON, P. 2012. Expanding the phenotype associated with 
a desmoplakin dominant mutation: Carvajal/Naxos syndrome associated 
with leukonychia and oligodontia. Int J Cardiol, 161, 50-2. 
BOYCE, A. E., MCGRATH, J. A., TECHANUKUL, T., MURRELL, D. F., CHOW, C. W., 
MCGREGOR, L. & WARREN, L. J. 2012. Ectodermal dysplasia-skin fragility 
syndrome due to a new homozygous internal deletion mutation in the PKP1 
gene. Australas J Dermatol, 53, 61-5. 
BRANCOLINI, C., BENEDETTI, M. & SCHNEIDER, C. 1995. Microfilament 
reorganization during apoptosis: the role of Gas2, a possible substrate for 
ICE-like proteases. EMBO J, 14, 5179-90. 
BRANCOLINI, C., SGORBISSA, A. & SCHNEIDER, C. 1998. Proteolytic processing of 
the adherens junctions components beta-catenin and gamma-
catenin/plakoglobin during apoptosis. Cell Death Differ, 5, 1042-50. 
BRATTSAND, M., STEFANSSON, K., HUBICHE, T., NILSSON, S. K. & EGELRUD, T. 2009. 
SPINK9: a selective, skin-specific Kazal-type serine protease inhibitor. J 
Invest Dermatol, 129, 1656-65. 
BRENNAN, D. & MAHONEY, M. G. 2009. Increased expression of Dsg2 in malignant 
skin carcinomas: A tissue-microarray based study. Cell Adh Migr, 3, 148-54. 
216 
 
BRENNAN, D., PELTONEN, S., DOWLING, A., MEDHAT, W., GREEN, K. J., WAHL, J. K., 
3RD, DEL GALDO, F. & MAHONEY, M. G. 2012. A role for caveolin-1 in 
desmoglein binding and desmosome dynamics. Oncogene, 31, 1636-48. 
BREUNINGER, S., REIDENBACH, S., SAUER, C. G., STROBEL, P., PFITZENMAIER, J., 
TROJAN, L. & HOFMANN, I. 2010. Desmosomal plakophilins in the prostate 
and prostatic adenocarcinomas: implications for diagnosis and tumor 
progression. Am J Pathol, 176, 2509-19. 
BROOKE, M. A., ETHERIDGE, S. L., KAPLAN, N., SIMPSON, C., O'TOOLE, E. A., ISHIDA-
YAMAMOTO, A., MARCHES, O., GETSIOS, S. & KELSELL, D. P. 2014. iRHOM2-
dependent regulation of ADAM17 in cutaneous disease and epidermal 
barrier function. Hum Mol Genet, 23, 4064-76. 
BROOKE, M. A., NITOIU, D. & KELSELL, D. P. 2012. Cell-cell connectivity: 
desmosomes and disease. J Pathol, 226, 158-71. 
BROWN, W. M. & DZIEGIELEWSKA, K. M. 1997. Friends and relations of the cystatin 
superfamily--new members and their evolution. Protein Sci, 6, 5-12. 
BURGESON, R. E. & NIMNI, M. E. 1992. Collagen types. Molecular structure and tissue 
distribution. Clin Orthop Relat Res, 250-72. 
BUTH, H., LUIGI BUTTIGIEG, P., OSTAFE, R., REHDERS, M., DANNENMANN, S. R., 
SCHASCHKE, N., STARK, H. J., BOUKAMP, P. & BRIX, K. 2007. Cathepsin B is 
essential for regeneration of scratch-wounded normal human epidermal 
keratinocytes. Eur J Cell Biol, 86, 747-61. 
BUTH, H., WOLTERS, B., HARTWIG, B., MEIER-BORNHEIM, R., VEITH, H., HANSEN, 
M., SOMMERHOFF, C. P., SCHASCHKE, N., MACHLEIDT, W., FUSENIG, N. E., 
BOUKAMP, P. & BRIX, K. 2004. HaCaT keratinocytes secrete lysosomal 
cysteine proteinases during migration. Eur J Cell Biol, 83, 781-95. 
 
 
217 
 
BUTLER, M. W., FUKUI, T., SALIT, J., SHAYKHIEV, R., MEZEY, J. G., HACKETT, N. R. & 
CRYSTAL, R. G. 2011. Modulation of cystatin A expression in human airway 
epithelium related to genotype, smoking, COPD, and lung cancer. Cancer Res, 
71, 2572-81. 
CABRAL, R. M., KURBAN, M., WAJID, M., SHIMOMURA, Y., PETUKHOVA, L. & 
CHRISTIANO, A. M. 2012a. Whole-exome sequencing in a single proband 
reveals a mutation in the CHST8 gene in autosomal recessive peeling skin 
syndrome. Genomics, 99, 202-8. 
CABRAL, R. M., LIU, L., HOGAN, C., DOPPING-HEPENSTAL, P. J., WINIK, B. C., ASIAL, 
R. A., DOBSON, R., MEIN, C. A., BASELAGA, P. A., MELLERIO, J. E., NANDA, A., 
BOENTE MDEL, C., KELSELL, D. P., MCGRATH, J. A. & SOUTH, A. P. 2010a. 
Homozygous mutations in the 5' region of the JUP gene result in cutaneous 
disease but normal heart development in children. J Invest Dermatol, 130, 
1543-50. 
CABRAL, R. M., TATTERSALL, D., PATEL, V., MCPHAIL, G. D., HATZIMASOURA, E., 
ABRAMS, D. J., SOUTH, A. P. & KELSELL, D. P. 2012b. The DSPII splice variant 
is crucial for desmosome-mediated adhesion in HaCaT keratinocytes. J Cell 
Sci, 125, 2853-61. 
CABRAL, R. M., WAN, H., COLE, C. L., ABRAMS, D. J., KELSELL, D. P. & SOUTH, A. P. 
2010b. Identification and characterization of DSPIa, a novel isoform of 
human desmoplakin. Cell Tissue Res, 341, 121-9. 
CALKINS, C. C., SETZER, S. V., JENNINGS, J. M., SUMMERS, S., TSUNODA, K., AMAGAI, 
M. & KOWALCZYK, A. P. 2006. Desmoglein endocytosis and desmosome 
disassembly are coordinated responses to pemphigus autoantibodies. J Biol 
Chem, 281, 7623-34. 
CARRAGHER, N. O. & FRAME, M. C. 2004. Focal adhesion and actin dynamics: a place 
where kinases and proteases meet to promote invasion. Trends Cell Biol, 14, 
241-9. 
218 
 
CASPAR, D. L., GOODENOUGH, D. A., MAKOWSKI, L. & PHILLIPS, W. C. 1977. Gap 
junction structures. I. Correlated electron microscopy and x-ray diffraction. J 
Cell Biol, 74, 605-28. 
CASSIDY, A. J., VAN STEENSEL, M. A., STEIJLEN, P. M., VAN GEEL, M., VAN DER 
VELDEN, J., MORLEY, S. M., TERRINONI, A., MELINO, G., CANDI, E. & MCLEAN, 
W. H. 2005. A homozygous missense mutation in TGM5 abolishes epidermal 
transglutaminase 5 activity and causes acral peeling skin syndrome. Am J 
Hum Genet, 77, 909-17. 
CHALABREYSSE, L., SENNI, F., BRUYERE, P., AIME, B., OLLAGNIER, C., BOZIO, A. & 
BOUVAGNET, P. 2011. A new hypo/oligodontia syndrome: Carvajal/Naxos 
syndrome secondary to desmoplakin-dominant mutations. J Dent Res, 90, 58-
64. 
CHAN, K. T., BENNIN, D. A. & HUTTENLOCHER, A. 2010. Regulation of adhesion 
dynamics by calpain-mediated proteolysis of focal adhesion kinase (FAK). J 
Biol Chem, 285, 11418-26. 
CHAN, Y. M., YU, Q. C., FINE, J. D. & FUCHS, E. 1993. The genetic basis of Weber-
Cockayne epidermolysis bullosa simplex. Proc Natl Acad Sci U S A, 90, 7414-
8. 
CHARPENTIER, E., LAVKER, R. M., ACQUISTA, E. & COWIN, P. 2000. Plakoglobin 
suppresses epithelial proliferation and hair growth in vivo. J Cell Biol, 149, 
503-20. 
CHAVANAS, S., BODEMER, C., ROCHAT, A., HAMEL-TEILLAC, D., ALI, M., IRVINE, A. 
D., BONAFE, J. L., WILKINSON, J., TAIEB, A., BARRANDON, Y., HARPER, J. I., DE 
PROST, Y. & HOVNANIAN, A. 2000. Mutations in SPINK5, encoding a serine 
protease inhibitor, cause Netherton syndrome. Nat Genet, 25, 141-2. 
CHEN, M. A., BONIFAS, J. M., MATSUMURA, K., BLUMENFELD, A. & EPSTEIN, E. H., JR. 
1993. A novel three-nucleotide deletion in the helix 2B region of keratin 14 
in epidermolysis bullosa simplex: delta E375. Hum Mol Genet, 2, 1971-2. 
219 
 
CHEN, X., BONNE, S., HATZFELD, M., VAN ROY, F. & GREEN, K. J. 2002. Protein 
binding and functional characterization of plakophilin 2. Evidence for its 
diverse roles in desmosomes and beta -catenin signaling. J Biol Chem, 277, 
10512-22. 
CHEN, Y. J., CHANG, J. T., LEE, L., WANG, H. M., LIAO, C. T., CHIU, C. C., CHEN, P. J. & 
CHENG, A. J. 2007. DSG3 is overexpressed in head neck cancer and is a 
potential molecular target for inhibition of oncogenesis. Oncogene, 26, 467-
76. 
CHEN, Y. J., LEE, L. Y., CHAO, Y. K., CHANG, J. T., LU, Y. C., LI, H. F., CHIU, C. C., LI, Y. C., 
LI, Y. L., CHIOU, J. F. & CHENG, A. J. 2013. DSG3 facilitates cancer cell growth 
and invasion through the DSG3-plakoglobin-TCF/LEF-Myc/cyclin D1/MMP 
signaling pathway. PLoS One, 8, e64088. 
CHERNYAVSKY, A. I., ARREDONDO, J., KITAJIMA, Y., SATO-NAGAI, M. & GRANDO, S. 
A. 2007. Desmoglein versus non-desmoglein signaling in pemphigus 
acantholysis: characterization of novel signaling pathways downstream of 
pemphigus vulgaris antigens. J Biol Chem, 282, 13804-12. 
CHIDGEY, M., BRAKEBUSCH, C., GUSTAFSSON, E., CRUCHLEY, A., HAIL, C., KIRK, S., 
MERRITT, A., NORTH, A., TSELEPIS, C., HEWITT, J., BYRNE, C., FASSLER, R. & 
GARROD, D. 2001. Mice lacking desmocollin 1 show epidermal fragility 
accompanied by barrier defects and abnormal differentiation. J Cell Biol, 155, 
821-32. 
CHOI, H. J., GROSS, J. C., POKUTTA, S. & WEIS, W. I. 2009. Interactions of plakoglobin 
and beta-catenin with desmosomal cadherins: basis of selective exclusion of 
alpha- and beta-catenin from desmosomes. J Biol Chem, 284, 31776-88. 
CHOI, H. J., PARK-SNYDER, S., PASCOE, L. T., GREEN, K. J. & WEIS, W. I. 2002. 
Structures of two intermediate filament-binding fragments of desmoplakin 
reveal a unique repeat motif structure. Nat Struct Biol, 9, 612-20. 
CHOI, H. J. & WEIS, W. I. 2005. Structure of the armadillo repeat domain of 
plakophilin 1. J Mol Biol, 346, 367-76. 
220 
 
CHRISTIANO, A. M. & UITTO, J. 1994. Molecular pathology of the elastic fibers. J 
Invest Dermatol, 103, 53S-57S. 
CIRILLO, N. & AL-JANDAN, B. A. 2013. Desmosomal adhesion and pemphigus 
vulgaris: the first half of the story. Cell Commun Adhes, 20, 1-10. 
CIRILLO, N., LANZA, A. & PRIME, S. S. 2010. Induction of hyper-adhesion attenuates 
autoimmune-induced keratinocyte cell-cell detachment and processing of 
adhesion molecules via mechanisms that involve PKC. Exp Cell Res, 316, 580-
92. 
CITI, S. & CORDENONSI, M. 1998. Tight junction proteins. Biochim Biophys Acta, 
1448, 1-11. 
COLLINS, J. E., LEGAN, P. K., KENNY, T. P., MACGARVIE, J., HOLTON, J. L. & GARROD, 
D. R. 1991. Cloning and sequence analysis of desmosomal glycoproteins 2 
and 3 (desmocollins): cadherin-like desmosomal adhesion molecules with 
heterogeneous cytoplasmic domains. J Cell Biol, 113, 381-91. 
CONACCI-SORRELL, M., ZHURINSKY, J. & BEN-ZE'EV, A. 2002. The cadherin-catenin 
adhesion system in signaling and cancer. J Clin Invest, 109, 987-91. 
COONROD, E. M., DURTSCHI, J. D., VANSANT WEBB, C., VOELKERDING, K. V. & 
KUMANOVICS, A. 2014. Next-generation sequencing of custom amplicons to 
improve coverage of HaloPlex multigene panels. Biotechniques, 57, 204-7. 
CORRADO, D., MIGLIORE, F., BASSO, C. & THIENE, G. 2006a. Exercise and the risk of 
sudden cardiac death. Herz, 31, 553-8. 
CORRADO, D., THIENE, G., NAVA, A., ROSSI, L. & PENNELLI, N. 1990. Sudden death 
in young competitive athletes: clinicopathologic correlations in 22 cases. Am 
J Med, 89, 588-96. 
CORRADO, E., MILIO, G. & NOVO, S. 2006b. Response to letter by Drs. Mohammed 
Abbas, Maria Sessa, and Francesco Corea. Arch Med Res, 37, 810-1. 
221 
 
COTTIN, P., BRUSTIS, J. J., POUSSARD, S., ELAMRANI, N., BRONCARD, S. & 
DUCASTAING, A. 1994. Ca(2+)-dependent proteinases (calpains) and muscle 
cell differentiation. Biochim Biophys Acta, 1223, 170-8. 
COX, M. G., VAN DER ZWAAG, P. A., VAN DER WERF, C., VAN DER SMAGT, J. J., 
NOORMAN, M., BHUIYAN, Z. A., WIESFELD, A. C., VOLDERS, P. G., VAN 
LANGEN, I. M., ATSMA, D. E., DOOIJES, D., VAN DEN WIJNGAARD, A., 
HOUWELING, A. C., JONGBLOED, J. D., JORDAENS, L., CRAMER, M. J., 
DOEVENDANS, P. A., DE BAKKER, J. M., WILDE, A. A., VAN TINTELEN, J. P. & 
HAUER, R. N. 2011. Arrhythmogenic right ventricular 
dysplasia/cardiomyopathy: pathogenic desmosome mutations in index-
patients predict outcome of family screening: Dutch arrhythmogenic right 
ventricular dysplasia/cardiomyopathy genotype-phenotype follow-up 
study. Circulation, 123, 2690-700. 
CROUCH, D. H., FINCHAM, V. J. & FRAME, M. C. 1996. Targeted proteolysis of the focal 
adhesion kinase pp125 FAK during c-MYC-induced apoptosis is suppressed 
by integrin signalling. Oncogene, 12, 2689-96. 
D'ALESSIO, M., FORTUGNO, P., ZAMBRUNO, G. & HOVNANIAN, A. 2013. Netherton 
syndrome and its multifaceted defective protein LEKTI. G Ital Dermatol 
Venereol, 148, 37-51. 
DALAL, D., JAMES, C., DEVANAGONDI, R., TICHNELL, C., TUCKER, A., PRAKASA, K., 
SPEVAK, P. J., BLUEMKE, D. A., ABRAHAM, T., RUSSELL, S. D., CALKINS, H. & 
JUDGE, D. P. 2006. Penetrance of mutations in plakophilin-2 among families 
with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll 
Cardiol, 48, 1416-24. 
DAVIES, M. E. & BARRETT, A. J. 1984. Immunolocalization of human cystatins in 
neutrophils and lymphocytes. Histochemistry, 80, 373-7. 
DEDIEU, S., POUSSARD, S., MAZERES, G., GRISE, F., DARGELOS, E., COTTIN, P. & 
BRUSTIS, J. J. 2004. Myoblast migration is regulated by calpain through its 
involvement in cell attachment and cytoskeletal organization. Exp Cell Res, 
292, 187-200. 
222 
 
DELA CADENA, R. A. & COLMAN, R. W. 1991. Structure and functions of human 
kininogens. Trends Pharmacol Sci, 12, 272-5. 
DELMAR, M. & MCKENNA, W. J. 2010. The cardiac desmosome and arrhythmogenic 
cardiomyopathies: from gene to disease. Circ Res, 107, 700-14. 
DELVA, E., JENNINGS, J. M., CALKINS, C. C., KOTTKE, M. D., FAUNDEZ, V. & 
KOWALCZYK, A. P. 2008. Pemphigus vulgaris IgG-induced desmoglein-3 
endocytosis and desmosomal disassembly are mediated by a clathrin- and 
dynamin-independent mechanism. J Biol Chem, 283, 18303-13. 
DELVA, E., TUCKER, D. K. & KOWALCZYK, A. P. 2009. The desmosome. Cold Spring 
Harb Perspect Biol, 1, a002543. 
DERAISON, C., BONNART, C., LOPEZ, F., BESSON, C., ROBINSON, R., JAYAKUMAR, A., 
WAGBERG, F., BRATTSAND, M., HACHEM, J. P., LEONARDSSON, G. & 
HOVNANIAN, A. 2007. LEKTI fragments specifically inhibit KLK5, KLK7, and 
KLK14 and control desquamation through a pH-dependent interaction. Mol 
Biol Cell, 18, 3607-19. 
DESAI, B. V., HARMON, R. M. & GREEN, K. J. 2009. Desmosomes at a glance. J Cell Sci, 
122, 4401-7. 
DIMAS, A. S., STRANGER, B. E., BEAZLEY, C., FINN, R. D., INGLE, C. E., FORREST, M. S., 
RITCHIE, M. E., DELOUKAS, P., TAVARE, S. & DERMITZAKIS, E. T. 2008. 
Modifier effects between regulatory and protein-coding variation. PLoS 
Genet, 4, e1000244. 
DING, X., AOKI, V., MASCARO, J. M., JR., LOPEZ-SWIDERSKI, A., DIAZ, L. A. & FAIRLEY, 
J. A. 1997. Mucosal and mucocutaneous (generalized) pemphigus vulgaris 
show distinct autoantibody profiles. J Invest Dermatol, 109, 592-6. 
DUSEK, R. L. & ATTARDI, L. D. 2011. Desmosomes: new perpetrators in tumour 
suppression. Nat Rev Cancer, 11, 317-23. 
 
223 
 
EGBERTS, F., HEINRICH, M., JENSEN, J. M., WINOTO-MORBACH, S., PFEIFFER, S., 
WICKEL, M., SCHUNCK, M., STEUDE, J., SAFTIG, P., PROKSCH, E. & SCHUTZE, 
S. 2004. Cathepsin D is involved in the regulation of transglutaminase 1 and 
epidermal differentiation. J Cell Sci, 117, 2295-307. 
ELLIS, A., FIELD, J. K., FIELD, E. A., FRIEDMANN, P. S., FRYER, A., HOWARD, P., LEIGH, 
I. M., RISK, J., SHAW, J. M. & WHITTAKER, J. 1994. Tylosis associated with 
carcinoma of the oesophagus and oral leukoplakia in a large Liverpool 
family--a review of six generations. Eur J Cancer B Oral Oncol, 30B, 102-12. 
ERKEN, H., YARIZ, K. O., DUMAN, D., KAYA, C. T., SAYIN, T., HEPER, A. O. & TEKIN, M. 
2011. Cardiomyopathy with alopecia and palmoplantar keratoderma (CAPK) 
is caused by a JUP mutation. Br J Dermatol, 165, 917-21. 
ERSOY-EVANS, S., ERKIN, G., FASSIHI, H., CHAN, I., PALLER, A. S., SURUCU, S. & 
MCGRATH, J. A. 2006. Ectodermal dysplasia-skin fragility syndrome resulting 
from a new homozygous mutation, 888delC, in the desmosomal protein 
plakophilin 1. J Am Acad Dermatol, 55, 157-61. 
FARQUHAR, M. G. & PALADE, G. E. 1963. Junctional complexes in various epithelia. J 
Cell Biol, 17, 375-412. 
FIDLER, L. M., WILSON, G. J., LIU, F., CUI, X., SCHERER, S. W., TAYLOR, G. P. & 
HAMILTON, R. M. 2009. Abnormal connexin43 in arrhythmogenic right 
ventricular cardiomyopathy caused by plakophilin-2 mutations. J Cell Mol 
Med, 13, 4219-28. 
FRANCO, S. J., RODGERS, M. A., PERRIN, B. J., HAN, J., BENNIN, D. A., CRITCHLEY, D. 
R. & HUTTENLOCHER, A. 2004. Calpain-mediated proteolysis of talin 
regulates adhesion dynamics. Nat Cell Biol, 6, 977-83. 
FRANKE, W. W., BORRMANN, C. M., GRUND, C. & PIEPERHOFF, S. 2006. The area 
composita of adhering junctions connecting heart muscle cells of vertebrates. 
I. Molecular definition in intercalated disks of cardiomyocytes by 
immunoelectron microscopy of desmosomal proteins. Eur J Cell Biol, 85, 69-
82. 
224 
 
FRANKE, W. W., SCHUMACHER, H., BORRMANN, C. M., GRUND, C., WINTER-
SIMANOWSKI, S., SCHLECHTER, T., PIEPERHOFF, S. & HOFMANN, I. 2007. 
The area composita of adhering junctions connecting heart muscle cells of 
vertebrates - III: assembly and disintegration of intercalated disks in rat 
cardiomyocytes growing in culture. Eur J Cell Biol, 86, 127-42. 
FUCHS, E. 1990. Epidermal differentiation: the bare essentials. J Cell Biol, 111, 2807-
14. 
FUCHS, E. 2007. Scratching the surface of skin development. Nature, 445, 834-42. 
FURUKAWA, C., DAIGO, Y., ISHIKAWA, N., KATO, T., ITO, T., TSUCHIYA, E., SONE, S. & 
NAKAMURA, Y. 2005. Plakophilin 3 oncogene as prognostic marker and 
therapeutic target for lung cancer. Cancer Res, 65, 7102-10. 
FUTEI, Y., AMAGAI, M., HASHIMOTO, T. & NISHIKAWA, T. 2003. Conformational 
epitope mapping and IgG subclass distribution of desmoglein 3 in 
paraneoplastic pemphigus. J Am Acad Dermatol, 49, 1023-8. 
GABRIJELCIC, D., SVETIC, B., SPAIC, D., SKRK, J., BUDIHNA, M., DOLENC, I., POPOVIC, 
T., COTIC, V. & TURK, V. 1992. Cathepsins B, H and L in human breast 
carcinoma. Eur J Clin Chem Clin Biochem, 30, 69-74. 
GALLICANO, G. I., BAUER, C. & FUCHS, E. 2001. Rescuing desmoplakin function in 
extra-embryonic ectoderm reveals the importance of this protein in 
embryonic heart, neuroepithelium, skin and vasculature. Development, 128, 
929-41. 
GALLICANO, G. I., KOUKLIS, P., BAUER, C., YIN, M., VASIOUKHIN, V., DEGENSTEIN, L. 
& FUCHS, E. 1998. Desmoplakin is required early in development for 
assembly of desmosomes and cytoskeletal linkage. J Cell Biol, 143, 2009-22. 
GARROD, D. R., BERIKA, M. Y., BARDSLEY, W. F., HOLMES, D. & TABERNERO, L. 2005. 
Hyper-adhesion in desmosomes: its regulation in wound healing and 
possible relationship to cadherin crystal structure. J Cell Sci, 118, 5743-54. 
225 
 
GARROD, D. R., MERRITT, A. J. & NIE, Z. 2002. Desmosomal cadherins. Curr Opin Cell 
Biol, 14, 537-45. 
GERULL, B., HEUSER, A., WICHTER, T., PAUL, M., BASSON, C. T., MCDERMOTT, D. A., 
LERMAN, B. B., MARKOWITZ, S. M., ELLINOR, P. T., MACRAE, C. A., PETERS, 
S., GROSSMANN, K. S., DRENCKHAHN, J., MICHELY, B., SASSE-KLAASSEN, S., 
BIRCHMEIER, W., DIETZ, R., BREITHARDT, G., SCHULZE-BAHR, E. & 
THIERFELDER, L. 2004. Mutations in the desmosomal protein plakophilin-2 
are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet, 
36, 1162-4. 
GETSIOS, S., HUEN, A. C. & GREEN, K. J. 2004. Working out the strength and flexibility 
of desmosomes. Nat Rev Mol Cell Biol, 5, 271-81. 
GODSEL, L. M., DUBASH, A. D., BASS-ZUBEK, A. E., AMARGO, E. V., KLESSNER, J. L., 
HOBBS, R. P., CHEN, X. & GREEN, K. J. 2010. Plakophilin 2 couples actomyosin 
remodeling to desmosomal plaque assembly via RhoA. Mol Biol Cell, 21, 
2844-59. 
GODSEL, L. M., HSIEH, S. N., AMARGO, E. V., BASS, A. E., PASCOE-MCGILLICUDDY, L. 
T., HUEN, A. C., THORNE, M. E., GAUDRY, C. A., PARK, J. K., MYUNG, K., 
GOLDMAN, R. D., CHEW, T. L. & GREEN, K. J. 2005. Desmoplakin assembly 
dynamics in four dimensions: multiple phases differentially regulated by 
intermediate filaments and actin. J Cell Biol, 171, 1045-59. 
GOLDBACH-MANSKY, R., LEE, J., MCCOY, A., HOXWORTH, J., YARBORO, C., SMOLEN, 
J. S., STEINER, G., ROSEN, A., ZHANG, C., MENARD, H. A., ZHOU, Z. J., PALOSUO, 
T., VAN VENROOIJ, W. J., WILDER, R. L., KLIPPEL, J. H., SCHUMACHER, H. R., 
JR. & EL-GABALAWY, H. S. 2000. Rheumatoid arthritis associated 
autoantibodies in patients with synovitis of recent onset. Arthritis Res, 2, 
236-43. 
GOLDBERG, G. S., VALIUNAS, V. & BRINK, P. R. 2004. Selective permeability of gap 
junction channels. Biochim Biophys Acta, 1662, 96-101. 
226 
 
GOLL, D. E., THOMPSON, V. F., LI, H., WEI, W. & CONG, J. 2003. The calpain system. 
Physiol Rev, 83, 731-801. 
GREEN, A., GREEN, H., REHNBERG, M., SVENSSON, A., GUNNARSSON, C. & 
JONASSON, J. 2014. Assessment of HaloPlex Amplification for Sequence 
Capture and Massively Parallel Sequencing of Arrhythmogenic Right 
Ventricular Cardiomyopathy-Associated Genes. J Mol Diagn. 
GREEN, K. J. & GAUDRY, C. A. 2000. Are desmosomes more than tethers for 
intermediate filaments? Nat Rev Mol Cell Biol, 1, 208-16. 
GREEN, K. J., GETSIOS, S., TROYANOVSKY, S. & GODSEL, L. M. 2010. Intercellular 
junction assembly, dynamics, and homeostasis. Cold Spring Harb Perspect 
Biol, 2, a000125. 
GROSSMANN, K. S., GRUND, C., HUELSKEN, J., BEHREND, M., ERDMANN, B., FRANKE, 
W. W. & BIRCHMEIER, W. 2004. Requirement of plakophilin 2 for heart 
morphogenesis and cardiac junction formation. J Cell Biol, 167, 149-60. 
GUPTA, A., NITOIU, D., BRENNAN-CRISPI, D., ADDYA, S., RIOBO, N.A., KELSELL, D.P. 
& MAHONEY, M.G. 2015. Cell cycle- and cancer-associated gene networks 
activated by dsg2: evidence of cystatin a deregulation and a potential role in 
cell-cell adhesion. PLoS One, 10, e0120091. 
HABER, R. M. & ROSE, T. H. 1986. Autosomal recessive pachyonychia congenita. Arch 
Dermatol, 122, 919-23. 
HAKIMELAHI, S., PARKER, H. R., GILCHRIST, A. J., BARRY, M., LI, Z., BLEACKLEY, R. 
C. & PASDAR, M. 2000. Plakoglobin regulates the expression of the anti-
apoptotic protein BCL-2. J Biol Chem, 275, 10905-11. 
HALPER, J. & KJAER, M. 2014. Basic components of connective tissues and 
extracellular matrix: elastin, fibrillin, fibulins, fibrinogen, fibronectin, 
laminin, tenascins and thrombospondins. Adv Exp Med Biol, 802, 31-47. 
227 
 
HANAKAWA, Y., SELWOOD, T., WOO, D., LIN, C., SCHECHTER, N. M. & STANLEY, J. R. 
2003. Calcium-dependent conformation of desmoglein 1 is required for its 
cleavage by exfoliative toxin. J Invest Dermatol, 121, 383-9. 
HANNA, R. A., CAMPBELL, R. L. & DAVIES, P. L. 2008. Calcium-bound structure of 
calpain and its mechanism of inhibition by calpastatin. Nature, 456, 409-12. 
HASHIMOTO, K., HAMZAVI, I., TANAKA, K. & SHWAYDER, T. 2000. Acral peeling skin 
syndrome. J Am Acad Dermatol, 43, 1112-9. 
HATSELL, S. J., STEVENS, H., JACKSON, A. P., KELSELL, D. P. & ZVULUNOV, A. 2003. 
An autosomal recessive exfoliative ichthyosis with linkage to chromosome 
12q13. Br J Dermatol, 149, 174-80. 
HATZFELD, M. 2005. The p120 family of cell adhesion molecules. Eur J Cell Biol, 84, 
205-14. 
HATZFELD, M. 2007. Plakophilins: Multifunctional proteins or just regulators of 
desmosomal adhesion? Biochim Biophys Acta, 1773, 69-77. 
HATZFELD, M., HAFFNER, C., SCHULZE, K. & VINZENS, U. 2000. The function of 
plakophilin 1 in desmosome assembly and actin filament organization. J Cell 
Biol, 149, 209-22. 
HEID, H. W., SCHMIDT, A., ZIMBELMANN, R., SCHAFER, S., WINTER-SIMANOWSKI, 
S., STUMPP, S., KEITH, M., FIGGE, U., SCHNOLZER, M. & FRANKE, W. W. 1994. 
Cell type-specific desmosomal plaque proteins of the plakoglobin family: 
plakophilin 1 (band 6 protein). Differentiation, 58, 113-31. 
HENNIES, H. C., HAGEDORN, M. & REIS, A. 1995. Palmoplantar keratoderma in 
association with carcinoma of the esophagus maps to chromosome 17q distal 
to the keratin gene cluster. Genomics, 29, 537-40. 
HERNANDEZ-MARTIN, A., TORRELO, A., CIRIA, S., COLMENERO, I., AGUILAR, A., 
GRIMALT, R. & GONZALEZ-SARMIENTO, R. 2013. Ectodermal dysplasia-skin 
fragility syndrome: a novel mutation in the PKP1 gene. Clin Exp Dermatol, 38, 
787-90. 
228 
 
HERRON, B. J., RAO, C., LIU, S., LAPRADE, L., RICHARDSON, J. A., OLIVIERI, E., 
SEMSARIAN, C., MILLAR, S. E., STUBBS, L. & BEIER, D. R. 2005. A mutation in 
NFkB interacting protein 1 results in cardiomyopathy and abnormal skin 
development in wa3 mice. Hum Mol Genet, 14, 667-77. 
HEUSER, A., PLOVIE, E. R., ELLINOR, P. T., GROSSMANN, K. S., SHIN, J. T., WICHTER, 
T., BASSON, C. T., LERMAN, B. B., SASSE-KLAASSEN, S., THIERFELDER, L., 
MACRAE, C. A. & GERULL, B. 2006. Mutant desmocollin-2 causes 
arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet, 79, 
1081-8. 
HOFMANN, I., MERTENS, C., BRETTEL, M., NIMMRICH, V., SCHNOLZER, M. & 
HERRMANN, H. 2000. Interaction of plakophilins with desmoplakin and 
intermediate filament proteins: an in vitro analysis. J Cell Sci, 113 ( Pt 13), 
2471-83. 
HOFMANN, I., SCHLECHTER, T., KUHN, C., HERGT, M. & FRANKE, W. W. 2009. 
Protein p0071 - an armadillo plaque protein that characterizes a specific 
subtype of adherens junctions. J Cell Sci, 122, 21-4. 
HOLTHOFER, B., WINDOFFER, R., TROYANOVSKY, S. & LEUBE, R. E. 2007. Structure 
and function of desmosomes. Int Rev Cytol, 264, 65-163. 
HOUBEN, C. H., CHU, W., CHEUNG, G., LEE, K. & YEUNG, C. 2008. Antenatal ovarian 
torsion: a "free-floating" cyst. Ultraschall Med, 29, 311-3. 
HOUBEN, E., DE PAEPE, K. & ROGIERS, V. 2007. A keratinocyte's course of life. Skin 
Pharmacol Physiol, 20, 122-32. 
HOVNANIAN, A. 2013. Netherton syndrome: skin inflammation and allergy by loss 
of protease inhibition. Cell Tissue Res, 351, 289-300. 
HSU, C. Y., HENRY, J., RAYMOND, A. A., MECHIN, M. C., PENDARIES, V., NASSAR, D., 
HANSMANN, B., BALICA, S., BURLET-SCHILTZ, O., SCHMITT, A. M., 
TAKAHARA, H., PAUL, C., SERRE, G. & SIMON, M. 2011. Deimination of human 
filaggrin-2 promotes its proteolysis by calpain 1. J Biol Chem, 286, 23222-33. 
229 
 
HU, P., BERKOWITZ, P., MADDEN, V. J. & RUBENSTEIN, D. S. 2006. Stabilization of 
plakoglobin and enhanced keratinocyte cell-cell adhesion by intracellular O-
glycosylation. J Biol Chem, 281, 12786-91. 
HUEN, A. C., PARK, J. K., GODSEL, L. M., CHEN, X., BANNON, L. J., AMARGO, E. V., 
HUDSON, T. Y., MONGIU, A. K., LEIGH, I. M., KELSELL, D. P., GUMBINER, B. M. 
& GREEN, K. J. 2002. Intermediate filament-membrane attachments function 
synergistically with actin-dependent contacts to regulate intercellular 
adhesive strength. J Cell Biol, 159, 1005-17. 
IHRIE, R. A., MARQUES, M. R., NGUYEN, B. T., HORNER, J. S., PAPAZOGLU, C., 
BRONSON, R. T., MILLS, A. A. & ATTARDI, L. D. 2005. Perp is a p63-regulated 
gene essential for epithelial integrity. Cell, 120, 843-56. 
INOUE, A., YAMAZAKI, M., ISHIDOH, K. & OGAWA, H. 2004. Epidermal growth factor 
activates m-calpain, resulting in apoptosis of HaCaT keratinocytes. J 
Dermatol Sci, 36, 60-2. 
ISHIDA-YAMAMOTO, A., IGAWA, S. & KISHIBE, M. 2011. Order and disorder in 
corneocyte adhesion. J Dermatol, 38, 645-54. 
ISHII, K., AMAGAI, M., HALL, R. P., HASHIMOTO, T., TAKAYANAGI, A., GAMOU, S., 
SHIMIZU, N. & NISHIKAWA, T. 1997. Characterization of autoantibodies in 
pemphigus using antigen-specific enzyme-linked immunosorbent assays 
with baculovirus-expressed recombinant desmogleins. J Immunol, 159, 
2010-7. 
IWATSUKI, K., TAKIGAWA, M., IMAIZUMI, S. & YAMADA, M. 1989. In vivo binding site 
of pemphigus vulgaris antibodies and their fate during acantholysis. J Am 
Acad Dermatol, 20, 578-82. 
JAHODA, C. A., KLJUIC, A., O'SHAUGHNESSY, R., CROSSLEY, N., WHITEHOUSE, C. J., 
ROBINSON, M., REYNOLDS, A. J., DEMARCHEZ, M., PORTER, R. M., SHAPIRO, 
L. & CHRISTIANO, A. M. 2004. The lanceolate hair rat phenotype results from 
a missense mutation in a calcium coordinating site of the desmoglein 4 gene. 
Genomics, 83, 747-56. 
230 
 
JANICKE, R. U., NG, P., SPRENGART, M. L. & PORTER, A. G. 1998. Caspase-3 is 
required for alpha-fodrin cleavage but dispensable for cleavage of other 
death substrates in apoptosis. J Biol Chem, 273, 15540-5. 
JARVINEN, M. & HOPSU-HAVU, V. K. 1975. Alpha-N-benzoylarginine-2-
naphthylamide hydrolase (cathepsin B1?) from rat skin. I. Preliminary 
experiments with skin extract. Acta Chem Scand B, 29, 671-6. 
JENKO, S., DOLENC, I., GUNCAR, G., DOBERSEK, A., PODOBNIK, M. & TURK, D. 2003. 
Crystal structure of Stefin A in complex with cathepsin H: N-terminal 
residues of inhibitors can adapt to the active sites of endo- and 
exopeptidases. J Mol Biol, 326, 875-85. 
JONKMAN, M. F., PASMOOIJ, A. M., PASMANS, S. G., VAN DEN BERG, M. P., TER 
HORST, H. J., TIMMER, A. & PAS, H. H. 2005. Loss of desmoplakin tail causes 
lethal acantholytic epidermolysis bullosa. Am J Hum Genet, 77, 653-60. 
JOSHI-MUKHERJEE, R., COOMBS, W., MUSA, H., OXFORD, E., TAFFET, S. & DELMAR, 
M. 2008. Characterization of the molecular phenotype of two 
arrhythmogenic right ventricular cardiomyopathy (ARVC)-related 
plakophilin-2 (PKP2) mutations. Heart Rhythm, 5, 1715-23. 
KAMATA, Y., TANIGUCHI, A., YAMAMOTO, M., NOMURA, J., ISHIHARA, K., 
TAKAHARA, H., HIBINO, T. & TAKEDA, A. 2009. Neutral cysteine protease 
bleomycin hydrolase is essential for the breakdown of deiminated filaggrin 
into amino acids. J Biol Chem, 284, 12829-36. 
KANNANKERIL, P. J., BHUIYAN, Z. A., DARBAR, D., MANNENS, M. M., WILDE, A. A. & 
RODEN, D. M. 2006. Arrhythmogenic right ventricular cardiomyopathy due 
to a novel plakophilin 2 mutation: wide spectrum of disease in mutation 
carriers within a family. Heart Rhythm, 3, 939-44. 
KAPPRELL, H. P., OWARIBE, K. & FRANKE, W. W. 1988. Identification of a basic 
protein of Mr 75,000 as an accessory desmosomal plaque protein in stratified 
and complex epithelia. J Cell Biol, 106, 1679-91. 
231 
 
KATO, T., TAKAI, T., MITSUISHI, K., OKUMURA, K. & OGAWA, H. 2005. Cystatin A 
inhibits IL-8 production by keratinocytes stimulated with Der p 1 and Der f 
1: biochemical skin barrier against mite cysteine proteases. J Allergy Clin 
Immunol, 116, 169-76. 
KAWASAKI, H., EMORI, Y. & SUZUKI, K. 1993. Calpastatin has two distinct sites for 
interaction with calpain--effect of calpastatin fragments on the binding of 
calpain to membranes. Arch Biochem Biophys, 305, 467-72. 
KELLY, D. E. 1966. Fine structure of desmosomes. , hemidesmosomes, and an 
adepidermal globular layer in developing newt epidermis. J Cell Biol, 28, 51-
72. 
KEPPLER, D. & SIERRA, F. 2005. Role of cystatins in tumor neovascularization. 
Future Oncol, 1, 661-72. 
KIELTY, C. M. & SHUTTLEWORTH, C. A. 1997. Microfibrillar elements of the dermal 
matrix. Microsc Res Tech, 38, 413-27. 
KIMURA, T. E., MERRITT, A. J. & GARROD, D. R. 2007. Calcium-independent 
desmosomes of keratinocytes are hyper-adhesive. J Invest Dermatol, 127, 
775-81. 
KING, I. A., SULLIVAN, K. H., BENNETT, R., JR. & BUXTON, R. S. 1995. The 
desmocollins of human foreskin epidermis: identification and chromosomal 
assignment of a third gene and expression patterns of the three isoforms. J 
Invest Dermatol, 105, 314-21. 
KITAJIMA, Y. 2013. New insights into desmosome regulation and pemphigus 
blistering as a desmosome-remodeling disease. Kaohsiung J Med Sci, 29, 1-
13. 
 
 
232 
 
KLAUKE, B., KOSSMANN, S., GAERTNER, A., BRAND, K., STORK, I., BRODEHL, A., 
DIEDING, M., WALHORN, V., ANSELMETTI, D., GERDES, D., BOHMS, B., 
SCHULZ, U., ZU KNYPHAUSEN, E., VORGERD, M., GUMMERT, J. & MILTING, H. 
2010. De novo desmin-mutation N116S is associated with arrhythmogenic 
right ventricular cardiomyopathy. Hum Mol Genet, 19, 4595-607. 
KLJUIC, A., BAUER, R. C. & CHRISTIANO, A. M. 2004. Genomic organization of mouse 
desmocollin genes reveals evolutionary conservation. DNA Seq, 15, 148-52. 
KLJUIC, A., BAZZI, H., SUNDBERG, J. P., MARTINEZ-MIR, A., O'SHAUGHNESSY, R., 
MAHONEY, M. G., LEVY, M., MONTAGUTELLI, X., AHMAD, W., AITA, V. M., 
GORDON, D., UITTO, J., WHITING, D., OTT, J., FISCHER, S., GILLIAM, T. C., 
JAHODA, C. A., MORRIS, R. J., PANTELEYEV, A. A., NGUYEN, V. T. & 
CHRISTIANO, A. M. 2003a. Desmoglein 4 in hair follicle differentiation and 
epidermal adhesion: evidence from inherited hypotrichosis and acquired 
pemphigus vulgaris. Cell, 113, 249-60. 
KLJUIC, A., GILEAD, L., MARTINEZ-MIR, A., FRANK, J., CHRISTIANO, A. M. & 
ZLOTOGORSKI, A. 2003b. A nonsense mutation in the desmoglein 1 gene 
underlies striate keratoderma. Exp Dermatol, 12, 523-7. 
KO, M. S. & MARINKOVICH, M. P. 2010. Role of dermal-epidermal basement 
membrane zone in skin, cancer, and developmental disorders. Dermatol Clin, 
28, 1-16. 
KOCH, P. J., MAHONEY, M. G., ISHIKAWA, H., PULKKINEN, L., UITTO, J., SHULTZ, L., 
MURPHY, G. F., WHITAKER-MENEZES, D. & STANLEY, J. R. 1997. Targeted 
disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice 
causes loss of keratinocyte cell adhesion with a phenotype similar to 
pemphigus vulgaris. J Cell Biol, 137, 1091-102. 
KOS, J., MITROVIC, A. & MIRKOVIC, B. 2014. The current stage of cathepsin B 
inhibitors as potential anticancer agents. Future Med Chem, 6, 1355-71. 
233 
 
KOS, J., SMID, A., KRASOVEC, M., SVETIC, B., LENARCIC, B., VRHOVEC, I., SKRK, J. & 
TURK, V. 1995. Lysosomal proteases cathepsins D, B, H, L and their inhibitors 
stefins A and B in head and neck cancer. Biol Chem Hoppe Seyler, 376, 401-5. 
KOTTKE, M. D., DELVA, E. & KOWALCZYK, A. P. 2006. The desmosome: cell science 
lessons from human diseases. J Cell Sci, 119, 797-806. 
KOWALCZYK, A. P., HATZFELD, M., BORNSLAEGER, E. A., KOPP, D. S., BORGWARDT, 
J. E., CORCORAN, C. M., SETTLER, A. & GREEN, K. J. 1999. The head domain of 
plakophilin-1 binds to desmoplakin and enhances its recruitment to 
desmosomes. Implications for cutaneous disease. J Biol Chem, 274, 18145-8. 
KOWALCZYK, A. P., STAPPENBECK, T. S., PARRY, D. A., PALKA, H. L., VIRATA, M. L., 
BORNSLAEGER, E. A., NILLES, L. A. & GREEN, K. J. 1994. Structure and 
function of desmosomal transmembrane core and plaque molecules. Biophys 
Chem, 50, 97-112. 
KROGER, C., LOSCHKE, F., SCHWARZ, N., WINDOFFER, R., LEUBE, R. E. & MAGIN, T. 
M. 2013. Keratins control intercellular adhesion involving PKC-alpha-
mediated desmoplakin phosphorylation. J Cell Biol, 201, 681-92. 
KRUNIC, A. L., STONE, K. L., SIMPSON, M. A. & MCGRATH, J. A. 2013. Acral peeling 
skin syndrome resulting from a homozygous nonsense mutation in the CSTA 
gene encoding cystatin A. Pediatr Dermatol, 30, e87-8. 
KUBO, A., SHIOHAMA, A., SASAKI, T., NAKABAYASHI, K., KAWASAKI, H., ATSUGI, T., 
SATO, S., SHIMIZU, A., MIKAMI, S., TANIZAKI, H., UCHIYAMA, M., MAEDA, T., 
ITO, T., SAKABE, J., HEIKE, T., OKUYAMA, T., KOSAKI, R., KOSAKI, K., KUDOH, 
J., HATA, K., UMEZAWA, A., TOKURA, Y., ISHIKO, A., NIIZEKI, H., KABASHIMA, 
K., MITSUHASHI, Y. & AMAGAI, M. 2013. Mutations in SERPINB7, encoding a 
member of the serine protease inhibitor superfamily, cause Nagashima-type 
palmoplantar keratosis. Am J Hum Genet, 93, 945-56. 
KUOPIO, T., KANKAANRANTA, A., JALAVA, P., KRONQVIST, P., KOTKANSALO, T., 
WEBER, E. & COLLAN, Y. 1998. Cysteine proteinase inhibitor cystatin A in 
breast cancer. Cancer Res, 58, 432-6. 
234 
 
KURZEN, H., MOLL, I., MOLL, R., SCHAFER, S., SIMICS, E., AMAGAI, M., WHEELOCK, 
M. J. & FRANKE, W. W. 1998. Compositionally different desmosomes in the 
various compartments of the human hair follicle. Differentiation, 63, 295-
304. 
KURZEN, H., MUNZING, I. & HARTSCHUH, W. 2003. Expression of desmosomal 
proteins in squamous cell carcinomas of the skin. J Cutan Pathol, 30, 621-30. 
LAH, T. T., KOKALJ-KUNOVAR, M., STRUKELJ, B., PUNGERCAR, J., BARLIC-MAGANJA, 
D., DROBNIC-KOSOROK, M., KASTELIC, L., BABNIK, J., GOLOUH, R. & TURK, V. 
1992. Stefins and lysosomal cathepsins B, L and D in human breast 
carcinoma. Int J Cancer, 50, 36-44. 
LAHTINEN, A. M., LEHTONEN, A., KAARTINEN, M., TOIVONEN, L., SWAN, H., WIDEN, 
E., LEHTONEN, E., LEHTO, V. P. & KONTULA, K. 2008. Plakophilin-2 missense 
mutations in arrhythmogenic right ventricular cardiomyopathy. Int J Cardiol, 
126, 92-100. 
LAI CHEONG, J. E., WESSAGOWIT, V. & MCGRATH, J. A. 2005. Molecular 
abnormalities of the desmosomal protein desmoplakin in human disease. 
Clin Exp Dermatol, 30, 261-6. 
LEGAN, P. K., YUE, K. K., CHIDGEY, M. A., HOLTON, J. L., WILKINSON, R. W. & GARROD, 
D. R. 1994. The bovine desmocollin family: a new gene and expression 
patterns reflecting epithelial cell proliferation and differentiation. J Cell Biol, 
126, 507-18. 
LEINONEN, T., PIRINEN, R., BOHM, J., JOHANSSON, R., RINNE, A., WEBER, E. & 
KOSMA, V. M. 2007. Biological and prognostic role of acid cysteine proteinase 
inhibitor (ACPI, cystatin A) in non-small-cell lung cancer. J Clin Pathol, 60, 
515-9. 
LELOUP, L., MAZERES, G., DAURY, L., COTTIN, P. & BRUSTIS, J. J. 2006. Involvement 
of calpains in growth factor-mediated migration. Int J Biochem Cell Biol, 38, 
2049-63. 
235 
 
LENARCIC, B., KRIZAJ, I., ZUNEC, P. & TURK, V. 1996. Differences in specificity for 
the interactions of stefins A, B and D with cysteine proteinases. FEBS Lett, 
395, 113-8. 
LETAVERNIER, E., DANSOU, B., LOCHNER, M., PEREZ, J., BELLOCQ, A., 
LINDENMEYER, M. T., COHEN, C. D., HAYMANN, J. P., EBERL, G. & BAUD, L. 
2011. Critical role of the calpain/calpastatin balance in acute allograft 
rejection. Eur J Immunol, 41, 473-84. 
LI, C., CHEN, L., WANG, J., ZHANG, L., TANG, P., ZHAI, S., GUO, W., YU, N., ZHAO, L., LIU, 
M. & YANG, S. 2011. Expression and clinical significance of cathepsin B and 
stefin A in laryngeal cancer. Oncol Rep, 26, 869-75. 
LI, D., ZHANG, W., LIU, Y., HANELINE, L. S. & SHOU, W. 2012. Lack of plakoglobin in 
epidermis leads to keratoderma. J Biol Chem, 287, 10435-43. 
LI, J. & RADICE, G. L. 2010. A new perspective on intercalated disc organization: 
implications for heart disease. Dermatol Res Pract, 2010, 207835. 
LI, W., DING, F., ZHANG, L., LIU, Z., WU, Y., LUO, A., WU, M., WANG, M., ZHAN, Q. & 
LIU, Z. 2005. Overexpression of stefin A in human esophageal squamous cell 
carcinoma cells inhibits tumor cell growth, angiogenesis, invasion, and 
metastasis. Clin Cancer Res, 11, 8753-62. 
LIN, T. K., CRUMRINE, D., ACKERMAN, L. D., SANTIAGO, J. L., ROELANDT, T., UCHIDA, 
Y., HUPE, M., FABRIAS, G., ABAD, J. L., RICE, R. H. & ELIAS, P. M. 2012. Cellular 
changes that accompany shedding of human corneocytes. J Invest Dermatol, 
132, 2430-9. 
LIN, Z., ZHAO, J., NITOIU, D., SCOTT, C. A., PLAGNOL, V., WILSON, N., COLE, C., 
SCHWARTZ, M., MCLEAN, I., SMITH, F., WANG, H., FENG, C., DUO, L., ZHOU, E. 
Y., REN, Y., DAI, L., CHEN, Y., ZHANG, J., XU, X., O’TOOLE, E. A., KELSELL, D. P. 
& YANG, Y. 2015. Loss-of-function mutations in CAST cause peeling skin, 
leukonychia, acral punctate keratoses, cheilitis and knuckle pads (PLACK) 
syndrome. The American Journal of Human Genetics, 96, 440-7. 
236 
 
LIU, Z. J., LI, H. F., TAN, G. H., TAO, Q. Q., NI, W., CHENG, X. W., XIONG, Z. Q. & WU, Z. 
Y. 2014. Identify mutation in amyotrophic lateral sclerosis cases using 
HaloPlex target enrichment system. Neurobiol Aging, 35, 2881 e11-5. 
LOFFEK, S., BRUCKNER-TUDERMAN, L. & MAGIN, T. M. 2012. Involvement of the 
ubiquitin-proteasome system in the stabilization of cell-cell contacts in 
human keratinocytes. Exp Dermatol, 21, 791-3. 
MACHLEIDT, W., BORCHART, U., FRITZ, H., BRZIN, J., RITONJA, A. & TURK, V. 1983. 
Protein inhibitors of cysteine proteinases. II. Primary structure of stefin, a 
cytosolic protein inhibitor of cysteine proteinases from human 
polymorphonuclear granulocytes. Hoppe Seylers Z Physiol Chem, 364, 1481-
6. 
MAGISTER, S. & KOS, J. 2013. Cystatins in immune system. J Cancer, 4, 45-56. 
MAHONEY, M. G., WANG, Z., ROTHENBERGER, K., KOCH, P. J., AMAGAI, M. & 
STANLEY, J. R. 1999. Explanations for the clinical and microscopic 
localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest, 103, 
461-8. 
MALLET, A., KYPRIOTOU, M., GEORGE, K., LECLERC, E., RIVERO, D., MAZEREEUW-
HAUTIER, J., SERRE, G., HUBER, M., JONCA, N. & HOHL, D. 2013. Identification 
of the first nonsense CDSN mutation with expression of a truncated protein 
causing peeling skin syndrome type B. Br J Dermatol, 169, 1322-5. 
MAO, X., CHOI, E. J. & PAYNE, A. S. 2009. Disruption of desmosome assembly by 
monovalent human pemphigus vulgaris monoclonal antibodies. J Invest 
Dermatol, 129, 908-18. 
 
 
 
237 
 
MARCUS, F. I., MCKENNA, W. J., SHERRILL, D., BASSO, C., BAUCE, B., BLUEMKE, D. A., 
CALKINS, H., CORRADO, D., COX, M. G., DAUBERT, J. P., FONTAINE, G., GEAR, 
K., HAUER, R., NAVA, A., PICARD, M. H., PROTONOTARIOS, N., SAFFITZ, J. E., 
SANBORN, D. M., STEINBERG, J. S., TANDRI, H., THIENE, G., TOWBIN, J. A., 
TSATSOPOULOU, A., WICHTER, T. & ZAREBA, W. 2010. Diagnosis of 
arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed 
modification of the task force criteria. Circulation, 121, 1533-41. 
MATHOT, L., WALLIN, M. & SJOBLOM, T. 2013. Automated serial extraction of DNA 
and RNA from biobanked tissue specimens. BMC Biotechnol, 13, 66. 
MATSUSHITA, Y., SHIMADA, Y., KAWARA, S., TAKEHARA, K. & SATO, S. 2005. 
Autoantibodies directed against the protease inhibitor calpastatin in 
psoriasis. Clin Exp Immunol, 139, 355-62. 
MCGRATH, J. A., MCMILLAN, J. R., SHEMANKO, C. S., RUNSWICK, S. K., LEIGH, I. M., 
LANE, E. B., GARROD, D. R. & EADY, R. A. 1997. Mutations in the plakophilin 
1 gene result in ectodermal dysplasia/skin fragility syndrome. Nat Genet, 17, 
240-4. 
MCKENNA, W. J., THIENE, G., NAVA, A., FONTALIRAN, F., BLOMSTROM-LUNDQVIST, 
C., FONTAINE, G. & CAMERINI, F. 1994. Diagnosis of arrhythmogenic right 
ventricular dysplasia/cardiomyopathy. Task Force of the Working Group 
Myocardial and Pericardial Disease of the European Society of Cardiology 
and of the Scientific Council on Cardiomyopathies of the International 
Society and Federation of Cardiology. Br Heart J, 71, 215-8. 
MCKOY, G., PROTONOTARIOS, N., CROSBY, A., TSATSOPOULOU, A., ANASTASAKIS, 
A., COONAR, A., NORMAN, M., BABOONIAN, C., JEFFERY, S. & MCKENNA, W. J. 
2000. Identification of a deletion in plakoglobin in arrhythmogenic right 
ventricular cardiomyopathy with palmoplantar keratoderma and woolly 
hair (Naxos disease). Lancet, 355, 2119-24. 
MENG, W. & TAKEICHI, M. 2009. Adherens junction: molecular architecture and 
regulation. Cold Spring Harb Perspect Biol, 1, a002899. 
238 
 
MENZIES, F. M., GARCIA-ARENCIBIA, M., IMARISIO, S., O'SULLIVAN, N. C., RICKETTS, 
T., KENT, B. A., RAO, M. V., LAM, W., GREEN-THOMPSON, Z. W., NIXON, R. A., 
SAKSIDA, L. M., BUSSEY, T. J., O'KANE, C. J. & RUBINSZTEIN, D. C. 2014. 
Calpain inhibition mediates autophagy-dependent protection against 
polyglutamine toxicity. Cell Death Differ. 
MERNER, N. D., HODGKINSON, K. A., HAYWOOD, A. F., CONNORS, S., FRENCH, V. M., 
DRENCKHAHN, J. D., KUPPRION, C., RAMADANOVA, K., THIERFELDER, L., 
MCKENNA, W., GALLAGHER, B., MORRIS-LARKIN, L., BASSETT, A. S., 
PARFREY, P. S. & YOUNG, T. L. 2008. Arrhythmogenic right ventricular 
cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder 
caused by a missense mutation in the TMEM43 gene. Am J Hum Genet, 82, 
809-21. 
MERTENS, C., KUHN, C. & FRANKE, W. W. 1996. Plakophilins 2a and 2b: constitutive 
proteins of dual location in the karyoplasm and the desmosomal plaque. J Cell 
Biol, 135, 1009-25. 
MERTENS, C., KUHN, C., MOLL, R., SCHWETLICK, I. & FRANKE, W. W. 1999. 
Desmosomal plakophilin 2 as a differentiation marker in normal and 
malignant tissues. Differentiation, 64, 277-90. 
MEURS, K. M., MAUCELI, E., LAHMERS, S., ACLAND, G. M., WHITE, S. N. & LINDBLAD-
TOH, K. 2010. Genome-wide association identifies a deletion in the 3' 
untranslated region of striatin in a canine model of arrhythmogenic right 
ventricular cardiomyopathy. Hum Genet, 128, 315-24. 
MEYER-HOFFERT, U. 2009. Reddish, scaly, and itchy: how proteases and their 
inhibitors contribute to inflammatory skin diseases. Arch Immunol Ther Exp 
(Warsz), 57, 345-54. 
MEYER-HOFFERT, U. & SCHRODER, J. M. 2011. Epidermal proteases in the 
pathogenesis of rosacea. J Investig Dermatol Symp Proc, 15, 16-23. 
 
239 
 
MEYER-HOFFERT, U., WU, Z., KANTYKA, T., FISCHER, J., LATENDORF, T., 
HANSMANN, B., BARTELS, J., HE, Y., GLASER, R. & SCHRODER, J. M. 2010. 
Isolation of SPINK6 in human skin: selective inhibitor of kallikrein-related 
peptidases. J Biol Chem, 285, 32174-81. 
MEYER-HOFFERT, U., WU, Z. & SCHRODER, J. M. 2009. Identification of lympho-
epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related 
peptidase 5-specific protease inhibitor. PLoS One, 4, e4372. 
MINOBE, E., ASMARA, H., SAUD, Z. A. & KAMEYAMA, M. 2011. Calpastatin domain L 
is a partial agonist of the calmodulin-binding site for channel activation in 
Cav1.2 Ca2+ channels. J Biol Chem, 286, 39013-22. 
MOLDOVEANU, T., GEHRING, K. & GREEN, D. R. 2008. Concerted multi-pronged 
attack by calpastatin to occlude the catalytic cleft of heterodimeric calpains. 
Nature, 456, 404-8. 
MOON, R. T., BOWERMAN, B., BOUTROS, M. & PERRIMON, N. 2002. The promise and 
perils of Wnt signaling through beta-catenin. Science, 296, 1644-6. 
MOOSBRUGGER-MARTINZ, V., JALILI, A., SCHOSSIG, A. S., JAHN-BASSLER, K., 
ZSCHOCKE, J., SCHMUTH, M., STINGL, G., ECKL, K. M., HENNIES, H. C. & 
GRUBER, R. 2014. Epidermal barrier abnormalities in exfoliative ichthyosis 
with a novel homozygous loss-of-function mutation in CSTA. Br J Dermatol. 
MORETTI, D., DEL BELLO, B., ALLAVENA, G. & MAELLARO, E. 2014. Calpains and 
cancer: Friends or enemies? Arch Biochem Biophys, 564C, 26-36. 
NAKAJIMA, R., TAKAO, K., HUANG, S. M., TAKANO, J., IWATA, N., MIYAKAWA, T. & 
SAIDO, T. C. 2008. Comprehensive behavioral phenotyping of calpastatin-
knockout mice. Mol Brain, 1, 7. 
NAKAJIMA, T., KANEKO, Y., IRIE, T., TAKAHASHI, R., KATO, T., IIJIMA, T., ISO, T. & 
KURABAYASHI, M. 2012. Compound and digenic heterozygosity in 
desmosome genes as a cause of arrhythmogenic right ventricular 
cardiomyopathy in Japanese patients. Circ J, 76, 737-43. 
240 
 
NAKANO, S. J. & TLUCZEK, A. 2014. Genomic breakthroughs in the diagnosis and 
treatment of cystic fibrosis. Am J Nurs, 114, 36-43; quiz 44-5. 
NASSAR, D., LETAVERNIER, E., BAUD, L., ARACTINGI, S. & KHOSROTEHRANI, K. 
2012. Calpain activity is essential in skin wound healing and contributes to 
scar formation. PLoS One, 7, e37084. 
NAVA, P., LAUKOETTER, M. G., HOPKINS, A. M., LAUR, O., GERNER-SMIDT, K., 
GREEN, K. J., PARKOS, C. A. & NUSRAT, A. 2007. Desmoglein-2: a novel 
regulator of apoptosis in the intestinal epithelium. Mol Biol Cell, 18, 4565-78. 
NEKRASOVA, O. & GREEN, K. J. 2013. Desmosome assembly and dynamics. Trends 
Cell Biol, 23, 537-46. 
NIJMAN, I. J., MOKRY, M., VAN BOXTEL, R., TOONEN, P., DE BRUIJN, E. & CUPPEN, E. 
2010. Mutation discovery by targeted genomic enrichment of multiplexed 
barcoded samples. Nat Methods, 7, 913-5. 
NISHIFUJI, K., SHIMIZU, A., ISHIKO, A., IWASAKI, T. & AMAGAI, M. 2010. Removal of 
amino-terminal extracellular domains of desmoglein 1 by staphylococcal 
exfoliative toxin is sufficient to initiate epidermal blister formation. J 
Dermatol Sci, 59, 184-91. 
NITOIU, D., ETHERIDGE, S. L. & KELSELL, D. P. 2014. Insights into desmosome 
biology from inherited human skin disease and cardiocutaneous syndromes. 
Cell Commun Adhes, 21, 129-40. 
NORGETT, E. E., HATSELL, S. J., CARVAJAL-HUERTA, L., CABEZAS, J. C., COMMON, J., 
PURKIS, P. E., WHITTOCK, N., LEIGH, I. M., STEVENS, H. P. & KELSELL, D. P. 
2000. Recessive mutation in desmoplakin disrupts desmoplakin-
intermediate filament interactions and causes dilated cardiomyopathy, 
woolly hair and keratoderma. Hum Mol Genet, 9, 2761-6. 
 
 
241 
 
NORGETT, E. E., LUCKE, T. W., BOWERS, B., MUNRO, C. S., LEIGH, I. M. & KELSELL, D. 
P. 2006. Early death from cardiomyopathy in a family with autosomal 
dominant striate palmoplantar keratoderma and woolly hair associated with 
a novel insertion mutation in desmoplakin. J Invest Dermatol, 126, 1651-4. 
NORMAN, M., SIMPSON, M., MOGENSEN, J., SHAW, A., HUGHES, S., SYRRIS, P., SEN-
CHOWDHRY, S., ROWLAND, E., CROSBY, A. & MCKENNA, W. J. 2005. Novel 
mutation in desmoplakin causes arrhythmogenic left ventricular 
cardiomyopathy. Circulation, 112, 636-42. 
NORTH, A. J., CHIDGEY, M. A., CLARKE, J. P., BARDSLEY, W. G. & GARROD, D. R. 1996. 
Distinct desmocollin isoforms occur in the same desmosomes and show 
reciprocally graded distributions in bovine nasal epidermis. Proc Natl Acad 
Sci U S A, 93, 7701-5. 
ODA, H. & TAKEICHI, M. 2011. Evolution: structural and functional diversity of 
cadherin at the adherens junction. J Cell Biol, 193, 1137-46. 
OJI, V., ECKL, K. M., AUFENVENNE, K., NATEBUS, M., TARINSKI, T., ACKERMANN, K., 
SELLER, N., METZE, D., NURNBERG, G., FOLSTER-HOLST, R., SCHAFER-
KORTING, M., HAUSSER, I., TRAUPE, H. & HENNIES, H. C. 2010. Loss of 
corneodesmosin leads to severe skin barrier defect, pruritus, and atopy: 
unraveling the peeling skin disease. Am J Hum Genet, 87, 274-81. 
OKTARINA, D. A., VAN DER WIER, G., DIERCKS, G. F., JONKMAN, M. F. & PAS, H. H. 
2011. IgG-induced clustering of desmogleins 1 and 3 in skin of patients with 
pemphigus fits with the desmoglein nonassembly depletion hypothesis. Br J 
Dermatol, 165, 552-62. 
ONO, Y. & SORIMACHI, H. 2012. Calpains: an elaborate proteolytic system. Biochim 
Biophys Acta, 1824, 224-36. 
OXFORD, E. M., MUSA, H., MAASS, K., COOMBS, W., TAFFET, S. M. & DELMAR, M. 
2007. Connexin43 remodeling caused by inhibition of plakophilin-2 
expression in cardiac cells. Circ Res, 101, 703-11. 
242 
 
PALUNGWACHIRA, P., KAKUTA, M., YAMAZAKI, M., YAGUCHI, H., TSUBOI, R., 
TAKAMORI, K. & OGAWA, H. 2002. Immunohistochemical localization of 
cathepsin L and cystatin A in normal skin and skin tumors. J Dermatol, 29, 
573-9. 
PARRISH, E. P., STEART, P. V., GARROD, D. R. & WELLER, R. O. 1987. Antidesmosomal 
monoclonal antibody in the diagnosis of intracranial tumours. J Pathol, 153, 
265-73. 
PASDAR, M., LI, Z. & CHAN, H. 1995. Desmosome assembly and disassembly are 
regulated by reversible protein phosphorylation in cultured epithelial cells. 
Cell Motil Cytoskeleton, 30, 108-21. 
PIEPERHOFF, S., BARTH, M., RICKELT, S. & FRANKE, W. W. 2010. Desmosomal 
molecules in and out of adhering junctions: normal and diseased States of 
epidermal, cardiac and mesenchymally derived cells. Dermatol Res Pract, 
2010, 139167. 
PIEPERHOFF, S., SCHUMACHER, H. & FRANKE, W. W. 2008. The area composita of 
adhering junctions connecting heart muscle cells of vertebrates. V. The 
importance of plakophilin-2 demonstrated by small interference RNA-
mediated knockdown in cultured rat cardiomyocytes. Eur J Cell Biol, 87, 399-
411. 
PIGORS, M., KIRITSI, D., KRUMPELMANN, S., WAGNER, N., HE, Y., PODDA, M., 
KOHLHASE, J., HAUSSER, I., BRUCKNER-TUDERMAN, L. & HAS, C. 2011. Lack 
of plakoglobin leads to lethal congenital epidermolysis bullosa: a novel 
clinico-genetic entity. Hum Mol Genet, 20, 1811-9. 
PIHLSTROM, L., RENGMARK, A., BJORNARA, K. A. & TOFT, M. 2014. Effective variant 
detection by targeted deep sequencing of DNA pools: an example from 
Parkinson's disease. Ann Hum Genet, 78, 243-52. 
 
243 
 
PILICHOU, K., NAVA, A., BASSO, C., BEFFAGNA, G., BAUCE, B., LORENZON, A., FRIGO, 
G., VETTORI, A., VALENTE, M., TOWBIN, J., THIENE, G., DANIELI, G. A. & 
RAMPAZZO, A. 2006. Mutations in desmoglein-2 gene are associated with 
arrhythmogenic right ventricular cardiomyopathy. Circulation, 113, 1171-9. 
POKUTTA, S. & WEIS, W. I. 2007. Structure and mechanism of cadherins and 
catenins in cell-cell contacts. Annu Rev Cell Dev Biol, 23, 237-61. 
PROTONOTARIOS, N. & TSATSOPOULOU, A. 2004. Naxos disease and Carvajal 
syndrome: cardiocutaneous disorders that highlight the pathogenesis and 
broaden the spectrum of arrhythmogenic right ventricular cardiomyopathy. 
Cardiovasc Pathol, 13, 185-94. 
QUARTA, G., MUIR, A., PANTAZIS, A., SYRRIS, P., GEHMLICH, K., GARCIA-PAVIA, P., 
WARD, D., SEN-CHOWDHRY, S., ELLIOTT, P. M. & MCKENNA, W. J. 2011. 
Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: 
impact of genetics and revised task force criteria. Circulation, 123, 2701-9. 
RAMOS, E., LEVINSON, B. T., CHASNOFF, S., HUGHES, A., YOUNG, A. L., THORNTON, 
K., LI, A., VALLANIA, F. L., PROVINCE, M. & DRULEY, T. E. 2012. Population-
based rare variant detection via pooled exome or custom hybridization 
capture with or without individual indexing. BMC Genomics, 13, 683. 
RAMPAZZO, A., NAVA, A., MALACRIDA, S., BEFFAGNA, G., BAUCE, B., ROSSI, V., 
ZIMBELLO, R., SIMIONATI, B., BASSO, C., THIENE, G., TOWBIN, J. A. & 
DANIELI, G. A. 2002. Mutation in human desmoplakin domain binding to 
plakoglobin causes a dominant form of arrhythmogenic right ventricular 
cardiomyopathy. Am J Hum Genet, 71, 1200-6. 
RAO, M. V., MOHAN, P. S., PETERHOFF, C. M., YANG, D. S., SCHMIDT, S. D., STAVRIDES, 
P. H., CAMPBELL, J., CHEN, Y., JIANG, Y., PASKEVICH, P. A., CATALDO, A. M., 
HAROUTUNIAN, V. & NIXON, R. A. 2008. Marked calpastatin (CAST) 
depletion in Alzheimer's disease accelerates cytoskeleton disruption and 
neurodegeneration: neuroprotection by CAST overexpression. J Neurosci, 28, 
12241-54. 
244 
 
RASANEN, O., JARVINEN, M. & RINNE, A. 1978. Localization of the human SH-
protease inhibitor in the epidermis. Immunofluorescent studies. Acta 
Histochem, 63, 193-6. 
RAWLINGS, N. D. & BARRETT, A. J. 1990. Evolution of proteins of the cystatin 
superfamily. J Mol Evol, 30, 60-71. 
RENKO, M., POZGAN, U., MAJERA, D. & TURK, D. 2010. Stefin A displaces the 
occluding loop of cathepsin B only by as much as required to bind to the 
active site cleft. FEBS J, 277, 4338-45. 
RESNIK, N., SEPCIC, K., PLEMENITAS, A., WINDOFFER, R., LEUBE, R. & VERANIC, P. 
2011. Desmosome assembly and cell-cell adhesion are membrane raft-
dependent processes. J Biol Chem, 286, 1499-507. 
RICKMAN, L., SIMRAK, D., STEVENS, H. P., HUNT, D. M., KING, I. A., BRYANT, S. P., 
EADY, R. A., LEIGH, I. M., ARNEMANN, J., MAGEE, A. I., KELSELL, D. P. & 
BUXTON, R. S. 1999. N-terminal deletion in a desmosomal cadherin causes 
the autosomal dominant skin disease striate palmoplantar keratoderma. 
Hum Mol Genet, 8, 971-6. 
RINNE, A. 2010. Epidermal SH-protease inhibitor (ACPI, cystatin A) in cancer. A 
short historical review. Pathol Res Pract, 206, 259-62. 
RINNE, A., JARVINEN, M. & RASANEN, O. 1978. A protein reminiscent of the 
epidermal SH-protease inhibitor occurs in squamous epithelia of man and 
rat. Acta Histochem, 63, 183-92. 
RINNE, A., JARVINEN, M., RASANEN, O. & DORN, A. 1980. [Demonstration of an 
epidermal SH-protease inhibitor in normal epithelium and in some human 
neoplasms--an immunological study (author's transl)]. Acta Histochem Suppl, 
22, 325-9. 
RIVENBARK, A. G. & COLEMAN, W. B. 2009. Epigenetic regulation of cystatins in 
cancer. Front Biosci (Landmark Ed), 14, 453-62. 
245 
 
RUIZ, P., BRINKMANN, V., LEDERMANN, B., BEHREND, M., GRUND, C., 
THALHAMMER, C., VOGEL, F., BIRCHMEIER, C., GUNTHERT, U., FRANKE, W. 
W. & BIRCHMEIER, W. 1996. Targeted mutation of plakoglobin in mice 
reveals essential functions of desmosomes in the embryonic heart. J Cell Biol, 
135, 215-25. 
RUNSWICK, S. K., O'HARE, M. J., JONES, L., STREULI, C. H. & GARROD, D. R. 2001. 
Desmosomal adhesion regulates epithelial morphogenesis and cell 
positioning. Nat Cell Biol, 3, 823-30. 
SAARINEN, S., VAHTERISTO, P., LEHTONEN, R., AITTOMAKI, K., LAUNONEN, V., 
KIVILUOTO, T. & AALTONEN, L. A. 2012. Analysis of a Finnish family confirms 
RHBDF2 mutations as the underlying factor in tylosis with esophageal 
cancer. Fam Cancer, 11, 525-8. 
SALEHIN, D., FROMBERG, I., HAUGK, C., DOHMEN, B., GEORG, T., BOHLE, R. M., 
BAUERSCHLAG, D., THILL, M. & FRIEDRICH, M. 2011. Immunhistochemical 
analysis for expression of calpain 1, calpain 2 and calpastatin in ovarian 
cancer. Eur J Gynaecol Oncol, 32, 628-35. 
SAMUELOV, L., SARIG, O., HARMON, R. M., RAPAPORT, D., ISHIDA-YAMAMOTO, A., 
ISAKOV, O., KOETSIER, J. L., GAT, A., GOLDBERG, I., BERGMAN, R., SPIEGEL, 
R., EYTAN, O., GELLER, S., PELEG, S., SHOMRON, N., GOH, C. S., WILSON, N. J., 
SMITH, F. J., POHLER, E., SIMPSON, M. A., MCLEAN, W. H., IRVINE, A. D., 
HOROWITZ, M., MCGRATH, J. A., GREEN, K. J. & SPRECHER, E. 2013. 
Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and 
metabolic wasting. Nat Genet, 45, 1244-8. 
SATO, A., SAKAMOTO, N., ANDO, K., KANESHIRO, T., UEKITA, H., SUGIMOTO, K., 
YAMAKI, T., KUNII, H., NAKAZATO, K., SUZUKI, H., SAITOH, S., SATO, M., 
TAMAGAWA, K., ARIMURA, T., KIMURA, A. & TAKEISHI, Y. 2012. Dilated 
phase of hypertrophic cardiomyopathy caused by two different sarcomere 
mutations, treated with surgical left ventricular reconstruction and cardiac 
resynchronization therapy with a defibrillator. Intern Med, 51, 2559-64. 
246 
 
SATO, M., AOYAMA, Y. & KITAJIMA, Y. 2000. Assembly pathway of desmoglein 3 to 
desmosomes and its perturbation by pemphigus vulgaris-IgG in cultured 
keratinocytes, as revealed by time-lapsed labeling immunoelectron 
microscopy. Lab Invest, 80, 1583-92. 
SCHAFER, S., STUMPP, S. & FRANKE, W. W. 1996. Immunological identification and 
characterization of the desmosomal cadherin Dsg2 in coupled and uncoupled 
epithelial cells and in human tissues. Differentiation, 60, 99-108. 
SCHAFFER, J. V., BAZZI, H., VITEBSKY, A., WITKIEWICZ, A., KOVICH, O. I., KAMINO, 
H., SHAPIRO, L. S., AMIN, S. P., ORLOW, S. J. & CHRISTIANO, A. M. 2006. 
Mutations in the desmoglein 4 gene underlie localized autosomal recessive 
hypotrichosis with monilethrix hairs and congenital scalp erosions. J Invest 
Dermatol, 126, 1286-91. 
SCHERER, S. E., MUZNY, D. M., BUHAY, C. J., CHEN, R., CREE, A., DING, Y., DUGAN-
ROCHA, S., GILL, R., GUNARATNE, P., HARRIS, R. A., HAWES, A. C., 
HERNANDEZ, J., HODGSON, A. V., HUME, J., JACKSON, A., KHAN, Z. M., KOVAR-
SMITH, C., LEWIS, L. R., LOZADO, R. J., METZKER, M. L., MILOSAVLJEVIC, A., 
MINER, G. R., MONTGOMERY, K. T., MORGAN, M. B., NAZARETH, L. V., SCOTT, 
G., SODERGREN, E., SONG, X. Z., STEFFEN, D., LOVERING, R. C., WHEELER, D. 
A., WORLEY, K. C., YUAN, Y., ZHANG, Z., ADAMS, C. Q., ANSARI-LARI, M. A., 
AYELE, M., BROWN, M. J., CHEN, G., CHEN, Z., CLERC-BLANKENBURG, K. P., 
DAVIS, C., DELGADO, O., DINH, H. H., DRAPER, H., GONZALEZ-GARAY, M. L., 
HAVLAK, P., JACKSON, L. R., JACOB, L. S., KELLY, S. H., LI, L., LI, Z., LIU, J., LIU, 
W., LU, J., MAHESHWARI, M., NGUYEN, B. V., OKWUONU, G. O., PASTERNAK, 
S., PEREZ, L. M., PLOPPER, F. J., SANTIBANEZ, J., SHEN, H., TABOR, P. E., 
VERDUZCO, D., WALDRON, L., WANG, Q., WILLIAMS, G. A., ZHANG, J., ZHOU, 
J., ALLEN, C. C., AMIN, A. G., ANYALEBECHI, V., BAILEY, M., BARBARIA, J. A., 
BIMAGE, K. E., BRYANT, N. P., BURCH, P. E., BURKETT, C. E., BURRELL, K. L., 
CALDERON, E., CARDENAS, V., CARTER, K., CASIAS, K., CAVAZOS, I., CAVAZOS, 
S. R., CEASAR, H., CHACKO, J., CHAN, S. N., CHAVEZ, D., CHRISTOPOULOS, C., 
CHU, J., COCKRELL, R., COX, C. D., DANG, M., DATHORNE, S. R., DAVID, R., 
247 
 
DAVIS, C. M., DAVY-CARROLL, L., DESHAZO, D. R., et al. 2006. The finished 
DNA sequence of human chromosome 12. Nature, 440, 346-51. 
SCHMEISER, K. & GRAND, R. J. 1999. The fate of E- and P-cadherin during the early 
stages of apoptosis. Cell Death Differ, 6, 377-86. 
SCHMIDT, A., LANGBEIN, L., RODE, M., PRATZEL, S., ZIMBELMANN, R. & FRANKE, W. 
W. 1997. Plakophilins 1a and 1b: widespread nuclear proteins recruited in 
specific epithelial cells as desmosomal plaque components. Cell Tissue Res, 
290, 481-99. 
SCOTT, C. A. & KELSELL, D. P. 2011. Key functions for gap junctions in skin and 
hearing. Biochem J, 438, 245-54. 
SCOTT, D. K., LORD, R., MULLER, H. K., MALLEY, R. C. & WOODS, G. M. 2007. 
Proteomics identifies enhanced expression of stefin A in neonatal murine 
skin compared with adults: functional implications. Br J Dermatol, 156, 1156-
62. 
SEKIGUCHI, M., FUTEI, Y., FUJII, Y., IWASAKI, T., NISHIKAWA, T. & AMAGAI, M. 2001. 
Dominant autoimmune epitopes recognized by pemphigus antibodies map 
to the N-terminal adhesive region of desmogleins. J Immunol, 167, 5439-48. 
SEN-CHOWDHRY, S., MORGAN, R. D., CHAMBERS, J. C. & MCKENNA, W. J. 2010. 
Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. Annu 
Rev Med, 61, 233-53. 
SHIMIZU, A., ISHIKO, A., OTA, T., TSUNODA, K., AMAGAI, M. & NISHIKAWA, T. 2004. 
IgG binds to desmoglein 3 in desmosomes and causes a desmosomal split 
without keratin retraction in a pemphigus mouse model. J Invest Dermatol, 
122, 1145-53. 
 
 
248 
 
SHIMIZU, H., MASUNAGA, T., ISHIKO, A., KIKUCHI, A., HASHIMOTO, T. & 
NISHIKAWA, T. 1995. Pemphigus vulgaris and pemphigus foliaceus sera 
show an inversely graded binding pattern to extracellular regions of 
desmosomes in different layers of human epidermis. J Invest Dermatol, 105, 
153-9. 
SHIMOMURA, Y., SAKAMOTO, F., KARIYA, N., MATSUNAGA, K. & ITO, M. 2006. 
Mutations in the desmoglein 4 gene are associated with monilethrix-like 
congenital hypotrichosis. J Invest Dermatol, 126, 1281-5. 
SHIRAKATA, Y., AMAGAI, M., HANAKAWA, Y., NISHIKAWA, T. & HASHIMOTO, K. 
1998. Lack of mucosal involvement in pemphigus foliaceus may be due to 
low expression of desmoglein 1. J Invest Dermatol, 110, 76-8. 
SHWAYDER, T., CONN, S. & LOWE, L. 1997. Acral peeling skin syndrome. Arch 
Dermatol, 133, 535-6. 
SIMPSON, M. A., COOK, R. W., SOLANKI, P., PATTON, M. A., DENNIS, J. A. & CROSBY, 
A. H. 2009a. A mutation in NFkappaB interacting protein 1 causes 
cardiomyopathy and woolly haircoat syndrome of Poll Hereford cattle. Anim 
Genet, 40, 42-6. 
SIMPSON, M. A., MANSOUR, S., AHNOOD, D., KALIDAS, K., PATTON, M. A., MCKENNA, 
W. J., BEHR, E. R. & CROSBY, A. H. 2009b. Homozygous mutation of 
desmocollin-2 in arrhythmogenic right ventricular cardiomyopathy with 
mild palmoplantar keratoderma and woolly hair. Cardiology, 113, 28-34. 
SINHA, A. A., QUAST, B. J., KORKOWSKI, J. C., WILSON, M. J., REDDY, P. K., EWING, S. 
L., SLOANE, B. F. & GLEASON, D. F. 1999. The relationship of cathepsin B and 
stefin A mRNA localization identifies a potentially aggressive variant of 
human prostate cancer within a Gleason histologic score. Anticancer Res, 19, 
2821-9. 
 
249 
 
SKLYAROVA, T., BONNE, S., D'HOOGE, P., DENECKER, G., GOOSSENS, S., DE RYCKE, 
R., BORGONIE, G., BOSL, M., VAN ROY, F. & VAN HENGEL, J. 2008. Plakophilin-
3-deficient mice develop hair coat abnormalities and are prone to cutaneous 
inflammation. J Invest Dermatol, 128, 1375-85. 
SMITH, E. A. & FUCHS, E. 1998. Defining the interactions between intermediate 
filaments and desmosomes. J Cell Biol, 141, 1229-41. 
SOBOLIK-DELMAIRE, T., REDDY, R., PASHAJ, A., ROBERTS, B. J. & WAHL, J. K., 3RD 
2010. Plakophilin-1 localizes to the nucleus and interacts with single-
stranded DNA. J Invest Dermatol, 130, 2638-46. 
SODERSTROM, K. O., LAATO, M., WU, P., HOPSU-HAVU, V. K., NURMI, M. & RINNE, A. 
1995. Expression of acid cysteine proteinase inhibitor (ACPI) in the normal 
human prostate, benign prostatic hyperplasia and adenocarcinoma. Int J 
Cancer, 62, 1-4. 
SODERSTROM, K. O., RINNE, R., HOPSU-HAVU, V. K., JARVINEN, M. & RINNE, A. 1994. 
Identification of acid cysteine proteinase inhibitor (cystatin A) in the human 
thymus. Anat Rec, 240, 115-9. 
STAEHELIN, L. A. 1974. Structure and function of intercellular junctions. Int Rev 
Cytol, 39, 191-283. 
STAHLEY, S. N., SAITO, M., FAUNDEZ, V., KOVAL, M., MATTHEYSES, A. L. & 
KOWALCZYK, A. P. 2014. Desmosome assembly and disassembly are 
membrane raft-dependent. PLoS One, 9, e87809. 
STANLEY, J. R. & AMAGAI, M. 2006. Pemphigus, bullous impetigo, and the 
staphylococcal scalded-skin syndrome. N Engl J Med, 355, 1800-10. 
 
 
 
250 
 
STEVENS, H. P., KELSELL, D. P., BRYANT, S. P., BISHOP, D. T., SPURR, N. K., 
WEISSENBACH, J., MARGER, D., MARGER, R. S. & LEIGH, I. M. 1996. Linkage 
of an American pedigree with palmoplantar keratoderma and malignancy 
(palmoplantar ectodermal dysplasia type III) to 17q24. Literature survey 
and proposed updated classification of the keratodermas. Arch Dermatol, 
132, 640-51. 
STODDARD, J. L., NIEMELA, J. E., FLEISHER, T. A. & ROSENZWEIG, S. D. 2014. 
Targeted NGS: A Cost-Effective Approach to Molecular Diagnosis of PIDs. 
Front Immunol, 5, 531. 
STORME, M. L., SINNAEVE, B. A. & VAN BOCXLAER, J. F. 2005. The use of tryptic 
marker-peptides for the quantitative analysis of cystatin C. J Sep Sci, 28, 
1759-63. 
STROJAN, P., ANICIN, A., SVETIC, B., SMID, L. & KOS, J. 2011. Proteolytic profile of 
cysteine proteases and inhibitors determines tumor cell phenotype in 
squamous cell carcinoma of the head and neck. Int J Biol Markers, 26, 247-54. 
STROJAN, P., BUDIHNA, M., SMID, L., SVETIC, B., VRHOVEC, I., KOS, J. & SKRK, J. 2000. 
Prognostic significance of cysteine proteinases cathepsins B and L and their 
endogenous inhibitors stefins A and B in patients with squamous cell 
carcinoma of the head and neck. Clin Cancer Res, 6, 1052-62. 
SUTTON, L. A., LJUNGSTROM, V., MANSOURI, L., YOUNG, E., CORTESE, D., 
NAVRKALOVA, V., MALCIKOVA, J., MUGGEN, A. F., TRBUSEK, M., 
PANAGIOTIDIS, P., DAVI, F., BELESSI, C., LANGERAK, A. W., GHIA, P., 
POSPISILOVA, S., STAMATOPOULOS, K. & ROSENQUIST, R. 2014. Targeted 
next-generation sequencing in chronic lymphocytic leukemia: a high-
throughput yet tailored approach will facilitate implementation within a 
clinical setting. Haematologica. 
SYRRIS, P., WARD, D., ASIMAKI, A., EVANS, A., SEN-CHOWDHRY, S., HUGHES, S. E. & 
MCKENNA, W. J. 2007. Desmoglein-2 mutations in arrhythmogenic right 
ventricular cardiomyopathy: a genotype-phenotype characterization of 
familial disease. Eur Heart J, 28, 581-8. 
251 
 
SYRRIS, P., WARD, D., EVANS, A., ASIMAKI, A., GANDJBAKHCH, E., SEN-CHOWDHRY, 
S. & MCKENNA, W. J. 2006. Arrhythmogenic right ventricular 
dysplasia/cardiomyopathy associated with mutations in the desmosomal 
gene desmocollin-2. Am J Hum Genet, 79, 978-84. 
SZEGEDI, A., PAYER, E., CZIFRA, G., TOTH, B. I., SCHMIDT, E., KOVACS, L., BLUMBERG, 
P. M. & BIRO, T. 2009. Protein kinase C isoenzymes differentially regulate the 
differentiation-dependent expression of adhesion molecules in human 
epidermal keratinocytes. Exp Dermatol, 18, 122-9. 
TAKANO, E., NOSAKA, T., LEE, W. J., NAKAMURA, K., TAKAHASHI, T., FUNAKI, M., 
OKADA, H., HATANAKA, M. & MAKI, M. 1993. Molecular diversity of 
calpastatin in human erythroid cells. Arch Biochem Biophys, 303, 349-54. 
TAKANO, E., UEDA, M., TSUNEKAWA, S., MURAKAMI, T., MAKI, M., HATANAKA, M. & 
MURACHI, T. 1991. Molecular diversity of erythrocyte calpastatin. Biomed 
Biochim Acta, 50, 517-21. 
TAKANO, J., TOMIOKA, M., TSUBUKI, S., HIGUCHI, M., IWATA, N., ITOHARA, S., MAKI, 
M. & SAIDO, T. C. 2005. Calpain mediates excitotoxic DNA fragmentation via 
mitochondrial pathways in adult brains: evidence from calpastatin mutant 
mice. J Biol Chem, 280, 16175-84. 
TAKEICHI, M. 1977. Functional correlation between cell adhesive properties and 
some cell surface proteins. J Cell Biol, 75, 464-74. 
TAKEICHI, M. 1990. Cadherins: a molecular family important in selective cell-cell 
adhesion. Annu Rev Biochem, 59, 237-52. 
TAMAI, K., KANEDA, Y. & UITTO, J. 2009. Molecular therapies for heritable blistering 
diseases. Trends Mol Med, 15, 285-92. 
TAN, Y., DOURDIN, N., WU, C., DE VEYRA, T., ELCE, J. S. & GREER, P. A. 2006. 
Ubiquitous calpains promote caspase-12 and JNK activation during 
endoplasmic reticulum stress-induced apoptosis. J Biol Chem, 281, 16016-24. 
252 
 
TANAKA, A., LAI-CHEONG, J. E., CAFE, M. E., GONTIJO, B., SALOMAO, P. R., PEREIRA, 
L. & MCGRATH, J. A. 2009. Novel truncating mutations in PKP1 and DSP cause 
similar skin phenotypes in two Brazilian families. Br J Dermatol, 160, 692-7. 
TAYLOR, M., GRAW, S., SINAGRA, G., BARNES, C., SLAVOV, D., BRUN, F., PINAMONTI, 
B., SALCEDO, E. E., SAUER, W., PYXARAS, S., ANDERSON, B., SIMON, B., 
BOGOMOLOVAS, J., LABEIT, S., GRANZIER, H. & MESTRONI, L. 2011. Genetic 
variation in titin in arrhythmogenic right ventricular cardiomyopathy-
overlap syndromes. Circulation, 124, 876-85. 
TEMM-GROVE, C. J., WERT, D., THOMPSON, V. F., ALLEN, R. E. & GOLL, D. E. 1999. 
Microinjection of calpastatin inhibits fusion in myoblasts. Exp Cell Res, 247, 
293-303. 
TOWBIN, J. A. 2008. Arrhythmogenic right ventricular cardiomyopathy: a paradigm 
of overlapping disorders. Ann Noninvasive Electrocardiol, 13, 325-6. 
TSELEPIS, C., CHIDGEY, M., NORTH, A. & GARROD, D. 1998. Desmosomal adhesion 
inhibits invasive behavior. Proc Natl Acad Sci U S A, 95, 8064-9. 
TUCKER, D. K., STAHLEY, S. N. & KOWALCZYK, A. P. 2014. Plakophilin-1 protects 
keratinocytes from pemphigus vulgaris IgG by forming calcium-independent 
desmosomes. J Invest Dermatol, 134, 1033-43. 
TURK, B., KRIZAJ, I., KRALJ, B., DOLENC, I., POPOVIC, T., BIETH, J. G. & TURK, V. 1993. 
Bovine stefin C, a new member of the stefin family. J Biol Chem, 268, 7323-9. 
UEYAMA, H., KUMAMOTO, T., FUJIMOTO, S., MURAKAMI, T. & TSUDA, T. 1998. 
Expression of three calpain isoform genes in human skeletal muscles. J 
Neurol Sci, 155, 163-9. 
UZUMCU, A., NORGETT, E. E., DINDAR, A., UYGUNER, O., NISLI, K., KAYSERILI, H., 
SAHIN, S. E., DUPONT, E., SEVERS, N. J., LEIGH, I. M., YUKSEL-APAK, M., 
KELSELL, D. P. & WOLLNIK, B. 2006. Loss of desmoplakin isoform I causes 
early onset cardiomyopathy and heart failure in a Naxos-like syndrome. J 
Med Genet, 43, e5. 
253 
 
VAN DER ZWAAG, P. A., COX, M. G., VAN DER WERF, C., WIESFELD, A. C., JONGBLOED, 
J. D., DOOIJES, D., BIKKER, H., JONGBLOED, R., SUURMEIJER, A. J., VAN DEN 
BERG, M. P., HOFSTRA, R. M., HAUER, R. N., WILDE, A. A. & VAN TINTELEN, J. 
P. 2010. Recurrent and founder mutations in the Netherlands : Plakophilin-2 
p.Arg79X mutation causing arrhythmogenic right ventricular 
cardiomyopathy/dysplasia. Neth Heart J, 18, 583-91. 
VAN TINTELEN, J. P., VAN GELDER, I. C., ASIMAKI, A., SUURMEIJER, A. J., WIESFELD, 
A. C., JONGBLOED, J. D., VAN DEN WIJNGAARD, A., KUKS, J. B., VAN 
SPAENDONCK-ZWARTS, K. Y., NOTERMANS, N., BOVEN, L., VAN DEN 
HEUVEL, F., VEENSTRA-KNOL, H. E., SAFFITZ, J. E., HOFSTRA, R. M. & VAN 
DEN BERG, M. P. 2009. Severe cardiac phenotype with right ventricular 
predominance in a large cohort of patients with a single missense mutation 
in the DES gene. Heart Rhythm, 6, 1574-83. 
VASILOPOULOS, Y., CORK, M. J., TEARE, D., MARINOU, I., WARD, S. J., DUFF, G. W. & 
TAZI-AHNINI, R. 2007. A nonsynonymous substitution of cystatin A, a 
cysteine protease inhibitor of house dust mite protease, leads to decreased 
mRNA stability and shows a significant association with atopic dermatitis. 
Allergy, 62, 514-9. 
VASILOPOULOS, Y., WALTERS, K., CORK, M. J., DUFF, G. W., SAGOO, G. S. & TAZI-
AHNINI, R. 2008. Association analysis of the skin barrier gene cystatin A at 
the PSORS5 locus in psoriatic patients: evidence for interaction between 
PSORS1 and PSORS5. Eur J Hum Genet, 16, 1002-9. 
VASIOUKHIN, V., BOWERS, E., BAUER, C., DEGENSTEIN, L. & FUCHS, E. 2001. 
Desmoplakin is essential in epidermal sheet formation. Nat Cell Biol, 3, 1076-
85. 
WAHL, J. K., 3RD 2005. A role for plakophilin-1 in the initiation of desmosome 
assembly. J Cell Biochem, 96, 390-403. 
 
254 
 
WALLIS, S., LLOYD, S., WISE, I., IRELAND, G., FLEMING, T. P. & GARROD, D. 2000. The 
alpha isoform of protein kinase C is involved in signaling the response of 
desmosomes to wounding in cultured epithelial cells. Mol Biol Cell, 11, 1077-
92. 
WANG, H., CAO, X., LIN, Z., LEE, M., JIA, X., REN, Y., DAI, L., GUAN, L., ZHANG, J., LIN, 
X., ZHANG, J., CHEN, Q., FENG, C., ZHOU, E. Y., YIN, J., XU, G. & YANG, Y. 2015. 
Exome sequencing reveals mutation in GJA1 as a cause of keratoderma-
hypotrichosis-leukonychia totalis syndrome. Hum Mol Genet, 24, 243-50. 
WATT, F. M., MATTEY, D. L. & GARROD, D. R. 1984. Calcium-induced reorganization 
of desmosomal components in cultured human keratinocytes. J Cell Biol, 99, 
2211-5. 
WEI, C. J., XU, X. & LO, C. W. 2004. Connexins and cell signaling in development and 
disease. Annu Rev Cell Dev Biol, 20, 811-38. 
WEISKE, J., SCHONEBERG, T., SCHRODER, W., HATZFELD, M., TAUBER, R. & HUBER, 
O. 2001. The fate of desmosomal proteins in apoptotic cells. J Biol Chem, 276, 
41175-81. 
WENDT, A., THOMPSON, V. F. & GOLL, D. E. 2004. Interaction of calpastatin with 
calpain: a review. Biol Chem, 385, 465-72. 
WHITTOCK, N. V., ASHTON, G. H., DOPPING-HEPENSTAL, P. J., GRATIAN, M. J., 
KEANE, F. M., EADY, R. A. & MCGRATH, J. A. 1999. Striate palmoplantar 
keratoderma resulting from desmoplakin haploinsufficiency. J Invest 
Dermatol, 113, 940-6. 
WHITTOCK, N. V., WAN, H., MORLEY, S. M., GARZON, M. C., KRISTAL, L., HYDE, P., 
MCLEAN, W. H., PULKKINEN, L., UITTO, J., CHRISTIANO, A. M., EADY, R. A. & 
MCGRATH, J. A. 2002. Compound heterozygosity for non-sense and mis-
sense mutations in desmoplakin underlies skin fragility/woolly hair 
syndrome. J Invest Dermatol, 118, 232-8. 
255 
 
WITHANA, N. P., BLUM, G., SAMENI, M., SLANEY, C., ANBALAGAN, A., OLIVE, M. B., 
BIDWELL, B. N., EDGINGTON, L., WANG, L., MOIN, K., SLOANE, B. F., 
ANDERSON, R. L., BOGYO, M. S. & PARKER, B. S. 2012. Cathepsin B inhibition 
limits bone metastasis in breast cancer. Cancer Res, 72, 1199-209. 
WOLF, A. & HATZFELD, M. 2010. A role of plakophilins in the regulation of 
translation. Cell Cycle, 9, 2973-8. 
WOLFF, K., GOLDSMITH, L., KATZ, S., GILCHREST, B. A., PALLER, A. & LEFFELL, D. J. 
2007. Fitzpatrick's Dermatology In General Medicine, Seventh Edition, 
McGraw-Hill. 
XU, T., YANG, Z., VATTA, M., RAMPAZZO, A., BEFFAGNA, G., PILICHOU, K., SCHERER, 
S. E., SAFFITZ, J., KRAVITZ, J., ZAREBA, W., DANIELI, G. A., LORENZON, A., 
NAVA, A., BAUCE, B., THIENE, G., BASSO, C., CALKINS, H., GEAR, K., MARCUS, 
F., TOWBIN, J. A. & MULTIDISCIPLINARY STUDY OF RIGHT VENTRICULAR 
DYSPLASIA, I. 2010. Compound and digenic heterozygosity contributes to 
arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol, 55, 587-
97. 
YAMADA, S., POKUTTA, S., DREES, F., WEIS, W. I. & NELSON, W. J. 2005. 
Deconstructing the cadherin-catenin-actin complex. Cell, 123, 889-901. 
YAMAZAKI, M., ISHIDOH, K., SUGA, Y., SAIDO, T. C., KAWASHIMA, S., SUZUKI, K., 
KOMINAMI, E. & OGAWA, H. 1997. Cytoplasmic processing of human 
profilaggrin by active mu-calpain. Biochem Biophys Res Commun, 235, 652-6. 
YAN, S., SAMENI, M. & SLOANE, B. F. 1998. Cathepsin B and human tumor 
progression. Biol Chem, 379, 113-23. 
YIN, T. & GREEN, K. J. 2004. Regulation of desmosome assembly and adhesion. Semin 
Cell Dev Biol, 15, 665-77. 
YONEMURA, S. 2011. Cadherin-actin interactions at adherens junctions. Curr Opin 
Cell Biol, 23, 515-22. 
256 
 
ZHAO, R., GUAN, D. W., ZHANG, W., DU, Y., XIONG, C. Y., ZHU, B. L. & ZHANG, J. J. 2009. 
Increased expressions and activations of apoptosis-related factors in cell 
signaling during incised skin wound healing in mice: a preliminary study for 
forensic wound age estimation. Leg Med (Tokyo), 11 Suppl 1, S155-60. 
ZHENG, R., BU, D. F. & ZHU, X. J. 2005. Compound heterozygosity for new splice site 
mutations in the plakophilin 1 gene (PKP1) in a Chinese case of ectodermal 
dysplasia-skin fragility syndrome. Acta Derm Venereol, 85, 394-9. 
ZHURINSKY, J., SHTUTMAN, M. & BEN-ZE'EV, A. 2000. Differential mechanisms of 
LEF/TCF family-dependent transcriptional activation by beta-catenin and 
plakoglobin. Mol Cell Biol, 20, 4238-52. 
ZLOTOGORSKI, A., MAREK, D., HOREV, L., ABU, A., BEN-AMITAI, D., GERAD, L., 
INGBER, A., FRYDMAN, M., REZNIK-WOLF, H., VARDY, D. A. & PRAS, E. 2006. 
An autosomal recessive form of monilethrix is caused by mutations in DSG4: 
clinical overlap with localized autosomal recessive hypotrichosis. J Invest 
Dermatol, 126, 1292-6. 
 MULTALIN INTERFACE PAGE  
http://bioinfo.genotoul.fr/multalin/multalin.html 
 
NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION 
http://www.ncbi.nlm.nih.gov/ 
 
1000 GENOMES 
http://www.1000genomes.org/ 
 
ENSEMBL 
http://www.ensembl.org/ 
 
257 
 
 
 
 
 
 
-Appendices- 
 
 
 
 
 
 
 
 
258 
 
Appendix A. Patient samples for genetic screening 
 
Patient study ID 
 
Country 
of origin 
of sample 
 
Screening technique 
 
Disease 
ARVC 2010 
0001 
UK 385K Sequence Capture 
Array 
ARVC 
ARVC 2010 
0002 
UK 385K Sequence Capture 
Array 
ARVC 
ARVC 2010 
0003 SA 
UK 385K Sequence Capture 
Array 
ARVC 
ARVC 2010 
0003 AA 
UK 385K Sequence Capture 
Array 
ARVC 
ARVC 2010 
0004 
UK 385K Sequence Capture 
Array 
ARVC 
ARVC 2010 
0005 
UK 385K Sequence Capture 
Array 
ARVC 
ARVC 2010 
0006 
UK 385K Sequence Capture 
Array 
ARVC 
ARVC 2010 
0007 
UK 385K Sequence Capture 
Array 
ARVC 
ARVC 2010 
0008 
UK 385K Sequence Capture 
Array 
ARVC 
ARVC 2010 
0009 
UK 385K Sequence Capture 
Array 
ARVC 
ARVC 2010 
0010 
UK 385K Sequence Capture 
Array 
ARVC 
ARVC 2010 
0011 
UK 385K Sequence Capture 
Array 
ARVC 
ARVC 2010 
0012 
UK HaloPlex Targeted 
Resequencing 
ARVC 
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Patient study ID 
 
Country 
of origin 
of sample 
 
Screening technique 
 
Disease 
ARVC 2010 
0013 
UK HaloPlex Targeted 
Resequencing 
ARVC 
ARVC 2010 
0014 
UK HaloPlex Targeted 
Resequencing 
ARVC 
ARVC 2010 
0015 
UK HaloPlex Targeted 
Resequencing 
ARVC 
ARVC 2010 
0016 
UK HaloPlex Targeted 
Resequencing 
ARVC 
ARVC 2011 
0017 
UK HaloPlex Targeted 
Resequencing 
ARVC 
ARVC 2011 
0018 
UK HaloPlex Targeted 
Resequencing 
ARVC 
ARVC 2011 
0019 
UK HaloPlex Targeted 
Resequencing 
ARVC 
ARVC 2011 
0020A 
UK HaloPlex Targeted 
Resequencing 
ARVC 
ARVC 2011 
0020D 
UK HaloPlex Targeted 
Resequencing 
ARVC 
ARVC 2011 
0021 
UK HaloPlex Targeted 
Resequencing 
ARVC 
ARVC 2011 
0022 
UK HaloPlex Targeted 
Resequencing 
ARVC 
FP9310 NZ HaloPlex Targeted 
Resequencing 
ARVC 
LU4246 NZ HaloPlex Targeted 
Resequencing 
ARVC 
RN2662 NZ HaloPlex Targeted 
Resequencing 
ARVC 
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Patient study ID 
 
Country 
of origin 
of sample 
 
Screening technique 
 
Disease 
RY8012 NZ HaloPlex Targeted 
Resequencing 
ARVC 
CM4130 NZ HaloPlex Targeted 
Resequencing 
ARVC 
LI8441 NZ HaloPlex Targeted 
Resequencing 
ARVC 
LN2209 NZ HaloPlex Targeted 
Resequencing 
ARVC 
YP8962 NZ HaloPlex Targeted 
Resequencing 
ARVC 
CJ0829 NZ HaloPlex Targeted 
Resequencing 
ARVC 
LK7659 NZ HaloPlex Targeted 
Resequencing 
ARVC 
LH5926 NZ HaloPlex Targeted 
Resequencing 
ARVC 
LI8308 NZ HaloPlex Targeted 
Resequencing 
ARVC 
LH5930 NZ HaloPlex Targeted 
Resequencing 
ARVC 
NE2908 NZ HaloPlex Targeted 
Resequencing 
ARVC 
OG0660 NZ HaloPlex Targeted 
Resequencing 
ARVC 
LW9068 NZ HaloPlex Targeted 
Resequencing 
ARVC 
LJ6113 NZ HaloPlex Targeted 
Resequencing 
ARVC 
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Patient study ID 
 
Country 
of origin 
of sample 
 
Screening technique 
 
Disease 
LI7542 NZ HaloPlex Targeted 
Resequencing 
ARVC 
LI8325 NZ HaloPlex Targeted 
Resequencing 
ARVC 
MC5702 NZ HaloPlex Targeted 
Resequencing 
ARVC 
LH5931 NZ HaloPlex Targeted 
Resequencing 
ARVC 
WN2786 NZ HaloPlex Targeted 
Resequencing 
ARVC 
LV7711 NZ HaloPlex Targeted 
Resequencing 
ARVC 
FT6012 NZ HaloPlex Targeted 
Resequencing 
ARVC 
FT6011 NZ HaloPlex Targeted 
Resequencing 
ARVC 
9395171 UK HaloPlex Targeted 
Resequencing 
Unknown 
9305427 UK HaloPlex Targeted 
Resequencing 
Unknown 
BLGC DNA657 UK Exome capture hypotrichosis and 
PPK 
BLGC DNA656 UK Exome capture hypotrichosis and 
PPK 
BLGC DNA658 UK Control parent Parent of 
hypotrichosis and 
PPK patient 
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Patient study ID 
 
Country 
of origin 
of sample 
 
Screening technique 
 
Disease 
BLGC DNA655 UK Control parent Parent of 
hypotrichosis and 
PPK patient 
KL UK Sanger sequencing Acral Peeling 
Syndrome 
SL UK Sanger sequencing Acral Peeling 
Syndrome 
DK-2013-UNK-
04 
UK Exome capture PLACK Syndrome 
Control 
Genomic DNA 
UK Sanger sequencing N/A 
Table A. Patient samples with accompanying information. Forty-nine patients, 
diagnosed with ARVC, were recruited from Barts and The London NHS Trust and from two 
collaborating centres, Bristol Heart Institute and the Cardiac Inherited Disease Group based 
in Auckland, New Zealand (Dr Dominic Abrams). Two patients seen by Prof Edel O’Toole at 
the Royal London Hospital presented with unknown skin disorders. A family of four, were 
seen by Dr Celia Moss at the Birmingham Children’s Hospital and the affected patients were 
diagnosed with Hypotrochosis and PPK. Two patients seen by Dr Kapila Batta at the 
Watford General Hospital were diagnosed with Acral Peeling Skin Syndrome. One patient 
seen by Prof Edel O’Toole at the Royal London Hospital was diagnosed with a novel clinical 
entity PLACK syndrome. 
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Appendix B. Primers for mutation analysis 
B.1. Primers used for confirmation of capture array variants 
Gene 
(Exon) 
Forward primer seq (5’-3’) Reverse primer seq (5’-3’) AT 
(0C) 
Size 
(bp
) 
DSG2 
(15) 
AAGTTTGCCTGGGTCAAAAA ACTGGGAAGCTACTGCCAG
A 
56 157 
PKP2 
(10) 
TCCTTTTGTGTGTGGTCAGC CAGGCCCAATACTCACTGG
T 
57 209 
PKP2 
(3) 
TGTTAGCGACACCGTTTTTG GGAAGCCCTGTTCTGAGTG
A 
57 184 
PKP2 
(3) 
GCAACCTCTTGGAGAAGGAG CTCTCCTCCCGCTGGAAT 58 192 
PKP2 
(N/A) 
ATGCACGCGACCTTCTAAAC atcctgtttgctgccatgtt 58 184 
PKP2 
(N/A) 
gagcaagattccgtctcaaaa CTCGGGACTGTGTCAGGAA
T 
63 171 
DSP 
(11) 
TGCAGGTTGAAAATCTCCTC
T 
GTCTGGGTTACGAGGCTTC
A 
56 167 
Table B.1. Primers and cycling conditions used for sequencing of variations identified 
following the ARVC capture array. 
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B.2. Primers used to check for expression of cathepsins B and L by RT-PCR 
Gene 
(Exon) 
Forward primer sequence 
(5’-3’) 
Reverse primer sequence 
(5’-3’) 
AT 
(0C) 
Size 
(bp) 
CathB 
- 1,2,3 
CTAGGATCCGGCTTCCAAC CACCCAGGAAGGTACCACAT 62 212 
CathB 
- 8,9 
GGCCGAGATCTACAAAAACG CATTGTCACCCCAGTCAGTG 62 203 
CathL 
– 1 
GTCTTTTCAGGAGCCACTCG CGGTTCGTGGCTTGTTTACT ----- 177 
CathL 
– 2,3 
CTGGGAATTGCCTCAGCTAC TGAAGCTGTGTTTCCCTTCC 55 187 
Table B.2. Primers and cycling conditions used for RT-PCR of cathepsins B and L. 
 
B.3. Primers used to confirm DSP variation in hypotrichosis and PPK patients 
Exon Forward primer seq (5’-3’) Reverse primer seq (5’-3’) AT 
(0C) 
Size 
(bp) 
12 TTCATTTGAGGGGAAAAACG GCAAGGCATCGTGTGTCTAA 57 385 
Table B.3. Primers and cycling conditions used for sequencing of exon 15 of DSP to 
confirm variation in hypotrichosis and PPK patients and parents. 
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B.4. Primers used for confirmation of variations identified following HaloPlex targeted 
resequencing 
Gene 
(Exon) 
Forward primer seq (5’-3’) Reverse primer seq (5’-3’) AT 
(0C) 
DSP (23) CACCTGAGGGAAAAGCAGAG CATCAAGTGCTCCTTGGTCA 65 
PKP2 
(2) 
gcagGAAATCTTCACCGAAC ttgggaaaagtaaacactcaaaaa 61 
PKP2 
(14) 
gacttgaccctgggaagaaa GGTGTTTTCCTTTGGGGATT 64 
PKP2 
(9) 
tccttttgtgtgtggtcagC caggcccaatactcaTGGT 64 
PKP2 
(1) 
CCAGCTGAGTACGGCTACAT
C 
CTGCACCTGCTCCTGGAT 65 
PKP2 
(12) 
gcctcactcattctccctga ggccattattacctggctctg 64 
PKP2 
(4) 
GCTGCCATCCAGGATTTCT tttcagtgtgcaaagtcacca 65 
PKP2 
(11) 
caatctttttaatcaagtgttttgttt TTTTGGATTATGTTGTTCAATG
TG 
61 
PKP2 
(4) 
TCTGGAGCGAGCAGTGAGTA tgaaagtgtgttgcgctttg 58 
PKP2 
(10) 
GTGGCTCAGACAGTTGTCCA ccgactcacCAATTTCATTCT 65 
PKP2 
(6) 
TGCTTACGCTGACGGAGAAT cttctatcagggcagggtaca 64 
PKP2 
(12) 
ctgggcaacagagcaagatt CTCGGGACTGTGTCAGGAAT 65 
ADAM17 
(8) 
CGCATTCTCAAGTCTCCACA actgcttctgggtgtccatc 65 
Table B.4. Primers and cycling conditions used for confirmation of variations 
following HaloPlex targeted resequencing on patient genomic DNA. 
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B.5. Primers used for patient diagnosis screening of CSTA 
Exon Forward primer seq (5’-
3’) 
Reverse primer seq (5’-3’) AT 
(0C) 
Size 
(bp) 
1 cttgcccatttgttcatcct cctgaacaaagccacaaaca 61 431 
1A ttttccccatgcctctttgc CTCCTGGATTTCTGGAGTGGC
G 
65 200 
1B GTTCACTTTGGTTCCAGC
ATCCTG 
caaccacagcctttccacag 65 193 
2 tgaattcagcctaaagcaacaa tccaccacttggaaggaatc 63 454 
3 tttgtagacctgtggctctctc TGATGGTTATATTTATCAGCA
AGGA 
63 289 
Table B.5. Primers and cycling conditions used for patient diagnosis by PCR and 
Sanger sequencing of CSTA. 
B.6. Desmoplakin cDNA primers used for confirmation of site-directed mutagenesis 
Exo
n 
Forward primer seq (5’-3’) Reverse primer seq (5’-3’) Size 
(bp) 
1 CAACACCAACACCCAGCTC ATCAAGCAGTCGGAGCAGTT 522 
2 ACTCGGACGGCTACTGTCAA CAGGTCGGCTTTGATTTTGT 572 
3 TGGAGCAGCACATTAACAGC GCAGGGGTACTTCTTCCTGA 575 
4 TCTGAAAGAAAATGCTGCCTA TCATGGCCCTGATCTTCTCT 578 
5 GCAGTACTACGAAGCCATCTTG TGGTGAGAAGATCCCTGGTC 522 
6 CAGAAGATTCGCAGGCAGAT GCCAACAACGACTTCTTCAA 461 
7 CAGGCTCACTGAGGAGGAAA GGTATGTTCAGCAGAGTTTCCAG 570 
8 TTGCGCCAATTCAATTAAGG CCTTGCTTTCTGCAGTTGGT 580 
9 TGAGAAGATCACCCGACTGAC CTGCATGACCTGCTTCAGTT 577 
10 GAAGGCGAGCTGAAGAAAAC TCTCCTCTGTTCGCATCTGA 585 
11 CCACTGGCTCTGAGGTGTCT TTAACAATGGATGCCTGCTC 574 
12 CTCCTGCAAGAGGAAGAAGC CCTGTCTCAAATTTTCCCTCTC 587 
13 AGCTGCAGATCAGCAACAAC GGGCGCTGTCTGAGTTTATC 574 
14 AAGAGAGGTGCAGGCGTAAG TCTTGCCTGAAAATGGATCA 582 
15 TAGCTCGGGACCTCATTGAC TATGCCTGCTATGCAGCTTG 572 
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Exo
n 
Forward primer seq (5’-3’) Reverse primer seq (5’-3’) Size 
(bp) 
16 TGAGACCGTCCACTGTCAAT TCTTCAGTGTTGGGGTCAAA 583 
17 GGGGCTATTTCAATGAGGAA CGGGAGCTGCTAAAAACATC 577 
18 CAGCCTCACTCAATTTGCTG TTATCCTCCCATGCACTTCC 581 
19 AGCAGCAGAGGCAGTGAAAG AAGCACCGGGATTTTCTTTT 581 
20 GTCAGTTGGGAGTGGTTGCT TCCACACTCTGAAACTAAAGGAG
A 
513 
21 GGAGATAAAAATTAAATGGATC
ACTG 
TTTTTAATGGTATTTCTTCACAG
GT 
468 
Table B.6. Primers and cycling conditions for DSP I cDNA primers, used for 
verification of DSP I clones following site-directed mutagenesis. 
 
B.7. pCR II-TOPO specific primers used for amplification of inserted DSP fragment 
Exon Forward primer seq (5’-3’) Reverse primer seq (5’-3’) 
M13 GTAAAACGACGGCCAG CAGGAAACAGCTATGAC 
Table B.7. Primers used to verify the correct insertion of DSP cDNA in pCR II-TOPO 
and to check plasmid post site-directed mutagenesis. 
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Appendix C. Primary antibodies used for immunomicroscopy and 
western blotting 
Primary 
Antibody 
Clone Host 
WB 
dilution  
ICC 
dilution  
Source 
Mab anti-
CSTA 
--------- Ms 1:500 1:100 
Abcam 
(Cambridge, UK) 
Pab anti-
CSTA 
--------- Rb 1:500 1:50 Abcam 
Pab anti-
CAST 
H-300 Rb 1:1000 1:100 
Santa Cruz 
Biotechnology 
Mab anti-β-
actin 
AC-15 Ms 1:5000 --------- Sigma 
Pab anti-E-
cadherin 
HECD-1 Rb 1:1000 --------- Abcam 
Mab anti-
Tubulin 
DM1A Ms 1:10000 --------- Abcam 
Pab anti-
GAPDH 
--------- Rb 1:1000 --------- Abcam 
Pab anti-
Vinculin 
--------- Rb 1:1000 --------- Abcam 
Pab anti-
Lamin A 
--------- Rb 1:1000 --------- Abcam 
Mab anti-
LAMP1 
--------- Ms 1:1000 --------- Abcam 
Mab anti-
K14 
LL001 Ms --------- 1:100 CRUK 
Mab anti-
Pan-
cytokeratin 
AE1/AE
3 
Ms --------- 1:100 
Dako (Glostrup, 
Denmark) 
Mab anti-
Cath L 
33/2 Ms 1:200 1:50 Abcam 
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Primary 
Antibody 
Clone Host 
WB 
dilution  
ICC 
dilution  
Source 
Pab anti-
Cath B 
CA10 Rb 1:200 1:25 Abcam 
Mab anti-
Cath H 
--------- Ms --------- 1:25 Abcam 
Mab anti-
DSG1 
MCA22
71 
Ms 1:500 --------- AbD Serotec, Bio-Rad 
Mab anti-
DSG1/2 
DG3.10 Ms 1:500 1:250 
Progen 
(Heidelberg, Germany) 
Pab anti-
DSG2 
Ab10 Rb 1:10000 1:500 
Kind gift from Dr Mỹ 
Mahoney 
Pab anti-
DSC2 
--------- Rb 1:2000 --------- Progen 
Mab anti-
DSG 3 
5G11 Ms 1:200 --------- Abcam 
Mab anti-
DSG 3 
3G133 Ms 1:500 --------- Abcam 
Mab anti-
DSC3 
U114 Ms 1:250 --------- Progen 
Pab anti-
PKP2 
518 Rb 1:100 --------- Progen 
Mab anti-
PG 
5.1 Ms 1:1000 --------- 
AbD Serotec 
(Serotec, Kidlington, UK) 
Mab anti-
DSP I/II 
5-11F Ms 1:250 1:50 
Kind gift from Prof. 
David Garrod 
(Parrish et al., 1987) 
Table C. Primary antibodies used for western blotting and immunomicroscopy. 
Details of antibodies used, together with the source, clone and specific assay-specific 
dilutions.  
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Appendix D. Buffers 
Buffer Reagents 
RM+ 40μg/ml Hydrocortisone 
500μg/ml Insulin 
1μg/ml EGF 
10-8 (0.84 μg/ml) Cholera toxin 
500μg/ml Transferrin 
1.3μg/ml Lyothyronine (L4) 
Normal media (add to 
DMEM or DMEM-F12) 
10% (v/v) FBS  
2 mM L-glutamine  
100 U/ml Penicillin 
100 µg/ml Streptomycin 
1% RM+ 
TBE Buffer 9M Tris base 
9M Boric acid 
0.2M EDTA, pH 8.0 
DNA Loading Buffer 50% (v/v) Glycerol 
0.2% (w/v) Orange G 
Western Blotting 
Polyacrylamide Running 
Gel (10%) in 5 ml 
1.7 ml of Acrylamide mix [Protogel 30% (w/v) 
acrylamide : 0.8% (w/v) Bis-acrylamide 
stock solution (37.5:1)] 
1.9 ml of ddH2O 
1.3 ml of 1.5 M Tris, pH 8.8 
0.05 ml of 10% SDS 
0.05 ml of APS 
0.002 ml of TEMED 
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Buffer Reagents 
Western Blotting 
Polyacrylamide Stacking 
Gel (5%) in 1 ml 
0.17 ml of Acrylamide mix [Protogel 30% (w/v) 
acrylamide : 0.8% (w/v) Bis-acrylamide 
stock solution (37.5:1)] 
0.68 ml of ddH2O 
0.13 ml of 1.0 M Tris, pH 6.8 
0.01 ml of 10% SDS 
0.01 ml of APS 
0.001 ml of TEMED 
SDS Protein Loading 
Buffer 
0.100 M Tris-HCl, pH 6.8 
4% SDS 
20% Glycerol 
0.001% Bromophenol Blue 
1.44 M Beta-mercaptoethanol (10%) 
Western Blotting 
10x Running Buffer 
 
0.25M Tris base 
1.92M Glycine 
1% SDS 
Coomassie Stain 40% dH2O  
10% Acetic acid 
50% Methanol  
0.25% Coomassie Brilliant Blue R-250 
Ponceau Stain 20mg/ml Ponceau S 
0.3g Trichloroacetic acid 
Western Blotting 
10 x Transfer Buffer 
 
0.48M Tris base 
0.30M Glycine 
0.37% (w/v) SDS 
Add 20% (v/v) Methanol to 1 x Transfer Buffer 
Western Blotting 
10 x Transfer Buffer for 
DSP 
0.48M Tris base 
0.30M Glycine 
0.37% (w/v) SDS 
Add 5% (v/v) Methanol to 1 x Transfer Buffer  
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Buffer Reagents 
10 x TBS 
 
0.5M Tris-HCl, pH 7.5 
1.5M NaCl 
1 x T-TBS 
(Tween 20-TBS) 
 
0.05M Tris-HCl, pH 7.5 
0.15M NaCl 
0.1% (v/v) Tween-20 
Western Blotting 
Stripping Buffer 
62.5 mM Tris-HCl, pH6.8 
2% SDS 
0.7% β-Mercaptoethanol 
dH2O 
 
ELISA Wash Buffer, pH 
7.2-7.4 
0.05% Tween 20 
1 x PBS 
ELISA Reagent Diluent, pH 
7.2-7.4 
1% BSA 
1 x PBS 
ELISA Stop Solution 2N H2SO4 
Table D. Buffers used in Chapter 2 and the component reagents. 
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Appendix E. Generation of mutant DSP clones for in vitro analysis 
of ARVC and genodermatoses 
E.1. Selection of DSP constructs by restriction digest and sequencing 
This section is based on the identification of three novel mutations in the DSP gene 
in three individuals, as follows: one patient with cardiomyopathy, striate PPK and 
woolly hair; a second patient with cardiomyopathy and a third patient with 
hypotrichosis and PPK. The first patient, previously described by Norgett et al., 
presented with a heterozygous thirty base pair insertion in exon 14 of DSP, which 
would lead to a 10 amino acid insertion at the protein level (Norgett et al., 2006). 
The second patient, clinically diagnosed with cardiomyopathy and no cutaneous or 
hair phenotypes, was genetically analysed using a custom capture array, as 
described in Chapter 3, Table 3.1., and a novel heterozygous variation was identified 
in exon 11 of DSP (c.G1323C:p.K441N). The third patient together with two other 
siblings, were diagnosed with hypotrichosis and PPK and no obvious cardiac 
abnormalities at the time of examination. Exome analysis of this patient revealed a 
homozygous mutation in exon 12 of DSP (c.C1493T:p.P498L), which was confirmed 
in one other sibling and in heterozygous parents.  
As the 30 bp insertion mutation was previously cloned and stable mutant 
keratinocyte cell lines were generated by Dr Rita Cabral in our group, this section 
will focus on describing the cloning process for the second and third DSP mutations 
described above. 
A wild type DSP I cDNA clone was previously generated by Dr Rita Cabral, using 
three overlapping RT-PCR reactions using total RNA from primary normal human 
keratinocytes (NHK). Briefly, four cDNA fragments were PCR amplified and cloned 
individually into pCRII-TOPO vector, subsequently each fragment was extracted 
using restriction enzymes, and joined in a precise order due to common restriction 
sites. The final product which contained all fragments was then transfected into 
chemically competent E. coli cells, which were amplified and stored as glycerol 
stocks (Cabral et al., 2010b).  
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For the site-directed mutagenesis several DSP I clones which contain various pieces 
of the DSP I construct cloned into pCRII-TOPO were selected. A restriction digest 
with KpnI and NotI restriction enzymes which selectively cut at the ends of pCRII-
TOPO vector has confirmed the correct size fragments in selected clones. A fragment 
of approximately 4,000 bp was obtained for all clones and corresponds to the pCRII-
TOPO cloning vector. Alongside the fragment matching the size of the cloning vector, 
other fragments corresponding to the DSP I various piece combinations were 
observed as follows (Figure E.1.):  
lane 1 – final DSP I construct (pieces 1+2a+2b+3), digest failed;  
lane 2 – DSP I pieces 1+2a+2b, expected fragment of approximately 6,100 bp;  
lane 3 – DSP I piece 1, smear observed at approximately 4,000 bp which is the 
correct size for both the vector and DSP I piece 1;   
lane 4 – DSP I piece 3, expected fragment of approximately 3,600 bp;  
lane 5 – DSP I piece 2a, expected fragment of approximately 1,000 bp;  
lane 6 – DSP I pieces 2a+2b, expected fragment of approximately 2,000 bp;  
lane 7 – DSP I pieces 1+2a, expected fragment of approximately 5,200 bp;  
lane 8 – DSP I piece 2a, fragment of approximately 1,500 bp observed instead of the 
corresponding fragment of 1,000 bp;  
lane 9 – DSP I piece 1, smear observed at approximately 4,000 bp which is the 
correct size for both the vector and DSP I piece 1;  
lane 10 – DSP I pieces 2a+2b, expected fragment of approximately 2,000 bp;  
lanes 11, 12 and 13 – final DSP I constructs (pieces 1+2a+2b+3), expected fragment 
of approximately 9,700 bp was observed in all three lanes; all fragment sizes were 
determined by comparison to the 1 Kb plus ladder used as a size indicator.  
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Figure E.1.  Restriction digest with KpnI and NotI restriction enzymes on selected DSP 
I clones. 
The restriction digest observations were confirmed by Sanger sequencing of these 
clones, using the M13 (-20) forward and M13 reverse primers which anneal to the 
pCRII-TOPO cloning vector and sequence the inserted constructs (data not shown). 
Three clones which included fragment 1 of DSP I in pCRII-TOPO were selected. 
E.2. Site-directed mutagenesis and transformation of chemically competent bacterial 
cells 
Site-directed mutagenesis (SDM) is a technique that uses special custom made 
primers which include the desired change and are used to amplify the entire vector 
and insert, resulting in an identical vector which incorporates the desired mutation 
instead of the wild type sequence. SDM can be used to make single point mutations, 
replace amino acids and delete or insert single or multiple amino acids. The two 
primers anneal by complementarity to the region to be mutated and sequence the 
vector in both the forward and reverse directions.  
To further characterise the c.G1323C DSP mutation identified in the ARVC patient, 
and the c.C1493T DSP mutation identified in the hypotrichosis and PPK patient we 
have performed SDM on the selected DSP I clones which contain the required 
fragment 1 affected by these mutations (Figure E.2. A and B).  
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Figure E.2. Representation of annealing position of SDM primers with DSP c.G1323C 
(A) and DSP c.C1493T (B) mutations as expected post-SDM. 
DpnI restriction enzyme was used post-SDM to digest parental DNA vectors based 
on this enzyme’s specificity for methylated and hemimethylated DNA, thus selecting 
for mutation-containing newly synthesized vectors. These vectors were then 
transformed into chemically ultracompetent E. coli bacterial cells which were 
amplified and screened for the correct vector sequence expected following SDM 
(data not shown). All correctly amplified mutant vectors were sequenced further in 
order to eliminate any vectors which might have other mutations produced during 
the SDM process.  
Similarly to the 30 bp insertion mutant, the following steps would be to excise the 
mutated DSP clone from the pCRII-TOPO vector and insert it into pBABE-Puro 
retroviral expression vector which will be transfected into the immortalised 
keratinocyte cell line HaCaT. The mutant stable cell lines will be used for in vitro 
studies looking at the differences in expression and localisation of mutant DSP but 
also at the possible mechanisms of action behind the three DSP mutations, linked to 
the above mentioned cardio/cutaneous disorders. 
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Appendix F.  
F.1. Optimisations of CSTA siRNA mediated knockdown 
Prior to the CSTA siRNA-based analysis presented in Chapter 4, the transfection 
efficiency of the CSTA siRNA pool was assessed with varied cell densities and time 
points, in order to find the highest transfection and knockdown efficiency with the 
lowest cell death rate. Lipid-based transfections using the DharmaFECT transfection 
reagent (Thermo Fisher Scientific) were performed to deliver siRNAs into HaCaT 
cells.  
As shown in Figure F1.Ai., HaCaT cells were seeded at 2 x 105 and 4 x 105 cell 
densities and incubated with NTP siRNA and CSTA siRNA for 48 and 72 h. Western 
blotting of total cell lysates with an anti-cystatin A antibody revealed a significant 
reduction in cystatin A for both time points and cell densities, with a higher 
knockdown level achieved after 72 h (Figure F1.Aii.). As some of the analyses 
required extended time points we have used the same technique to check if the 
knockdown level was maintained up to 134 h. Cells were seeded at a 2 x 105 cell 
density and incubated with NTP and CSTA siRNA for 86, 110 and 134 h. Western 
blotting of total cell lysates revealed that the knockdown level was robust up to the 
longest analysed time point (Figure F1.Bi and Bii). These transfection conditions 
were used in all subsequent experiments. 
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Figure F.1. Optimisation of CSTA siRNA transfection in HaCaT cells. (Ai) Total protein 
from HaCaT cell lysates 48 h and 72 h after transfection with CSTA siRNA (lanes 3-4 and 7-
8) and NTP siRNA (lanes 1-2 and 5-6) was incubated with an anti-CSTA antibody (11 kDa). 
(Aii) Densitometric analysis of western blotting bands in (Ai) is showing a significant 
decrease in CSTA expression following CSTA siRNA-mediated knockdown, more 
accentuated after 72 h KD. Tubulin was used as a loading control (55 kDa). 
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Figure F.1. Optimisation of CSTA siRNA transfection in HaCaT cells (continued). (Bi) 
Total protein cell lysates after 86 h, 110 h and 134 h from CSTA siRNA (lanes 2, 4 and 6) and 
NTP siRNA cells (lanes 1, 3 and 5) were incubated with an anti-CSTA antibody. (Bii) 
Densitometric analysis of western blotting bands in (Bi) is showing a significant decrease 
in CSTA expression following CSTA siRNA-mediated knockdown, for all time points 
analysed. Tubulin was used as a loading control (55 kDa). 
F.2. Keratin 14 in non-stretched CSTA and NTP siRNA cells 
Immunocytochemistry of NTP and CSTA siRNA cells was performed using an 
antibody raised against keratin 14 (in green) (Figure F2.A and B). After 0 h stretch, 
under 100 X magnification, NTP cells (Figure F2.Aii) and CSTA siRNA treated cells 
(Figure F2.Bii) the intercellular connections and keratin filaments appeared intact.  
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Figure F.2. Keratin 14 in non-stretched CSTA KD cell monolayers. ICC with an anti-
keratin 14 antibody shows normal intercellular adhesion and keratin filaments in non-
stretched CSTA siRNA (A) cells in comparison to control NTP (B). Keratin 14 – in green; 
DAPI – in blue. Imaging was performed on the LSM 710 confocal microscope and images 
taken at 100 X (Scale bar – 20 µm).  
F.3. Analysis of expression of cathepsins B and L in siRNA-treated stretched and 
scratched monolayers 
The levels of secreted and intracellular cathepsins B and L were analysed in cell 
culture supernatants by ELISA following NTP and CSTA siRNA-treatment subjected 
to scratch and mechanical-stretch assays. The expression of the two cathepsins was 
initially analysed in NTP and CSTA siRNA treated cells prior to any stress being 
applied (Figure F3.A and B). The expression levels of both cathepsins increased 
upon scratch-wound in both control and CSTA siRNA cells with no significant 
difference between the two conditions (Figure F3.E and F). In mechanically-
stretched cell monolayers the expression of cathepsins B and L presented a small 
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decrease after 1 h stretch but did not alter significantly after 4 h stretch in 
comparison to non-stretched cells (Figure F3.C and D). A significant difference in 
secretion levels was observed between the two proteases, with cathepsin B being 
secreted at significantly higher levels compared to cathepsin L, following both 
scratch-wound and mechanically-induced stress assays. Cathepsin expression in 
stretched cells was assessed in triplicate and in scratched cells in duplicate; optical 
density analysis for the remaining two and respectively one repeat(s) is included 
below.  
 
Figure F.3. Expression of cathepsins B and L in CSTA KD cells following “scratch-
wound” and stretch assays. ELISA assay to assess the levels of secreted cathepsins B and 
L in culture supernatants post scratch-wound (0 h, 6 h, 16 h and 20 h post wound) or 
mechanical stretch (for 0 h, 1 h and 4 h) in CSTA siRNA compared to NTP siRNA. No 
significant difference was observed between CSTA siRNA and control cells. 
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Figure F.3. Expression of cathepsins B and L in CSTA KD cells following “scratch-
wound” and stretch assays (continued). ELISA assay to assess the levels of secreted 
cathepsins B and L in culture supernatants post scratch-wound (0 h, 6 h, 16 h and 20 h post 
wound) or mechanical stretch (for 0 h, 1 h and 4 h) in CSTA siRNA compared to NTP siRNA. 
No significant difference was observed between CSTA siRNA and control cells. 
F.4. Densitometric analysis of desmosome-associated proteins in CSTA siRNA treated 
cells  
Three independent CSTA knockdown experiments were performed and a number of 
western blots were carried out for each protein of interest. Antibodies targeting 
DSP, DSC2, DSC3, DSG2, DSG3, PG and PKP2 were used together with anti-vinculin 
or anti-GAPDH antibodies as loading controls. Densitometric measurements of 
western blots were calculated using an image analysis program (Image J, v1.47v) 
and are graphically depicted in Figure F4. No detectable differences were observed 
in the expression levels of DSG2, DSC2, DSC3, PG and PKP2, between CSTA siRNA 
cells and NTP control cells, in any of the independent knockdown experiments 
(Figure F4.C-G). Variable differences were seen for DSP (Figure F4.B) between 
independent knockdown experiments. DSG3 (Figure F4.A) presented a general 
trend of up-regulation of expression following CSTA knockdown in both stretched 
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and non-stretched cell monolayers with a small variability between independent 
knockdown experiments. The discrepancy between knockdown experiments could 
perhaps reflect the variability between western blots and a larger number of 
western blots for each knockdown repeat would be necessary to confirm the 
changes in the levels of expression of DSG3 and DSP.  
 
 
Figure F.4. Densitometric analysis of desmosomal proteins in CSTA KD cells. Protein 
levels of DSP, DSG3, DSC2, DSC3, PG and PKP2 calculated from densitometry measurements 
of western blot images and normalised to loading controls (Vinculin for DSP or GAPDH for 
all other proteins). Desmosome-associated protein expression levels are presented as a 
fraction of the total protein expression levels of non-stretched NTP cells. (A) DSG3 (n = 3) 
presented with a general trend of up-regulation in all knockdown repeats with different 
expression values, as seen through the standard error bars. (B) DSP (n = 3) gave variable 
results and will need to be analysed further. 
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Figure F.4. Densitometric analysis of desmosomal proteins in CSTA KD cells 
(continued). Protein levels of DSP, DSG2, DSG3, DSC2, DSC3, PG and PKP2 calculated from 
densitometry measurements of western blot images and normalised to loading controls 
(Vinculin for DSP or GAPDH for all other proteins). Desmosome-associated protein 
expression levels are presented as a fraction of the total protein expression levels of non-
stretched NTP cells. (C-G) No differences in expression were observed for DSG2, DSC2, 
DSC3, PKP2 and PG in CSTA KD cells compared to control (n = 3 for PKP2 and n = 2 for all 
other proteins). 
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Appendix G.  
G.1. Optimisation of CAST siRNA transfection 
A series of optimisations of CAST siRNA transfection were performed prior to the 
siRNA-based analyses presented in Chapter 5. The knockdown efficiency of the CAST 
siRNA pool was assessed over a number of time points by western blotting of total 
protein lysates.  Similarly to the CSTA siRNA transfections, the DharmaFECT 
transfection reagent was used to deliver siRNAs into HaCaT cells and CSTA siRNA 
was used as control of knockdown efficiency.  
Densitometric analysis of calpastatin following CAST knockdown, in comparison to 
NTP control, revealed a reduction in calpastatin for all of the time points analysed, 
significantly increasing after 72 h (Figure G1). As some of the CAST knockdown-
based analyses required extended time points we have checked if the knockdown 
level was maintained up to 120 h. These transfection conditions were used in all 
subsequent in vitro experiments. 
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Figure G.1. Densitometric analysis of CAST siRNA knockdown. Total protein lysates 
from CAST siRNA and NTP siRNA treated cells were incubated with an anti-calpastatin 
antibody. Calpastatin expression decreased significantly after 72 h. 
G.2. DSG3 expression in PK2 skin biopsies 
Due to the cell adhesion defect in CAST LOF skin, the analysis of the expression and 
localisation of the desmosome-associated proteins DSG2, DSP and DSG3 was 
performed in patient skin. Figure G2. shows the expression and localisation of DSG3 
in patient skin (Figure G2.B) in comparison to normal control skin (Figure G2.A.). 
The immunohistochemistry picture of calpastatin in PK2 skin is taken at a lower 
exposure than the one presented in figure 5.8. (Chapter 5), and it better shows a 
change in localisation of DSG3 from a predominantly membranous compartment to 
both a plasma membrane and cytoplasmic localisation. 
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Figure G.2. Immunofluorescence of DSG3 in skin sections from PK2. IHC with an anti-
DSG3 antibody (in green) in control skin (A) and skin sections from PK2 (B) in the absence 
(Ai and Bi) and presence (Aii and Bii) of DAPI as nuclear marker (in blue), revealed a 
significant increase in protein expression in affected skin compared to control skin. A 
change from a typical membranous localisation to a both membranous and cytoplasmic 
localisation of this protein was also noted. Imaging was performed with the Zeiss Meta 710 
confocal microscope and images were taken at 20 X magnification (A and B) (Scale bar – 20 
µm for A and B). 
G.3. Desmosome-associated protein expression in CAST siRNA cells 
Following observations on the altered expression and localisation of the 
desmosome-associated proteins DSG2, DSG3, and DSP I/II in affected skin, these 
proteins were investigated in CAST siRNA-treated cells before and after 4 h 
mechanically-induced stress. Total protein cell lysates from NTP and CAST siRNA-
treated HaCaT cells were analysed by western blotting with antibodies targeting PG 
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and DSP I. Densitometric measurements of western blots were calculated as 
previously described, and are graphically depicted in Figure G3. for DSP I and Figure 
G4. for PG. Both proteins appeared to have similar expression levels between CAST 
siRNA and NTP treated cells.  
 
 
Figure G.3. Expression of DSP I in CAST KD cells. Total protein cell lysates from CAST 
siRNA and NTP siRNA HaCaT cells, non-stretched and stretched for 4 h, were blotted and 
incubated with an anti-DSP I antibody. Protein levels of DSP I were calculated from 
densitometric measurements of the western blot images, normalised against vinculin as 
loading control and are presented as a fraction of the total protein levels in NTP siRNA cells 
(n = 1). 
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Figure G.3. Expression of PG in CAST KD cells (continued). Total protein cell lysates from 
CAST siRNA and NTP siRNA HaCaT cells, non-stretched and stretched for 4 h, were blotted 
and incubated with an anti-PG antibody. Protein levels of PG were calculated from 
densitometric measurements of the western blot images, normalised against GAPDH as 
loading control and are presented as a fraction of the total protein levels in NTP siRNA cells 
(n = 3). 
 
 
 
 
 
 
